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TNF  Tumour Necrosis Factor 
TNFRSF  Tumour Necrosis Factor Receptor Superfamily 
TOMM40  Translocase of Outer Mitochondrial Membrane 40 
Homolog 
TRAF6  Tumour Necrosis Factor Receptor (TNFR)-Associated 
Factor 6 
TRHR  Thyrotropin-Releasing Hormone Receptor 
TRIM63  Tripartite Motif Containing 63, E3 Ubiquitin Protein 
Ligase (also known as MURF 1) 
TSC  Tuberous Sclerosis 
TSH  Thyroid Stimulating Hormone  
TTC18  Tetratricopeptide Repeat Domain 18  
TWEAK  Tumour Necrosis Factor-Like Weak Inducer of 
Apoptosis 
Ub  Ubiquitin 
UCP  Uncoupling Protein  
UGI  Upper Gastrointestinal 
UK  United Kingdom 
UPP  Ubiquitin-Proteasome Pathway 
UTR  Untranslated Region  
VCAM  Vascular Cell Adhesion Molecule  
VDR  Vitamin D Receptor 
VHL  Von Hippel–Lindau 
WDR20  WD Repeat Domain 20 
WL  Weight Loss 
ZAG  Zinc-α2-glycoprotein (also known as AZGP1) 












Cancer cachexia is a chronic wasting syndrome characterised by loss of weight, 
composed principally of muscle and fat. Patients with advanced cachexia 
demonstrate loss of appetite, early satiety, severe weight loss, weakness, anaemia 
and fluid retention. Affected individuals are also likely to report/experience decreased 
quality of life, decreased levels of physical performance, increased levels of fatigue, 
increased risks of treatment failure (be it chemotherapy, radiotherapy or surgery), 
increased risks of treatment side effects, and an increased mortality rate. Cachexia is 
therefore an extremely important, yet often underappreciated cause of cancer patient 
morbidity and mortality which requires urgent attention. Weight loss is significantly 
associated with cancer morbidity and mortality. It has been observed that half of all 
cancer patients experience weight loss and one-third lose more than 5% of their 
original body weight. Skeletal muscle loss appears to be the most significant event in 
cachexia and is associated with a poor outcome. However it is not known why some 
patients with the same tumour lose weight and muscle mass whilst others do not. 
The main aim of this thesis was to determine if the genetic makeup of individual 
patients might contribute to their propensity to lose weight or skeletal muscle. 
Previous studies had suggested an association between weight loss and SNPs on 
genes concerned with innate immunity and particularly the cell adhesion molecule P-
selectin, however the strength of any gene association study depends on the precision 
with which it is possible to characterise the phenotype in question. A second aim of 
this thesis was to explore refining the clinical phenotyping of patients to discriminate 
those with evidence of muscle fibre atrophy versus those without.  
 
Phenotype 
The conventional phenotype for cachexia is weight loss (WL) but it is unknown the 
extent to which loss of body mass reflects loss of muscle or fat mass. Recent progress 
in cross sectional imaging analysis means that it is now possible to gain a direct 
measure of muscle mass from routine diagnostic CT scanning. However, in the 
absence of a longitudinal series of scans it is not possible to estimate whether low 
muscularity (LM) is longstanding or not. By combining a measure of active weight loss 
with low muscularity it was hoped that such a composite measure would reflect actual 
muscle loss / fibre atrophy. Compared with non-cachectic cancer patients, patients 
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with LM or LM+>2%WL, mean muscle fibre diameter was reduced by about 25% (p = 
0.02 and p = 0.001 respectively). No significant difference in muscle fibre diameter 
was observed if patients had WL alone. Regardless of classification, there was no 
difference in fibre number or proportion of fibre type across all myosin heavy chain 
isoforms. Mean muscle protein content was reduced and the ratio of RNA/DNA 
decreased in patients with either >5%WL or LM+>2%WL.  
These findings support the use of composite measures (WL and LM) to try and identify 
those patients with evidence of active muscle fibre atrophy. This novel clinical 
phenotyping provides an accurate method to enable the conduct of candidate gene 
studies in the investigation of the genetics of cancer cachexia where the primary focus 
is on muscle wasting rather than overall weight loss. 
 
Genotype 
In an ideal world it would be possible to explore the entire genome and look for 
associations with the different phenotypes of cachexia. However, to do so would 
require considerable resource in terms of the cost of genome wide analysis and the 
cost of phenotyping large enough cohorts of patients (3000-10000). To address these 
issues I therefore adopted a candidate gene approach. A total of 154 genes 
associated with cancer cachexia were identified and explored for associated 
polymorphisms. Of these 154 genes, 119 had a combined total of 281 polymorphisms 
with functional and/or clinical significance in terms of cachexia associated with them. 
Of these, 80 polymorphisms (in 51 genes) were replicated in more than one study 
with 24 polymorphisms found to influence two or more hallmarks of cachexia (i.e. 
inflammation, loss of fat mass and/or lean mass and reduced survival). Such election 
of candidate genes and polymorphisms is a key element of multigene study design. 
The systematic review provides a contemporary basis to select genes and/or 
polymorphisms for further association studies in cancer cachexia, and to develop their 
potential as susceptibility biomarkers of cachexia. 
 
Phenotype – genotype associations 
A total of 1276 patients were recruited, phenotyped and genotyped. There were 545 
new patients and 731 patients from a previous study. In our new cohort and in keeping 
with the previous literature, patients who carried the C allele of the rs6136 SNP in the 
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SELP gene, were at a reduced risk of developing cachexia defined by WL. This 
association applied to all degrees of weight loss (>5%, >10% or >15%), and not just 
at the >10% level as described previously in the literature.  
When examining newly identified SNPs in a stage 1 analysis for the weight loss 
phenotype that included 1276 cancer patients, twelve new candidate SNPs were 
significant. Six of these SNPs are associated with muscle metabolism in five genes 
(IGF1, CPN1, FOXO1, FOXO3, and ACVR2B), three are associated with adipose 
tissue metabolism in two genes (LEPR and TOMM40 (APOE on the reverse strand)), 
two with corticosteroid signalling in one gene (IFT172 (GCKR on the reverse strand)) 
and one with the immune response in one gene (TLR4). Two polymorphisms 
(rs1935949 and rs4946935) in the gene encoding for FOXO3 were consistently 
associated with WL of increasing severity (>5% and >10%). On the basis that WL is 
a continuum in the cachectic process, the observation that both SELP and FOXO3 
associate with the higher degrees of WL suggests that these genetic signatures may 
be of particular significance. The role of P-selectin in the genesis of cachexia remains 
to be determined.  
When examining all SNPs in a stage 1 analysis for the LM phenotype, 5 SNPs were 
associated significantly with the cachexia phenotype: (i) rs4291 in the angiotensin 
converting enzyme (ACE) gene in chromosome 17; this gene has been associated 
with muscle function and metabolism; (ii) rs10636 in chromosome 16 in the 
metallothionein 2a gene; this gene has been shown to be involved in zinc 
dyshomeostasis which may contribute to cancer cachexia; (iii) rs1190584 in 
chromosome 14 in the WDR20 gene; this gene encodes a WD repeat-containing 
protein that functions to preserve and regulate the activity of the USP12-UAF1 
deubiquitinating enzyme complex; (iv) rs3856806 in the peroxisome proliferator-
activated receptor gamma (PPARG) gene in chromosome 3 which has been 
demonstrated to be involved in fatty acid and glucose metabolism; and (v) rs3745012 
in chromosome 18 in the lipin 2 (LPIN2) gene; this gene represents a candidate gene 
for human lipodystrophy, characterised by loss of body fat, fatty liver, 
hypertriglyceridemia, and insulin resistance. 
When examining all SNPs in a stage 1 analysis for the LM +>2%WL phenotype 4 
SNPs were associated significantly with the cachexia phenotype. rs12409877 in the 
leptin receptor (LEPR) located on chromosome 3, LEPR binds leptin and is involved 
in adipose tissue regulation. rs2268757 located in the activin receptor type-2B 
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(ACVR2B) gene on chromosome 3, ACVR2B is a high affinity activin type 2 receptor 
which mediates signalling by a subset of TGF-β family ligands including myostatin, 
activin, GDF11 and others. SNPs in the tumour necrosis factor (TNF) (rs1799964) 
and ACE (rs4291) genes were also significantly associated with the phenotype.  
Whether genes demonstrating significant associations with the cachexia phenotypes 
had altered transcript expression in muscle from cancer patients with or without those 
phenotypes was also investigated. Expression of ACVR2B, FOXO1 and 3, LEPR, 
PPARG, TLR4, and TOMM40 transcripts was significantly associated with different 
levels of skeletal muscle index (SMI) or WL (P<0.05). Specifically, these were all 
negatively correlated with muscularity. FOXO1 and 3 and TOMM40 were the only 
genes significantly correlated with WL; these were correlated negatively with WL. 
Of the SNPs found to be significant across the range of phenotypes the majority are 
exons falling within coding sequences of genes or non-coding regions of genes. Some 
are introns in the intergenic regions between genes. SNPs may exert differing effects 
on genes leading to an aberrant gene product. Polymorphisms in promoter regions 
potentially contribute to differential gene expression, presumably affecting the binding 
of transcription factors to DNA.  Sequence variation in the 5’ untranslated region 
(UTR) could disrupt mRNA translation; mutations in the 3’ UTR could affect mRNA 
through post-transcriptional mechanisms such as splicing, maturation, stability and 
export. Polymorphisms in intronic regions may result in cis- or trans regulation of 
genes, unmask cryptic splice sites or promoters leading to alternative transcripts. 
Synonymous and non-synonymous SNPs in exons could alter protein function or 
activity and may introduce codon bias contributing to the relative abundance of the 
proteins, respectively, finally non sense mutations cause a stop altogether in the 
translation of mRNA. The genomic distribution of SNPs is not homogenous, SNPs 
usually occur in non-coding regions more frequently than in coding regions or, in 
general, where natural selection is acting and fixating the allele of the SNP that 
constitutes the most favourable genetic adaptation. It has been estimated that 10% of 
all SNPs in the genome are functional, thereby having the potential of altering some 
biological process. Whether altering function directly or potentially indirectly all could 
possibly be used as biomarkers of predisposition to develop cancer cachexia. 
The studies presented in this thesis identify new diagnostic criteria that identify 
patients with evidence of muscle atrophy. They also confirm previous associations 
with patients who carry the C allele of the rs6136 SNP in the SELP gene are at a 
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reduced risk of developing cachexia defined by WL and beg the question as to the 
role of this molecule in cachexia. Whilst achieving these outcomes this thesis also 
identifies a set of new SNPs that associate with the phenotype which is shown to 



































Cachexia (from Greek kakos "bad" and hexis "condition") or wasting syndrome is loss 
of weight, muscle atrophy, fatigue, weakness, and significant loss of appetite in 
someone who is not actively trying to lose weight. Cachexia has been known and 
observed for centuries. Hippocrates wrote that “the flesh is consumed and becomes 
water, the abdomen fills with water, the feet and legs swell, the shoulders, clavicles, 
chest, and thighs melt away. The illness is fatal.” (1). 
Weight loss in cancer patients is due to depletion of both adipose tissue and skeletal 
muscle mass, while the non-muscle protein compartment is relatively preserved, 
therefore distinguishing cachexia from simple starvation (2). Cachexia occurs in 
number of chronic diseases such as cancer, chronic obstructive pulmonary disease 
(COPD), chronic heart failure (CHF), and chronic kidney disease (CKD). It is 
associated with reduced response to therapies and ultimately accelerated death. 
Cachexia also impairs quality of life (QoL) and is a significant cause of morbidity and 
mortality (3). 
 
1.2 Definition of cachexia 
Weight loss is significantly associated with cancer morbidity and mortality (4, 5). 
Cachexia affects the majority of patients with advanced cancer and is associated with 
a reduction in treatment tolerance, disease response to therapy, quality of life and 
duration of survival. Cancer cachexia has been defined in a number of ways (6-10). 
However, one recent definition described cancer cachexia as a multifactorial 
syndrome characterised by an ongoing loss of skeletal muscle mass (with or without 
loss of fat mass) that cannot be fully reversed by conventional nutritional support and 
leads to progressive functional impairment. The pathophysiology is characterised by 
a negative protein and energy balance driven by a variable combination of reduced 
food intake and abnormal metabolism (11). 
Skeletal muscle loss appears to be the most significant event in cachexia and is 
associated with a poor outcome (11, 12). Death normally ensues when weight loss 
exceeds 30% (13). It is thought that more than 30% of cancer patients die due to 
cachexia; that more than 50% of cancer patients die with cachexia being present; and 
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that the overall mortality rate of patients with cancer cachexia reaches up to 80% (14) 
(15). Whilst malnutrition is reversible when adequate amounts of food are provided, 
cachexia is not fully treatable by this approach. Indeed, cachectic patients usually 
present with progressive weight loss along with body composition alterations and 
disturbed homeostasis of many body systems, particularly fat tissue and muscle (13, 
16).  
Systemic inflammation is thought to play an important role in the development of 
cancer cachexia. Weight loss, muscle atrophy and anorexia have been related, at 
least in part, to the effects of systemic inflammation (17, 18). C-reactive protein (CRP) 
is a good surrogate marker of a pro-inflammatory response and has been used to 
define patients with varying degrees of cachexia (19) (20). The use of CRP has been 
further verified as it is associated with a poorer prognosis in patients with cancer (21). 
Markers of systemic inflammation such as CRP have been included in a proposed 
composite definition of cachexia(22). 
 
1.3 Epidemiology of cancer cachexia 
By assessing the degree of weight loss, the incidence of cancer cachexia can be 
determined. It has been observed that half of all cancer patients experience weight 
loss and one-third lose more than 5% of their original body weight (23). The most 
complete study to date was performed in 1980 by Dewys and the Eastern Co-
operative Oncology Group (ECOG). It studied the prevalence and prognosis of weight 
loss in cancer patients who had not yet received chemotherapy (23). The incidence 
and degree of weight loss over the previous 6 months was recorded in a variety of 
tumours (Table 1.1). It was observed that the prevalence of weight loss in each tumour 
type also correlated with magnitude of weight loss.  
Of all the cancers observed, patients suffering with Upper GI (gastric and pancreatic) 
cancer had a high degree of weight loss. Weight loss in pancreatic cancer patients 
was only analysed over the preceding 2 months, adding further evidence that 
pancreatic cancer is particularly severe at causing cancer cachexia. Another study 
demonstrated that 85% of pancreatic cancer patients had lost a median of 14% of 
their premorbid stable weight at diagnosis and up to 25% at or near time of death (24). 
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Over this period, LBM fell from 43.4kg to 40.1kg and adipose mass decreased from 
12.5kg to 9.6kg (24).  
Patients with lung cancer also experience a high degree of cancer associated 
cachexia. Weight loss at presentation was reported by 59%, 58% and 76% of patients 
with small cell lung cancer (SCLC), unresectable NSCLC and mesothelioma 
respectively (25).  
Head and neck cancers are another group of patents who experience marked and 
severe weight loss. Prior to treatment it has been shown that 57% of head and neck 
cancer patients had lost approximately 10% of their premorbid body weight (26).  
The wide variation in weight loss found in the study by Dewys highlights both the 
importance of the cancer type but also the host’s response in determining the amount 
of weight loss any individual may or may not experience. Table 1.1 demonstrates the 
varying severity of weight loss experienced by having different types of cancer, it also 
demonstrates there are a certain percentage of patients suffering from similar cancers 
who do not experience weight loss. Part of the variation in who will and who will not 
develop cancer cachexia may be genetically determined and the work in the present 




Weight loss in the previous 6 
months % 
Percentage of 
patients with any 
weight loss 
Percentage of 
patients with no 
weight loss 
0-5 5-10 >10 
Gastric cancer 20 29 38 87 13 
Pancreatic cancer* 29 28 26 83 17 
Non-small cell lung cancer 25 21 15 61 39 
Small cell lung cancer 23 20 14 57 43 
Prostate cancer 28 18 10 56 44 
Colon cancer 26 14 14 54 46 
Unfavourable non-Hodgkin’s lymphoma 20 13 15 48 52 
Sarcoma 21 11 7 40 60 
Acute non-lymphocytic leukaemia 27 8 4 39 61 
Breast cancer 22 8 6 36 64 
Favourable non-Hodgkin’s lymphoma 14 8 10 32 68 
 
Table 1.1 - Cancer types with the highest prevalence of cachexia.  
Upper GI (gastric and pancreatic) cancer and lung cancer patients, in particular, demonstrate a high prevalence of cachexia. Cachexia is 
defined as the presence of weight loss over the preceding 6 months *(2 months for patients with pancreatic cancer). Adapted from Dewys 
et al, 1980 (23). 
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1.4 Staging of cancer cachexia as a spectrum 
Cancer cachexia can be classified as a progressive condition with three stages of 
clinical relevance: pre-cachexia, cachexia, and refractory cachexia (11) Figure 1.1. 
Each case will be different with not all patients crossing the entire spectrum. Early 
clinical and metabolic signs can be seen in pre-cachexia (eg, anorexia and impaired 
glucose tolerance). These often precede substantial involuntary weight loss (ie, ≥5%). 
Determining which patients will progress is dependent on a number of factors: these 
include the cancer phenotype and stage; the patient’s genotype; the presence of 
systemic inflammation; low food intake; and lack of response to anticancer therapy. 
Recently, a panel of experts proposed diagnostic criteria for cancer cachexia as the 
following: patients who have more than 5% loss of stable body weight over the past 6 
months, or a body mass index (BMI) less than 20 kg/m2 and ongoing weight loss of 
more than 2%, or sarcopenia and ongoing weight loss of more than 2% (11). When 
considering the severity of cachexia, it is important to consider the proportion of 
skeletal muscle mass loss and the residual mass still present. For example, a fall of 
5 kg/m2 in BMI from an initial value of 22 has more severe implications for the patient 
than the same loss from an initial value of 35. Recently, a robust grading system 
incorporating the independent prognostic significance of both BMI and %WL has been 
developed (27). Furthermore, a patient with a BMI of 30 and a history of weight loss 
is more at risk if muscle wasting has occurred (sarcopenic obesity), and less at risk if 
muscle protein mass remains intact (28). The final stage, refractory cachexia, is a 
result of very advanced cancer (pre-terminal) or rapidly progressive cancer 
unresponsive to anticancer therapy. This stage is associated with the presence of 
patient factors (i.e. bed-rest and immobilisation) that render active management of 
weight loss no longer possible or appropriate. Refractory cachexia is characterised 
by a low performance status (WHO score 3 or 4) and a life expectancy of less than 3 
months. Artificial nutritional support becomes futile due to the unlikely benefits in 
outcome. Best supportive care is initiated and the interventions focus typically on 
alleviating the consequences and complications of cachexia—eg, symptom control 
(appetite stimulation, management of nausea or eating-related distress of patients 





Figure 1.1 - Stages of cancer cachexia  
Cachexia represents a spectrum through which not all patients will progress. At 
present there are no robust biomarkers to identify those pre-cachectic patients who 
are likely to progress further or the rate at which they will do so. Refractory cachexia 
is defined essentially on the basis of the patient’s clinical characteristics and 
circumstances. Adapted from Fearon et al, 2011 (11). BMI=body-mass index. 
 
 
1.5 Mechanisms of Tissue Loss 
1.5.1 Anorexia / decreased food intake 
Body mass is clearly sensitive to food intake. The pathogenesis of cancer anorexia is 
multifactorial and involves a variety of mechanisms controlling energy homeostasis. 
The main regulator of the cancer anorexia-cachexia syndrome involves alterations in 
brain neurochemistry. The hypothalamic melanocortin system does not respond 
appropriately to peripheral inputs, and its activity switches to the promotion of 
catabolic stimuli promoting metabolism of carbohydrates, lipids, and proteins in 
peripheral tissues leading to insulin resistance, increased lipolysis, and accelerated 
muscle proteolysis (13) (Figure 1.2). Pro-inflammatory cytokines and hypothalamic 
serotonergic neurons have been implicated in the dysfunction of the hypothalamic 
melanocortin system (29). There are two main pathways in the control of feeding 
behaviour: these are the orexigenic neuropeptide Y (NPY), and the anorexigenic (pro-
opiomelanocortin) POMC systems (30). Both originate in the hypothalamic arcuate 
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nucleus (ARC) and extend projections widely over the brain (30). They operate in 
conjunction with each other and are intrinsically linked. POMC neurons are the source 
of the potent melanocortin neuropeptides, such as - melanocyte-stimulating 
hormone (MSH), which, via interaction with the central MC3/4 - receptors, induce an 
anorectic state. The role of cytokines in cancer anorexia may be affected through 
influence on both the NPY and POMC systems. Hypothalamic IL-1 mRNA has been 
shown to be significantly increased in methylcholanthrene-induced sarcoma bearing 
rats (31). Levels of IL-1 in cerebrospinal fluid of the same rats are also increased and 
inversely correlate with energy intake (31). However, injection of an IL-1 receptor 
antagonist prevents anorexia in the same model (32). In another experimental animal 
system, injection of IL-1β into the hypothalamus within hours causes significant 
change in gene expression in skeletal muscle including up regulation of the ubiquitin 
proteasome pathway (UPP). This clearly demonstrates the potential for neural control 
of muscle protein synthesis and degradation (33). This mechanism has not been fully 
explored in cancer cachexia.   
Anorexia is a contributor to the weight loss seen in cancer cachexia. Decreased food 
intake may also result from a number of secondary clinical factors such as 
disturbances in taste; side effects of chemo / radiotherapy, intestinal obstruction, early 
satiety, depression, pain, stomatitis, constipation, dyspnoea, and poor dietary habits. 
Decreased food intake is a common clinical manifestation of cancer occurring in 15% 
- 40% of patients upon presentation, and rising to nearer 80% in patients with 
metastatic disease (23). Secondary causes of impaired food intake should be 







Figure 1.2 – Integrative physiology of cancer cachexia. The cancer is able to activate 
pro inflammatory, acute phase, and neuro - endocrine responses. The consequences 
are reduced food intake, and altered protein metabolism.  
 
 
1.5.2 Increased energy expenditure  
There are now many ways to treat cancer involving a mix of surgical options and new 
systemic anti-tumour therapy. To enable tolerance of such treatments, patients have 
to maintain an adequate energy and protein balance. Total energy expenditure (TEE) 
is comprised of resting energy expenditure (REE), diet-induced energy expenditure 
(DEE), and the energy cost of physical activity (AEE). Approximately half of cancer 
patients are hypermetabolic, and weight-stable patients tend to have a lower REE 
(34). In patients with increased levels of inflammatory cytokines, resting energy 
expenditure (REE) was found to be significantly higher (35). These cytokines cause 
a cascade of cellular signalling which potentiates the acute phase response (APR). 
The mediators of the APR initiate a signalling cascade in the in liver altering protein 
synthesis, which shifts from production of albumin to acute phase proteins (APP), 
such as C-reactive protein (CRP), fibrinogen, serum amyloid A, and α-1 antitrypsin, 
in response to an insult such as inflammation. Hypoalbuminaemia is a key clinical 
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feature of cancer cachexia. The mechanisms by which this is thought to happen are 
an increase in the synthesis of positive reactants (36) coupled with an increased 
transcapillary escape rate for albumin (37). During periods of inflammation/injury the 
metabolic response of the body is to prioritise hepatic export protein synthesis by 
mobilising protein from skeletal muscle stores. The amino acids available from 
skeletal muscle breakdown differ from those that constitute acute phase proteins and 
therefore this may increase the need for degradation of skeletal muscle especially in 
times of low food intake (38). This is how an APR may contribute to excessive muscle 
wasting in semi staving, anorexic cancer patients.  
The APR is thought to be mainly regulated by IL-6. The APR is linked to the loss of 
body mass in patients with lung and gastrointestinal cancer (39), and in patients with 
non- small cell lung cancer (NSCLC), serum levels of IL-6 were found to correlate with 
concentrations of circulating CRP (40). Hypermetabolism has been shown to be 
related to systemic inflammation (35) and or the presence of an elevated adrenergic 
state (41). Both of these are controlled centrally via pathways such as the 
melanocortin type 4 receptor (42).  
Futile substrate cycles may also contribute to hypermetabolism. Despite adequate 
oxygen supply, most cancer cells use glycolysis as the principal method to generate 
ATP, and this phenomenon is called the Warburg effect (43). Such high glucose 
turnover, is useful in clinical practice as it forms the basis of deoxyglucose positron 
emission transition (PET) scanning to detect local or advanced disease. Increased 
glucose uptake and glycolysis has been ascribed to overexpression of various 
oncogenes (e.g., c-Myc, Ras, Akt), or loss of tumour suppressors (p53 and Vhl) (44, 
45), abnormal mitochondrial function (46), overexpression of type II hexokinase due 
to gene demethylation (47), or the hypoxic environment of the tumour and hypoxia-
inducible factor 1 effects on glucose metabolism. The Cori cycle converts excess 
lactate produced by the tumour to glucose in the liver via pathways that lead to 
increased consumption of ATP. Cori cycle activity in weight-losing cancer patients has 
been studied and shown to be upregulated (48), however, there is a poor correlation 
between tumour burden and an increased lactate production (49). Overall 
consumption of glucose via gluconeogenesis and glycogenolysis has been shown to 
be increased in weight-losing cancer patients (50) and it has been suggested that this 
may be responsible for 40% of the increase in energy expenditure in metastatic 
cancer patients (51).  
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Brown adipose tissue (BAT) activation is thought to occur in the cachexic process and 
contribute to hypermetabolism. Adaptive thermogenesis is a unique process whereby 
increased expression of UCP 1 in the mitochondria of BAT leads to dissipation of the 
proton gradient so that oxygen consumption is no longer coupled to ATP synthesis 
and heat is generated resulting in a hypermetabolic state (52, 53). F-
fluorodeoxyglucose (18F-FDG) PET-CT led to the idea that BAT activity was increased 
in patients with cancer. The existence of functional BAT was discovered by studying 
areas of increased metabolism and glucose uptake with 18FDG on the PET in areas 
that were unmistakably fat tissue on the basis of Hounsfield units on the CT (54). FDG 
specifically accumulates in BAT in proportion to the expression of UCP1 that is an 
exclusive constituent of BAT (55, 56) and BAT activity as assessed by the uptake of 
18F-FDG is positively correlated to a cold-induced rise in energy expenditure (57). It 
has been shown that levels of BAT are greatly reduced in obese individuals (53), this 
coupled with the idea that BAT contributes to increased levels of energy expenditure 
has lead it to be a target for the treatment of obesity (58). With regards to its influence 
in cancer cachexia, three retrospective studies addressed a possible relationship of 
BAT 18F-FDG activity with cancer, however none of these observed a higher incidence 
of BAT activity in active and/or PET-positive cancer patients (55, 59, 60). Another 
study assessed BAT activity from guanosine diphosphate (GDP) binding to 
mitochondria prepared from perioperative samples. This was found to be elevated in 
children with malignancy compared with a control group undergoing renal surgery 
(61). A further study showed that cancer patients had higher metabolic activity of 
identified BAT on FDG-PET. More active neoplastic status was associated with more 
vigorous activity of BAT (62). All these studies have focused on the glucose uptake 
contributing to BAT activity, however fatty acids contribute up to 90% of overall 
substrate use (63). One study in healthy individuals demonstrated increased uptake 
by BAT under cold-stressed conditions (64), no studies in cancer cachexia have to 
date been performed. To further explore the link between BAT and cancer cachexia, 
studies should focus on the question whether an abnormal thermoregulatory 
response exists in cancer cachexia, and the quantitative significance of BAT activity 





1.5.3 Other aspects of abnormal metabolism associated with 
cachexia 
1.5.3.1 Altered lipid metabolism 
Adipose tissue loss is seen at a greater rate in cancer cachexia than muscle loss (65). 
This is due to a combination of decreased food intake and increased inflammatory 
cytokines that either inhibit lipogenesis or promote lipolysis. Adipose tissue loss in 
cancer cachexia is thought to occur mainly as a result of increased lipolysis (66, 67). 
The triglyceride component of the lipid is broken down to form free fatty acids and 
glycerol, which are then released into the circulation. The main enzymes which 
process this breakdown are hormone sensitive lipase (HSL) and adipose triglyceride 
lipase (ATGL) (68). HSL, ATGL, plasma FFA, and glycerol all increase in patients 
suffering from cancer cachexia (67). The excess breakdown may be coupled with a 
decrease in lipogenesis, this leads to a net decrease of adipose tissue resulting in the 
observed overall loss. 
 
1.5.3.2 Altered protein metabolism 
Although there is depletion of both adipose tissue and lean body mass, it is skeletal 
muscle loss that has the greatest impact on patients and is associated with a poor 
outcome (11, 12, 69). In healthy adults, skeletal muscle mass is maintained by 
nutritional intake and physical activity, reflecting a dynamic balance between protein 
synthesis and degradation.  A predominance of either will result in muscle hypertrophy 
or atrophy.  Even small changes in protein synthesis or degradation will lead to large 
protein deficits over time due to the continuous process of protein turnover. The 
myofibril is the base unit of muscle comprising thick (predominantly myosin) and thin 
(predominantly actin) filaments.  Myofibrillar proteins account for more than 50% of 
protein in skeletal muscle and are integral to muscle contraction and function. The 
preservation or loss of these proteins will dictate the clinical symptoms and there is 
some evidence that they are targeted selectively in cancer cachexia (70, 71). 
 
1.5.3.3 Muscle protein kinetics in the healthy adult 
Insulin is the most important endocrine factor controlling skeletal muscle protein 
synthesis in the active, well-fed, healthy adult. Reduced peripheral insulin sensitivity 
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is described in terms of reduced glucose clearance by peripheral tissues, 
predominantly skeletal muscle. Glucose uptake and amino acid uptake are both under 
insulin control and impaired muscle protein synthesis can accompany reduced insulin 
sensitivity. Normalisation of peripheral insulin sensitivity in subjects whom which it is 
reduced may improve skeletal muscle protein synthesis. 
 
1.5.3.4 Muscle protein kinetics in cancer cachexia 
In cachexia, there is ongoing debate as to whether a reduction in protein synthesis, 
an increase in protein degradation or a combination of both is more relevant. Although 
evidence continues to emerge, it would appear that many of the relevant pathways 
are influenced by the presence of systemic inflammation (21, 72, 73). Inflammatory-
mediated signalling may limit muscle protein synthesis by several mechanisms. TNF-
α can activate the transcription factor NF-kB, which inhibits the synthesis of the 
muscle specific transcription factor MyoD, thereby inhibiting differentiation (74), the 
TGF-β family members induce muscle wasting downstream of SMAD activation (75), 
and IL-6 activates signalling by binding to ligand-specific receptors either in soluble 
or membrane-bound forms to induce the signal transducers and activators of 
transcription-1 and -3 (STAT1/3), ERK and PI3K-AKT pathways (76, 77). The ERK 
pathway has been previously implicated in cancer cachexia and muscle wasting (78) 
and the AKT pathway is primarily responsible for anabolism in skeletal muscle (79). 
Recently a study used a novel technique to measure habitual myofibrillar protein 
synthesis in patients with cancer compared with healthy controls. Contrary to previous 
studies, there was no evidence of suppression of myofibrillar protein synthesis in 
patients with cancer cachexia. This finding implies a small increase in muscle 
breakdown may account for muscle wasting (80). 
 
1.5.3.5 Proteolytic pathways 
Many research groups have focused investigation on mechanisms responsible for 
skeletal muscle protein degradation in cancer cachexia. Although there are four 
mammalian proteolytic enzyme systems (the proteasome, lysosomal/autophagy 
pathway, caspases and calpains), it is the proteasome and lysosomal pathways which 
have received most attention.   
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The majority of signalling pathways contributing to muscle atrophy in pre-clinical 
models are mediated through activation of the ubiquitin-proteasome proteolytic 
pathway (UPP) (81, 82). The muscle-specific E3 ubiquitin ligases, MuRF-1 and 
MAFbx/atrogin-1 are up regulated in animal models of atrophy (83, 84), and MuRF1 
selectively targets the myofibrillar protein myosin heavy chain resulting in muscle 
wasting (70, 71). However, the role of the E3 ligases in human cachexia is less well 
defined. Studies including patients following bed rest, limb amputation for vascular 
disease, limb immobilisation, COPD, amyotrophic lateral sclerosis and ageing 
demonstrate both increased and decreased expression of MuRF1 and MAFBx (85-
88) and evidence for an increase in human cancer cachexia is lacking (89). There is 
also data that suggests dissociation between protein dynamics in vivo and activation 
of UPP signalling in human skeletal muscle (90).   
Upstream of the E3 ligases, the insulin regulated transcription factors FOXO1 and 
FOXO3a have been shown to increase expression of MuRF1 and MAFbx in animal 
models of cachexia (91, 92). Furthermore in both myotube and mouse models of 
muscle atrophy, several autophagy genes that are upregulated appear to be under 
control of FOXO3 (91-94), linking the autophagy and proteasomal systems. This 
makes the FOXO transcription factors attractive therapeutic targets and indeed, early 
evidence of FOXO inhibition in pre-clinical models is promising (95). 
In cancer patients there are few studies relating to the role of the autophagy pathway 
in muscle wasting. Increased cathepsin D and acid phosphatase activity has been 
demonstrated in patients with varying tumour types and degrees of weight loss (96) 
and lung cancer patients undergoing resection were shown to have increased levels 
of cathepsin B (97). Likewise, expression of the autophagy-related genes 
GABARAPL1 and BNIP3 has been associated with the presence of systemic 
inflammation and/or weight loss (89), suggesting a potential role in the development 
of human cancer cachexia. 
 
1.6 Mediators of Tissue Loss 
Cancer cachexia is brought about by a complex interaction between the tumour and 
the host’s mechanisms responsible for processes including; regulation of body 
composition (adipose and muscle mass), food intake, and energy expenditure. 
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Alterations in cytokine concentrations, neuroendocrine activation, and production of 
cachectic factors by the tumour lead to imbalances of these processes and promote 
cachexia resulting in a number of metabolic changes that are often characterized by 
negative energy balance, increased thermogenesis and anorexia (98) (Figure 1.3).  
 
 
Figure 1.3 - Proposed mediators and mechanisms implicated in cachexia 
 
1.6.1 Changes in muscle and adipose tissue mass 
1.6.1.1 Adipokines  
Adipose tissue, like skeletal muscle is an active metabolic and endocrine organ. A 
number of inflammatory cytokines secreted by adipose tissue have been shown with 
varying effect to influence the development of diseases such as insulin resistance, 
diabetes, and cancer cachexia by acting on muscle and fat metabolism. Adipokines, 
include IL-6, TNF-α, IL-1, leptin, zinc-α-2-glycoprotein (ZAG) [other name: Lipid 
Mobilising Factor (LMF)], and resistin (99). The catabolic effects of cytokines on 
adipose tissue triglyceride metabolism have been proposed as a contributor to the 
development of cachexia (100). 
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IL-6 secretion by adipose tissue appears to play a different role compared with its 
secretion by skeletal muscle (Figure 1.4). In adipose tissue, IL-6 has been shown to 
be up regulated in insulin resistant and obese patients (5). Visceral adipose tissue 
secretes more IL-6 than subcutaneous adipose tissue and is the main source of 
adipose tissue secreted IL-6. Higher concentrations of IL-6 in the obese population 
are thought to cause hepatic CRP production, a major risk index for cardiovascular 
disease (101). The IL-6 receptor signals via the JAK/STATs (Janus kinases/signal 
transducers and activators of transcription) signal transduction pathway. Downstream 
activation results in STAT phosphorylation and translocation to the nucleus to regulate 
genetic transcription (102). How IL-6 affects insulin action is not well established. 
However, it is widely accepted this adipokine is associated with insulin resistance in 
the obese patient (5, 103). Il-6 plays an established role in cancer cachexia, circulating 
levels of IL-6 have been shown to correlate with weight loss in cancer patients, and 
importantly, IL-6 levels correlate with reduced survival (104, 105). Gain- and loss-of-
function experiments in tumour bearing mice also support the requirement of IL-6 in 
regulating cachexia (106-108). 
TNF-α has been shown to play a role in both animal models and humans in insulin 
resistance (109). TNF-α has a bearing on lipid metabolism in cancer cachexia via the 
following ways. It regulates cholesterol metabolism and other adipocyte-derived 
adipokines, suppresses free fatty acid (FFA) uptake and promotion of lipogenesis, as 
well as inducing lipolysis. Finally it is able to inhibit lipid-metabolism-related enzyme 
activity (110). TNF-α has been shown to initially have a protective role to try and limit 
adipose tissue mass by stimulating lipolysis and decreasing LPL expression and 
activity (111). TNF-α also has a role in the inhibition of adipose hypertrophy (112) 
possibly via paracrine signalling. TNF-α plays an established role in cancer cachexia, 
it inhibits both adipocyte and skeletal myocyte differentiation (113, 114) and 
contributes to insulin resistance in part by impinging on the insulin signalling pathway 
(115). Addition of TNF-α is sufficient to promote atrophy in cultured myotubes, 
resulting from the induction of E3 ligase genes that mediate the breakdown of 
myofibrillar proteins by the ubiquitin- proteasome pathway (116-119).  
Leptin is produced by adipose tissue and acts on the hypothalamus to regulate the 
amount of energy stored in fat via its influence on appetite. There is little doubt this 
adipokine has a positive association with BMI (120, 121). Reduction of circulating 
leptin has also been markedly shown as a result of bariatric surgery (122). Studies of 
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leptin deficient mice (ob/ob), have demonstrated this adipokine is fundamental in the 
control of body weight and lipid metabolism (123). Experimental administration of 
leptin has been shown to reduce food intake and promote weight loss (124). 
Physiologically, leptin is thought to protect adipocytes from lipotoxicity by inhibiting 
lipogenesis and increasing fatty acid oxidation (124). These studies highlight the role 
of leptin in regulation of body weight. Furthermore, leptin deficient ob/ob mice have 
been shown to develop obesity due to lack of appetite suppression. Pathologically, 
leptin may also act as an adipokine potentiating the chronic inflammation seen in 
obesity and insulin resistance. Studies have shown hyperleptinemia is associated with 
a chronic inflammatory state in the non-obese (125). Although leptin reduces appetite, 
levels tend to be exceptionally high in the obese implying leptin resistance (126, 127).  
Adiponectin is produced by the adipocyte and has been shown to increase insulin 
sensitivity. Unlike other adipokines associated with chronic inflammation, adiponectin 
is inversely related to insulin resistance and BMI. It appears to have protective 
metabolic and anti-inflammatory properties (128). 
ZAG is involved in the specific mobilisation of adipose tissue and increased oxidation 
of released fatty acids (possibly via induction of uncoupling protein (UCP) 
expression). ZAG mobilises fat via the β3 – adrenergic receptor. It is produced by 
both host and certain tumours. Adipose tissue secretes large amounts of ZAG, and 
this is accelerated in patients with cancer cachexia and correlates with reported 
weight loss (129).  
 
1.6.1.2 Myokines  
Skeletal muscle, like adipose tissue is now widely viewed as an endocrine organ, with 
many studies demonstrating that cytokines produced by muscle fibres exert paracrine 
and endocrine effects; such cytokines (IL-6, IL-15, and TNF-α) have been labelled 
myokines (5) and exert metabolic effects on a number of other tissues including the 
liver and adipose tissue. 
IL-6 secretion via skeletal muscle has been shown to increase during exercise when 
insulin action is enhanced (Figure 1.4). It is proposed that IL-6 acts both locally via 
activation of AMPK in response to muscle contraction but also has endocrine 
functions. Intramuscular IL-6 expression is regulated by a network of signalling 
cascades that are likely to involve cross-talk between the Ca2+/NFAT and 
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glycogen/p38 MAPK pathways. Further studies suggest that IL-6 derived from muscle 
mediates anti-inflammatory effects and IL-6 can inhibit TNF production and stimulate 
synthesis of cytokine antagonists such as IL-1 receptor antagonist (IL-1ra) and IL-10 
(5). This may account for IL-6 being both primarily involved not only in local glucose 
uptake but also in adipose tissue lipolysis. IL-6 is widely known to act as both a pro 
and anti – inflammatory cytokine. This is determined mainly by concentration and 
which tissue it is acting on, whether muscle, adipose tissue or immune cell (130). In 
addition, a recent study found that skeletal muscle protein synthesis was dramatically 
reduced by relatively low-dose IL-6 infusion in humans (131).  
IL-15 is an important myokine in the regulation of skeletal muscle (132). IL-15 has a 
role in the differentiation of myocytes and the ability of muscle fibres to increase the 
density of contractile proteins (133). This is confirmed with mouse models where 
skeletal myoblast differentiation occurs under certain conditions in response to IL-15 
(134). Mechanisms include the transcription factor PPAR-ɣ activating protein 
synthesis (135). IL-15 has also been shown to regulate muscle mass in response to 
resistance exercise training in humans. A recent study proposed that IL-15 is 
predominantly expressed by MyHC II skeletal muscle fibres, and that resistance 
exercise regulates IL-15 expression in muscle (136) IL-15 mRNA level was enhanced 
in skeletal muscles dominated by MyHC II fibres and resistance exercise induced 
increased muscular IL-15 mRNA levels. IL-15 mRNA levels in skeletal muscle were 
not paralleled by similar changes in muscular IL-15 protein expression suggesting that 
muscle IL-15 may exist in a translationally inactive pool (136). IL-15 has also been 
proposed to play a role in the prevention of diabetes by modulating glucose uptake in 
skeletal muscle (137). A recent study analysed the effects of IL-15 on glucose 
metabolism in skeletal muscle. A single dose of IL-15 resulted in a significant increase 
in glucose uptake in human skeletal muscle, animal models, and in C2C12 cells (137). 
TNF-α, has been shown to be released by both adipose tissue and muscle. When 
acting on muscle, TNF-α has been shown to play a role in muscle protein degradation, 
it has also been shown to induce muscle cell apoptosis (138). TNF-α can activate the 
transcription factor NF-kB, which inhibits the synthesis of the muscle specific 
transcription factor MyoD, thereby inhibiting differentiation (74). Release of TNF-α 
may augment skeletal muscle insulin resistance as well as signalling and potentiating 
a similar response in adipose tissue. Preliminary reports have described marked 
elevations in myostatin (a negative regulator of muscle mass that inhibits myogenic 
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proliferation and differentiation) in cachectic cancer patients. Animal models suggest 
that the inflammatory cytokine TNF-α is at least partially responsible for increased 
myostatin (139). TNF-α is also known to negatively influence the anabolic mTOR 
signaling pathway, which is a major mediator of anabolic responses in skeletal muscle 
(140).  
Inflammatory stimulation activates pathways associated with muscle protein 
breakdown (141). In murine models of cancer cachexia, the ubiquitin proteasome 
pathway is greatly influenced (82). Many of these effects are thought to occur through 
activation of NF-kB by upstream factors such as TNF-α (142). NF-kB stimulates 
transcription of the ubiquitin E3 ligase muscle ring finger (MuRF)-1, which is known to 
positively regulate activity of the ubiquitin proteasome pathway (143). 
The interplay of anabolic and catabolic hormones has a distinct role in the 
development of skeletal muscle wasting. The catabolic molecules myostatin and 
activin are two members of the TGF-β superfamily that play an important role in 
growth and are thought to be responsible for the development of cachexia in mice 
(144). In mice, both molecules bind to activin receptor type-2B (ACVRIIB), a receptor 
in muscle, to initiate a signalling cascade leading to increased expression of MuRF1 
and MAFbx/Atrogin-1 and subsequent degradation of myofibrillar proteins (79). In 
mice bearing the C26 tumour, administration of a soluble ACVRIIB decoy receptor 
resulted not only in reversal of muscle wasting but an increase in survival (145).  
 
1.6.1.3 Adipose – muscle cross talk  
IL-6 has a different role to play in exercise compared with insulin resistance / diabetes. 
Chronically elevated IL-6 levels lead to inappropriate hyperinsulinaemia, reduced 
body mass, and impaired insulin – stimulated glucose uptake in skeletal muscle (146). 
Conversely, IL-6 knockout mice develop obesity and insulin resistance, providing 
evidence against a causative effect of IL-6 in insulin resistance (147). Clearly IL-6 has 
numerous roles to play depending on the clinical context, one proposal is that after 
the peak of IL-6 after exercise, baseline levels return to lower than original and muscle 
based receptors are down regulated (148). Thus changes in IL-6 levels appear to 
signify a change between a physiological response and a pathophysiological one.  
The myokine IL-15 is an anabolic factor involved in the development of skeletal 
muscle, it has also been shown to play a part in lipid metabolism (149). In a study by 
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Nielsen and co-workers, a negative association between IL-15 concentration and 
trunk fat mass, but not limb fat mass following exercise was observed. IL-15 secretion 
from muscle can reduce visceral fat without any change to muscle mass 
demonstrating a potent endocrine function (132). Argiles and co-workers have shown 
IL-15 acting not just on adipose tissue but on endothelial cells, the gastrointestinal 
tract, and the liver (150). IL-15 could have therapeutic roles in the treatment of a 
number of diseases. In obesity it has been shown to have an antiadipogenic effect 
and could be used to prevent lipogenesis. Animal models receiving IL-15 
demonstrated a 33% decrease of white adipose tissue mass. This is achieved through 
a reduction of lipogenesis coupled with a decreased uptake of VLDL triacylglycerol 
through lipoprotein lipase (LPL) (151). IL-15 facilitates glucose uptake by insulin 
sensitive tissues such as skeletal muscle (150). Argiles and co-workers propose a 
reciprocal control between adipose and skeletal muscle size. They propose that IL-
15 is released from skeletal muscle with the aim of controlling fat deposition and, thus, 
adipose tissue growth and mass. The anabolic effects of IL-15 have also been shown 
in animal models (151). In rats bearing the Yoshida AH-130 ascites hepatoma, IL-15 
treatment partly inhibited skeletal muscle wasting by decreasing protein degradation 
rates to values even lower than those observed in non-tumour-bearing animals. 
These alterations in protein breakdown rates were associated with an inhibition of the 
ATP-ubiquitin-dependent proteolytic pathway. This opens the potential for IL-15 to be 
used as a therapeutic in wasting diseases such as cancer cachexia.  
TNF-α has been shown to play a role in both animal models and humans with insulin 
resistance (109). TNF-α may initially have a protective role and limit adipose tissue 
mass by stimulating lipolysis and decreasing LPL expression and activity (111). TNF-
α also acts to inhibit adipose hypertrophy (112) possibly via paracrine signalling. This 
however, results in an increase in insulin resistance and prevents glucose entry into 
the cell, all mechanisms designed to prevent the adipocyte from accumulating 
substrates for energy storage. The role of TNF-α in obesity and insulin resistance 
remains poorly explained. TNF-α may well play a role in the inflammatory response 
to insulin resistance but secretion from other sources other than adipose tissue may 
be important. 
Leptin from adipose tissue is responsible for an increase in fatty acid (FA) oxidation 
and reduced esterification in resting rodent skeletal muscle (127). In the absence of 
leptin, obese human skeletal muscle demonstrates significantly elevated levels of 
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total FA uptake and enhanced rates of FA esterification into triacylglycerol compared 
with lean subjects (127). In the presence of leptin, lean muscle demonstrates elevated 
rates of endogenous and exogenous palmitate oxidation. Leptin also reduces the ratio 
of esterification to exogenous oxidation, demonstrating the increased partitioning of 
FA toward oxidation and away from storage. Contrary to these findings in lean muscle, 
leptin has no effect on FA metabolism in skeletal muscle of the obese. Thus, leptin 
increases FA oxidation in skeletal muscle of lean, but not obese humans, 
demonstrating the development of leptin resistance in obese human skeletal muscle 
(127). Leptin has a fundamental role to play in adipose tissue regulation both in health 
and disease, some of which influences skeletal muscle.   
Adiponectin induces fatty acid oxidation in skeletal muscle and reduced levels are 
associated with insulin resistance both in mice and humans (152, 153). The proposed 
mechanism centres around activation of AMP activated protein kinase (AMPK), which 
is known to regulate cellular malonyl CoA concentrations by inhibiting acetyl CoA 
carboxylase (154). Consequently there is a decrease in lipogenesis associated with 
increased mitochondrial fatty acid beta-oxidation. Adiponectin may also have a role 
in damping down the inflammatory effects of TNF-α, while TNF-α and IL-6 have a role 
in decreasing adiponectin levels (155) (Figure 1.4). 
Adipokines and myokines interact and play a complex role in insulin resistance, 
obesity, and the regulation of skeletal muscle. It would appear that regulation of any 
of these adipose – muscle derived cytokines has a direct effect on the others and the 
mass / composition of a variety of tissues in the body. Adipokines have a number of 
primary and secondary effects throughout the body; however, all seem to be 
associated directly or indirectly in regulating a chronic inflammatory state which 
influences insulin resistance and body composition. Adipokines may also have a role 
in pre-cachexia, cachexia and refractory cachexia states. Disruption in the normal 
physiology of fat metabolism in cancer plays a crucial role in distant organ signalling. 
On development of insulin resistance, other organs such as the liver, skeletal muscle, 
and the hypothalamus alter their responsiveness and change how they react to insulin 
(109). Therefore adipose tissue and skeletal muscle can be seen as a producer of 
cytokines, hormones, and lipids that signal these distant organs to regulate systemic 
metabolic homeostasis and metabolism. Therapeutic targets may be available to 
modulate this process. There is little doubt that adipokines and myokines are 
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intricately involved in adipose – muscle tissue cross talk both in normal physiology 
and pathophysiology. 
Factors such as zinc-α2-glycoprotein (ZAG, or otherwise known as lipid mobilizing 
factor) (156), known to degrade adipose tissue and proteolysis-inducing factor (PIF) 
(157) known to degrade muscle have been linked with weight loss in cancer patients 
(158), although the human form and mechanism of PIF in cancer cachexia has yet 
to be fully identified (159).   
 
 
Figure 1.4 - Adipose - muscle cross-talk. The main myokines and adipokines involved 
in the potential interactions are shown. Obesity and exercise represent opposite 
situations concerning expression of these molecules and thus different metabolic 
balance concerning fatty acid metabolism and insulin sensitivity. In cancer patients 
the secretion of the main cytokines leads to degradation of both adipose and muscle 






1.7 Fat loss 
The incidence of obesity and diabetes continues to increase worldwide. The obese 
patient is generating a new challenge in medicine and treatment. The physiology of 
obese patients differs remarkably from a normal weighted individual. Recently, 
patients suffering from advanced cancer have been found to be overweight rather 
than underweight (161). This has been shown to confound conventional 
measurements for risk stratification such as BMI. A recent study of pancreatic cancer 
patients has shown that severe muscle depletion when combined with obesity to be 
an independent adverse prognostic indicator in this patient group and should be 
considered as an alternative and more powerful means of risk stratification (12). It is, 
however, unclear how muscle depletion combined with overweight / obesity causes 
accelerated demise. The adipokines secreted by excess adipose tissue may act as 
systemic inflammatory mediators, inducing of insulin resistance in skeletal muscle and 
leading to a further increase in muscle protein loss. Increased lipolysis appears to be 
a key factor underlying fat loss, though decreases in lipid deposition and adipocyte 
development may also contribute (162). The balance between lipogenesis and 
lipolysis is integral to the net loss of adipose tissue in cancer cachexia and genes 
regulating this process may vary in different individuals, this is discussed further in 
Chapters 5 and 6.  
 
1.8 Muscle loss 
In healthy adults, skeletal muscle mass is maintained within relatively narrow limits, 
reflecting a dynamic balance between protein synthesis and degradation.  A 
predominance of either will result in muscle hypertrophy or atrophy.  Even small 
changes in protein synthesis or degradation will lead to large protein deficits over time 
due to the continuous process of protein turnover. In cancer cachexia, there is 
ongoing debate as to whether a reduction in protein synthesis, an increase in protein 
degradation or a combination of both is more relevant. Although there is depletion of 
both adipose tissue and lean body mass, it is skeletal muscle loss that has the 
greatest impact on patients’ function and quality of life and is clearly associated with 
a poor outcome (11, 12, 69). The balance between synthesis and degradation is 
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integral to the net loss of muscle tissue in cancer cachexia and genes regulating this 
process may vary in different individuals. The known morphology, mediators, and 
mechanisms involved in controlling muscle mass in cancer cachexia are discussed in 
detail throughout this thesis (Chapter 2) and for the first time a validated definition 
incorporating muscle mass (Chapter 4) is used in the discovery of SNPs in genes 
regulating these processes (Chapter 6). 
  
1.9 Biomarkers 
Refractory cancer cachexia is easy to identify, however, at such an advanced stage 
it is usually a pre terminal event and very difficult to treat. Early identification of 
patients at risk of cachexia and the institution of prophylactic measures to attenuate 
its progression is vital to patient survival and outcome. Biomarkers which are readily 
assessable in patients with cachexia need to be identified (Figure 1.5). Being able to 
predict who is at risk from developing cancer cachexia will help in diagnosis and 
provide a platform to assess novel therapies aimed at treating cancer cachexia.  
 




1.9.1 Plasma biomarkers of cachexia 
As mentioned previously, CRP is a robust marker of systemic inflammation in cancer 
patients and has been associated with the presence of anorexia, hypermetabolism, 
accelerated weight loss and shortened survival (163-165). The acute phase response 
itself has been implicated in the pathogenesis of cancer cachexia (22). The presence 
or absence of an APR as indexed by an elevated CRP has been incorporated into a 
three-factor mathematical definition of cachexia for patients with pancreatic cancer 
(22). Whilst the underlying process of inflammation seems to be a key factor in the 
progression of cancer cachexia, other cytokines have been studied as potential 
biomarkers (166-169). The latter however, have not shown the reproducibility of CRP, 
this may be due to the complex interplay of local versus systemic mediators of 
inflammation and the differing processes they initiate on varying tissues (as described 
in section 1.7.1). In relation to the neuroendocrine axis affecting food intake, insulin 
resistance and hypercortisolaemia have been documented in the cachectic cancer 
patient (170, 171). However, these have not been studied in detail in terms of the 
early cachectic process. Angiotensin II produces muscle catabolism and weight loss 
in murine models and such effects have been attenuated by angiotensin converting 
enzyme (ACE) inhibitors (172), this may represent a future biomarker for cancer 
cachexia. Lastly, leptin and ghrelin are implicated in the regulation of food intake (173, 
174). All these potential mediators represent targets for development of novel 
biomarkers to assess patients at risk from developing cancer cachexia. 
 
1.9.2 Muscle biomarkers of cachexia 
The main details of muscle biology in cancer cachexia are discussed in Chapter 2. 
Briefly, the molecular mechanisms surrounding muscle atrophy (UPP and autophagy 
pathway) or hypertrophy (mainly IGF-1 mediated signalling) have now been described 
in detail (18). Cancer cachexia leads to a complex alteration in these mechanisms 
and is likely to cause suppression of the hypertrophy pathways and upregulation of 
the atrophy pathways (175). The ubiquitin–proteasome pathway (UPP) is a catabolic 
pathway in cancer cachexia and in acute animal models seems to be the main 
pathway attributed to excess skeletal muscle wasting (82). The UPP has been 
documented in rodent models of cancer-associated muscle-wasting to be 
overactivated (81). Although this has been carried through to human research, it has 
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not been a consistent finding (176, 177). It is thought that the presence of systemic 
inflammation may lead to the over-activation of the UPP (178). Recent data have 
suggested that systemic inflammation may act in part through dysregulation of the 
dystrophin glycoprotein complex (DGC) (179). The DGC is a muscle-specific protein 
manifold that anchors muscle fibre membranes in place and prevents them from being 
torn by shear forces produced during muscle contraction. The dysregulation of DGC 
has been shown to correlate positively with weight loss in patients with 
gastrooesophageal adenocarcinoma (179). It remains, however, difficult to use 
skeletal muscle as an early biomarker as, at present, this would require percutaneous 
or open biopsy. 
 
1.9.3 Urinary markers of cancer cachexia 
Urine is also useful to both observe and to screen for potential biomarkers as it can 
be sampled very easily in a non-invasive way. Urine can also be collected in large 
quantities, is comparatively stable in terms of its molecular constituents, and has been 
shown to yield both metabolic (180, 181) and proteinaceous (182-184) discriminators 
in patients with pancreatic cancer. These ‘fingerprinting’ approaches have the 
advantage of predictive models with higher accuracy than single markers alone but 
their applicability in the clinical setting is still questionable due to technical issues. 
Multiplexing of various specific markers, e.g. the reported 810 antibody-panel (185), 
might provide a way forward, though economically this might be not feasible as a 
general screening tool. Single molecule identification of urinary markers in pancreatic 
cancer using mass spectrometry has yielded a number of interesting potential 
biomarkers (e.g. annexin A2, gelsolin, CD59 and S100A9) (182), though the utility of 
these markers is unknown due to a lack of further validation. However, independent 
studies have shown that some proteins such as S100A9 (186), CD59 (187) and 
gelsolin (188) are at least associated with cancer of the upper gastrointestinal tract or 
cultured pancreatic cells.  
Proteolysis-inducing factor was first identified as a glycosylated polypeptide using an 
antibody cloned from splenocytes of mice transplanted with the murine 
adenocarcinoma 16 (MAC16) tumour (189). This antibody bound to a 24kDa 
sulphated glycoprotein, which was also present in the urine of cachectic human 
cancer patients (189). A hybridoma was subsequently developed for the production 
of the antibody, for use in purification of PIF by affinity chromatography and for assay 
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of physiological samples. Immunoreactivity with the murine anti-PIF antibody has 
since been described in the urine of weight-losing patients with carcinoma of the 
pancreas, breast, ovary, lung, colon, rectum and liver (189). Patients with pancreatic 
cancer demonstrating PIF immunoreactivity in urine had a significantly greater total 
weight loss and rate of weight loss than patients whose urine did not (158). 
Furthermore, isolation of protein with PIF immunoreactivity from human urine induced 
muscle wasting when injected into mice (190). PIF is thought to induce muscle 
wasting via both increased degradation and decreased synthesis of muscle protein 
(191).  
Urine in particular has the potential to yield many more specific biomarkers due to its 
complexity to contain far more observable proteins than previously thought (LSSR 
database at www.PADB.org lists more than 5000 unique proteins), and identification 
of valid biomarkers and devising specific clinically-transferable detection methods 
might allow large-scale preventative/diagnostic as well as prognostic disease 
screening in the near future. 
 
1.9.4 Genetic biomarkers of cachexia  
Currently with all the available patient demographics and clinical risk factors for 
cachexia, it is not possible to predict who will develop cancer cachexia and who will 
not (Figure 1.6). Ultimately, with the advent of new biomarkers this may be possible, 
but even more important is the identification of the speed at which a patient develops 
the syndrome. It has been proposed such a variation may, in part, be due to the 
patient’s genotype rather than the tumour phenotype (Figure 1.6).  
Genetic association studies are one of the most common approaches to find genes 
involved in complex traits. The candidate gene approach to conducting genetic 
association studies focuses on associations between genetic variation within pre-
specified genes of interest and phenotypes or disease states. Association studies 
identify polymorphisms in which an allele occurring in the general population occurs 
at a different frequency in the disease group. In these instances, the disease 
associated allele does not cause the disease in the same way that a Mendelian 
mutation does, but increases susceptibility to the disease as a genetic risk factor, 
most likely in conjunction with other genetic and/or environmental risk factors.  
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Association studies can either be direct or indirect. In direct association studies, target 
polymorphisms which are themselves putative functional variants (for example a SNP 
variant in a gene at a codon that changes an amino acid) are genotyped in both the 
general (control) and also trait (disease) population. A statistically different frequency 
of the alleles and/or genotypes in the control population versus the disease group 
would suggest that the polymorphism in question has a direct effect on disease 
pathogenesis. However, it is likely that many causal variants contributing to complex 
disorders will be non-coding. These variants could include those that affect gene 
regulation, expression or alternative splicing and such functional variants are difficult 
to predict. For this reason, most association studies are indirect; where the 
polymorphisms genotyped in the control populations and trait populations are 
surrogates for the unknown causal locus.  
Identifying susceptibility genes for complex disorders by the indirect method depends 
on the existence of an association between the causal variants and surrounding 
polymorphisms nearby. This association is termed linkage disequilibrium (LD) and is 
defined as the non-random association of alleles at two or more loci and describes a 
situation in which correlation between nearby variants such that the alleles at 
neighbouring markers (observed on the same chromosome) are associated within a 
population more than if they were expected by chance. Candidate genes are most 
often selected for study based on a prior knowledge of the gene’s biological functional 
impact on the trait or disease in question. The rationale behind focusing on allelic 
variation in specific, biologically relevant regions of the genome is that certain 
mutations will directly impact the function of the gene in question, and lead to the 
phenotype or disease state being investigated.  
Suitable candidate genes are generally selected based on known biological, 
physiological, or functional relevance to the disease in question. This approach is 
limited by its reliance on existing knowledge about known or theoretical biology of 
disease. However, more recently developed molecular tools are allowing insight into 
disease mechanisms and pinpointing potential regions of interest in the genome. 
Genome-wide association studies and quantitative trait locus (QTL) mapping examine 
common variation across the entire genome, and as such can detect a new region of 
interest that is in or near a potential candidate gene. Microarray data allow 
researchers to examine differential gene expression between cases and controls, and 
can help pinpoint new potential genes of interest. In addition, the availability of genetic 
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information through online databases enables researchers to mine existing data and 
web-based resources for new candidate gene targets. Cancer cachexia is a 
multifactorial disease caused by the interplay of a number of different processes all 
driven by different genes which would make it highly suited to a candidate gene 
approach. However to identify a genetic predisposition or biomarker to cancer 
cachexia, an exhaustive review of known functional or influential polymorphisms 
involved in the causative processes is needed to conduct a candidate gene study.  
 
1.9.5 Candidate gene association analysis in cachexia  
The finding that only a proportion of patients with chronic disease develop cachexia 
has prompted studies looking for genetic polymorphisms that may underlie differential 
susceptibility (192) (Figure 1.6). The most frequent targets for these studies to date 
have been genes encoding pro-inflammatory cytokines, such as TNF-α and some of 
the interleukins. This is based on the hypothesis that continued systemic inflammation 
plays a central role to the pathogenesis of cachexia. However, as new pathways and 
genes evolve (specifically in muscle and adipose tissue biology) and phenotypic 
definitions continue to evolve, there is a need to re-strategise the selection of 
candidate genes to drive association studies.  
The case to support a genetic predisposition to cachexia is strengthened from the 
known genetic contribution to the activity of a variety of key mechanisms that underlie 
the cachexia syndrome. In a previous systematic review on the identification of 
possible genetic polymorphisms involved in cancer cachexia, a total of 184 
polymorphisms with functional or clinical relevance to cancer cachexia were identified 
in 92 candidate genes (193). Following this review, a candidate gene study identified 
23 significant SNPs associated with cachexia based on definitions of weight loss and 
systemic inflammation (as indexed with CRP), and a SNP in the SELP gene encoding 
for P – Selectin was validated in an independent cohort. P – selectin binds to 
leukocytes and in certain inflammatory conditions, the plasma concentration of 
soluble P – selectin is elevated (194). Most of the work on identification of SNPs 
involved in cancer cachexia to date has led to the discovery of other SNPs involved 
in the innate immune system, mainly in the interleukin family of cytokines (195-202) 
(Table 1.2). SNPs in other biological processes have also been studied for their 
association with cancer cachexia (203, 204) (205) (Table 1.2). By altering the 
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phenotype to include a degree of skeletal muscle quantification, it may be possible to 
identify SNPs associated with muscle tissue biology as altered in cancer cachexia.  
 
 
Figure 1.6 - In the post human genome era, one of the major goals of biology is to 
bridge successfully the gap between genotype and phenotype. This process of linking 
genotype and phenotype plays a crucial role in understanding the numerous and 
varied biological processes which contribute to overall cellular, tissue and organism 
responses, particularly within a disease state such as cancer cachexia. By identifying 
SNPs in the patients genotype it may be possible characterise any potential 
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more than 5% of body weight 
or weight loss of more than 2% 
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with a body mass index (BMI) 







N/A 1853 patients with 
cancer at different 
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VDR 43 patients with 
cancer from various 
sites and stages  
Guidelines for diagnosis of 
cancer associated cachexia 
provided by the Italian 




rs6136 SELP 775 patients with 
UGI and pancreatic 
cancers 
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(1) >5% Weight loss 
(2) >10% Weight loss 
(3) >15% Weight loss 
(4 – 6) The above with CRP 





N/A 1797 patients with 
cancer at different 
sites, stages and 
with different 
performance status 
 BMI: <20 kgm–2 
 Karnofsky score: <80 
 CRP: <10 mg l–1 
 Appetite loss: a response 
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EORTC QLQ-C30 item 
‘have you lacked 
appetite?’ 
>3 features = Severe cachexia 
2 or 3 features = Mild cachexia 
<2 = No cachexia 
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(208) 
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Jatoi 
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Table 1.2 - Published associations of genetic variants in cancer cachexia 
 
1.10 Clinical Consequences and Management 
of Cachexia 
 
1.10.1 Reduced physical performance 
The objective clinical consequences of cachexia are profound including shortened 
survival (23), impaired response to anti-cancer therapy (23), impaired immunity (210), 
reduced performance status (PS) (211), reduced physical activity (PA) (211) and 
worsened QoL (Figure 1.7). Depletion of skeletal muscle is the key component of 
weight loss that underpins many of the symptoms experienced by cachectic cancer 
patients. Muscle wasting leads to reduced exercise capacity and increased fatigue 
(212), which results in the lower PS scores, reduced PA and worsened QoL scores 
observed. It has been proposed that the response to muscle loss and function in 
cancer cachexia may be sexually diamorphic (213). In gastrointestinal cancer 
patients, it has been shown that there is variability in lower limb muscle function, 
mechanical quality and mass according to both the degree of weight loss and patient 
sex (213). While lower limb muscle mass, strength and power was shown to decline 
in male cancer patients, females appeared to experience attenuated loss of muscle 
mass and power. Mechanical quality was reduced in both male and female cancer 
patients, but only in females did it decline progressively with cachexia. These changes 
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lead to a significant reduction in patient’s quality of life. One proposed mechanism to 
account for sexual dimorphism may be to do with sex hormone production. It has been 
demonstrated that hypogonadism (low total and/or free testosterone levels) is 
associated with poorer survival in male cancer patients (214). It is also well 
established that low testosterone levels impact on muscle mass and function (214). 
Furthermore, testosterone replacement has been shown to prevent loss of muscle in 
ageing males (215). These findings are consistent with recent literature suggesting 
sexual dimorphism may impact on the effects of systemic disease such as cirrhosis 
(216) and must be considered when treating cachexia in clinical practice. Cachexia 
has a detrimental effect on a patient’s QoL. Patients with cancer cachexia report 
altered body image, which impacts their emotions, spirituality, relationships, and 
social functioning. Lives are restricted and isolated, which is compounded by 
emotional distancing by carers and healthcare professionals (217). These patients 
also experience anorexia and increased fatigue (22, 218). Overall, this results in 
decreased performance status and QoL indices (219). 
The devastating effect of cachexia is further characterized by considering the free-
living physical activity of patients. In a study examining patients using an electrical 
activity monitor worn over a period of 1 week, patients with cancer cachexia 






Figure 1.7 – Clinical features frequently associated with cancer cachexia 
 
Many other patient variables contribute to the heterogeneity of cancer cachexia such 
as age, co morbidity, stage of disease, treatment, and genetics. An individualised 
management plan can be based on the patient’s baseline characteristics and the 
mechanisms most likely to contribute to weight loss and their potential reversibility. 
Many cancer patients undergoing treatment are malnourished and a number of 
interventions such as chemotherapy and radiotherapy further exacerbate this. A multi-
professional and multimodal approach, including nutrition and physical activity 
interventions aimed at preventing or delaying cancer-related malnutrition has been 
suggested to be of key importance for the efficacy of the oncological therapies (220). 
A number of RCTs have also demonstrated adequate feeding via enteral or parenteral 
methods improve outcome and reduce the side effect profile of chemo / radiotherapy 
35 
 
and surgery (221, 222). Prevention of the anorexia component of cancer cachexia via 
adequate nutrition remains a primary goal in the treatment of cancer, but other 
mechanisms are at play that prevent primary nutrition reversing the weight loss. 
Exercise may help prevent anabolic resistance observed in older adults or in 
immobilised or chronically ill patients by encouraging muscle protein synthesis and 
anabolism. Proposed mechanisms whereby exercise may have these effects include 
improved amino acid sensitivity and (or) insulin sensitivity of muscle(223). Recent 
research has also demonstrated that immobilisation induces anabolic resistance in 
human myofibrillar protein synthesis with low and high dose amino acid infusion (224). 
Post-absorptive muscle protein synthesis is reduced in the muscle of an immobilised 
limb. It has been shown that suppressed muscle protein synthesis also extends to the 























1. Regardless of tumour type, host genetic variation contributes to the 
prevalence of cancer cachexia 
2. New biological mechanisms, new genes, and new signalling pathways are 
being discovered that may influence the course of cancer cachexia in general 
and cancer associated muscle atrophy in particular 
3. Genetic variants that associate with cancer cachexia may differ according to 
the phenotypic definition of cancer cachexia (especially in the presence or 
absence of muscle fibre atrophy) 
4. Skeletal muscle atrophy may not be clearly identified by the presence of 
weight loss and may be better identified by a combination of weight loss and 
low muscularity (identified on diagnostic CT scan) 
5. Gene expression in muscle may vary with pro-cachectic genotypes 
 
1.12 Aims 
1. To refine clinical identification of cancer patients with muscle fibre atrophy 
using a combination of self-reported weight loss and low muscularity 
(identified on diagnostic CT scan) as defined as per international consensus 
definition of cancer cachexia 
2. To undertake a systematic review to explore new genetic polymorphisms in 
potential candidate genes involved in the development of cancer cachexia  
3. To validate previous findings of genes associated with cancer cachexia as 
defined by weight loss alone 
4. To undertake genetic association studies assessing for susceptibility to 
cachexia as informed by the results of the systematic review and the presence 
of muscle fibre atrophy as defined by a combination of weight loss and low 
muscularity 
5. To look for evidence from the transcriptome in skeletal muscle of genes 






Weight loss has long been seen as the hallmark of cancer cachexia and the 
relationship between changes in total body weight over time and cancer outcomes 
are highly correlated. It is widely accepted that changes in body weight may involve 
any of its major tissue compartments (lean tissues, adipose tissues, and bone) and 
that within these compartments; there may be specific changes in the mass of 
individual organs and tissues. 
In Chapter 1, the rationale and background to a potential genetic predisposition to 
cancer cachexia is reviewed. Many of the current associations have been found 
exclusively in the genes regulating inflammation, however by incorporating skeletal 
muscle into the phenotype definition of cachexia and studying SNPs associated with 
altered muscle mass / function it may be possible to identify new targets by using an 
updated candidate gene list.  
With skeletal muscle being shown to be an increasingly important marker of outcome 
and survival and also being incorporated into a definition of cancer cachexia (11), 
Chapter 2 outlines the current knowledge of the mechanisms associated with changes 
in skeletal muscle composition from animal models and how these have been related 
to human models.  
Chapter 3 outlines the materials and methods involved in all the studies in the thesis.  
Chapter 4 investigates the changes in muscle fibre biology with regards to 
morphological structure and composition, the alterations in various pathways that may 
account for altered fibre size and relates these changes to the different clinical 
diagnostic criteria that have been proposed. 
Chapter 5 presents a contemporary review of the literature with regards to a greater 
understanding of the processes involved in cancer cachexia. To enable further 
candidate gene selection studies, new targets need to be identified in order to 
maximise the potential for associations. To accommodate the evolving phenotype 
definitions and the current state of the understanding of cachexia, candidate genes or 
pathways related to the biology of muscle, inflammation, adipose tissue, obesity, 
diabetes and molecular mechanisms of cancer in general, as well as factors affecting 




Chapter 6 utilised a candidate gene approach to evaluate the association between 
genetic polymorphisms and the presence of cancer cachexia in patients recruited 
across six centres. The primary objective of this study was to further replicate our 
findings from a previous association study which identified the SNP rs6136 in the 
SELP gene and a number of other polymorphisms as promising candidates 
influencing genetic predisposition to cachexia. The second objective was to explore 
the association with 92 predefined new candidate SNPs and WL. The third objective 
was to compare the entire panel of candidate SNPs and their association with LM with 
and without WL. Also investigated was whether genes demonstrating significant 
associations with the cachexia phenotypes had altered transcript expression in 
muscle from cancer patients with or without those phenotypes. 
Chapter 7 summarises and discusses the relevance of the work presented throughout 
the thesis. It also outlines the significance of the findings in relation to current work 



















Mechanisms and Mediators of 
Muscle Wasting in Animal 













Skeletal muscle loss appears to be the most significant clinical event in cancer 
cachexia. When considering how to phenotype cachexia for genetic association 
studies, muscle wasting is therefore a key domain. With regards to such muscle loss, 
despite extensive study in a range of models, there is ongoing debate as to whether 
a reduction in protein synthesis, an increase in degradation or a combination of both 
is the more relevant. Each model differs in terms of key mediators and the pathways 
activated in skeletal muscle. Certain models do suggest that decreased synthesis 
accompanied by enhanced protein degradation via the ubiquitin proteasome pathway 
(UPP) is important. Murine models tend to involve rapid development of cachexia and 
may represent more acute muscle atrophy rather than the chronic wasting observed 
in humans. There is a paucity of human data both at a basic descriptive level and at 
a molecular / mechanism level. Progress in treating the human form of cancer 
cachexia can only move forwards through carefully designed large randomised 




Weight loss in cancer patients is associated with excess morbidity and mortality (4, 
5). Cachexia affects the majority of patients with advanced cancer and is associated 
with a reduction in treatment tolerance, response to therapy, quality of life and 
duration of survival. Cancer cachexia has recently been defined as a multifactorial 
syndrome characterised by an ongoing loss of skeletal muscle mass (with or without 
loss of fat mass) that cannot be fully reversed by conventional nutritional support and 
leads to progressive functional impairment (11). Although there is depletion of both 
adipose tissue and lean body mass, it is skeletal muscle loss that has the greatest 
impact on patients’ function and quality of life and is clearly associated with a poor 






Heterogeneity both in clinical and animal models is one of the key issues that has 
impaired research into cancer cachexia. Cachexia is not a single phenomenon but 
evolves through a spectrum of pre cachexia, cachexia, and refractory cachexia (11). 
The incidence and severity of cachexia can vary according to tumour type, site, and 
mass (23) as well as the individual host response. Equally, the contribution of reduced 
food intake versus abnormal metabolism can vary considerably (225). The 
components of such abnormal metabolism also vary, and within the same model / 
individual can evolve with time such that hypermetabolism (226) or activation of 
proteolytic pathways (227) occurs during the early phase of cachexia but not during a 
more advanced phase. In humans the cause of such heterogeneity relates not only to 
the clinical status of the patient and specific effects of the tumour (e.g. causing bowel 
obstruction, tissue destruction or concomitant infection) but also to co-existing 
morbidities (e.g. heart failure, chronic renal failure, or chronic obstructive pulmonary 
disease), age-related sarcopenia and the possibility of a genetic predisposition to 





Figure 2.1 – Heterogeneity in cancer cachexia. Weight loss is the key diagnostic 
criteria for the presence of cancer cachexia. In turn, weight loss may be due to loss 
of fat and / or lean tissue. Skeletal muscle is a major component of lean body mass 
and represents the main labile protein reserve in the body. Many factors influence the 
extent to which fat or skeletal muscle is lost in cancer patients.  
 
There are numerous animal models of cancer cachexia. A recent review concluded 
that for research into cancer cachexia where there is little evidence of systemic 
inflammation, the murine adenocarcinoma 16 mouse (MAC-16) and XK1 murine 
tumour models are useful (228). Weight loss in mice bearing the MAC-16 tumour 
appears to be independent of reduced food intake or inflammation (228). In contrast 
the XK1 model demonstrates reduced food intake. All other models induce a host 
inflammatory response. In the Walker 256 and MCG - 101 models tumour growth is 
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extremely rapid resulting in a tumour mass exceeding 10% of host body weight in a 
matter of days (228). This highlights the problems with the translational value of 
relatively acute onset cancer cachexia seen in murine models compared with humans 
where a cancer may spread over a period of months or years (with similar time scale 
for the evolution of cachexia). One of the most popular models at present is a 
particular clone of the colon-26 adenocarcinoma (C26) tumour in mice. This is thought 
to be a mainly IL-6 dependant model of cachexia (107). Whether, in fact, this can be 
considered as representative of the majority of cancer patients remains highly 
speculative.  
 
2.4 Skeletal muscle morphology in cancer-
associated myopenia: murine models 
Skeletal muscle is composed of muscle fibres which are classified according to their 
speed of contraction and predominant type of energy metabolism. Muscle fibres can 
be classified as type I, slow-twitch and type II, fast-twitch fibres based on their 
predominant myosin heavy chain (MyHC) isoform content. Generally, type I and type 
IIa fibres utilise oxidative phosphorylation as their energy source, whereas type IIx 
and IIb fibers harness anaerobic metabolism to generate ATP (229, 230). Both the 
percentage and structural morphology of the fibre type will determine the phenotypic 
capacity and functional performance of any given muscle. Environmental factors in 
both health and disease have a direct impact on muscles leading to changes in fibre 
type and morphology which lead to changes in muscle functionality; such processes 
include aging, exercise, diabetes, disuse atrophy, chronic heart failure, and cachexia 
(231-244). The change, preservation or loss of fibres may influence clinical symptoms 
and there is some evidence that fibre type is targeted selectively in cancer cachexia 
(70, 71). Ongoing loss of protein in muscle tissue leads to muscle fibre shrinkage and 
a reduction in CSA. This loss of CSA leads to the main muscle groups in the body 
undergoing changes in fibre composition which leads to a marked loss of aerobic 





2.4.1 Fibre size and type in cancer associated myopenia 
The model that has been most frequently studied is the C26 tumour grown 
subcutaneously in mice (Table 2.1). The predominant muscles studied include the 
gastrocnemius and soleus from the lower limb. Unlike humans, no model uses old, 
co-morbid mice undergoing concomitant anticancer therapy! A common finding is a 
decrease in fibre size.  With regards to fibre type, evidence from animal models 
suggests that type II fibres are targeted selectively (179) with relative preservation of 
type I fibres in fasting (249), exposure to Glucocorticoids (250, 251), sepsis (252) and 
in the gastrocnemius muscle of the C26 model of cancer cachexia (253).  Not all 
studies have demonstrated type 1 and 2 fibre differences. Indeed, in a recent 
exposition of the C26 cachectic mouse model, both glycolytic and oxidative fibres of 
(extensor digitorum longus) EDL muscle underwent wasting (254), whilst in a previous 
study using the same mouse model there was a significant increase in the amount of 
type 2b MyHC and a significant decrease in the amount of type 1 MyHC in soleus 
muscle (255).  
The activity patterns of muscle are also key in determining phenotype. If muscle cells 
are recruited infrequently, they develop into fast/glycolytic units whereas if they are 
recruited more often, they form slow/oxidative units.  In the C26 mouse model of 
cancer cachexia, there have been reports of switching of myosin isoforms in the 























Table 2.1 – Experimental animal data on myosin composition of muscles in cancer 
cachexia 
 
2.4.2 Fibre RNA, DNA, and protein content in cancer associated 
myopenia 
A reduction in total RNA content has been associated with a depression in protein 
synthesis in mice bearing the human hypernephroma XK1 (256) and in mice bearing 
the MAC-16 tumour (257). Timing of sampling may be important in the results 
obtained from such muscle biopsies. A reduction in the RNA content in the muscle of 
mice bearing the Ehrlich ascites tumour has also been reported, but this occurred 
later than the onset of depressed protein synthesis (258). 
Protein content expressed in relation to wet weight of muscle has been shown to 
decrease progressively (in excess of 50%) in the gastrocnemius muscle of mice 
bearing the MAC-16 tumour (257). Similar changes have been documented in the 
Yoshida ascites hepatoma A130 cachexia model (259). This suggests that not only is 
there loss of fibre diameter, but that the quality of the fibre is altered with loss of either 
sarcoplasmic or myofibrillar protein. DNA content of the gastrocnemius muscle has 
been shown to remain relatively constant, despite the finding of a decrease in protein 
















































and RNA content (257). Clearly not all DNA in a muscle can be ascribed to myonuclei. 
However, these findings are consistent with the trend towards fibre cytoplasmic 
atrophy without a decrease in myonuclear number observed in mature mice that 
undergo long term denervation injury (260).  The issue of whether nuclear domain 
size is reduced in cancer cachexia remains to be resolved. In particular, whether 
apoptosis in skeletal muscle is increased in cancer cachexia (261) and the degree to 
which DNA content is maintained or not via a compensatory increase in myonuclear 
number (possibly via satellite cell nuclei incorporation) is not known. Features of 
cachexia such as hypogonadism (resulting in low testosterone) or systemic 
inflammation (associated with high IL-6) could influence such regenerative capacity.  
 
2.4.3 Dystrophin glycoprotein complex (DGC) 
It is also important to recognise that in cancer cachexia there may be changes in the 
muscle cytoskeleton as well as in the myofibrillar contractile apparatus. In recent 
years, it has been demonstrated that alterations in the muscular dystrophy-associated 
DGC also occur in skeletal muscle (179). Using both the C26 and Lewis lung 
carcinoma (LLC) murine cancer models, it was shown that muscles from tumour-
bearing mice exhibited membrane abnormalities, accompanied by reduced dystrophin 
(core DGC member) expression and increased glycosylation of DGC proteins (179). 
The DGC is thought to play a key role in maintaining muscle integrity during 
contraction cycles and clearly loss of this function may exacerbate overall damage to 
the muscle.   
 
2.5 Mediators of cancer associated myopenia: 
murine models 
2.5.1 Pro-inflammatory mediators 
Mediators regulating skeletal muscle atrophy in cachexia are thought to derive from 
immune or tumour cells, or the targeted tissues undergoing wasting (both adipose 
tissue and skeletal muscle). Inflammation is thought to be of paramount importance. 
Cancer cells rely on the production of pro-inflammatory mediators for growth, 
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protection from apoptosis, and promotion of angiogenesis/metastasis. The tumour 
may consequently initiate a cytokine cascade that has multiple, direct, and distant 
effects including the initiation of skeletal muscle protein degradation. 
CHO cells transfected with the human TNF-α gene induced cachexia when implanted 
into nude mice (262). A similar finding was observed with CHO cells constitutively 
producing IFN-γ (263).  An anti-IFN-γ monoclonal antibody was able to reverse the 
wasting syndrome associated with the murine Lewis lung carcinoma (264). TNF-α and 
IFN-γ work co-operatively to down-regulate transcription of the MyHC gene in vitro 
and in vivo, but not other core myofibrillar proteins (253). Furthermore, MyHC protein 
expression was decreased in a specific fashion in the C26 model (253), a largely IL-
6 dependent model (265). TNFα has been shown in vitro to inhibit both adipocyte and 
skeletal myocyte differentiation (113, 114). It also plays a role in insulin resistance 
attenuating the insulin signalling pathway (115). The presence of TNFα promoted 
atrophy in cultured myotubes, resulting from the induction of E3 ligase genes that 
mediate the breakdown of myofibrillar proteins by the UPP (116-119). TWEAK, 
another important cytokine with structural properties similar to TNFα, can induce a 
cachectic phenotype in part by the induction of the E3 ligase MuRF1, and the 
subsequent degradation of MyHC at the thick filament of the sarcomere (266, 267). A 
variety of tumours have been shown to secrete IL-6 and this can be amplified by host-
derived proinflammatory cytokines (e.g., IL-1). Experiments regulating function in 
tumour bearing mice also support the requirement of IL-6 in cachexia (106, 107, 265). 
In mice with a mutation in the APC tumour suppressor gene, elevated circulating IL-6 
levels are associated with the presence of muscle wasting (268). Knockout of IL-6 
prevents loss of muscle weight and epididymal fat, and reduces intestinal polyp 
number, implying the existence of an IL-6 cytokine amplification loop between host 
and tumour cells.  
Other cytokines may be potential repressors of cachexia. For example, IL-4, IL-10 and 
IL-13 all demonstrate anti-inflammatory, and hence potentially anti-cachectic activity 
(269). In the C26 mouse model, IL-10 gene transfer reduced cachexia and prolonged 
survival (270). Other cytokines (e.g. IL-15) may have potential ‘antioxidant’ properties 
that can counter the excess levels of reactive oxygen and nitrogen species (caused 
by the inefficiency of host antioxidant enzymes) that have been proposed as 
mediators of muscle atrophy (271). IL-15 was capable of inhibiting skeletal muscle 
wasting in the Yoshida AH-130 rat ascites hepatoma model by decreasing muscle 
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protein degradation rates (151). Overexpression of IL-15 in cultured myotubes 
induced a hypertrophic morphology and increased myofibrillar protein accumulation 
in co-cultured cells (272).  
 
2.5.2 Catabolic mediators 
The interplay of anabolic and catabolic hormones has a distinct role in the 
development of skeletal muscle wasting. The catabolic molecules myostatin and 
activin are two members of the TGF-β superfamily that play an important role in 
growth and are thought to be responsible for the development of cachexia in mice 
(144). In mice, both molecules bind to activin receptor type-2B (ACVR2B), a receptor 
in muscle, to initiate a signalling cascade leading to increased expression of MuRF1 
and MAFbx/Atrogin-1 and subsequent degradation of myofibrillar proteins (79). In 
mice bearing the C26 tumour, administration of a soluble ACVR2B decoy receptor 
resulted not only in reversal of muscle wasting but an increase in survival (145).  
 
2.5.3 Anabolic mediators 
The anabolic hormone IGF1 has been implicated in the development of cancer 
cachexia in murine models. In the rat AH-130 hepatoma ascites model of cancer 
cachexia, muscle expression of IGF-1 mRNA decreased progressively whereas IGF-
1 receptor and insulin receptor mRNA levels increased compared with controls (273). 
Furthermore, circulating levels of IGF-1 and insulin were reduced. However, the exact 
mechanism of IGF-1 down-regulation and any role in muscle wasting in this scenario 
is unclear, as administration of exogenous IGF-1 to tumour-bearing rats did not 
prevent cachexia (273), and other studies have shown, at least in experimental animal 
models of cancer cachexia, the IGF-1 signal transduction pathway is not down-





2.6 Mechanisms of cancer associated 
myopenia: murine models 
2.6.1 Protein degradation pathways 
Skeletal muscle atrophy may occur as a result of decreased synthesis, increased 
degradation or both (79). In cancer cachexia it is evident that there is a complex 
interplay between synthesis and degradation. In mice bearing the MAC-16 
adenocarcinoma, weight loss was accompanied by loss of whole body nitrogen in 
proportion to the overall loss of body mass. Using L-[4-3H]phenylalanine to label 
proteins in the gastrocnemius muscle to determine rates of synthesis and 
degradation, a significant depression (60%) in protein synthesis occurred in animals 
with a weight loss between 15 and 30%. This was accompanied by an increase in 
protein degradation, which increased with increasing weight loss between 15 and 
30% (277). Three major pathways that may contribute to such increased protein 
degradation include the UPP, autophagy / lysosomal pathway, and the calcium 
dependant enzymes (e.g. calpains) (100). 
 
2.6.1.1 Ubiquitin proteasome pathway 
Various factors including malnutrition, impaired physical activity and the production of 
catabolic molecules (e.g., glucocorticoids and/or cytokines) upregulate rates of 
muscle proteolysis (278). A common end point in pathways implicated for increased 
protein breakdown involves two muscle-specific E3 ubiquitin protein ligases, which 
target specifically a limited number of proteins for breakdown by the Proteasome. 




Figure 2.2 - Signalling pathways that regulate protein synthesis / degradation in 
skeletal muscle. Regulation of muscle synthesis via IGF – 1 induced hypertrophy (A). 
Myokine activated JAK/STAT pathway involved in the acute phase response and 
muscle degradation (B). TGF – β induced SMAD pathway, activated by myostatin and 
activin leading to degradation (C). Calcium mediated mechanisms of muscle 
breakdown (D). Muscle breakdown via activation of E3 ligases leads to muscle 
breakdown via the UPP (E). Activation and transcription of autophagy genes (F). 
Synthetic inhibition of ACVR2B blocks SMAD signalling leading to muscle 
hypertrophy via blockade of the degradation pathway (G). NF – ϰβ signalling via 
TRAF6 leading to degradation (H). 
 
2.6.1.1.1 Pro inflammatory cytokine activation of the UPP 
TNFα, TWEAK or IL-1 signal to activate the NF–ϰβ pathway. NF–ϰβ influences a 
variety of pathways including apoptosis, inflammation and differentiation. Pro-
inflammatory cytokines induce the cytosolic release of NF–ϰβ from its inhibitory Iϰβ 
proteins to allow translocation of NF–ϰβ into the nucleus and subsequent transcription 
of proteolytic pathway components (142). In both myocytes and murine models, the 
cytokine-induced activation of NF–ϰβ has been shown to inhibit muscle differentiation 
and function through the suppression of MyoD mRNA and protein (113). NF–ϰβ is 
required to up-regulate the expression of the key E3 ligases (MuRF-1 and 
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MAFbx/atrogin-1) which mediate sarcomeric breakdown and inhibition of protein 
synthesis (79). MuRF1 is up-regulated in multiple settings of muscle atrophy (83). This 
E3 ubiquitin ligase is responsible for mediating the ubiquitination of the thick filament 
of the sarcomere MyHC (71), and other thick filament components (70). MuRF-1 has 
also been shown to target for breakdown troponin I (279) and actin (280), which are 
components of the thin filament. Furthermore in the latter study it was also shown that 
MuRF-1 protein levels are up-regulated in muscles of non-cachectic cancer patients. 
The cytokine TWEAK, in particular, induces MuRF1 upregulation via NF–ϰβ, resulting 
in MyHC loss (267). Inhibition of classical NF–ϰβ is sufficient to decrease significantly 
tumour induced muscle loss, at least in Yoshida AH-130 ascites hepatoma tumour 
bearing rats in part, by inhibiting the up-regulation of MuRF1 (143, 281).  
MAFbx/Atrogin-1 is a highly specific marker of muscle atrophy as demonstrated in 
other conditions causing cachexia such as immobilisation, denervation, and 
glucocorticoid excess (83, 84). MAFbx up regulation occurs mainly via p38 activation 
(116). MAFbx causes the ubiquitination of eIF3f which is directly involved in skeletal 
muscle protein synthesis (282). Thus MAFbx may provide a key link between the 
simultaneous regulation of both protein degradation and synthesis in certain models 
of cachexia (277). Another E3 ligase, Fbxo40 has been implicated in skeletal muscle 
atrophy (283). It has been suggested Fbox40 induces the ubiquitination of IRS1 
therefore decreasing protein synthesis. Up regulation of Fbox40 has been seen in 
denervation but, at present little evidence suggests this may occur in other models of 
cachexia (283). 
Administration of anti-murine IL-6 receptor antibody to C26 bearing mice reduced 
weight loss of the gastrocnemius muscle to 84% of that of control mice. The enzymatic 
activity of cathepsin B+L and mRNA levels of cathepsin L and poly-Ub were 
significantly depressed in control mice compared with C26 bearing mice, indicating 
that both the lysosomal cathepsin pathway and the ATP-dependant proteolytic 
pathway might be involved (284). The direct regulation of E3 ligase expression during 
IL-6-induced muscle atrophy is controversial (285). Although less evidence exists to 
demonstrate that IL-6 can lead directly to lipid mobilization or altered skeletal muscle 
protein turnover, there is general acceptance from mouse models (286) that IL-6 is 
produced from activated macrophages and may contribute to net muscle loss in 
cancer cachexia by stimulating the liver (287) to induce an acute phase protein 
response and subsequent reprioritisation of peripheral protein metabolism. The IL-6 
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receptor signals via the Janus associated kinase / signal transducer and activator of 
transcription (JAK/STAT) signal transduction pathway (Figure 2.2). Downstream 
activation results in STAT phosphorylation and translocation to the nucleus to regulate 
genetic transcription (102).  
 
2.6.1.1.2 TGF-β family activating the ubiquitin proteasome pathway 
A more recent factor, which has captured the attention of many investigators, is the 
TGF-β family member, myostatin. Genetic null animals for myostatin, demonstrate 
dramatic muscle hypertrophy (288). Myostatin is synthesised and secreted mainly 
from skeletal muscle cells. Myostatin acts firstly by signalling through the activin type 
II receptor, which then recruits an Alk family kinase, resulting in the activation of a 
SMAD2 and SMAD3 transcription factor complex (289, 290) (Figure 2.2). Secondly, 
Akt and downstream TORC1 pathways that promote synthesis are down regulated 
(289, 291). Myostatin excess causes an increase in skeletal muscle atrophy (292), 
whilst inhibition causes a marked increase in muscle mass and myofibre size (293-
296). Myostatin antagonism has been shown to prevent cancer cachexia in the LLC 
mouse model (297). Activin A and B are other members of the TGF-β family that have 
been found to be up regulated in skeletal muscle after activation of the TNFα /TAK-1 
signalling pathway (298). Both Activin A and Activin B are potent growth and 
differentiation factors with a broad spectrum of biological effects, including modulation 
of embryogenesis, neuroprotection, apoptosis, and fibrosis. These TGF-β molecules 
commonly bind to the ACVR2B receptor to initiate a signalling cascade leading to 
increased expression of MAFbx/Atrogin-1 and MuRF1 and subsequent degradation 
of myofibrillar proteins (79). Direct evidence linking muscle wasting to survival of the 
host with cancer cachexia has been lacking until recently (145, 299-301). As 
mentioned previously, Zhou and co-workers found C26 bearing mice that preserving 
muscle mass is vitally important in the organism’s survival: ACVR2B antagonism 
prolonged survival and prevented muscle wasting and reversed muscle loss (145). 
Further work demonstrated that ACVR2B pathway activation induced the ubiquitin 
ligases critical in muscle wasting and enhanced ubiquitination of muscle proteins, and 
these effects were completely abolished by ACVR2B antagonism. It was also shown 
that ACVR2B-SMAD signalling stimulated FOXO3 activity in muscle, which induced 
transcription of MAFbx/Atrogin-1 and MuRF1. Finally ACVR2B antagonism was 
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shown to dramatically stimulate satellite cell proliferation, which presumably also 
contributed to the observed rapid reversal of muscle loss in treated animals. 
 
2.6.1.1.3 Deubiquitinating enzymes  
Protein ubiquitination is a reversible process. Much attention has been focused on 
identification of the enzymes responsible for conjugation of ubiquitin to proteins. 
However, deconjugation of ubiquitin plays an important role in regulating ubiquitin-
dependent pathways (302, 303). Previous studies have shown increased levels of 
ubiquitination of muscle proteins in several catabolic conditions including cancer (304-
307). In Wistar rats bearing the Yoshida sarcoma, administration of a xanthine 
derivative close to pentoxifylline that inhibits TNF production, torbafylline (also known 
as HWA 448) prevented muscle wasting by suppressing elevated proteasome - 
dependent proteolysis and accumulation of Ub-protein conjugates (304). However, 
the deubiquinating enzyme USP 19 was shown to be overexpressed in two models of 
rats bearing the Yoshida sarcoma or hepatoma (308). Whether suppression of 
deubiquitination contributes to cancer cachexia remains unresolved. 
 
2.6.1.2 Autophagy / lysosomal pathway 
Intracellular lysosomes contain a number of enzymes required for the digestion of 
macromolecules, including proteases, carbohydrases, lipases and nucleases. 
Cathepsins L, B, D and H are the major lysosomal proteases and determine primarily 
the proteolytic capacity of lysosomes (100). Cathepsin-L, in particular, is induced early 
in catabolic states, and levels correlate with increased protein breakdown. Increased 
cathepsin activity has been demonstrated in various models of muscle wasting, 
including cancer cachexia, diabetes mellitus, dexamethasone-induced atrophy, 
disuse, fasting and muscular dystrophy (309, 310). The autophagy pathway is 
necessary to drive substrates to lysosomes, and lysosomal proteolysis is dependent 
on the activity of cathepsins (311).  In a recent study, autophagy was shown to be 
increased in the muscle of mice implanted with the C26 tumour (312). In most 
mechanistic studies, induction of autophagy has been associated with increased 
activation of FOXO3A-dependent transcription of autophagy-related genes such as 
LC3B and BNIP3  (94) (Figure 2.2). An elevation of total lysosomal protease activities 
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has been observed in muscles and liver of DBA/2 mice inoculated with L1210 tumour 
cells  (313, 314) along with increased muscle levels of cathepsin L mRNA in septic 
rats (315). Autophagy has been demonstrated to play a role in cardiac atrophy 
associated with cancer cachexia (316).  In the C26 tumour mouse model, autophagy 
(without UPP activation) in cardiac muscle was demonstrated to be responsible for 
loss of both myofibrillar and sarcomeric proteins. The findings in skeletal muscle in 
cancer cachexia models are less clear, some have shown a selective targeting of 
MyHC (253), whereas other studies do not support a selective sparing of MyHC (317). 
Furthermore, studies into variety of other catabolic conditions appear not to show a 
selective sparing of MyHC (318, 319).  
 
2.6.1.3 Calpains 
Several different calcium-dependent enzyme systems exist, including the calpains. 
The calpains are a family of intracellular, non-lysosomal, calcium-regulated cysteine 
proteases that mediate cleavage of specific substrates in a large number of regulatory 
cell processes (320). In excessive amounts, calpains are capable of degrading 
cytoskeletal elements, ion channels, other enzymes, cellular adhesion molecules and 
cell surface receptors. The ubiquitous calpains 1 and 2 (also called µ and m) have 
been implicated in both the initial degradation of myofibrillar proteins during muscle 
wasting (321) and the necrosis associated with muscular dystrophy (322). Calpains 
have also been implicated in the degradation of sarcomeric and cytoskeletal proteins 
in cultured myotubes (323) (Figure 2.2). In this particular study, the addition of a 
calpain inhibitor resulted in a 20% reduction in overall protein degradation.  Similarly, 
this was reported in a mouse hindlimb suspension model where inhibition of calpain 
activity preserved sarcomere structure and furthermore prevented a fall in the 
isometric force generating capability (324). Ubiquitous calpain activity is under the 
control of the endogenous inhibitor calpastatin, and downregulation of calpastatin 
expression has been suggested as one potential mechanism of muscle atrophy. In 
contrast, overexpression of calpastatin may have potential therapeutic benefits 
against muscle atrophy. In animal models, transgenic overexpression of calpastatin 
can reduce both the atrophy caused by unloading and the necrosis associated with 
muscular dystrophy (325). There is little evidence in the literature to allow assessment 
of the role of calpains in models of cancer cachexia. 
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 2.6.2 Protein synthesis pathways 
The primary role of suppressed protein synthesis in cancer cachexia has been 
suggested by studies with mice bearing the MAC-16 adenocarcinoma. Using L-[4-
3H]phenylalanine to label proteins in the gastrocnemius muscle to determine rates of 
protein synthesis, a significant depression (60%) occurred in animals with a weight 
loss between 15 and 30% (277). In muscle insulin receptor knockout mice, there is 
evidence that reductions in muscle mass and function are due to depression of 
synthesis and not an increase in degradation (326). Two major targets for reduced 
protein synthesis in cachexia include either inhibition of amino acid uptake or the 
suppression of RNA expression or translation (253).  Indeed, some tumour models 
show as much as a 40% decrease in total muscle RNA compared with control animals 
(256, 327). The concept that skeletal muscle protein synthesis in cachexia is reduced 
simply due to anorexia alone (100) seems unlikely.  In animal models where anorexia 
is absent, depression of protein synthesis has also been demonstrated suggesting 
that the protein synthetic machinery is defective (277). In the MAC-16 cancer cachexia 
model, catabolism and anabolism appear to occur in tandem with up to a 60% fall in 
protein synthesis (328).  In another animal model, the Apc(Min/+) mouse, a reduction 
in protein synthesis seemed to precede a rise in proteolysis, suggesting differential 
time-dependant activation of pathways (276).   
The predominant regulator of skeletal muscle hypertrophy is through stimulation of 
the PI3K/Akt pathway by insulin or IGF-1 (329-331) (Figure 2.2).  Mice in which Akt is 
transgenically expressed and inducibly activated in skeletal muscle demonstrate 
dramatic hypertrophy upon the activation signal (332-334), helping to prove that Akt 
is the pathway that is sufficient to mediate hypertrophy downstream of IGF1 
upregulation. Activation of Akt leads to an increase in the mTOR/p70S6K pathways 
and a rise in protein synthesis. As well as inducing protein synthesis, IGF1 can inhibit 
skeletal muscle atrophy. In the presence of up regulated IGF1 signalling, the atrophy 
genes MuRF-1 and MAFbx/atrogin-1 are actively inhibited (83).  
  
2.6.3 Fat-muscle cross talk  
Recent work suggests molecular cross-talk between adipose tissue and muscle that 
occurs through adipokines and myokines. Integrative physiology in obesity and 
diabetes has long emphasised the importance of chronic inflammation, increased 
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adipocyte lipolysis, and increased levels of circulating free fatty acids in the adipose–
muscle cross-talk that contributes to lipotoxicity and insulin resistance in muscle. 
Intracellular accumulation of diacylglycerol triggers activation of novel protein kinases 
C with subsequent impairments in insulin signalling (335). A recent study in mice 
bearing the IL-6 producing, pro-cachectic C26 tumor showed that genetic ablation of 
adipose triglyceride lipase prevented the increase in lipolysis and the net mobilisation 
of adipose tissue associated with tumour growth (103). Unexpectedly, skeletal muscle 
mass was preserved and activation of proteasomal degradation and apoptotic 
pathways in muscle was averted. Ablation of hormone-sensitive lipase had similar, 
but weaker, effects. Physiologically important and previously unrecognised crosstalk 
between adipose tissue and skeletal muscle may therefore exist in the context of 
cancer cachexia (336-338). 
 
2.7 Skeletal muscle morphology and function 
in cancer associated myopenia: clinical data 
Results from morphological studies in humans to date are shown in Table 2.2. The 
limited data available suggest loss of MyHC and reduction in fibre CSA. The rectus 
muscle of patients with oesophago-gastric cancer cachexia (236) has been shown to 
lose MyHC content as well as undergo a reduction in fibre size. Similarly, the rectus 
muscle of patients with colorectal cancer has also been shown to lose MyHC content 
(339). In pancreatic cancer patients with cachexia MyHC protein levels were 
decreased by 45% when compared with controls (238). It has been suggested, based 
on MRI CSA muscle measurements and ex vivo muscle biopsies, that cancer-related 
cachexia is associated with a loss of muscle volume, but not of muscle function (239). 
After normalizing measured muscle strength for reduced CSA in cachectic patients, 
although muscle volume was diminished, the principal ability to generate force was 
maintained. The morphological basis for this finding seemed to be smaller mean fibre 
diameter associated with an increased total fibre number per area (239). In contrast, 
in a larger series of upper GI cancer patients, muscle mechanical quality measured 
by knee extensor strength per unit quadriceps CSA was shown to be reduced. 
Furthermore the degree of impairment of lower limb muscle mass, quality and function 
and the impact on quality of life varied with weight-loss and sex (213).  Few other 
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studies have been conducted to resolve these findings and human data into fibre size, 
type, myonuclear, and protein content remain limited. 
 
 
Table 2.2 - Clinical data on myosin composition of skeletal muscle in cancer cachexia 
 
2.8 Mediators of cancer associated myopenia: 
clinical data 
Unlike murine models where various highly specific treatments have been tested (e.g. 
ACVR2B receptor), there are few licensed treatments for cancer cachexia in humans 
and therefore the data on mediators and mechanisms are mostly of an observational 
nature. This naturally restricts the conclusions that can be reached. There has, 
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however, been a recent increase in phase II/III clinical trial activity and results from 
these trials promise to provide much needed insight.  
 
2.8.1 Systemic mediators of cachexia 
As in animal models, cancer cachexia in humans is considered, at least in part, to 
result from interactions between the host and the tumour. 
 
2.8.1.1 The Acute Phase Response 
An organism responds to the presence of acute infection, tissue injury, trauma or 
surgery by mounting an acute phase response (APR), this is designed to help limit 
tissue injury by the increased synthesis of key defence / repair proteins by the liver. 
However, in certain circumstances when dietary protein intake is limited and the APR 
is prolonged or severe, an APR can exacerbate muscle wasting by increasing the 
demands for certain amino acids to support increased hepatic export protein 
synthesis.  
 
2.8.2 Pro-inflammatory cytokines 
Pro-inflammatory cytokines, in particular IL-6, IL-1, TNF and IFN-γ, are central to 
systemic inflammation and the induction of an APR. Cytokine interaction between 
host and tumour cells within the tumour are thought to activate peripheral blood 
mononuclear cells (PBMC) passing through the tumour vasculature. Increased pro-
inflammatory cytokine release by PBMCs has been demonstrated in cancer patients 
with evidence of an APR (340) (341). Moreover, patients with pancreatic cancer and 
cachexia appear to have higher intra-tumoural IL-6 expression and this is associated 
with increased PBMC IL-6 production (342). Tumour associated macrophages (TAM) 
may be one important cellular sub-type involved in the intra-tumoural interaction 
between host and tumour cells (343). In cancer, host mononuclear cells are recruited 
to tumours by various signals including hypoxia. The resultant Th-2 type micro-
environment may favour tumour progression via the promotion of angiogenesis, the 
remodelling of the extracellular matrix to allow invasion, and the suppression of 




Despite the pivotal role of pro-inflammatory cytokines in the aetiology of cancer 
cachexia in animal models, human trials to date using cytokine antagonists have not 
generally been successful at ameliorating muscle loss. The use of infliximab, an anti-
TNF-α monoclonal anitibody (mAb), in conjunction with docetaxel was shown to be 
associated with increased fatigue and worsened QoL scores in NSCLC patients 
compared with docetaxel and placebo, and therefore the trial was stopped (344). 
Neither arm of the study demonstrated attenuation of weight loss. A further trial of 
infliximab with gemcitabine in pancreatic cancer patients was unable to demonstrate 
a significant improvement in LBM or survival (345), whereas a trial of etanercept, a 
TNF-α inhibitor, in cachectic cancer patients was not associated with weight gain or 
improved survival (346). Trials of pentoxyfilline, a cytokine inhibitor, have also shown 
little clinical benefit in the treatment of cachexia and anorexia in cancer patients (347). 
In human trials of an anti-IL6 mAb early clinical studies in patients with non-small-cell 
lung cancer has shown it to be safe and well tolerated. Treatment with an anti-IL6 
mAb (BMS-945429) improved lung symptoms, reversed fatigue, and a trend towards 
a decrease in the loss of lean body mass was noted (348). In another study of patients 
with cholangiocarcinoma, selumetinib (MAPK1 and IL-6 secretion inhibitor) was 
shown to promote a gain in muscle mass (349).  
 
2.8.3 Other circulating mediators 
2.8.3.1 Calcium and Vitamin D 
A potential role for calcium and vitamin D in muscle wasting relates to evidence from 
the myopathy (predominantly type II fibre atrophy) seen in osteomalacia, which can 
be exacerbated in ageing (350).  In sarcopenia, women with low vitamin D have been 
shown to have approximately twice the risk of reduced muscle mass and strength and 
a similar relationship was observed with raised parathyroid hormone levels (351).  
Vitamin D deficiency has been reported in over 80% of cancer patients (352) and may 
be particularly prominent in patients receiving chemotherapy (353). A retrospective 
study of advanced cancer patients reported 70% vitamin D insufficiency and an 
association with anorexia and fatigue (354). In cachectic cancer patients, vitamin D 
gene receptor polymorphisms have been linked to a more aggressive form of 
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cachexia (205). Although these findings suggest a role for vitamin D in cachexia, 
studies directly linking it with muscle mass in cancer cachexia patients are lacking.  
 
2.8.3.2 Glucocorticoids 
In cachectic pancreatic cancer patients, elevated serum levels of cortisol have been 
shown, along with elevated cortisol:insulin ratios (37). Glucocorticoids are 
administered frequently to cancer patients undergoing chemotherapy or radiotherapy. 
This cancer therapy is often associated with exacerbation of muscle wasting. 
Glucocorticoid atrophy seems specific to type II fibres. Mechanism may involve 
upregulation of protein degradation pathways, upregulation of myostatin and 
enhanced glutamine synthetase activity (355).  Glucocorticoids inhibit physiological 
secretion of growth hormone and appear to reduce IGF-1 activity in target organs.  
 
2.8.3.3 Insulin 
Insulin can stimulate protein synthesis via the PI3K/Akt pathway. Both low insulin 
production and peripheral insulin resistance has been demonstrated in cancer 
cachexia (100). In cancer patients, treatment with low dose insulin therapy as part of 
a combination therapy regimen resulted in a rise in carbohydrate intake, and increase 
in body fat, and a fall in serum-free fatty acids.  Despite these findings however, there 
was no change in lean body mass, maximum exercise capacity or spontaneous 
physical activity (356). Higher serum insulin did not change IGF-I levels, which may 
explain the dissociated effects by insulin on whole body fat and lean tissue. 
 
2.8.3.4 Ghrelin 
A randomised controlled trial has investigated the effects of intravenous ghrelin taken 
at both low dose and high dose in patients with a variety of advanced metastatic 
cancer. No difference between treatments was seen for nutritional intake, symptoms, 
adverse effects or tolerability (357). In another study, 31 patients with metastatic 
gastrointestinal cancer were randomised in a double-blind manner to ghrelin at 2 
different doses subcutaneously daily for 8 weeks.  In the high-dose group (versus the 
low-dose group) appetite scores were significantly better, and there was a trend to 
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less fat-free mass loss and improved energy balance.  There were no differences in 
food intake, quality of life or physical activity (358). The studies to date are small 
phase I and phase II trials, and therefore, results should be treated with caution. A 
phase III, randomised, placebo-controlled clinical trial assessing anamorelin 
hydrochloride in patients with non-small-cell lung cancer-associated cachexia is 
currently recruiting patients (clinicaltrails.gov/NCT01505764). 
 
2.8.3.5 Androgens 
Testosterone inhibits release of TNF, IL-1, IL-6 from macrophages and stimulates 
production of IL-10 (359-361).  Low testosterone levels (hypogonadism) may thus 
lead to an increase in pro-inflammatory cytokine production.  A recent study looking 
at hypogonadism in male cancer patients demonstrated low levels of testosterone in 
the presence of high plasma IL-6 (362). In males with pancreatic cancer, systemic 
inflammation was associated with hypogonadism which in turn was associated with 
shortened survival (214). Despite these findings, trials have not been able to show an 
improvement with exogenous androgens. A trial of nandrolone decanoate in patients 
with advanced NSCLC demonstrated a trend for decreased weight loss (363). In 
another study comparing fluoxymesterone with megestrol acetate or dexamethasone,  
fluoxymesterone was inferior in terms of appetite and weight gain (364). Recently, 
SARMs have received much attention as potential muscle-targeted treatments for 
cancer cachexia. In humans, Phase I and II clinical trials have shown that SARMs 
increased LBM and enhanced functional status (365). In a recent phase IIb 
randomised, double blind, placebo controlled study, treatment with  enobosarm (GTx-
024) was shown to significantly increase lean body mass and muscle function in 120 
healthy elderly men and women (366) At present, enobosarm is being assessed in a 
randomised, placebo-controlled, phase III clinical trial in patients with non-small-cell 
lung cancer receiving first-line chemotherapy treatment 
(clinicaltrails.gov/NCT01355497).  
 
2.8.3.6 Myostatin  
In a recent study of myostatin expression in muscle biopsies from non weight losing 
lung and gastric cancer patients, there was evidence of increased expression in the 
gastric cancer patients (301).  This suggests that in human cancer cachexia, 
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myostatin alterations may vary by primary tumour site. There are at least two ongoing 
phase II trials of anti myostatin strategies (clinicaltrials.gov/NCT01505530), 
(clinicaltrails.gov/NCT01433263). 
 
2.8.3.7 Dietary factors 
Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid found in fish 
oil. Polyunsaturated fatty acids have been shown to reduce cancer cachexia (367). 
EPA causes a reduction in the production of pro-inflammatory cytokines in patients 
with cancer as well as PIF. A number of trials demonstrated preservation of LBM, 
increased physical activity, improved appetite and weight gain with taking either fish 
oil or EPA alone in weight-losing cancer patients (368-371). However phase III, large, 
randomised clinical trials failed to show the benefit of EPA over placebo on LBM (372-
374). However, in the last 2 years, several studies have again pointed towards 
potential benefits of EPA for attenuating LBM loss, as well as maintenance or gain of 
LBM. Megastrol acetate, a steroidal progestin and progesterone derivative with 
appetite stimulating properties and the anti-inflammatory, ibuprofen have been given 
together and observed to increase body weight and lead to a reduction in C-reactive 
protein concentrations (375). Megastrol acetate, in conjunction with formoterol has 
also been shown to improve muscle mass and function (376). More research is 
needed on drugs such as eicosapentaenoic acid as well as focusing on multimodal 
approaches combining drugs and non-drug interventions. 
 
2.9 Mechanisms of cancer associated 
myopenia: clinical data 
2.9.1 UPP / E3 ubiquitin ligases 
In many acute models of cachexia, including cancer, the UPP is thought to be 
fundamental in the process of muscle atrophy (83, 84). However, human 
investigations have failed to be conclusive.  Studies including patients in ICU with 
sepsis, following bed rest, amputation for vascular disease, limb immobilisation, 
COPD, amyotrophic lateral sclerosis and ageing have demonstrated both increased 
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and decreased expression of MuRF1 and MAFBx/atrogin-1 (85-88, 377-379).  
Likewise, investigations of UPP activity in quadriceps muscle biopsies have shown 
similar levels to healthy controls in patients with lung cancer and weight loss <10% 
(termed pre-cachexia by the authors) (380).  In a transcriptomic study of UGI cancer 
patients, candidate genes including FOXO and ubiquitin E3 ligases, were not related 
to weight loss. Furthermore, promoter analysis identified that weight loss-associated 
genes had fewer FOXO binding sites than expected by chance (89) (Table 2.3). 
Another study in lung cancer patients with low weight loss (mean 2.9%) demonstrated 
no change in components of the UPP using Northern blotting, but a suggestion that 
the lysosomal pathway was increased (97) (Table 2.3).  In contrast, in gastric cancer 
patients with average weight loss 5.2%, increased UPP activity (determined by 
measurement of RNA and cleavage of specific fluorogenic substrates) was seen 
compared with controls, with a further effect with increasing tumour stage, weight loss 
and lower albumin (381) (Table 2.3).  The same group also demonstrated higher 
levels of ubiquitin mRNA in gastric cancer patients compared with controls, but there 
was no relationship with weight loss.  This led the authors to conclude that the UPP 
was activated early in disease before there was overt clinical evidence of cachexia 
(382).  In another investigation using dot blot for components of the UPP in patients 
with various cancers and minimal weight change, mRNA levels were increased by 2-
4x in cancer patients (383) (Table 2.3).  The authors concluded that the UPP was 
upregulated before protein breakdown is increased given that patients had minimal 
weight loss.  The concept of changes in activation of the UPP according to where a 
patient is on the cancer cachexia journey is supported by the observations by Khal et 
al in both humans with cancer cachexia (384) (Table 2.3) and the MAC-16 murine 
cachexia model (227).  However, in these studies, UPP activity seemed to increase 













Williams (383) GI 0 – 10% ↑    
Bossola (381) GI >5%  ↑   
Khal (227) GI >10% ↑    
Stephens (89) GI >5% =    
Smith (385) GI 0 – 5% =  ↑  
Jagoe (97) Lung <5% =   ↑ 
 
Table 2.3 – Findings of different studies in humans on potential mechanisms of 
skeletal muscle protein degradation 
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2.9.2 Autophagy / Lysosomal pathway 
Human studies have reported increased cathepsin D enzyme activity in cancer 
patients (96) and cathepsin B mRNA in lung cancer patients (97) Table 2.3.  In the 
latter study, cathepsins B levels were higher in early versus late stage tumours. 
Components of the UPP were unchanged in cancer patients, and thus the authors 
concluded that lysosomal proteolysis may be relevant early and the UPP may be 
activated later in the disease process (97) Table 2.3.  This perhaps has some appeal 
because, although one study detected radio-labelled myofibrillar proteins in 
lysosomes (386), there is other evidence to suggest that lysosomal proteolysis in 
isolation is not sufficient to degrade myofibrillar proteins (70, 387, 388).   
 
2.9.3 Calpains 
Calpains are capable of degrading cytoskeletal elements, ion channels, other 
enzymes, cellular adhesion molecules and cell surface receptors. Furthermore, 
calpains cleave the enzyme xanthine dehydrogenase to xanthine oxidase, thus 
indirectly creating the formation of superoxide radicals. Calpains have been 
implicated in the degradation of sarcomeric and cytoskeletal proteins in cultured 
myotubes (323). Gastric cancer patients with minimal weight loss (average 1%), had 
an increase in rectus muscle calpain activity by 70% compared with controls, 
suggesting a role for the calpains early in the cachexia journey before significant 
clinical changes are apparent (385) Table 2.3. 
 
2.9.4 Caspases 
Caspases are a group of enzymes usually associated with the induction of cellular 
apoptosis in response to death signals. There is some evidence for a role for 
apoptosis in muscle wasting experienced by cachectic patients. Muscle biopsies from 
weight-losing patients with upper GI cancer showed a three-fold increase in muscle 
DNA fragmentation compared with control subjects (389). Furthermore, the increase 
in DNA fragmentation was associated with a four-fold increase in poly (adenosine 
diphosphate-ribose) polymerase (PARP) cleavage, indicating the presence of 
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apoptosis (389). No human studies to date have focused on targeting caspases or 
apoptosis in the prevention of cancer cachexia. 
 
2.9.5 Myogenesis 
Decrease in skeletal muscle regeneration may also contribute to the loss of skeletal 
muscle mass in cancer cachexia. In both health and disease, skeletal muscle is able 
to undergo an extensive repair process aimed at preventing the loss of muscle mass 
via activation of satellite cells (390) (391). The satellite cell starts off as a myogenic 
precursor during embryonic development, and upon muscle injury starts proliferating 
with a variety of genes being regulated. Myogenin is subsequently up-regulated 
leading to terminal differentiation, followed by a permanent exit from the cell cycle. In 
a recent study looking at patients with gastric cancer these genes were found to be 
up regulated compared with a control group (392), whether this suggests potential for 
muscle regeneration during cancer cachexia is unknown.  
 
2.10 Future prospects 
The heterogeneity between morphology, mediators, and mechanisms of animal 
models and human cancer cachexia is vast. There are some comparisons that can 
be drawn from the two but it must be realised that these may represent distinct 
disease processes. The relatively acute wasting seen in young, metabolically active 
animal models may have little bearing on the chronic disease patho - physiology seen 
in cancer patients with chronic wasting. Progress in treating the human form of cancer 
cachexia can only move forwards through carefully designed large randomised 
controlled clinical trials of specific therapies with validated biomarkers of relevance to 
underlying mechanisms. The following Chapters will try to elucidate some of the 
morphology, mediators, and mechanisms underlying the human form of cancer 
cachexia to provide a robust phenotype to consider in a genetic analysis of patients 
with cancer cachexia. Chapter 4 looks at the clinical classification of cancer cachexia 























3.1 Ethical approval 
All studies contained in this thesis received full ethical permission from their respective 
host institutions. Ethical approval for research carried out in Edinburgh was granted 
by the Lothian Research Ethics Committee (reference 06/S1103/75 for the 
phenotyping study and 08/S1103/19 for the genotyping study, see appendix) 
 
3.2 Study participants 
3.2.1 Clinical Classification of Cancer Cachexia: Phenotypic 
Correlates in Human Skeletal Muscle study (Chapter 4) 
Patients were recruited to this study between August 2007 and October 2010. All 
patients were above 18 years of age had a diagnosis of upper gastro-intestinal cancer 
(oesophageal, gastric, pancreatic) and were undergoing surgery with the intent of 
resection of the primary tumour. All patients were enrolled before any treatment was 
initiated and within 1-2 weeks of diagnosis. Newly diagnosed patients were identified 
principally from the regional oesophago-gastric and hepatobiliary cancer 
multidisciplinary team (MDT) meetings at the Royal Infirmary of Edinburgh, UK. The 
oesophago-gastric and hepatobiliary MDTs provides regional referral services for 
patients with oesophageal, gastric and pancreatic cancer from the Lothian and 
Borders regions. Patients with newly diagnosed upper gastro-intestinal cancer within 
these regions are referred to the MDTs which meet on a weekly basis to discuss all 
new referrals and to decide on individual patient management strategies. Participants 
were recruited at their surgical clinic appointments at the Royal Infirmary of Edinburgh. 
All procedures were approved by the NHS Lothian local research ethics committee. 






3.2.2 Genetic signatures associated with susceptibility to cancer 
cachexia vary according to weight-loss or low muscle mass 
phenotype (Chapter 6) 
The main study cohort was recruited for this study between January 2004 and 
November 2012 from the following six institutions: 
1) NHS Lothian, Edinburgh, UK 
2) Cross Cancer Institute, Edmonton, Canada 
3) McGill Cancer Center, Montreal, Canada 
4) Palliative Research Centre, Norwegian University of Science and Technology 
(NTNU), Norway 
5) Cantonal Hospital, St Gallen, Switzerland 
6) Department of Medical Oncology, University Hospital of Larissa 
 
All subjects participated in clinical or research studies on cancer cachexia at the host 
institutions under ethically approved protocols allowing for analysis of patients’ DNA. 
Recruitment was conducted at first presentation (treatment naive) to surgical, 
oncology or palliative care clinics at each institution. Recruitment was performed 
sequentially with the following exclusion criteria: (i) under 18 years of age; (ii) cognitive 
impairment; (iii) inability to give written, informed consent; (iv) presence of underlying 
infection; (v) on corticosteroids. Patients recruited generally had cancer types with 
propensity to develop cachexia (e.g. gastric/oesophageal, pancreatic, lung). 
NHS Lothian 
All patients recruited had either a confirmed diagnosis of gastro-oesophageal or 
pancreatic malignancy. Approximately 430 retrospective patients recruited for 
previous studies with blood stored in a tissue bank with relevant phenotypic data were 
entered into the study. These patients were identified principally from the regional 
oesophago-gastric and hepatobiliary cancer multidisciplinary team (MDT) meetings 
at the Royal Infirmary of Edinburgh, UK. Patients were recruited at first presentation 
to surgical or oncological clinic at Royal Infirmary of Edinburgh or Western General 
Hospital, Edinburgh, UK. 
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Cross Cancer Institute 
Approximately 190 patients were entered into the study. All patients had been 
previously recruited for clinical research studies with relevant phenotypic data and 
had blood stored in a tissue bank. All patients had a confirmed diagnosis of non-small 
cell lung cancer (NSCLC). 
McGill Cancer Center 
All patients recruited had confirmed diagnosis of colorectal, pancreatic or non-small 
cell lung cancers. Patients had previously participated in clinical research studies with 
relevant phenotypic data and had blood stored in a tissue back. Approximately 260 
patients were entered into the study. 
Norway Palliative Research Centre 
Approximately 245 patients were entered into the study. All patients had been 
previously recruited for clinical research studies with relevant phenotypic data and 
had blood stored in a tissue bank. All patients had a confirmed diagnosis of lung 
cancer. 
Cantonal Hospital  
All patients were recruited from Oncology & Palliative Medicine, Cantonal Hospital, 
St. Gallen, Switzerland from January 2007 to December 2008. Patients with all proven 
malignancies were considered and 84 patients were retrospectively recruited. 
Larrisa Department of Medical Oncology 
All patients were recruited from Department of Medical Oncology, University Hospital 
of Larissa, Greece from January 2010 to December 2011. Patients with all proven 
malignancies were considered and 67 patients were prospectively recruited. 
Newly recruited patients 
Out of the patients recruited for this study (n=1276), 731 were used in a previous 
study identifying SNPs associated with the genetics of cancer cachexia. Further 
phenotyping including identification of CT scans used to compute levels of muscularity 
were obtained for these subjects. A further 545 patients were recruited for use in the 




3.3 Clinical and pathological data collection 
Demographic data was recorded and included age and sex for each patient. The date 
of diagnosis was also recorded in all instances. 
Histological confirmation of disease was obtained where possible and patients were 
staged according to the American Joint Committee on Cancer stage groupings 
(AJCC). Tumours of the gastro-oesophageal junction were classified according to 
Siewert and Stein and those classified as type I and II were staged as oesophageal 
tumours and type III as gastric cancers. 
 
3.4 Nutritional assessment (Chapter 4 and 6) 
All patients underwent measurements of height and weight at the time of recruitment. 
Pre-morbid weight was recalled by the patient and verified where possible from the 
medical notes. There is evidence to support the reliability of self-reported weight and 
weight history (Perry et al, 1995; Stunkard & Albaum, 1981). Individual weight loss 
was calculated and expressed as percentage of pre-morbid body weight lost. Height 
and weight data were subsequently used to compute a common anthropometric 
descriptor, body mass index (BMI) (kg/m²). 
 
3.5 Collection of biological samples (Chapter 4 
and 6) 
3.5.1 Blood collection (Chapter 4 and 6) 
Patients recruited for the phenotypic definition and candidate gene studies had up to 
10ml of blood collected into EDTA tubes and tubes with gel separator and clot 
activator. The blood was usually collected when the patients were having blood taken 
as part of their on-going clinical care as requested by their supervising clinician and 




3.5.2 Rectus abdominis muscle biopsy and storage for biochemical 
analysis (Chapter 4 and 6) 
For all patients recruited in the phenotypic study and the transcriptomic part of the 
genetics study, biopsies were taken at the start of open abdominal surgery under 
general anaesthesia. Patients had fasted overnight prior to surgery. The edge of the 
rectus abdominis was exposed and a 1cm3 specimen removed using sharp 
dissection. The biopsy was cleaned of gross blood contamination.  Obvious fat/fibrous 
tissue was removed prior to placement in a cryotube and being snap frozen in liquid 
nitrogen and stored at -80°C. 
 
3.5.3 Rectus abdominis muscle sample preparation for cryo-
section (Chapter 4) 
For patients recruited for the phenotypic definition study, a 0.1 – 0.5cm3 section of 
muscle was cut.  Liquid nitrogen was used to cool isopentane solvent in a tube to a 
temperature of ~-190°C. The section of muscle was stitched onto a segment of cork.  
OCT solution was placed at the junction between the cork base and the muscle.  This 
was then lowered with the cork uppermost (i.e. muscle first) into cooled solvent and 
held for approximately 5 minutes (until the muscle was frozen).  Samples were then 
stored at -80°C until use. 
 
3.6 Blood assays (Chapter 4 and 6) 
3.6.1 Measurement of C-reactive protein (CRP)  
Serum CRP concentration was measured using an automated immuno-turbidimetric 
assay. Using this assay, a concentration of 10mg/l represents the upper limit of normal 




3.7 Body composition analysis (Chapter 4 and 
6) 
3.7.1 Estimation of total body skeletal and adipose tissue using 
computed tomography (CT) scans 
Digitally stored CT images completed with a spiral CT scanner for initial staging and 
routine diagnostic purposes were analysed using semi-automated software which 
permitted specific tissue demarcation using Hounsfield unit thresholds of –29 to +150 
for skeletal muscles (393), –150 to -50 for visceral adipose tissue (394), and –190 to 
–30 for subcutaneous adipose tissue (393). Cross-sectional areas (cm2) are 
computed for each tissue by summing tissue pixels and multiplying by the pixel 
surface area. A transverse CT image from the third lumbar vertebrae (L3) was 
assessed for each scan date and tissue volumes estimated (395) (Figure 3.1). The 
muscles in the L3 region contain psoas, erector spinae, quadratus lumborum, 
transversus abdominus, external and internal obliques, and rectus abdominus. All CT 
images were analysed by a single trained observer, tissue boundaries were manually 
corrected as needed. Cross-sectional area for muscle was normalized for stature 
(cm2/m2). Cut offs for low muscularity were either based on a CT-based sarcopenic 
obesity study of cancer patients by Prado et al. (i.e., L3 skeletal muscle index: ≤38.5 
cm2/m2 for women and ≤52.4 cm2/m2 for men) (28) (used in Chapter 4), or an updated 
CT-based sarcopenic obesity study of cancer patients by Martin et al. and adjusted 
for BMI (396) (used in Chapter 6) (Figure 3.2). 
Estimates of whole body stores were generated from the raw data (cm2) using the 
regression equations by Mourtzakis et al. (397), which show a close correlation 
between muscle and fat areas in CT images at the third lumbar vertebrae and whole 
body compartments of fat-free mass (FFM) and fat mass (FM) respectively. 
 Total body fat-free mass (FFM) (kg) = 0.3 × [skeletal muscle at L3 (cm2)] + 
6.06 (r = 0.94) 
 Total body fat mass (FM) (kg) = 0.042 × [total adipose tissue at L3 (cm2)] + 
11.2 (r = 0.88) 





Figure 3.1 - Cross sectional CT images at L3 showing demarcation of skeletal muscle 






Figure 3.2 - Skeletal muscle depletion is a powerful prognostic factor, independent of 
BMI. Panels B1-3 highlight variation in BMI for female patients with identical SMIs (29.7 
cm2/m2) and different BMIs. Panels B4-6 highlight variation in SMI for overweight 
female patients with identical BMIs (29.4 kg/m2) and different SMIs (adapted from 
(396). 
 
3.8 Cellular methods (Chapter 4 and 6) 
3.8.1 Immunohistochemistry (Chapter 4)  
The frozen muscle sections were co-stained for laminin (L9393, Sigma-Aldrich, 
Buchs, Switzerland) and myosin heavy chain type I or IIa to distinguish each fibre type 
(BA-D5 for type I, SC-71 for type IIa). The paraffin sections were stained for phospho-
STAT3 (D3A7, Cell Signaling Technologies, Danvers, MA, USA) with a Ventana 
discovery XT (Roche group, Tucson, USA). Images of the entire tissue section were 
acquired using a VS120 slide scanner (Olympus Corporation, Tokyo, Japan). The 
distribution of myosin heavy chain fibre types, the cross section area of the individual 
fibres in the section, and the phospho-STAT3 positive nuclei and staining density were 
analysed using the proprietary image analysis platform ASTORIA (Automated Stored 
Image Analysis) developed by Novartis/Preclinical Safety. 
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3.8.2 Tissue Preparation for DNA, RNA and Protein extractions 
(Chapter 4) 
Skeletal muscle tissue was minced and ground on dry ice. Aliquots were weighed 
using an analytical balance (Mettler Toledo) and stored at -80°C until use.  
 
3.8.3 DNA and RNA extraction and linearity of the extraction 
method (Chapter 4) 
DNA and RNA from human skeletal muscle tissue was extracted and purified with the 
automated Maxwell 16 system (Promega, Duebendorf, Switzerland). To determine 
the linearity of the extraction methods using the Maxwell 16 system, DNA and RNA 
was extracted from 4mg, 6mg, 8mg, and 10mg of muscle, respectively.  Calculating 
the total DNA and RNA content per wet weight (which in a linear extraction system 
should be equal for all aliquots), allowed us to define the linear range of the Maxwell 
16 extraction system. Based on these preliminary studies, aliquots of 4-8mg human 
skeletal muscle tissue were used for all subsequent DNA and RNA extractions. Using 
more starting material drastically reduced the total DNA and RNA content per wet 
weight (data not shown).   
For DNA extraction, the Maxwell 16 LEV Blood DNA Kit (Promega) was used with a 
slightly adapted protocol compared with the manual’s instructions. Briefly, 300µl of 
Tail Lysis Buffer from the kit ReliaPrep gDNA Tissue Miniprep System (Promega) was 
added to minced and ground human skeletal muscle tissue in Precellys 24 lysing kit 
tubes. Tissue was further homogenized using the high-throughput homogenizer 
Precellys 24, for 10s. After cooling on ice for 5 minutes, 30µl of the protein K and 5µl 
of the 1-Thiolglycerol solution were added. This mixture was incubated at 56°C for 2 
hrs. Afterwards, the lysate was transferred into well 1 of the LEV Blood DNA cartridge, 
and diluted with 300µl nuclease-free water. For the elution, 50µl of elution buffer was 
added into elution tubes. The Maxwell 16 instrument was started using the DNA Blood 
program. 
For RNA extraction, the Maxwell 16 LEV simplyRNA Tissue Kit was used (Promega), 
following the manual’s instructions. Briefly, minced and ground human muscle tissue 
was incubated in 200µl of chilled 1-Thioglycerol/Homogenization solution and further 
homogenized using the Precellys 24 system (see DNA). Afterwards, the samples 
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were heated at 70°C for 2 min, then the lysates were allowed to cool down. 200µl of 
lysis buffer was added to the cooled-down homogenate, mixed vigorously, followed 
by transfer of the total 400µl into well 1 of the Maxwell 16 LEV cartridge. 5µl of DNAse 
was added to well 4 of the cartridge and, 50µl RNAse-free water was added to 0.5ml 
Elution Tubes and the RNA extraction program was started at the Maxwell 16 
instrument.  
Extracted DNA and RNA were measured spectrometrically using a Trinean 
DropSense Instrument (Trinean, Gentbrugge, Belgium) for quantity and quality. 
 
3.8.4 Protein extractions (Chapter 4) 
To extract proteins, 300 µl of PhosphoSafe Extraction Reagent (Millipore) was added 
to a specific amount (between 8 and 18mg) of homogenized human skeletal muscle 
tissue. To further homogenize the samples, the Precellys 24 system was used (see 
section above). After incubation on ice for 5 min, the lysates were spun at 800xg for 
5 min at 4°C. Supernatants were transferred into new tubes and spun for another 12 
min at 1600xg at 4°C. Supernatants were collected and protein concentrations 
measured using the BCA Protein Assay Kit (Pierce) with BSA as a standard. 
Afterwards, phosphatase inhibitor cocktail (Roche) was added and the samples were 
stored at -80°C until further use. 
 
3.8.5 Western blots (Chapter 4) 
20 µg of human skeletal muscle protein extracts (see above) in reducing Laemmli 
SDS sample buffer were boiled for 5 min at 95°C and then  separated by SDS-PAGE 
on 4-20% gradient gels (Bio-Rad, Cressier, Switzerland), blotted to Nitrocellulose 
membranes (Bio-Rad) using the Trans-Blot Turbo Transfer System (Bio-Rad), 
blocked for 1h in 5% non-fat milk in Tris-buffered saline+0.05% Tween-20, incubated 
overnight with primary antibody, rinsed, and incubated for 1h with peroxidase-
conjugated goat anti-rabbit IgG (1:5000) (Santa Cruz, Heidelberg, Germany) at room 
temperature. Blots were developed using ECL (Roche, Rotkreuz, Switzerland) or 
SuperSignal West Femto substrate (Thermo Scientific, Wohlen, Switzerland) and 
exposed to Kodak film (Kodak, Rochester, NY, USA). 
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Rabbit monoclonal antibodies used were: Beclin-1 (clone D40C5), Atg5 (clone D1G9) 
, Atg7 (clone D12B11), Atg12 (clone D88H11), SMAD3 (clone C67H9), phospho-
NF𝜅B p65 (Ser536) (clone 93H1) and α-tubulin (clone 11H10) (all from Cell Signaling 
Technologies, Danvers, MA, USA), phospho-SMAD3 (Ser423/Ser425, clone 
EP823Y) (Millipore, Billerica, MA, USA). Rabbit polyclonal antibodies used were: 
Gelsolin (Cell Signaling Technologies). 
Western blots were analyzed densitometrically using ImageJ software version 1.45 
(NIH, Bethesda, MD, USA; http://rsbweb.nih.gov/ij). Band intensity of each sample 
was normalised to that of α-tubulin. 
 
3.8.6 DNA extraction from blood (Chapter 6) 
Genomic DNA was extracted from samples of blood taken in EDTA tubes. The Wizard 
Genomic DNA purification kit (Promega, Southampton, U.K) was used. Whole blood 
was centrifuged at 1,500g for 5 minutes at 4°C. 300 μl of the cellular layer was added 
to 900 μl of cell lysis solution in a 1.5 ml micro centrifuge tube and mixed thoroughly 
by inverting the tubes several times. The mixture was incubated for 10 minutes at 
room temperature followed by centrifugation at 15,000g for 20 seconds also at room 
temperature. The supernatant was discarded and the process of adding cell lysis 
solution, incubation and centrifugation was repeated once more. 300 μl of nuclei lysis 
solution was added to the pellet and the tube was vortexed to resuspend the white 
cells. The solution was pipetted gently several times to lyse the white cells. 1.5 μl of 
RNase solution (Promega) was added to each tube, mixed and incubated at 37°C for 
15 minutes. After allowing the tubes to cool to room temperature, 100 μl of protein 
precipitation solution was added and mixed by vortex for 15 seconds. Samples were 
then centrifuged at 15,000g for 3 minutes at room temperature. The supernatants 
were then transferred to a clean 1.5 ml micro centrifuge tube and mixed with 300 μl 
of pure isopropanol. Gentle mixing reveals the appearance of the DNA as white 
thread-like strands. Further centrifugation at 15,000g for 1 minute at room 
temperature allows the DNA to be collected as a pellet at the bottom of the tube. The 
supernatant in then decanted and 300 μl of ethanol 70% is added to wash the pellet. 
The samples were then centrifuged again for a further minute at 15,000g and the 
ethanol carefully aspirated away. 100 μl of DNA rehydration solution (10 mM Tris-HCl 
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and 1 mM EDTA) was added to each tube and samples were incubated at 65°C for 1 
hour. DNA samples were then stored at 4°C. 
 
3.8.7 Quantification of DNA (Chapter 6) 
DNA concentrations were measured using a Nanodrop ND-1000 spectrophotometer. 
Absorbance at 260nm were used for quantification of nucleic acids, optical density of 
1 corresponding to 50ng/μl DNA. Absorbance ratios (260 nm/280 nm) of 
approximately 1.8 for DNA indicated that the nucleic acid preparations were 
sufficiently free from protein contamination for downstream experiments. 
 
3.9 Single nucleotide polymorphism (SNP) 
genotyping (Chapter 6) 
Genotyping of the samples were performed on the Sequenom iPLEX Gold platform 
(San Diego, CA, USA) or TaqMan assay (for rs4280262) using services from the 
McGill University and Genome Quebec Innovation Center, Montreal, Quebec, 
Canada. The iPLEX assay is based on a simple single-base primer extension assay. 
A protocol overview is provided in Figure 3.3. Polymorphisms selected were validated 
for assay feasibility using DNA from apparently healthy Caucasian subjects (n=92) 
from Coriell Institute (Coriell Panel, Coriell Institute of Medicine, CA, USA) (398). 
Deviations from Hardy-Weinberg equilibrium (HWE) were assessed in the Coriell 
panel of control population using 2 test with 1 degree of freedom (df); a p-value 




1) The iPLEX assay is truly homogeneous, in the sense that after PCR, reagents are 
added to the reaction cocktail in a three step protocol. No transfer or pipeting into 
different reaction containers is required.  
2) PCR primers are designed in a region of approximately 100 base pairs around the 
SNP of interest and an extension primer is designed immediately adjacent to the 
SNP. The assay design is performed in a highly automated fashion by the 
AssayDesigner software module.  
3) The starting point of the iPLEX assay is PCR amplification, followed by the addition 
of Shrimp Alkaline Phosphatase (SAP) to inactivate remaining nucleotides in the 
reaction.  
4) Following a brief incubation, the primer extension mixture is added and conducted 
using a standardized cycling program.  
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5) Finally, CleanResin is added to the mixture to prepare it for deposition on a 384-
well SpectroChip®.  
6) SpectropChips enable an automated readout and data analysis by a Compact TM 
MALDI-TOF mass-spectrometer. Data analysis is performed on the Typer 
Software Module 
Figure 3.3 - Work flow for genotyping using the Sequenom iPLEX Gold platform 
(Adapted from iPLEX® Sequenom protocol) for processing and genotyping patient 
samples from Chapter 6 
 
3.10 Microarray analysis (Chapter 6) 
Total RNA was isolated using Trizol (Sigma-Aldrich, Oakville, ON, CAN), purified 
using Qiagen RNeasy columns (Mississauga, ON, CAN), quantified using a 
NanoDrop 1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) 
and its integrity evaluated using a Bioanalyzer 2100 (Agilent Technologies, Santa 
Clara, CA, USA) according to manufacturer’s protocols. All RNA samples had RNA 
Integrity Numbers (RIN) greater than 7.0. 
RNA was subjected to linear amplification and Cy3 labeling and hybridization to 
Agilent Whole Human Genome Arrays using Agilent kits (One Color Low RNA Input 
Linear Amplification Kit Plus, One Color RNA Spike-In Kit and Gene Expression 
Hybridization Kit). The arrays were scanned using an Agilent Scanner, the data was 
extracted and quality was evaluated using Feature Extraction Software 10.5.1 
(Agilent). The data was normalized using GeneSpring GX 11.5.1 (Agilent) (Figure 3.4 
and 3.5). The data used in this publication have been deposited in the U.S. National 
Center for Biotechnology Information (NCBI) Gene Expression Omnibus25 and are 




Figure 3.4 - Work flow for sample preparation and array processing to quantify gene 






Figure 3.5 Schematic of amplified cRNA procedure. Generation of targets for a one-
color microarray experiment, the Cy3-labeled “A” sample was produced and 






3.11.1 General statistics 
General statistical analyses were performed using SPSS® Version 20.0 (SPSS, 
Chicago, Illinois, USA). Data are presented as mean ± standard deviation unless 
otherwise stated. In Chapter 4 comparisons between groups were performed using 
unpaired Student’s t tests, whereas possible relationships were evaluated using 
Pearson’s correlations. Results were considered significant if p values were less than 
0.05. 
 
3.11.2 SNP genotyping statistical analysis (Chapter 6) 
Statistical analyses were performed using PLINK (version 1.06) (399). Unconditional 
logistic regression was employed to calculate ORs and their 95% CI for the minor 
allele of individual SNPs and its association with each proposed cachexia phenotype. 
All analyses were adjusted for covariates that may affect WL: age at diagnosis, sex, 
pre-diagnosis BMI, tumour type and stage.  
Patients meeting the criteria for each of the proposed cachexia phenotypes were 
compared with patients who had lost <5% body weight as control.  
To account for multiple testing, permutation testing was performed by running the 
adaptive permutation test in PLINK within each proposed phenotype. Permutation 
tests are often employed to adjust groups of correlated tests for multiple testing, since 
conventional methods such as Bonferroni correction are overly conservative when 
tests are correlated(400). The adaptive permutation test in PLINK gives up permuting 
SNPs that are clearly not going to be significant. This greatly speeds up the 
permutation procedure, as SNPs that are not significant will drop out quickly, making 
it possible to evaluate properly the significance of the handful of SNPs that require 
millions of permutations.  
Finally, candidate genes (and the SNPs in the corresponding gene regions) were 
grouped based on known functional similarity according to gene ontology using 
AmiGO (Supplementary Table 2). The set-based test in PLINK was used to analyse 
association between grouped SNPs and cachexia = phenotypes. The set-based test 
selects the best set of SNPs whose mean of these single SNP statistics is significant 
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after permutation, which is particularly suited to large scale candidate gene 
studies(401). The empirical p-values of the set-based test were obtained by a 
permutation of 10 000 times of phenotype labels. 
 
3.11.3 Transcriptomic study (Chapter 6) 
Pearson correlation analysis was conducted to assess the linear relationship between 
the considered phenotypes independently (SMI or WL) with the expression of 
transcripts from select candidate genes. T-test analysis was conducted to compare 
how SMI (or WL) values differed for patients with high expression versus those with 
low expression for each of the candidate genes. The high and low expression groups 
for each gene transcript were determined by sorting patients by expression intensity 
and subsequently splitting the patients into three equally sized groups: those with high 
expression, mid- expression and low expression. The extremes of gene expression 
were compared while leaving out middle values. Comparison of the distal ends of 
gene expression maximizes the chance of detecting differences. Given the inherent 
variation in measures of gene expression, separation of the compared categories in 
this fashion also limits potential classification error. The cases considered for SMI and 
WL phenotypes for gene expression were based on sorting of transcript expression 
in all of the samples and binning based on extremes of gene expression as described 
above. The samples used for SNP studies (based on WL or muscularity) are non-
matched as these two were independently designed studies. Transcriptome profiles 
were obtained from a single biopsy specimen along the disease trajectory of patients 
(static but not a dynamic read-out). Caution was exercised in over-interpreting the 
data with the emphasis to seek nominal relationships as it was not possible to 
delineate the expression from early vs. late response genes. A mechanistic 
understanding of the role of early and late response genes and their spatiotemporal 
relationships could be clearly discerned in animal models of cachexia (207), as 
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One impediment towards the effective treatment of cachexia is a validated 
classification system. The aim of this Chapter was to investigate the changes in 
muscle fibre biology with regards to morphological structure and composition, to study 
alteration in various pathways that may account for altered fibre size and relate these 
changes to the different diagnostic criteria that have been proposed as part of the 
recent international consensus on the classification of cancer cachexia (11). The 
validated criteria could then be used to phenotype patients for gene – association 
studies (Chapter 6). 
 
4.1.2 Methods 
41 patients with resectable upper gastrointestinal (GI) or pancreatic cancer underwent 
characterisation for cachexia based on weight-loss (WL) and/or low muscularity (LM). 
Four diagnostic criteria were used >5%WL, >10%WL, LM, and LM+>2%WL. All 
patients underwent biopsy of the rectus muscle. Analysis included 
immunohistochemistry for fibre size and type, protein and nucleic acid concentration, 
Western blots for markers of autophagy, SMAD signalling, and inflammation.   
 
4.1.3 Findings 
Compared with non-cachectic cancer patients, patients with LM or LM+>2%WL, mean 
muscle fibre diameter was reduced by about 25% (p=0.02 and p=0.001 respectively). 
No significant difference in fibre diameter was observed if patients had WL alone. 
Regardless of classification, there was no difference in fibre number or proportion of 
fibre type across all myosin heavy chain isoforms. Mean muscle protein content was 
reduced and the ratio of RNA/DNA decreased in patients with either >5%WL or 
LM+>2%WL. Compared with non-cachectic patients, SMAD3 protein levels were 
increased in patients with >5%WL (p=0.022) and with >10%WL, beclin (p=0.05) and 
ATG5 (p=0.01) protein levels were increased. There were no differences in phospho-






Muscle fibre size, biochemical composition and pathway phenotype can vary 
according to whether the diagnostic criteria for cachexia are based on weight loss 
alone, a measure of low muscularity alone or a combination of the two. For 
characterisation / biomarker studies (e.g. gene association) or intervention trials 
(where the primary end-point is a change in muscle mass or function), use of 
combined diagnostic criteria may allow identification of a more homogeneous patient 
cohort, reduce the sample size required and enhance the time scale within which trials 




Cancer cachexia has been defined recently as a multifactorial syndrome 
characterised by an ongoing loss of skeletal muscle mass (with or without loss of fat 
mass) that cannot be fully reversed by conventional nutritional support and leads to 
progressive functional impairment (11). Skeletal muscle loss appears to be the most 
significant event in cancer cachexia and is associated with a poor outcome (11, 12). 
The international consensus on the classification of cancer cachexia suggested that 
diagnostic criteria should take into account not only that weight loss is a signal event 
of the cachectic process but that the initial reserve of the patient should also be 
considered (either low BMI or low level of muscularity). Although the latter concept 
has some validation in terms of clinical risk (12), there has been no evaluation of the 
biological correlates in terms of changes within skeletal muscle itself.  
Human skeletal muscle is composed of muscle fibres that are classified depending 
on their speed of contraction and predominant type of energy metabolism. Muscle 
fibres can be classified as type I (slow-twitch) and type II (fast-twitch) fibres based on 
their predominant myosin heavy chain (MyHC) isoform content. Generally, type I and 
type IIa fibres utilise oxidative phosphorylation, whereas type IIx and IIb fibres harness 
primarily anaerobic metabolism to generate ATP. Both the percentage and structural 
morphology of the fibre type will determine the phenotypic capacity and functional 
performance of any given muscle. Environmental factors in both health and disease 
have a direct impact leading to changes in fibre type / morphology and consequent 
functionality; such processes include aging, exercise, chronic disease, and cachexia 
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(232, 236-239). The change, preservation or loss of fibres may influence clinical 
symptoms and there is some evidence that all types of MyHC is targeted selectively 
in cancer cachexia (70). Ongoing loss of protein in muscle tissue may lead to muscle 
fibre shrinkage and a reduction in cross-sectional area (CSA). Equally, loss of muscle 
fibre CSA may lead to loss of aerobic capacity (VO2 max) in healthy subjects as well 
as cancer patients (237, 245). 
Although systemic inflammation is generally thought to be an important upstream 
mediator of cancer cachexia(18), the precise molecular mechanisms that mediate the 
changes in protein synthesis and degradation that ultimately lead to atrophy of muscle 
fibres in cancer cachexia in humans are not known. For each animal model that has 
been studied, different pathways have been implicated. From such animal models 
there is a predominant impression that increased degradation via activation of the 
ubiquitin proteasome pathway (UPP) is important (18). In contrast, human data is very 
limited. Activation of protein degradation via the UPP has not been a consistent finding 
(177) (402). This has led to suggestions that autophagy may be important or that 
pathways that may influence both synthesis and degradation may be important (e.g. 
TGF-β / SMAD signalling) (290). 
In the present Chapter it was chosen to evaluate the relationship between the different 
cachexia definitions, systemic inflammation (serum C-reactive protein) and potential 
inflammatory signalling pathways within muscle (phospho-STAT3 and phospho-
NFkB). Also examined was the potential for associations between the various 
cachexia definitions and activation of autophagy pathways or TGF-β / SMAD 
signalling. 
The aim of this Chapter was to investigate the changes in muscle fibre biology with 
regards to morphological structure and composition, to study alteration in various 
pathways that may account for altered fibre size and relate these changes to the 
different diagnostic criteria that have been proposed as part of the recent international 
consensus on the classification of cancer cachexia (11). For characterisation / 
biomarker studies (e.g. gene association) or intervention trials (where the primary 
end-point is a change in muscle mass or function), use of combined, biologically 
validated diagnostic criteria may allow identification of a more homogeneous patient 
cohort, identify robust biomarkers e.g. gene association, and reduce the sample size 




4.3 Materials and methods 
(Detailed methodology is found in Chapter 3) 
 
4.3.1 Patient recruitment, identification, consent and ethics 
Patients with resectable disease and suitable for the study were identified via the 
upper gastrointestinal cancer multi-disciplinary team (MDT) meetings at the Royal 
Infirmary, Edinburgh, UK.  Written consent was given prior to entry into the study.  All 
procedures were approved by the NHS Lothian local research ethics committee. The 
study conformed to the standards set by the Declaration of Helsinki (further details in 
Chapter 3). 
 
4.3.2 Calculation of weight loss 
Pre-morbid weight was recalled by the patient and verified where possible from the 
medical notes. Although there may be recall bias, evidence to support the reliability 
of self-reported weight and weight history (403, 404) is well documented. Individual 
weight loss was calculated and expressed as percentage of pre-morbid body weight 
lost. 
 
4.3.3 Classification of cancer cachexia 
I) Weight loss >5% over past 6 months (in absence of simple starvation) 
(WL>5%) 
II) Weight loss >10% over past 6 months (in absence of simple starvation) 
(WL>10%) 
III) Stature adjusted skeletal muscle index consistent with low muscularity 
(LM) (see ‘CT-image analysis’ for cut-offs) 
IV) Stature adjusted skeletal muscle index consistent with low muscularity and 





4.3.4 Rectus abdominis muscle biopsy 
All biopsies were taken at the start of open abdominal surgery under general 
anaesthesia. The edge of the rectus abdominis was exposed and a 1cm3 specimen 
removed using sharp dissection. The biopsy was cleaned of gross blood 
contamination.  Obvious fat/fibrous tissue was removed prior to placement in a 
cryotube and being snap frozen in liquid nitrogen and stored at -80°C. 
 
4.3.5 Rectus abdominis muscle sample preparation for cryo-
section 
A 0.1 – 0.5cm3 section of muscle was cut.  Liquid nitrogen was used to cool 
isopentane solvent in a tube to a temperature of ~-190°C. The section of muscle was 
stitched onto a segment of cork.  OCT solution was placed at the junction between 
the cork base and the muscle.  This was then lowered with the cork uppermost (i.e. 
muscle first) into cooled solvent and held for approximately 5 minutes (until the muscle 
was frozen).  Samples were then stored at -80°C until use. 
 
4.3.6 CT image analysis 
CT scans used for analysis were performed solely for routine cancer care. The 
technique for CT image analysis has been described in detail in Chapter 3.  
Estimates of whole body stores were generated from the raw data (cm2) using the 
regression equations by Mourtzakis et al.(397), as detailed in Chapter 3 
Cutoffs for low muscularity were based on a CT-based sarcopenic obesity study of 
cancer patients by Prado et al. (i.e., L3 skeletal muscle index: ≤38.5 cm2/m2 for women 
and ≤52.4 cm2/m2 for men) (28). 
 
4.3.7 Immunohistochemistry  
The frozen muscle sections were co-stained to distinguish each fibre type. The 
paraffin sections were stained for phospho-STAT3. Images of the entire tissue section 
were acquired using a VS120 slide scanner (Olympus Corporation, Tokyo, Japan). 
91 
 
The distribution of myosin heavy chain fibre types, the cross section area of the 
individual fibres in the section, and the phospho-STAT3 positive nuclei and staining 
density were analysed using the proprietary image analysis platform ASTORIA 
(Automated Stored Image Analysis) developed by Novartis/Preclinical Safety. Further 
details in Chapter 3. 
 
4.3.8 Tissue Preparation for DNA, RNA and Protein extractions 
Skeletal muscle tissue was minced and ground on dry ice. Aliquots were weighed 
using an analytical balance (Mettler Toledo) and stored at -80°C until use.  
 
4.3.9 DNA and RNA extraction and linearity of the extraction 
method 
DNA and RNA from human skeletal muscle tissue was extracted and purified with the 
automated Maxwell 16 system (Promega, Duebendorf, Switzerland). Aliquots of 4-
8mg human skeletal muscle tissue were used for all subsequent DNA and RNA 
extractions. Further details in Chapter 3. 
For DNA extraction, the Maxwell 16 LEV Blood DNA Kit (Promega) was used with a 
slightly adapted protocol compared with the manual’s instructions (Chapter 3). For 
RNA extraction, the Maxwell 16 LEV simplyRNA Tissue Kit was used (Promega), 
following the manual’s instructions (Chapter 3).  
 
4.3.10 Protein extractions 
Protein was extracted according to the methods in Chapter 3 and the samples were 
stored at -80°C until further use. 
 
4.3.11 Western blots 
Western blotting was performed in line with the methods set out in Chapter 3, then 
were analyzed densitometrically using ImageJ software version 1.45 (NIH, Bethesda, 
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MD, USA; http://rsbweb.nih.gov/ij). Band intensity of each sample was normalised to 
that of α-tubulin. 
 
4.3.12 C - reactive protein (CRP) 
Serum CRP concentration was measured with an automated immunoturbidimetric 
assay by clinical chemistry department, Royal infirmary Edinburgh, using blood 
collected from patients at the time of recruitment and before any therapeutic 
intervention. 
 
4.3.13 Statistical analysis 
Results are expressed as mean (± SEM). Comparisons between groups were 
performed using unpaired Student’s t tests, whereas possible relationships were 
evaluated using Pearson’s correlations. Results were considered significant if p 
values were less than 0.05. The program SPSS (version 20, SPSS, Chicago, IL, USA) 
was used for all the statistical tests. 
 
4.4 Results 
4.4.1 Patient demographics 
A total of 41 cancer patients with resectable UGI or pancreatic cancer were recruited. 
In general, patients were over 65 years of age, predominantly male and had 
sustained, on average, 5% loss of weight compared with pre-illness levels (Table 4.1). 
Patients were grouped based upon the concepts of the International Classification 
Framework (11) according to weight loss or weight loss in association with low 
muscularity. The specific phenotypes considered were weight loss >5% (WL>5%), 
weight loss >10% (WL>10%), low muscularity (LM), and LM with weight loss >2% 
(LM+>2% WL). Although BMI was reduced in all groups classified as cachectic, only 






Table 4.1 - Demographic data of the patients involved in the study. Data (except gender split) are presented as mean (SEM). * = cachexia 
group significantly different from the non-cachexia group, (p < 0.05 by Student’s t test). Abbreviations – CRP = C - reactive protein, BMI = 
Body Mass Index. 
 All 
Patients 
(n = 41) 
Weight 
Stable  
(n = 23) 
Weight 
Loss >5%  
(n = 18) 
p Weight 
Stable  




(n = 11) 
p Normal 
Muscularity 
(n = 9) 
Low 
Muscularity 
(n = 32) 
p Not Low 
Muscularity 
+ >2% W/L  
(n = 24) 
Low 
Muscularity 
+ >2% W/L 
(n = 17) 
p 
Age 65 ± 2 67 ± 2 63 ± 2 0.216 65 ± 2 66 ± 2 0.849 61 ± 3 66 ± 2 0.128 65 ± 2 66 ± 2 0.727 





83 ± 3 83 ± 4 81 ± 4 0.748 82 ± 3 83 ± 5 0.912 86 ± 7 81 ± 3 0.487 84 ± 4 81 ± 4 0.602 
Weight 
Loss (%) 
5 ± 1 0 ± 1 12 ± 1 0.000* 2 ± 1 15 ± 2 0.000* 5 ± 3 6 ± 1 0.752 2 ± 1 11 ± 1 0.000* 
BMI 26 ± 1 28 ± 1 24 ± 1 0.016* 27 ± 1 24 ± 1 0.048* 29 ± 2 25 ± 1 0.050* 28 ± 1 24 ± 1 0.013* 
Body Fat 
(kg) 





(kg / m2) 
16 ± 0 16 ± 1 15 ± 1 0.057 16 ± 1  15 ± 1  0.143 17 ± 1 15 ± 0 0.026* 17 ± 1 14 ± 0 0.001* 
CRP 
(mg/L) 




4.4.2 Muscle fibre size, number, and type 
If patients were classified as cachectic by LM or LM + >2%WL, fibre size was reduced 
significantly (all types of myosin heavy chain fibre) when compared with non-cachectic 
patients and controls (Figure 4.1A). The association of cachexia with reduced fibre 
size was not observed if patients were classified according to WL alone. 
Representative immunohistological sections demonstrating differences in fibre 
diameter between a healthy control and an individual in Group II versus Group IV is 
shown in Figure 4.1B. Immunohistology for type I and IIa resulted in complementary 
staining in general, whereas fibre type IIb resulted in very low staining intensity as 
reported elsewhere (405); therefore quantitative analysis was done only with type I 
and IIa but not with type IIb (Table 4.2). As would be expected from a decrease in 
fibre size, there was a trend across all groups for fibre density to increase in those 
with cachexia. However, due to large variability, this was not statistically significant. 
There was no evidence of selective fibre atrophy across any of the classification 










Figure 4.1 - Fibre type cross sectional area (FCSA) according to different definitions 
of cachexia. (A) Mean (± SEM) fibre size for both MyHC1 and MyHCIIa. A comparison 
is made between patients with the proposed cachexia definition absent (dark grey) 
and those with the proposed cachexia definition present (light grey) for the four 
definitions set out in Methods (I-IV). (*, P < 0.05 and **, P < 0.01, by Student’s t test). 
(B) Immunohistological sections of muscle for a healthy control, patient with weight 
loss alone (10.1%) (Group II), and patient with low muscularity and >2% weight loss 



































(n = 27) 
Weight 
Stable  



























y + >2% 
W/L  
(n = 15) 
Low 
Muscularity 
+ >2% W/L 
(n = 12) 
p-  
Value 
Age 66 ± 2 67 ± 2 64 ± 2 0.321 66 ± 2 65 ± 2 0.791 63 ± 3 66 ± 2 0.370 65 ± 2 66 ± 2 0.882 
Sex (M:F) 24 : 3 15 : 0  9 : 3  18 : 1 6 : 2  4 : 0 20 : 3  15 : 0 9 : 3  
Pre Illness 
Weight (kg) 
85 ± 4 83 ± 5 88 ± 5 0.537 83 ± 4 89 ± 6 0.482 104 ± 12 82 ± 3 0.018* 86 ± 5 84 ± 5 0.737 
Weight Loss 
(%) 
5 ± 1 0 ± 1 12 ± 1 0.000* 2 ± 1 14 ± 2 0.000* 5 ± 2 5 ± 2 0.947 1 ± 1 11 ± 2 0.000* 
BMI at time 
of biopsy 
26 ± 1 27 ± 2 25 ± 1 0.381 29 ± 1 25 ± 1 0.454 33 ± 3 25 ± 1 0.003* 28 ± 1 24 ± 1 0.035* 
Body Fat 
(kg) 




48 ± 2 49 ± 2 46 ± 2 0.217 48 ± 2 46 ± 2 0.459 59 ± 3 46 ± 1 0.000* 51 ± 2 44 ± 2 0.012* 
Free Fat 
Mass Index  
(FFM) (kg / 
m2) 

















Table 4.2 - Myosin heavy chain fibre data of the patients involved in the study. Data (except gender split) are presented as mean (SEM). * 
= cachexia group significantly different from the non-cachexia group, (p < 0.05 by Student’s t test). Abbreviations – BMI = Body Mass 





(n = 27) 
Weight 
Stable  



























y + >2% 
W/L  
(n = 15) 
Low 
Muscularity 
+ >2% W/L 























































































0.119 937 ± 179 1296 ± 
169 







627 ± 96 525 ± 160 756 ± 92 0.427 506 ± 
127 
915 ± 133 0.217 406 ± 86 666 ± 
112 
0.353 653 ± 
160 
596 ± 97 0.777 
Group 
MyHCIIa 
621 ± 94 503 ± 147 769 ± 
101 
0.067 519 ± 
120 
863 ± 131 0.163 594 ± 117 693 ± 
106 
0.706 682 ± 
146 
676 ± 142 0.976 
Fibre Type 
(%) 
             
MyHCI 48 ± 3 49 ± 4 41 ± 3 0.128 48 ± 3 38 ± 5 0.079 43 ± 3 46 ± 3 0.691 48 ± 4 42 ± 4 0.230 
MyHCIIa 55 ± 2 52 ± 3 59 ± 2 0.107 54 ± 3 58 ± 3 0.388 64 ± 3 53 ± 2 0.099 55 ± 3 55 ± 3 0.978 
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4.4.3 Protein content 
The results for skeletal muscle protein content are shown in Figure 4.2A. When 
compared with non-cachectic patients, muscle protein content was reduced 
significantly (approximately 13%) in patients with either >5% WL or LM + >2%WL 
(Figure 4.2A and Table 4.3). However if the LM criteria were applied alone no 
difference in the protein content was observed. In addition, patients with >10% WL 
showed a 10% reduction in protein content when compared with non-cachectic 
patients but this difference did not reach statistical significance (Figure 4.2A and Table 
4.3).  
 
4.4.4 RNA, DNA, and RNA / DNA Ratio 
The results for skeletal muscle DNA and RNA content are also shown in Figure 
4.2(B,C, and D) and Table 4.3. RNA content was not significantly different in cachectic 
patients when compared with non-cachectic patients according to any of the 
diagnostic criteria (Figure 4.2B and Table 4.3). In contrast, DNA content was 
increased by 50% with >5% WL but decreased by ~40% in patients with LM (Figure 
4.2C). The ratio of RNA / DNA was decreased (approximately 30%) in patients with 







Figure 4.2 - Variations in protein and nucleic acid content according to the different 
definitions of cancer cachexia. A comparison is made between patients with the 
proposed cachexia definition absent (dark grey) and those with the proposed 
cachexia definition present (light grey) for the four definitions set out in the methods 
(I-IV). (A) Mean (± SEM) wet weight protein content. (B) Mean (± SEM) RNA content. 
(C) Mean (± SEM) DNA content. (C) Mean (± SEM) RNA / DNA ratio. (*, P < 0.05 by 




Table 4.3 - Protein, DNA, and RNA content of the patients involved in the study. Data (except gender split) are presented as mean (SEM). 
* = cachexia group significantly different from the non-cachexia group, (p < 0.05 by Student’s t test). 
 All 
Patients 
(n = 32) 
Weight 
Stable  
(n = 17) 
Weight Loss 
>5%  





(n = 22) 
Weight Loss 
>10%  





(n = 7) 
Low 
Muscularity 





+ > 2% W/L  
(n = 18) 
Low 
Muscularity 
+ > 2% 
W/L 
































0.83 ± 0.09 0.71 ± 0.07 0.273 0.79 ± 0.07 0.75 ± 0.09 0.742 0.63 ± 
0.05 





4.4.5 Autophagy pathways 
All raw Western blotting data can be seen in Figure 4.6. In patients with >10% WL, 
Beclin and ATG5 protein levels were increased significantly in cachectic patients 
when compared with non-cachectic patients (Figure 4.3). ATG7 and 12 levels were 
not different in cachectic patients when compared with non – cachectic patients 





Figure 4.3 - Skeletal muscle Beclin and ATG5 protein levels in patients with or without 
>10% weight loss (Group II). Western blot analysis with indicated antibodies, α-tubulin 
was used as a loading control. Graph shows the mean (± SEM) protein level 





Table 4.4 - Western blots for protein markers of cellular signalling. Data are presented as mean (SEM). Immunohistology data is shown for 
phospho-STAT3 and is recorded as staining density of nuclei (A.U.). * = cachexia group significantly different from the non-cachexia group, 





(n = 14) 
Weight Loss 
>5%  





(n = 19) 
Weight Loss 
>10%  





(n = 8) 
Low 
Muscularity 





>2% W/L  




(n = 11) 
p-  
Value 
Beclin (A.U) 0.73 ± 0.03 0.77 ± 0.04 0.452 0.72 ± 0.02 0.81 ± 0.05 0.050* 0.70 ± 0.03 0.77 ± 0.03 0.232 0.72 ± 0.03 0.79 ± 0.04 0.153 
ATG5 (A.U) 0.80 ± 0.03  0.83 ± 0.04 0.614 0.77 ± 0.03 0.9 ± 0.04 0.013* 0.75 ± 0.05 0.84 ± 0.03 0.137 0.81 ± 0.03 0.82 ± 0.05 0.865 
ATG12 (A.U) 0.86 ± 0.04 0.87 ± 0.04 0.898 0.84 ± 0.03 0.93 ± 0.05 0.090 0.83 ± 0.05 0.89 ± 0.03 0.313 0.86 ± 0.03 0.88 ± 0.04 0.720 
ATG7 (A.U) 0.89 ± 0.05 0.87 ± 0.05 0.741 0.85 ± 0.04 0.96 ± 0.07 0.136 0.85 ± 0.08 0.89 ± 0.04 0.617 0.89 ± 0.04 0.86 ± 0.06 0.682 
phospho-
SMAD3 (A.U) 
0.88 ± 0.04 0.98 ± 0.04 0.116 0.91 ± 0.04 0.97 ± 0.04 0.343 0.87 ± 0.07 0.95 ± 0.03 0.171 0.90 ± 0.04 0.98 ± 0.04 0.191 




1.08 ± 0.06 1.08 ± 0.05 0.972 1.07 ± 0.05 1.11 ± 0.07 0.630 0.98 ± 0.05 1.12 ± 0.05 0.107 1.06 ± 0.05 1.12 ± 0.06 0.467 
phospho-NF-
κB (A.U) 






17.9 ± 1.34 15.5 ± 0.62 0.105 17.4 ± 1.03 15.1 ± 0.74 0.170 16.3 ± 0.95 16.7 ± 1.00 0.817 17.2 ± 1.10 15.6 ± 0.80 0.311 
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4.4.6 SMAD signalling 
In patients with >5% WL, SMAD3 protein levels were significantly increased when 
compared with non-cachectic patients (Figure 4.4). There were no significant 





Figure 4.4 - Total SMAD3, phospho-SMAD3 and ratio of phospho-SMAD3 / SMAD3 
in patients with or without >5% WL (Group I) levels. Western blot analysis with 
indicated antibodies, α-tubulin was used as a loading control. Graph shows the mean 












4.4.7 Inflammatory pathways 
Systemic inflammation was estimated using patients’ serum CRP levels (Table 4.1). 
Patients were classified as having systemic inflammation if their CRP was ≥ 10 mg/L. 
There was no difference in the proportion of patients with or without systemic 
inflammation according to the definition of cachexia. Levels of phospho-NFκB and 
phospho-STAT3 were not significantly different in patients with or without cachexia 






Figure 4.5 - Inflammatory pathways in patients with (CRP >10mg/L) and without (CRP 
≤10mg/L) systemic inflammation. (A) Graph shows the mean (± SEM) protein level of 
phospho-NF-κB, represented in arbitrary units (A.U). (B) Representative 
immunohistochemistry and nuclei count of phospho-STAT3 (area shown is 
representative of field) of a patient with or without systemic inflammation. (C) Graph 
shows the staining density of phospho-STAT3 nuclei (A.U.) (± SEM) in the presence 





Figure 4.6 - Western Blots (beclin, atg5, atg7, atg12, p-NFKB, P-SMAD3, SMAD3, 
and alpha tubulin) of protein extracts from the skeletal muscle of healthy controls (C) 
and cancer patients with (Y: yes) or without (N: no) weight-loss (WL) >5% or >10% of 
pre-illness stable weight. Each gel for each protein was run separately. Alpha-tubulin 
(loading control) was not included in each gel but rather was used as a benchmark 
for the standardised 20 micro gram of protein added to every well of each gel. The 















4.5.1 Fibre size 
The diagnostic criterion for cancer cachexia has long been based on weight loss alone 
(11) and can reflect loss in either fat or lean tissue compartments. Given that the key 
tissue loss in cancer cachexia is considered to be skeletal muscle, a recent consensus 
process suggested that the diagnostic criteria for cachexia should also take account 
of low baseline levels of muscularity (11). In the present study, when patients were 
classified as cachectic or not according to ≥ 5% weight loss there was no significant 
difference in whole body muscularity (FFMI) or muscle fibre CSA. In contrast, when 
patients were classified according to low muscularity and ≥ 2% weight loss, FFMI was 
decreased and fibre cross sectional area was also significantly reduced (Figure 4.1). 
Such findings demonstrate that heterogeneity in relation to low muscularity and fibre 
atrophy may be reduced according to the clinical definition of cachexia. This finding 
may be important especially when considering inclusion criteria for clinical trials that 
aim to test the efficacy of drugs targeted at reversal of muscle wasting in cancer 
patients. The reduction in fibre size in all MyHC isoforms observed in the present 
study is consistent with previous animal (254) and human studies of cancer cachexia 
(236-239). The rectus muscle of patients with oesophago-gastric cancer cachexia has 
been shown to lose all type MyHC content as well as undergo a reduction in fibre size 
(236).  Equally, in pancreatic cancer patients with cachexia, both type I and type II 
MyHC protein levels were decreased by 45% when compared with controls (238).  
 
4.5.2 Fibre type 
In order to study differences in muscle fibre morphology and composition within the 
different cachexia categories, immunohistochemical analysis of human muscle 
samples was performed. For that, the staining methods for the myosin heavy chain 
antibodies specific for the different fibre types (I, IIa, and IIb) was established and 
validated. Staining for type I and IIa fibres resulted in strong specific staining 
specificity, however only weak staining was observed against type IIb MyHC, this 
finding has also been reported elsewhere (405). The predominant types of MyHC fibre 
in rectus abdominis muscle are I and IIa and only <8% of type IIb positive fibres have 
previously been described (406). Of the adult skeletal isoforms, each are expressed 
to varying degrees in both mouse and human skeletal muscle. However, although 
MyHCIIb is highly expressed at both the messenger RNA (mRNA) and protein level 
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in murine skeletal muscle, evidence to date suggests that this isoform is effectively 
only expressed at the mRNA level in a very small subset of specialised muscles in 
the adult human (407). As mentioned above, MyHCIIb expression is typically 
associated with high forces of contraction combined with rapid contractile 
characteristics and it has been suggested that the contractile characteristics of 
MyHCIIb may be incompatible with the biomechanical constraints of larger muscles 
(408), which may account for the lack of specificity found in the rectus muscle of our 
patient population. 
In cachexia there is conflicting evidence as to whether there is selective loss of fibre 
type. There was no evidence for selective loss of fibre type in the present study (Table 
4.2). Evidence from animal models suggests that Type II fibres are targeted 
selectively (179), with relative preservation of type I fibres in fasting (249), exposure 
to glucocorticoids (250), sepsis (252) and in the gastrocnemius muscle of the C26 
model of cancer cachexia (253, 327).  Models of cardiac cachexia, however have 
suggested a trend to selective loss of type I fibres and an increase in type II fibre 
(240). Furthermore, not all groups have demonstrated Type I and II fibre differences 
even in animals. Indeed in a recent study of the C26 cachectic mouse model, both 
glycolytic and oxidative fibres of (extensor digitorum longus) EDL muscle underwent 
wasting (254), whilst in a previous study using the same mouse model there was a 
significant increase in the amount of MyHCIIb and a significant decrease in the 
amount of type 1 MyHC in soleus muscle (255). It is currently not entirely clear which 
type of fibres are affected in human cancer cachexia, however, in patients with 
oesophago-gastric cancer cachexia early loss of all MyHC isoforms has been 
reported (236).   
The activity patterns of a muscle are also key in determining phenotype. If muscle 
cells are recruited infrequently they develop into fast/glycolytic units whereas if they 
are recruited more often, they form slow/oxidative units.  In the C26 mouse model of 
cancer cachexia, there have been reports of switching of myosin isoforms in the 
soleus muscle of cachectic mice (255). In pancreatic cancer patients with cachexia, 
no difference in the ratio of fast/slow myosin isoform was demonstrated compared 





4.5.3 Muscle RNA, DNA, and protein content  
In the present study, when compared with non-cachectic patients, muscle protein 
content was reduced significantly (approximately 13%) if patients were classified as 
cachectic by either >5% WL (p=0.015) or LM + >2%WL (p=0.035), and by 10% in 
patients with >10% WL. Protein content expressed in relation to wet weight of muscle 
has been shown to decrease progressively (in excess of 50%) in the gastrocnemius 
muscle of mice bearing the MAC-16 tumour (257). This suggests that not only is there 
loss of fibre diameter, but that the quality of the fibre is altered with loss of either 
sarcoplasmic or myofibrillar protein. Such changes in fibre composition may 
contribute to the reduced muscle mechanical quality (force per unit cross-sectional 
area) observed in human cancer cachexia (213). 
 A reduction in both RNA content and activity in skeletal muscle has been attributed 
to a depression of protein synthesis in mice bearing the MAC16 tumour (257) . In the 
present study, RNA content was unaltered in cachectic patients (classified either with 
>5% WL or LM + >2% WL) compared with non-cachectic patients. A reduction in the 
RNA content in the muscle of mice bearing the Ehrlich ascites tumour has also been 
reported, but this occurred later than the observed depression in the rate of protein 
synthesis (258). Whether muscle protein synthesis is depressed in human cancer 
cachexia remains to be resolved (18). 
In a murine model of cancer cachexia DNA content of the gastrocnemius muscle has 
been shown to remain relatively constant, despite the finding of a decrease in protein 
and RNA content (257). The current study demonstrated DNA content was increased 
by >50% with >5% WL but decreased by 40% in patients with LM (Figure 4.2C). 
Because mature myofibre nuclei are thought to be mitotically inactive, increased DNA 
content in skeletal muscle cells suggests activation of satellite cells (409) or infiltration 
by other cell types such as inflammatory cells or adipocytes. In the LM group, the 
decrease in DNA may be due to pre-existing age-related sarcopenia or other causes 
of muscle atrophy (e.g. immobilisation) and may relate to muscle specific apoptosis 
and reduction in cell number in keeping with a reduction in muscle mass on CT 
scanning. The diametrically opposite changes in muscle DNA content dependent on 
whether patients are classified according to weight-loss or low muscularity again 
underpin the potential diverse mechanisms whereby older cancer patients may 




The issue of whether nuclear domain size is reduced in cancer cachexia remains to 
be resolved. In particular, whether apoptosis in skeletal muscle is increased in cancer 
cachexia and the degree to which DNA content is maintained or not via a 
compensatory increase in myonuclear number (possibly via satellite cell nuclei 
incorporation) is not known. Features of cachexia such as hypogonadism (resulting 
in low testosterone) or systemic inflammation (associated with high IL-6) could 
influence such regenerative capacity. In the current study RNA / DNA was altered in 
the cachectic patients (independent of definition) compared with the non- cachectic 
patients. This may be due to the interplay of the mechanisms described above.  
 
4.5.4 Mechanisms  
Skeletal muscle atrophy may occur as a result of decreased synthesis, increased 
degradation or both (79). In mice bearing the MAC-16 adenocarcinoma, muscle loss 
is due to the combination of reduced synthesis and increased degradation (277). 
Similarly Samuels et al demonstrated reduced protein synthesis and increased 
degradation in skeletal muscle co-incident with the onset of cachexia in mice 
implanted with the C26 murine model (410). Recently a study used a novel technique 
to measure habitual myofibrillar protein synthesis in patients with cancer compared 
with healthy controls. Contrary to previous studies, there was no evidence of 
suppression of myofibrillar protein synthesis in patients with cancer cachexia. This 
finding implies a small increase in muscle breakdown may account for muscle wasting 
(80). 
 
4.5.5 Degradation pathways 
The majority of signalling pathways contributing to muscle atrophy in pre-clinical 
models are mediated through activation of the ubiquitin-proteasome proteolytic 
pathway (UPP) (82). The muscle-specific E3 ubiquitin ligases, MuRF-1 and 
MAFbx/atrogin-1 are up regulated in animal models of acute atrophy (83, 84), and 
MuRF1 selectively targets the myofibrillar protein myosin heavy chain resulting in 
muscle wasting (70). However, the role of the E3 ligases in human cachexia is less 
well defined. The current study did not measure directly these pathways as results 
from our previous investigation on a similar cohort of patients found no up regulation 
using a transcriptomics approach (89), this has also been validated recently in a 
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separate cohort of patients with gastric cancer(411). In the present study autophagy 
proteins (ATG) 5, 7, 12, and beclin 1 were studied. These proteins are necessary for 
autophagy due to their role in autophagosome elongation (412). When patients were 
classified according to >10% WL, Beclin and ATG5 protein levels were significantly 
increased in cachectic patients when compared with non-cachectic patients. In a 
previous study in a similar cohort of patients, the autophagy related genes 
GABRAPL1 and BNIP3 were increased in rectus muscle biopsies from cachectic 
versus non-cachectic patients (89). In normal muscle, low-protein diets up-regulate 
autophagy that leads to the loss of muscle mass at least partially through lysosomal 
degradation (413). Intriguingly, under other circumstances decreased autophagy can 
also lead to muscle atrophy. 
 
4.5.6 Systemic Inflammation 
Systemic inflammation is thought to be a major mediator of cancer cachexia (18). 
However, the relationship between inflammation in the systemic compartment versus 
muscle and the relationship of either to muscle loss in humans is not clear. In the 
systemic compartment, Il-6 is thought to be a major mediator and may signal within 
target organs via STAT-3. Alternatively, both IL-1 and TNF alpha may signal via NF-
kB. NF-kB regulation of muscle atrophy is predominantly executed by promoting 
proteasome-mediated degradation (143). Activation of NF-kB has been detected in 
both physiological and pathological atrophic conditions such as denervation, 
unloading, aging, cancer, sepsis, diabetes, and such atrophy can be reversed by 
pharmacologic or genetic NF-kB inhibition (414). In the present study although there 
was evidence for systemic inflammation in a proportion of patients, no significant 
difference was found in the levels of phospho-NFkB or phospho-STAT3 across any 
of the definitions of cachexia or in those with or without evidence of systemic 
inflammation. It is possible that inflammatory mediators have their main effects on 
muscle atrophy via central mechanisms mediated via the CNS (33).  
 
4.5.7 SMAD3 
It has been suggested that binding of myostatin to the ACVR2B receptor results in the 
phosphorylation of two serine residues of SMAD2 or SMAD3. This leads to the 
assembly of SMAD2/3 with SMAD4 to the heterodimer that is able to translocate to 
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the nucleus and activate transcription of target genes (415). One of the known 
downstream targets of SMAD signalling is MyoD, a transcriptional factor that is 
involved in skeletal muscle development and takes part in the repair of damaged 
skeletal muscle (416). Moreover, SMAD signalling targets other genes such as myf5 
and myogenin, known to be important for myogenesis (417). Myostatin is upregulated 
in cachexia and in states of muscle paralysis (418). Myostatin/ACVR2B activates 
SMAD2/3 signalling and importantly SMAD2/3 inhibition completely desensitises 
ACVR2B-induced muscle atrophy (290). Inhibition of myostatin by a dominant 
negative ACVR2B promotes muscle hypertrophy independent of muscle satellite cell 
recruitment consistent with a direct signalling effect on muscle catabolism (290). 
When patients were classified as cachectic according to >5% WL, SMAD3 protein 
levels were significantly increased in cachectic patients when compared with non-
cachectic patients. Equally there was a similar (but not significant) increase in 
phospho-SMAD3 associated with >5% weight loss. It is not known whether such 
increased protein levels indicate increased pathway activity independent of any 
alteration in the ratio of phospho-SMAD3/SMAD3.   
 
4.5.8 Limitations of study 
It is important to appreciate that the majority of patients in the present series will have 
had some degree of age-related sarcopenia, that this will necessarily co-exist with 
any cancer specific loss of skeletal muscle mass and that the diagnostic criteria used 
in the present study will not necessarily separate one from the other. The current study 
was not longitudinal and it was therefore not possible to document active muscle loss. 
It is also important to recognise that when patients were divided into different 
diagnostic categories the sample size in individual categories may have limited the 
ability to detect a statistical difference or not. This was an exploratory study and 
provides the basis for a larger study with adequate statistical power for definitive 
analysis.  
 
4.5.9 Conclusions   
In the present Chapter, when the diagnostic criteria for cachexia included both a 
measure of low muscularity and weight loss, muscle fibre size, protein content and 
RNA/DNA content were all reduced. Such consistent findings were not observed 
when cachexia was diagnosed based on weight-loss or low muscularity alone. 
Whereas fibre type is not targeted selectively, muscle fibre size, biochemical 
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composition and pathway phenotype can vary according to whether the criteria for 
cachexia include both a measure of low muscularity and weight loss. Such findings 
suggest that current diagnostic criteria identify groups of patients with different 
skeletal muscle phenotypes. Identification of a more homogeneous patient cohort for 
musculo-centric intervention trials may require use of combined criteria. The findings 
in this Chapter where therefore used in the accurate phenotyping of patients suffering 
from cancer cachexia to provide novel insights into genetic targets potentially 























Genetic basis of inter individual 
susceptibility to cancer 
cachexia: selection of potential 
candidate gene polymorphisms 








5.1.1 Aims  
Part of the variation in who will and who will not develop cancer cachexia may be 
genetically determined. As new definitions, classifications and biological targets 
continue to evolve a need for the reappraisal of the literature for future candidate 
association studies is needed. This Chapter summarises genes identified or 
implicated as well as putative candidate genes contributing to cachexia, identified 
through diverse technology platforms and model systems and forms the basis for 
selection of SNPs used in Chapter 6.  
 
5.1.2 Methods 
A systematic search covering 1986–2012 was performed for potential candidate 
genes/genetic polymorphisms relating to cancer cachexia. All candidate genes were 
reviewed for functional polymorphisms or clinically significant polymorphisms 
associated with cachexia using the OMIM and GeneRIF databases. Pathway analysis 
software was used to reveal possible network associations between genes. 
Functionality of SNPs/genes was explored based on published literature, algorithms 
for detecting putative deleterious SNPs and interrogating the database for expression 
Quantitative Trait Loci (eQTLs). 
 
5.1.3 Results 
A total of 154 genes associated with cancer cachexia were identified and explored for 
functional polymorphisms. Of these 154 genes, 119 had a combined total of 281 
polymorphisms with functional and/or clinical significance in terms of cachexia 
associated with them. Of these, 80 polymorphisms (in 51 genes) were replicated in 
more than one study with 24 polymorphisms found to influence two or more hallmarks 








Selection of candidate genes and polymorphisms is a key element of multigene study 
design. The present Chapter provides a contemporary basis to select genes and/or 
polymorphisms for further association studies in cancer cachexia (see Chapter 6). 
 
5.2 Introduction 
The degree of cancer cachexia patients suffer is variable depending upon the 
phenotype and genotype of both patient and tumour. It is likely there maybe cachexia 
prone genotypes as well as cachexia resistant genotypes. A recent longitudinal study 
of patients with a variety of cancers has demonstrated some will remain stable, lose 
or gain skeletal muscle or adipose tissue (419), further strengthening the concept of 
a genetic predisposition to wasting in the presence of cancer.  
Single nucleotide polymorphisms (SNPs) are the most common type of heritable and 
evolutionarily stable genetic variations in the population (420); other genetic 
polymorphisms include copy number aberrations, insertion, deletions and tandem 
repeats. SNPs may exert differing effects on genes leading to an aberrant gene 
product. Polymorphisms in promoter regions potentially contribute to differential gene 
expression, presumably affecting the binding of transcription factors to DNA.  SNPs 
present in the 5’ untranslated region (UTR) may alter mRNA translation, whereas 
SNPs in the 3’ UTR could alter mRNA via post-transcriptional mechanisms such as 
splicing, maturation, stability and export. Polymorphisms in intronic regions may result 
in cis- or trans regulation of genes, unmask cryptic splice sites or promoters leading 
to alternative transcripts. Synonymous and non-synonymous SNPs in exons could 
alter protein function or activity and may introduce codon bias contributing to the 
relative abundance of the proteins, respectively, finally non sense mutations cause a 
stop altogether in the translation of mRNA (421). The genomic distribution of SNPs is 
not homogenous, SNPs usually occur in non-coding regions more frequently than in 
coding regions or, in general, where natural selection is acting and fixating the allele 
of the SNP that constitutes the most favourable genetic adaptation (422). 




The case to support a genetic predisposition to cachexia is strengthened from the 
known genetic contribution to the activity of a variety of key mechanisms that underlie 
the cachexia syndrome. In a previous systematic review on the identification of 
possible genetic polymorphisms involved in cancer cachexia, a total of 184 
polymorphisms with functional or clinical relevance to cancer cachexia were identified 
in 92 candidate genes (193). Following this approach here in, 23 significant SNPs 
associated with cachexia based on definitions of weight loss and systemic 
inflammation (measured with CRP) were identified and a SNP in the SELP gene 
encoding for P – selectin was validated in an independent cohort. P – selectin binds 
to leukocytes and in certain inflammatory conditions, the plasma concentration of 
soluble P – selectin is highly elevated (194). By incorporating a definition based on 
systemic inflammation a SNP involved in the innate immune response was identified. 
Most of the work on identification of SNPs involved in cancer cachexia to date has led 
to the discovery of other SNPs involved in the innate immune system, mainly in the 
interleukin family of cytokines (195-202) (Table 5.1). SNPs in other biological 
processes have also been studied for their association with cancer cachexia (203, 
204) (205) (Table 5.1). By altering the phenotype for a degree of skeletal muscle 
quantification, it may be possible to identify SNPs associated with muscle tissue 
biology. 
The main aim of this thesis is to investigate further the potential genetic basis for 
cancer cachexia. To enable further candidate gene selection studies with larger 
cohorts, new targets need to be identified in order to maximise the potential for 
associations. An increase in sample size from before will increase the power of further 
studies to identify novel SNPs.  To accommodate the evolving phenotype definitions 
and the current state of the understanding of cachexia, the search was conducted for 
candidate genes or pathways related to the biology of muscle, inflammation, adipose 
tissue, obesity, diabetes and molecular mechanisms of cancer in general, as well as 
factors affecting survival and prediction of outcomes following treatments. There is an 
express need to re-strategise the selection of candidate genes to drive association 
studies since “omics” approaches uncovered the hitherto unexplored biological 
pathways in the past five years in the realm of cancer and genetic predisposition 
markers for a host of diseases and traits. In view of the increased understanding of 
the biology of cancer cachexia, the search terms used have been amended as both 
the biology and classification of cancer cachexia continues to evolve. This study 
suggests that insights into the functional significance of the candidate gene SNPs will 
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help explore the putative causality of the SNPs. These approaches would likely 
strengthen the premise for hypothesis driven phenotype-genotype association studies 
for polygenic diseases/traits, vis-à-vis potential to identify variants with higher effect 
size and hence heritable component of the cachexia risk in individuals. Functionality 
of SNPs/genes was explored based on published literature, algorithms for detecting 
putative deleterious SNPs and databases for expression Quantitative Trait Loci 
(eQTLs) (423-427). Inter-individual variations in susceptibility to cancer induced 
cachexia and the heritable component of the genome when fully delineated would 
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(1) >5% Weight loss 
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Phenotype is greater 
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The U.S. National Library of Medicine database, MEDLINE; the Excerpta Medica 
database, EMBASE; Cochrane Central Register of Controlled Trials, CENTRAL; and 
the database of the Cumulative Index to Nursing and Allied Health Literature, 
CINAHL, were searched through the National Library of Health website, the Cochrane 
library, PUBMED (free citation database of MEDLINE), and Grey literature online.   
The first aim was to identify articles with new potential candidate genes involved in 
the development of cancer cachexia using the key word search ‘genes/genetics and 
inflammation OR cancer OR cachexia OR weight loss OR body composition OR 
survival OR muscle OR adipose to provide an update on the existing database. To 
further identify related genes, new candidate genes were entered into a pathway 
functional analysis software (Ingenuity Pathways Analysis (IPA), Ingenuity Systems, 
Redwood, USA).  
The second and third aims were to find genetic polymorphisms with known functional 
or clinical significance in each of these new and existing genes using the key word 
search ‘(gene of interest) AND polymorphism(s). All identified candidate genes were 
reviewed for functional polymorphisms or clinically significant polymorphisms in terms 
of cachexia using OMIM, dbSNP and GeneRIF databases. The search was limited to 
reports within English language and a manual search of reference lists and 
conference proceedings followed with all cross-references screened.  
 
5.3.1 Study selection 
Published papers and or abstracts were screened after removing duplicates. Inclusion 
criteria were set as any study either involving genes in the selected domains or any 
study showing functional SNPs influencing these genes. Reasons for exclusion 
included studies of irrelevance to cancer cachexia, studies with no genes or functional 
polymorphisms identified, and complex polygenic phenotypes analysing random 
SNPs for association. The remaining papers were reviewed in full and only those 
involving genes in the development of cancer cachexia or any study showing 
functional SNPs influencing these genes, were included in the final analysis. 
In accordance with the previous review, candidate genes were grouped based on the 
role their product is postulated to have in the development of cancer cachexia (193), 
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these being the domains of: 
1. Inflammation 
a. Innate immune receptors and mediators of the immune response 
b. Cytokines 
c. Cytokine receptors and related binding proteins 
d. Acute phase protein reactants 
2. Central Homeostasis 
a. Energy production 
b. Insulin like growth factors and related proteins 
c. Corticosteroid signalling proteins 
3. Muscle  
a. Muscle function and structure 
b. Muscle synthesis 
c. Muscle proteolysis and degradation 
4. Adipose tissue 
a. Adipogenesis 
b. Lipid turnover and transport 




The updated summary Tables of polymorphisms are presented according to each 
category with ‘easy to see’ boxes that denote whether a polymorphism has any effect 
on inflammation, weight/body composition (i.e. lean mass/fat mass) and cancer 
survival. Also added is information on ancestral allele, SNP allele, type of SNP, 
polymorphism reference number (rs number), and mean allele frequency (MAF) 
based on a population with European ancestry derived from the HapMap or dbSNP 
databases. 
 
5.3.2 Pathway analysis 
The methods used for pathway analysis have been described before (193). Briefly, 
multiple genes within a single pathway are likely to influence the development of 
cancer cachexia. Pathway-based analyses using the ingenuity pathway analysis (IPA) 
software was used to determine further related genes in single pathways. Genes 
containing a SNP which had been validated in at least one study were entered into 
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the IPA analysis tool. The IPA software measured associations of these genes with 
other molecules, their network interactions, and biologic functions stored in its 
knowledge base. These genes were entered in the IPA algorithm, which recognizes 
functional networks by identifying interconnected molecules, including molecules not 
among these genes from the IPA knowledge base. The software generates networks 
and calculates a score for each. This represents the approximate ‘fit’ between the 
eligible focus molecules and each network. The network score is based on the 
hypergeometric distribution and is reported as the –log (Fisher’s exact test result). 
 
5.3.3 Putative functions 
To identify the likely effect of individual SNPs on nearby genes the Sorting Intolerant 
From Tolerant (SIFT; http://sift.bii.a-star.edu.sg/) program was used for non-
synonymous SNPs (428), SIFT is a program that predicts whether a non-synonymous 
SNP leading to an amino acid substitution affects protein function or not (428). To 
predict whether an amino acid substitution in a protein will affect protein function, SIFT 
considers the position at which the change occurred and the type of amino acid 
change. Given a protein sequence, SIFT chooses related evolutionarily conserved 
proteins and amino acid residues likely critical for structure or function and obtains an 
alignment of these proteins with the query. Based on the amino acids appearing at 
each position in the alignment, SIFT calculates the probability that an amino acid at a 
position is tolerated conditional on the most frequent amino acid being tolerated. If 
this normalised value is less than a cut-off, the substitution is predicted to be 
deleterious (429). Many of the amino acid substitutions are well tolerated since the 
SNPs tend to capture subtle effects, and the ones with drastically altered functions 
are not to the survival advantage of the species, hence are eliminated during the 
course of evolution. A limitation of SIFT program is that only non-synonymous 
substitutions are interrogated and those in the regulatory and intronic regions (>95% 
of the genome) are not considered.   
The SNP and copy number annotation (SCAN) database 
(http://www.scandb.org/newinterface/about.html) is a large-scale database providing 
a web-interface for easy search with a gene name or an input of SNP ID (rs#) (430). 
This database can use SNPs from 5' or 3' and intronic SNPs and their potential 
influence on the gene expression for nearby genes; gene expression if regulated on 
the same chromosome and within 100MB distance from the SNP could be categorized 
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as cis-regulatory SNPs, if not are called trans-SNPs. The SNPs are classified 
according to their effects on expression levels, i.e. expression quantitative trait loci 
(eQTLs) using SCAN database. Gene expression data and polymorphism data from 
HapMap population derived lymphoblastoid cell lines (Caucasian, Yoruba and Han 
Chinese/Japanese) are used to interrogate the cis- and trans effects from 
SNPs/genes. The findings for the selected SNPs for possible functional significance 
using this approach as well has been summarised. Generalizability of observations 
from genotype to expression from lymphoblastoid cell lines is not the same as 
correlations made with tissue specific expression, and therefore one should exercise 
caution in the interpretations of findings. However, several published studies attest to 
the utility of this approach to extrapolating genotype-phenotype correlations to be 
valid even to specific tissues, albeit for select candidate SNPs.  
 
5.4 Results 
A total of 281 polymorphisms in 154 genes were identified and explored for relevance 
to cancer cachexia (Tables, 5.2-5.16) (Figure 5.1). Of these genes, 88 were newly 
identified and 66 were from the previous review from our group (193). The 281 
functional polymorphisms with or without clinical significance to cancer cachexia (i.e. 
inflammation, loss of fat mass and/or lean mass and reduced survival) were found in 
119 genes with no SNPs of interest found in the remaining 35 genes. A pathway 
based analysis for relevance to cachexia and SNPs selected from these pathways is 





Figure 5.1 - The case to support a genetic predisposition to cachexia is strengthened 
from the known genetic contribution to the activity of a variety of key mechanisms that 
underlie the cachexia syndrome. This Chapter identified 281 single nucleotide 
polymorphisms in 154 candidate genes involved in these mechanisms that may 
contribute to the development of cancer cachexia. 
 
 
5.4.1 Polymorphisms involving innate immune receptors and 
mediators of the immune response 
(1) Inflammation 
Inflammation is widely accepted to play a dominant role in the host’s response to 
cancer and mediators regulating skeletal muscle atrophy in cachexia are thought to 
derive from immune or tumour cells, or the targeted tissues undergoing wasting (both 
adipose tissue and skeletal muscle) (431). Cancer cell rely on production of pro-
inflammatory mediators for growth, protection from apoptosis, and promotion of 
angiogenesis/metastasis. The tumour may consequently initiate a cytokine cascade 
that has multiple, direct, and distant effects including the initiation of skeletal muscle 
protein degradation. Host immunologic response to pro and anti-inflammatory 
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cytokines dictates to what degree the metabolic rates are altered. In experimental 
models, pro-inflammatory cytokines) lead to an acute phase response and tissue 
catabolism (166).  
 
(1a) Innate immune receptors and mediators of the immune response 
Table 5.2 shows the genes involved in the regulation of the innate immune response 
and how they may generate or suppress the inflammatory response to influence the 
rate of cancer cachexia. Variants of these genes which may influence their function 
are also listed. Since the previous review, focus has spread to include new genes 
(AKT2, AKT3, and COX2) (286) (432) which act via signalling pathways to alter the 
innate immune response. AKT regulates cellular survival and metabolism by binding 
and regulating many downstream effectors, e.g. NF-κB and Bcl-2 family proteins 
(433). IGF-1 induced AKT signalling is important in both the suppression of 
degradation and the induction of protein synthesis (331). AKT2 has been shown to 
induce glucose transport, a mouse model null for AKT2 demonstrated marked growth 
deficiency and displayed a diabetic phenotype (434); the role of AKT3 is less clear.  
Also of interest are variants coding for COX2, it is found in low levels in most cells 
under normal conditions but has been shown to be elevated during periods of 
inflammation. COX2 mediates the formation of prostaglandins from arachidonate and 
may have a role as a major mediator of inflammation and/or a role for prostanoid 
signalling (435).  
New variants in the genes coding for the Toll-like receptor (TLR) family and CAMs 
have been found. These genes are involved in both the induction of the innate and 
adaptive immune responses. TLRs activate intra-cellular signals, resulting in the 
activation of nuclear factor NF-κB, where it up regulates the expression of other 
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5.4.2 Polymorphisms of cytokines, cytokine receptors and related 
binding proteins 
(1b) Cytokines and (1c) cytokine receptors 
Mediators regulating cancer cachexia are thought to derive from immune or tumour 
cells, or the targeted tissues undergoing wasting (both adipose tissue and skeletal 
muscle). All cytokines induce immune and inflammatory responses. The resulting 
effects on cellular function are numerous. SNPs in genes of pro-inflammatory and 
anti-inflammatory cytokines are presented in Table 5.3.  
Cytokines bind to their appropriate receptor to initiate a downstream cascade of 
intracellular signalling. The signalling leads to either potentiation of the signal and to 
production of similar or other cytokines and their receptors or to a suppression of the 
signal (102). Since the last review, the gene encoding the IL-6R protein has been 
shown to play an important role in the mediation of IL-6 signalling, and a genetic 
variant in this gene has been shown to influence the CRP level (470). Genetic variants 
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5.4.3 Polymorphisms of acute phase proteins 
(1d) Acute phase protein reactants 
An organism responds to the presence of acute infection, tissue injury, trauma or 
surgery by mounting an acute phase response (APR), this is designed to help limit 
tissue injury by the increased synthesis of key defence / repair proteins by the liver. 
However, in certain circumstances when dietary protein intake is limited and the APR 
is prolonged or severe, an APR can exacerbate muscle wasting by increasing the 
demands for certain amino acids to support increased hepatic export protein 
synthesis, they have also been shown to be predictors of adverse outcomes in cancer 
patients (518). C-reactive protein (CRP) is an acute phase protein which influences 
the immune system. CRP genetic variants have been increasingly studied since the 
last review and some of these have been replicated in other studies. These represent 
promising targets for future genetic studies into links with degrees of cachexia. 
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5.4.4 Polymorphisms regulating energy production 
(2) Central Homeostasis 
(2a) Energy production 
The human body responds to stress with resilience and ultimately aims to maintain 
homeostasis. The mechanisms to respond to injury can ultimately prove detrimental 
to the host. For example, although the hepatic acute phase protein response is useful 
in acute injury (e.g., haemostasis and wound healing), if the response is prolonged 
and potentially futile (as in advanced cancer), then what results is an accelerated loss 
of skeletal muscle and excess morbidity and mortality. Depending on which type of 
cancer, patients with cachexia have been observed to have much higher resting 
energy expenditure (REE) (530). Gene polymorphisms in the regulatory pathways 
controlling energy intake and expenditure are discussed below. This domain also 
explores genes involved in growth and development, and metabolic pathways 
common to both muscle and adipose tissues. 
Table 5.6 shows the genes involved in energy production, these consist mainly of the 
uncoupling proteins. Uncoupling proteins are transporters present in the mitochondrial 
inner membrane that mediate a regulated discharge of the protein gradient that is 
generated by the respiratory chain. This serves to regulate functions such as 
thermogenesis, maintenance of the redox balance, or reduction in the production of 
reactive oxygen species (531). No new functional SNPs were found in this group 
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5.4.5 Polymorphisms of insulin like growth factors and related 
proteins 
(2b) Insulin like growth factors and related proteins 
The IGF signalling pathway consists of two main ligands (IGF-1 and IGF-2), two cell 
surface receptors (IGFR1 and IGFR2), and six high – affinity IGF-binding proteins 
(IGFBP1-6) (542). The predominant regulator of skeletal muscle hypertrophy is 
through stimulation of the PI3K/AKT pathway by insulin or IGF-1 (329-331).  Mice in 
which AKT is transgenically expressed and inducibly activated in skeletal muscle 
demonstrate dramatic hypertrophy upon the activation signal (332-334), helping to 
prove that AKT is the pathway that is sufficient to mediate hypertrophy downstream 
of IGF1 upregulation. Activation of AKT leads to an increase in the mTOR/p70S6K 
pathways and a rise in protein synthesis. As well as inducing protein synthesis, IGF1 
can inhibit skeletal muscle atrophy. In the presence of up regulated IGF1 signalling, 
the atrophy genes MuRF-1 and MAFbx/atrogin-1 are actively inhibited (83). A number 
of new genetic variants for IGF-1 and IGF-1R have been discovered recently and are 
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5.4.6 Polymorphisms of corticosteroid signalling proteins 
(2c) Corticosteroid signalling proteins 
Corticosteroids are steroid hormones secreted by the adrenal cortex and lead to 
changes in a number of organ systems. They exert their main effects on stress 
response, immune response and regulation of inflammation, carbohydrate 
metabolism and protein catabolism. A number of new genes have been included, the 
corticotropin-releasing hormone receptor 1 (CRHR1) binds to corticotropin-releasing 
hormone, a potent mediator of endocrine, autonomic, behavioural, and immune 
responses to stress. A number of polymorphisms in this gene have been shown to 
effect circulating levels of CRP and ICAM-1 (557). The glucokinase regulatory protein 
(GCKR) binds and moves glucokinase (GK), thereby controlling both activity and 
intracellular location (558) of this key enzyme of glucose metabolism (559). Genetic 
variants of this protein have also been linked with alterations in circulating CRP levels 
(470). The genetic variants of the components in the mechanism of corticosteroid 
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5.4.7 Polymorphisms regulating muscle biology 
(3) Muscle 
In healthy adults, skeletal muscle mass is maintained within relatively narrow limits, 
reflecting a dynamic balance between protein synthesis and degradation.  A 
predominance of either will result in muscle hypertrophy or atrophy.  Even small 
changes in protein synthesis or degradation will lead to large protein deficits over time 
due to the continuous process of protein turnover. In cancer cachexia, there is 
ongoing debate as to whether a reduction in protein synthesis, an increase in protein 
degradation or a combination of both is more relevant. Although there is depletion of 
both adipose tissue and lean body mass, it is skeletal muscle loss that has the 
greatest impact on patients’ function and quality of life and is clearly associated with 
a poor outcome (11, 12, 69). Highlighted below are the genetic variations that affect 
the structure and function of muscle as well as those that regulate muscle synthesis 
and degradation.  
 
(3a) Muscle structure and function 
IL-15 signals through IL-15 receptor alpha (IL-15RA) and is found in abundance in 
skeletal muscle. IL-15 is shown to be anabolic, marked by an increase in myosin 
heavy chain accumulation (272). ACTN3 (Alpha-actinin 3) binds to actin at the Z-line 
within muscle fibres and acts to anchor actin filaments. Polymorphisms in ACTN3, 
IL15 and IL15RA are shown in Table 5.9. 
Much recent work has focused on polymorphisms associated with alterations fat free 
mass in the gene encoding the vitamin D receptor (VDR). Promising new variants 
encoding for this protein are also included in supplementary Table 8. Inhibin β C 
(INHBC) is a newly added gene, it is part of the transforming growth factor β pathway 
regulating myostatin (a negative regulator of muscle mass). Polymorphisms identified 
with this gene are shown in Table 5.9. Another significant new addition to the genes 
implicated in cancer cachexia is thyrotropin-releasing hormone receptor (TRHR). 
Thyrotropin-releasing hormone is released by the anterior pituitary and acts on a 
number of tissues, including muscle to influence metabolic rates. Genetic variants are 
listed in Table 5.9. 
181 
 
New variants in the ACE gene have also been included. Alterations in this gene have 
led to differences in oxygen carrying capacity of muscles as well as increased 
vasoconstriction in blood vessels within the muscle architecture(571). Acute and 
chronic exposure to angiotensin II in animal models are associated with weight loss 
and enhanced protein breakdown in skeletal muscle (572). Genetic variants are listed 
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      None          
HINT3(17
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      None          
TIE1(89)       None          
 





(3b) Muscle synthesis 
The main signalling pathway for muscle synthesis is via the IGF-1/PI3K/AKT axis. 
Polymorphisms relating to these can be found in the insulin like growth factors and 
related proteins section (Table 5.7). mTOR, RUNX1, Phosphoinositide 3-kinase 
(PIK3) and various isoforms have been implicated in hypertrophy signals of muscle 
mass (286) and have been added to the list of genes, however very few studies have 
looked into how variants effect structure and function of these gene products. A 
number of genes from expression arrays were also included as cis- or trans acting 
polymorphisms on the genome may be affecting their expression. Genetic variants 
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SKI(286)       None           
Pax3       None          
Pax7       None          
Myogenin       None          
MyoD       None          
Myf5       None          
Myf6       None          
FOXK1(286
) 
      None          
NTF3(604)       None          
SOD-1(604)       None          
 








(3c) Muscle proteolysis 
In atrophying muscles, the ubiquitin ligases, MuRF1/atrogin-1 and MAFbx, are 
induced and this response is necessary for rapid atrophy. FOXO isoforms 1 and 3 are 
known to act on MuRF1 promoter to cause MuRF1 transcription and this leads to 
dramatic atrophy of myotubes and muscle fibres (286, 605). IKKα also influences the 
Ubiquitin Proteasome Pathway (UPP) and a number of functional polymorphisms are 
listed in supplementary Table 10. Another gene encoding for tumour necrosis factor 
receptor (TNFR)-associated factor 6 (TRAF6) is an important adaptor protein involved 
in receptor-mediated activation of various signaling pathways in response to cytokines 
and bacterial products. TRAF6 also possesses E3 ubiquitin ligase activity causing 
lysine-63-linked polyubiquitination of target proteins (606). 
A more recent factor, which has captured the attention of many investigators, is the 
TGF-β family member, myostatin. Genetic null animals for myostatin, demonstrate 
dramatic muscle hypertrophy (288). Myostatin is synthesised and secreted mainly 
from skeletal muscle cells. Myostatin acts firstly by signalling through the activin type 
II receptor (ACVR2B), which then recruits an Alk family kinase, resulting in the 
activation of a SMAD2 and SMAD3 transcription factor complex (289, 290).  
STAT3 has recently been shown to influence muscle wasting by altering the profile of 
genes expressed and translated in muscle such that amino acids liberated by 
increased proteolysis in cachexia are synthesised into acute phase proteins and 
exported into the blood (286).  
Peroxisome proliferator-activated receptor gamma (PPARγ) and 
its response gene, Acyl CoA synthetase 5 (ACSL5), have an important role in fatty 
acid metabolism and may affect weight loss in response to caloric restriction. Genetic 
polymorphisms have demonstrated reduced ACSL5 mRNA in skeletal muscle 
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5.4.8 Polymorphisms regulating adipose tissue biology 
(4) Adipose tissue 
The incidence of obesity and diabetes continues to increase worldwide. The obese 
patient is generating a new challenge in medicine and treatment. The physiology of 
obese patients differs remarkably from a normal weighted individual. Recently, 
patients suffering from advanced cancer have been found to be overweight rather 
than underweight (161). This has been shown to confound conventional 
measurements for risk stratification such as BMI. A recent study of pancreatic cancer 
patients has shown that severe muscle depletion when combined with obesity to be 
an independent adverse prognostic indicator in this patient group and should be 
considered as an alternative and more powerful means of risk stratification (12). It is 
however unclear how muscle depletion combined with overweight / obesity causes 
accelerated demise. The adipokines secreted by excess adipose tissue may act as 
systemic inflammatory mediators, inducing of insulin resistance in skeletal muscle and 
leading to a further increase in muscle protein loss. Increased lipolysis appears to be 
a key factor underlying fat loss, though decreases in lipid deposition and adipocyte 
development may also contribute (162). The following section examines 
polymorphisms in genes regulating adipose tissue metabolism. 
 
(4a) Adipogenesis 
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor 
proteins that function as transcription factors regulating the expression of genes (626). 
PPARα regulates key proteins involved in extracellular lipid metabolism, fatty acid 
oxidation and inflammation (627). PPARγ controls fat cell function and differentiation 
of new adipocytes and by inducing expression of genes promoting uptake of fatty 
acids, triglyceride synthesis and insulin sensitivity (628). Lipin proteins (lipin-1, lipin-2 
and lipin-3) also act as transcriptional coactivators that regulate expression of lipid 
metabolism genes (629). SNPs in the above genes are shown in Table 5.12. 
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(4b) Lipid turnover and transport 
The lipid metabolism protein apolipoprotein C-III (apoC-III) inhibits triglyceride 
hydrolysis. Genetic variants have been shown to have lower fasting and postprandial 
serum triglycerides, higher levels of HDL-cholesterol and lower levels of LDL-
cholesterol (641). A genetic link between lipid metabolism and inflammation has been 
suggested by the association between variation in the APOE gene and plasma CRP. 
A variant in the LRRFIP1 gene, which has been implicated in TNFa expression has 
been shown to be associated with adiposity and inflammation (642). 
A recent experiment in tumour bearing mice demonstrated during the early and 
intermediate phases of tumour growth and cachexia, food intake remained normal 
while plasma levels of proinflammatory cytokines and zinc-α2-glycoprotein rose. The 
investigators found that genetic ablation of adipose triglyceride lipase (ATGL) 
prevented an increase in lipolysis and the net mobilisation of adipose tissue 
associated with tumour growth. Unexpectedly, they also observed that skeletal-
muscle mass was preserved and that activation of proteasomal-degradation and 
apoptotic pathways in muscle was averted. Ablation of hormone-sensitive lipase 
(HSL) had similar but weaker effects. Genetic variants in both these new genes were 
explored and are listed in Table 5.13. 
Zinc-α-2-glycoprotein (ZAG), otherwise known as LMF, is involved in the specific 
mobilisation of adipose tissue, with increased oxidation of released fatty acids, 
possibly via induction of uncoupling protein (UCP) expression (643). ZAG isolated 
from the MAC16 murine tumour, or from the urine of patents with cancer cachexia, 
stimulates lipolysis directly through interaction with adenylate cyclase in a guanosine 
triphosphate (GTP)-dependent process (644, 645). A polymorphism associated with 
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(4c) Adipokines and adipokine receptors 
Adipose tissue, like skeletal muscle is an active metabolic and endocrine organ. A 
number of inflammatory cytokines secreted by adipose tissue have been shown with 
varying effect to influence the development of diseases such as insulin resistance, 
diabetes, and cancer cachexia by acting on muscle and fat metabolism (667). 
Adipokines regulate appetite, energy expenditure, insulin sensitivity, and the 
inflammatory response all of which have an important role in the pathogenesis of 
cancer cachexia (668). The adipokine resistin effects substrate metabolism through 
impairment of insulin action and insulin independent pathways (McTernan et al. 
2006). SNPs in the adipokine genes are shown  in Table 5.14.  
Adiponectin is secreted from adipose tissue and binds to a number of receptors 
including adiponectin receptors 1 and 2. Adiponectin is produced by the adipocyte 
and has been shown to decrease insulin resistance. Unlike other adipokines 
associated with chronic inflammation, adiponectin is inversely related to insulin 
resistance and BMI. It appears to have protective metabolic and anti-inflammatory 
properties (128). 
The adipokine, leptin plays a key role in regulating energy intake and energy 
expenditure, including appetite and metabolism. Polymorphisms in genes coding for 
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5.4.9 Polymorphisms regulating appetite 
(5) Appetite 
Muscle mass is clearly sensitive to food intake. The pathogenesis of cancer anorexia 
is multifactorial and reflects the complexity of the mechanisms controlling energy 
homeostasis under physiological conditions. The main molecular mechanisms 
regulating the cancer anorexia-cachexia syndrome include alterations in brain 
neurochemistry. In particular, the hypothalamic melanocortin system appears not to 
respond appropriately to peripheral inputs, and its activity is diverted largely toward 
the promotion of catabolic stimuli promoting metabolism of carbohydrates, lipids, and 
proteins in peripheral tissues leading to insulin resistance, increased lipolysis, and 
accelerated muscle proteolysis (13). Ghrelin is produced by the P/D1 cells of the 
stomach and acts as the natural counterpart to leptin. Ghrelin exerts its effects by 
promoting food intake (via the orexigenic NPY system) (688) and decreases 
sympathetic nerve activity (689).  G-protein coupled melanocortin receptors bind α-
melanocyte stimulating hormone (α-MSH). Melanocortin 3 and 4 receptors are 
involved in feeding behaviour and the regulation of metabolism (690). 
Neuropeptide Y (NPY) acts as a neurotransmitter in the brain and in the autonomic 
nervous system. An increase in NPY signalling leads to increased food intake (691). 
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5.4.10 Other notable polymorphisms 
(6) Others 
Metallothionein (MT) are low molecular weight proteins enriched with cysteine. MTs 
have the capacity to bind both physiological (such as zinc, copper, selenium) and 
xenobiotic (such as cadmium, mercury, silver, arsenic) heavy metals through the thiol 
group of its cysteine residues, which represents nearly the 30% of its amino acidic 
residues. Zinc homeostasis is often disrupted in cancer cachexia. It has been 
proposed that the acute phase response can mediate zinc redistribution and 
accumulation in skeletal muscle tissue and contribute to the activity of the UPP that 
regulates protein catabolism (703). 
The P2Y-receptors mediate the actions of extracellular nucleotides in cell-to-cell 
signalling. The P2Y11 receptor is highly expressed in immunocytes and may play a 
role in the differentiation of these cells (704). SNPs in these genes are listed in Table 
5.16. 
A number of new genes and SNPs are listed in Table 5.16, these have evolved from 
a recent candidate gene approach study identifying SNPs in cancer cachexia. Target 
SNPs identified from the previous review which were unable to be genotyped in a 
cancer population due to experimental design were substituted for the nearest SNP 
with a linkage disequilibrium of >0.9. These SNPs have been added to the current 
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5.5 Analysis of results 
5.5.1 Clinical significance 
Clinical significance was defined as any SNP affecting more than one of the 
recognised hall marks of cancer cachexia. Inflammation has been shown to influence 
the severity of cancer cachexia and was therefore identified as a clinical feature. 
Changes in body composition of muscle and/or fat mass form the basis of cancer 
cachexia, therefore SNPs that have the potential to alter an individual’s body 
composition, whether to increase or decrease these components will play a significant 
clinical role in the development of cancer cachexia or not. Lastly, any SNPs 
influencing overall survival were included in a definition of clinical significance.   
Out of 281 candidate polymorphisms that were identified and summarised here, the 
functional or clinical significance of 80 polymorphisms have been verified in more than 
one study. Of these 80 polymorphisms, 24 have been shown to have more than one 
association with clinical features associated with cancer cachexia (i.e. inflammation, 
changes in lean and/or fat mass, and overall survival), these are termed promising 
SNPs. An in-depth analysis of the 24 promising SNPs as biomarkers for susceptibility 
of cancer cachexia (Table 5.17) is presented below. Thirteen of these are new 
promising SNPs and eleven of these SNPs have been described previously as 
promising SNPs (193) but have been included for completeness. 
(1, 2) The G allele of TLR-1 (-7202A/G) (rs5743551) is associated with elevated 
TLR1-mediated cytokine production (439, 441). TLR1 (-7202G) marks a coding SNP 
that causes higher TLR1-induced NF-kB activation and higher cell surface TLR1 
expression (441). Toll-like receptor (TLR) pathways are critical components of the 
immune response to pathogens and disease (708). This particular polymorphism has 
been shown to lead to decreased survival in patients with sepsis (441) and NSCLC 
(440). In addition to this SNP in TLR-1, patients carrying the mutant allele T of TLR4 
1196C/T (Thr399Ile, rs4986791) had lower TNF-α and sTNFR2 levels compared to 
patients carrying wild-type alleles (446). These patients carrying the mutant 
phenotype have also been shown to have increased total body fat, visceral fat, liver 
fat and decreased insulin sensitivity (448). 
(3) Steps in the inflammatory process include accumulation of lipids, recruitment 
of leukocytes and smooth muscle cells into vessel walls, and accumulation of 
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extracellular matrix. Intercellular adhesion molecule-1 (ICAM-1) is integral in these 
cellular processes as interactions between ICAM-1 and activated receptors on the 
leukocytes result in firm adhesion and transmigration of leukocytes into the basement 
membrane of the vasculature. The T-allele of rs5491 encodes a lysine to methionine 
substitution in exon 2 in the N-terminal domain of ICAM-1 and results in a protein that 
is unable to bind to fibrinogen and has a decreased affinity for T-cells at lower ICAM-
1 concentrations compared to wild type ICAM-1 (709). This leads to increased 
circulating levels of sICAM-1 and an association with insulin resistance and the 
metabolic syndrome (461).  
(4) The C allele of the A37674C SELP polymorphism (rs6136) is associated with 
decreased serum P-selectin levels (462, 463). Localisation of neutrophils in acute 
inflammation and of macrophages in later stages of the inflammatory response are 
dependent on P-Selectin and serum levels of P-selectin have been found to be 
significant prognostic factors in survival in patients with gastric and colorectal 
malignancies (710, 711). Patients with cancer who carry the C-allele of the rs6136 
polymorphism in SELP gene are at reduced risk of developing cachexia as defined 
by weight loss >10% (207). 
(5-7) The cytokine TNF-α precipitates systemic inflammation via the acute phase 
reaction. The –308A allele (rs1800629) has been associated with an increased TNF-
α production as well as a 6-fold increase in transcription of the TNF gene (471, 472). 
Women carrying the A/A genotype have been linked to increased fat accumulation 
(712). The -863A allele (rs1800630) associated with decreased transcriptional activity 
and reduced serum TNF-α levels (473, 474, 476, 477). Obese people express 2.5-
fold more TNF mRNA in fat tissue (115). The -238A allele of the SNP rs361525 has 
shown decreased transcriptional activity of TNFα (473), as well as decreased 
peripheral mononuclear blood cells (PMBC) production of TNF-α after stimulation with 
T-cell mitogens (473). It has also been shown to decrease insulin resistance (474). 
(8) LTA is part of the tumour necrosis factor family, it is produced by lymphocytes, 
and mediates inflammatory responses, stimulation of immune system, and apoptosis 
(713). The G allele of the 252 A>G polymorphism (rs909253) has been associated 
with increased serum TNF-α levels (479, 480), and patients who are A/A 
homozygotes have been linked with better prognosis in lung cancer and gastric 




(9 - 11)  IL-1β is a product of the IL1B gene and plays a role in potentiating an 
inflammatory response. The -31 C>T (rs1143627) and -511 C>T (rs16944) 
polymorphisms in the promoter region of the IL1B gene have been linked with 
increased transcriptional activity of the IL1B gene and subsequently increased IL-1β 
production (484). These two alleles are also linked with poorer progression-free 
survival and overall survival in advanced gastric cancer (716). A synonymous C to T 
polymorphism at nucleotide position 3953 (rs1143634) has resulted in Increased IL-
1β levels (487). The T/T genotype has also been associated with lower plasma levels 
of IL-1 receptor antagonist (IL-1RA) (486). In addition, the T allele has found to be a 
major risk factor for cachexia in gastric cancer (209), as well as being linked to lower 
total fat mass (717). The T/T genotype was found to be associated with shorter 
survival in pancreatic cancer (718). These three SNPs may be potential candidates 
for cancer cachexia. 
(12) IL-6 mediates B-cell differentiation and maturation, immunoglobulin secretion, 
cytotoxic T-cell differentiation and acute-phase protein production (719). The -174 
G>C promoter polymorphism (rs1800795) in the IL6 gene has been associated with 
lower serum levels of IL-6(490). The G allele has been linked to higher fasting insulin 
and lower adiponectin levels which may have a role in the regulation of adiposity 
(491). In addition the C/C genotype has been associated with lower fat free mass and 
increased waist circumference (675, 720).  
(13) IL-18 is produced by macrophages and functions by binding to the interleukin-
18 receptor inducing cell-mediated immunity following infection. After stimulation with 
IL-18, natural killer (NK) cells and certain T cells release interferon-γ (IFN-γ) that plays 
an important role in activating the macrophages. Apart from its physiological role, IL-
18 is also able to induce severe inflammatory reactions. Individuals with the allele 
105AA (rs549908) demonstrated increased IL-18 production from LPS and 
A23187 + PMA stimulated monocytes (499). Haplotype of common alleles have been 
shown to be associated with significantly lower IL-18 (501). 
(14) IGF-1 is one of the most potent natural activators of the AKT signalling 
pathway which is the main stimulator of cell growth and multiplication. IGF-1 also 
mediates many of the growth-promoting effects of growth hormone (GH) (542). The 
genotype CC of rs7136446 associated with higher body fat and increased maximal 
force production (545), it has also been shown to be significantly associated with 
elevated levels of circulating IGF-I (543). 
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(15) The glucocorticoid receptor (GR, or GCR) also known as NR3C1 (nuclear 
receptor subfamily 3, group C, member 1) is the receptor to which cortisol and 
other glucocorticoids bind. In the absence of glucocorticoids, the glucocorticoid 
receptor (GR) resides in the cytosol complexed with a variety of proteins 
including heat shock protein 90 (hsp90), heat shock protein 70 (hsp70) and the 
protein FKBP52 (FK506-binding protein 52) (721). The endogenous glucocorticoid 
hormone cortisol diffuses through the cell membrane into the cytoplasm and binds to 
the glucocorticoid receptor (GR) resulting in release of the heat shock proteins. 
Activated GR can bind to the transcription factor NF-κB and prevent it from up 
regulating target genes (722). The mutant allele of the N363S (rs6195) SNP enhances 
glucocorticoid sensitivity by increasing gene transcription (560). Indeed, in various 
studies, a link was established between the N363S SNP and characteristics of a 
Cushingoid phenotype, including increased BMI and waist circumference, 
dyslipidaemia and augmented fasting insulin levels, indicating reduced insulin 
sensitivity (723, 724). 
(16) The glucokinase regulatory protein (GKRP) also known as glucokinase 
(hexokinase 4) regulator (GCKR) is a protein produced in hepatocytes. GKRP binds 
glucokinase (GK), thereby controlling both activity and intracellular location of this 
key enzyme of glucose metabolism (558, 725). The glucose-increasing major C allele 
of rs780094 of GCKR has been shown to be significantly associated with increased 
insulin resistance leading to development of T2DM and altered lipid metabolism (569, 
726).  
(17) CNTF is involved in the neuroendocrine signalling of appetite. It leads to 
marked weight loss through suppressed food intake without causing hunger or stress 
(727). CNTF receptor-α is abundantly expressed in skeletal muscle (728, 729). As 
such, recent studies have examined the roles of CNTF and CNTF genotype on 
neuromuscular disease and muscle function. CNTF administration has been shown 
to prevent losses of soleus muscle mass and function after hindlimb suspension in 
rats (729). In humans, the A allele mutation of rs1800169 possess significantly greater 
muscular strength and muscle quality at relatively fast contraction speeds than the 
ancestral G alelle individual (586). This polymorphism has also been associated with 




(18) The uptake of FFA by skeletal muscle for metabolism is initiated by 
transmembrane acyl-CoA synthetase long-chain (ACSL) proteins that esterify FFAs 
to acyl-coenzyme A (acyl-CoA) molecules. Acyl-CoA species are used mainly in both 
the synthesis of cellular lipids and the degradation of fatty acidsvia β-oxidation. Small 
increases in the expression of ACSL5 in skeletal muscle could have profound effects 
on FFA utilisation (613). A strong association between the common SNP rs2419621 
and rapid weight loss in obese Caucasian females in response to restricted diet has 
been demonstrated (607). The SNP located 12 nucleotides upstream of the second 
transcription start site of the ACSL5 gene is characterized by a cytosine 
[rs2419621(C)] to thymine [rs2419621(T)] transition. This study also demonstrated 
that the T allele is associated with a 2.2-fold increase of ACSL5 transcript level in 
skeletal muscle biopsies when compared to noncarriers (607). In a further study T 
allele variants were shown to create a functional cis-regulatory E-box element 
(CANNTG) that is recognised by the myogenic regulatory factor MyoD. The T allele 
promoted MyoD-dependent activation of a 1089-base pair ACSL5 promoter fragment 
in non-muscle CV1 cells. Differentiation of skeletal myoblasts significantly elevated 
expression of the ACSL5 promoter. The T allele variants sustained promoter activity 
48 h after differentiation, whereas the C allele variants showed a significant decline. 
These results revealed a mechanism for elevated transcription of ACSL5 in skeletal 
muscle of carriers of the rs2419621 (T) allele, associated with more rapid diet-induced 
weight loss. This is the first example of a MyoD binding polymorphism conferring 
differential promoter activity of a metabolic gene (613). 
(19) Lipoprotein lipase (LPL) plays a central role in the overall lipid metabolism and 
transport (730). The rs328 polymorphism in the LPL gene leads to a premature stop 
codon at amino acid 447. The stop codon results in lower LPL activity (656, 657), and 
is associated with lower levels of IL-8 (655). Individuals not in possession of the stop 
codon are associated with central obesity (731). 
(20) Zinc-α-2-glycoprotein (ZAG), otherwise known as LMF, is involved in the 
specific mobilisation of adipose tissue, with increased oxidation of released fatty 
acids, possibly via induction of uncoupling protein (UCP) expression (643). LMF 
isolated from the MAC16 murine tumour, or from the urine of patents with cancer 
cachexia, stimulated lipolysis directly through interaction with adenylate cyclase in a 
guanosine triphosphate (GTP) dependent process (644, 645). This effect was also 
produced by the interaction of LMF with the β3-adrenoceptor (732). Genotypes of 
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rs4215 in ZAG gene have been suggested to be significantly associated with obesity. 
The GG genotype subjects in rs4215 site have an increased susceptibility to obesity 
when compared with the AA+AG genotype subjects (664). In a separate study 
variations in the rs4215 genotype have been linked with changes in circulating levels 
of total cholesterol and LDL-C.  
(21) The adipokine resistin potentiates a pro inflammatory state, resistin also 
appears to have effects on substrate metabolism through impairment of insulin action 
and insulin independent pathways(733). The –420 C>G polymorphism (rs1862513) is 
shown to be linked to increased plasma resistin (669, 670), and individuals with the 
G/G genotype are associated with an increased prevalence of obesity (734). Overall, 
increased plasma resistin has to shown to correlate with increased CRP and insulin 
resistance (669, 735-738). 
(22, 23) Adiponectin is a protein hormone that is exclusively secreted from 
adipose tissue and modulates a number of metabolic processes, including glucose 
regulation and fatty acid catabolism (739). The ADIPOQ gene, which codes for 
adiponectin, has a 45 T>G polymorphism (rs2241766) that is associated with 
increased plasma adiponectin (675, 676). Individuals with G/G genotype have been 
observed to be leaner with less abdominal fat (740). The adiponectin receptors 
ADIPOR2, serves as a receptor for adiponectin and mediates 
increased AMPK and PPAR-α ligand activities, as well as fatty acid oxidation and 
glucose uptake by adiponectin(741). In peripheral monocytes, carriers of the major A 
allele (homozygotes and heterozygotes) of rs767870 polymorphism had higher levels 
of ADIPOR2 protein expression compared to homozygotes of the minor G allele (679). 
This same SNP has also been associated with liver fat content and the incidence of 
type II DM (680, 681).  
(24) Pro-inflammatory cytokines (TNFα and IL-1β) and hypothalamic serotonergic 
neurons have been implicated in the dysfunction of the hypothalamic melanocortin 
system (29). The orexigenic neuropeptide Y (NPY) peptide system appears to be 
strongly influential in the control of feeding (30). The pathway originates in the 
hypothalamic arcuate nucleus (ARC) and extend projections widely over the brain 
(30). The role of cytokines in cancer anorexia may be affected through influence on 
the NPY system. The genetic variant rs16139 causing, leucine7 to proline7 in the 
signal peptide of preproNPY has been associated with increased risk factor for many 
cardiovascular diseases, such as accelerated atherosclerosis (700). Furthermore, 
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elevated serum lipid levels have been associated with the P7 allele in certain 
populations (701). Additionally, the L7P polymorphism has been shown to increase 
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Table 5.17 - Polymorphisms replicated in more than one study and with at least two effects on clinical features associated with cancer 






5.5.2 Pathway analysis 
The 80 polymorphisms which have been verified in more than one study were found 
across 51 genes. These genes were entered into the IPA algorithm as focus genes 
and were found to be significantly interconnected in two major networks (Table 5.18). 








Top functions of 
network 
1 ADCY, ADRB1, ADRB2, ADRB3, 
Beta arrestin, CCL2, CRHR1, 
Cytochrome c, Endothelin, 
estrogen receptor, G protein, G 
protein alphai, G Protein β, GNRH, 
Gpcr, Gs-coupled receptor, 
IGF1R, IL-17f dimer, IL-6R, Jnk, 
LEP, MC3R, MC4R, Mmp, 
NADPH oxidase, NPY, P110, p85 
(pik3r), Pdgfr, PLC, Shc, TRHR, 
trypsin, TSH, Voltage gated 
calcium channel 




2 3 BETA HSD, ADIPOQ, 
ADIPOR2, Akt, AMPK, AZGP1, 
FOXO1, GHRL, Gm-csf, HLA-DQ, 
Igf, IGFBP3, IL-8r, jINK1/2, 
MTORC1, Na+, K+ - ATPase, 
Nr1h, Pde4, PEPCK, PIK3CB, 
Ppp2c, PRKAA, Proinsulin, Ptk, 
Rab5, Rxr, Scavenger receptor 
class A, sPla2, T3-TR-RXR, 
thymidine kinase, UCP2, UCP3, 
VDR, VitaminD3-VDR-RXR 









Table 5.18 - Ingenuity pathway analysis of genes that were replicated in more than 
one study (n = 51). *Focus genes in bold. The software illustrates networks graphically 
and calculates a score for each network, which represents the approximate ‘fit’ 
between the eligible focus molecules and each network. The network score is based 





Figure 5.2 - Connection map for first ranked network. Genes with variants that had 
functional or clinical associations replicated in at least one study were entered into 
the ingenuity pathway analysis software for an unsupervised functional analysis to 
discern regulatory networks that involved these molecules. Focus genes are shaded 
in grey. Solid lines show direct interaction (binding/physical contact); dashed lines 
show indirect interaction that is supported by the literature but possibly involving ≥1 
intermediate molecules that have not been investigated definitively. Molecular 
interactions that involved only binding are connected with a line without an arrowhead 








Figure 5.3 - Connection map for second ranked network. Genes with variants that 
had functional or clinical associations replicated in at least one study were entered 
into the ingenuity pathway analysis software for an unsupervised functional analysis 
to discern regulatory networks that involved these molecules. Focus genes are 
shaded in grey. Solid lines show direct interaction (binding/physical contact); dashed 
lines show indirect interaction that is supported by the literature but possibly involving 
≥1 intermediate molecules that have not been investigated definitively. Molecular 
interactions that involved only binding are connected with a line without an arrowhead 













5.5.3 Putative functions 
Since gene association studies often identify surrogates for putative causal SNPs, it 
is imperative that data from selected SNPs be subjected to further analysis using 
prediction tools to short list candidates for finer analysis before causality could be 
established. Unless causative SNPs/genes are identified, development of targeted 
therapeutics are difficult to achieve. Of the 42 non synonymous polymorphisms 
entered into the SIFT algorithm (Table 5.19) seven SNPs had a significant score 
(p<0.05) causing an intolerant change of amino acid. Since SIFT program only 
evaluates non synonymous SNPs, and the majority of polymorphisms lie within the 
regulatory regions at 3’, 5’ ends and in introns, the SNPs selected using the SCAN 
database for insights into the potential contribution of selected SNPs on gene 
regulatory functions (cis-or trans effects, eQTLs) were interrogated (423-427). 132 
SNPs as potential eQTLs in HapMap study populations (Caucasian, Yoruban, Han 
Chinese/Japanese) were identified (Table 5.20). Analysis of selected candidate SNPs 
for potential eQTLs revealed several target genes that are regulated both in cis- and 
trans, as to be expected. The fine regulation in complex biological networks by a SNP 
may be direct or indirect, and likely influence gene expression through short or long 
range interactions.  The prediction for regulation of expression was limited to those 
showing high statistical significance (p-value<10-4) and to any one of the HapMap 
populations. The promising candidates from SCAN database should be further 
validated by independent methods (RT-PCR) to confirm for direction and magnitude 
of expression changes in a tissue specific manner. In addition to pathway based 
candidate SNP approaches for cachexia, genome wide association studies have the 
potential to identify promising variants for further interrogation of the genome for 
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Table 5.19 - Polymorphisms of potential functional significance. Of the total number 
of candidate SNPs (n=281) selected for an association study for the phenotype of 
cachexia, seven SNPs with non-synonymous amino acid substitutions were predicted 
by SIFT to potentially influence structure or function of the encoded proteins. SNP ID 
(rs#), gene name, amino acid change, protein accession number and prediction 





Table 5.20 - Potential cis- and trans effects from select candidate gene polymorphisms- potential expression changes (eQTLs) in 
representative genes 
 
rs# Chromosome Position Alleles Gene Feature [Gene Accession #] Representative genes whose expression 
may be affected 
rs4833095 4 38476105 C/T TLR1 Reference[NM_003263.3] GPR137B: MFSD7: ARHGDIA: DEF8: 
ZDHHC4  
rs3804099 4 1.55E+08 C/T TLR2 Coding-
synonymous[NM_003264.3] 
BTBD12  
rs2569190 5 1.4E+08 A/G CD14 UTR-5[NM_000591.2] EIF4EBP1: ANKZF1:CCNB1IP1: PARS2  
rs7096206 10 54201691 C/G MBL2 Near-gene-5[NM_000242.1] ZFAND3  
rs5498 19 10256683 A/G ICAM1 Reference[NM_000201.2] PDSS2: UCP2: CLDN19: PCGF6: KIAA1754: 
NADK: FLJ45032: GLB1: PI4KB: PDK3: BST2: 
P2RX7: ZBTB3: ZER1: PEX19: SASH3: 
MTX2: ATP5SL: SNX2: C11orf49: PLTP: 
CYB561D2:SHMT1  
rs5491 19 10246540 A/T ICAM1 Reference[NM_000201.2] C19orf61: P2RY10: PPP2R5D: BRF2: 
C12orf32: ASCC2: ENTPD2: FBXO7: 
FAM110A: PSMB6: RPUSD3  
rs281432 19 10251658 C/G ICAM1 Intron[NM_000201.2] RAC2: ADO: SEMA6A: ALAD: P2RX7: SMTN: 
PXN: KCNIP2: LILRB4: PDE6G: RHOBTB2: 
MOBKL2A: LOC100130790: SLC16A3: GLTP  
rs3176860 1 1.01E+08 A/G VCAM1 Intron[NM_080682.1] TRAPPC4 
265 
 
rs2227956 6 31886251 C/T HSPA1L Reference[NM_005527.3] CYP1A2: HLA-DQB1: HLA-DQB2: HLA-DRB1: 
HLA-DRB2: HLA-DRB3: HLA-DRB4: HLA-
DRB5: LOC100133484: LOC100133583: 
LOC100133661: LOC100133811: LOC730415: 
RNASE2: ZNF749: hCG_1998957: HLA-
DQB1: HLA-DQB2: HLA-DRB1: HLA-DRB2: 
HLA-DRB3: HLA-DRB4: HLA-DRB5: HLA-
DRB6: LOC100133484: LOC100133583: 
LOC100133661: LOC100133811: LOC730415: 
RNASE2: ZNF749: hCG_1998957: PTGER4 
rs1130214 14 1.04E+08 G/T AKT1  Intron[NM_001014432.1] FUT8 YRI 
rs1800625 6 32260420 C/T AGER  Near-gene-5[NM_172197.1]  HLA-DQA1:HLA-DQA2:ATP13A2: PEX26: 
TUBA8: PISD: LOC100131053: PQLC2: 
PSCD3  
rs3774932 4 1.04E+08 A/G NFKB1 Intron[NM_003998.2] ADRA2B: ADPRHL1  
rs1801 4 1.04E+08 C/G NFKB1 Intron[NM_003998.2] TLE2: GDF7: WDR27: CYP4V2  
rs1800629 6 31651010 A/G TNF Near-gene-5[NM_000594.2] HLA-DQA1: HLA-DQA2: FAM20B: HLA-B: 
HLA-C: MICA: MICB: XXbac-BPG181B23.1 
rs1800630 6 31650455 A/C TNF Near-gene-5[NM_000594.2] GTF3C6 
rs1799964 6 31650287 C/T LTA Near-gene-3[NM_000595.2] GNAZ  
rs909253 6 31648292 C/T LTA Intron[NM_000595.2] ZNF600 : MORC2: AFTPH: HLA-DQA1: HLA-
DQA2: FNDC3A: ATG2B 
rs17561 2 1.13E+08 G/T IL1A Reference[NM_000575.3] SLC7A5: PSAT1:LOC284702: GPX7  
rs1800587 2 1.13E+08 C/T IL1A UTR-5[NM_000575.3] MRPS7  
rs1143627 2 1.13E+08 C/T IL1B Near-gene-5[NM_000576.2] OSBP  
rs2070874 5 1.32E+08 C/T IL4 UTR-5[NM_172348.1] MACROD1  
rs2243250 5 1.32E+08 C/T IL4 Near-gene-5[NM_172348.1] RECQL4: LRRC45: NFKBIL2: RRAS2: 
C19orf47: CHTF18: EIF3H: DBF4B  
rs2069835 7 22734396 C/T IL6 Intron[NM_000600.2] PGPEP1: PA2G4: LOC100144415: RAD9A  
266 
 
rs1554606 7 22735232 G/T IL6 Intron[NM_000600.2] C8orf59: CNR1: LNPEP: RPL23: SNORA21: 
LOC284702: TAS2R49: ADIPOR2: NUFIP2: 
EIF1AP1: EIF1AX: CUGBP1: ZNF706: 
BCL2L2  
rs2069845 7 22736674 A/G IL6 Intron[NM_000600.2] C8orf59: BCL2L2: CNR1:ADIPOR2: RPL23: 
SNORA21: ZC3H10: LNPEP: NUFIP2: OAZ2: 
TGFBR1: SDCBP2: TAS2R49  
rs1368439 5 1.59E+08 G/T IL12B UTR-3[NM_002187.2] C3orf62: NEURL: ZNF517: SEPN1  
rs2043055 11 1.12E+08 A/G IL18 Intron[NM_001562.2] EGFL8: PPT2: MRPL11: CEU: TWIST1  
rs549908 11 1.12E+08 G/T IL18 Reference[NM_001562.2] KCTD11: IFNA8: SEPX1: C21orf128  
rs360729 11 1.12E+08 A/T IL18 Intron[NM_001562.2] RPS27A: UBB YRI: UBC: SEPX1: RP9P: 
PVRIG: COX4I1: C19orf53: GPBAR1: IFNA8 
rs3882891 11 1.12E+08 A/C IL18 Intron[NM_001562.2] DRAM: ZNF566: FNBP4: HERPUD1: EMG1: 
OTUD5: RBM19: ZNF567: SPAG7: PRDM2: 
C10orf2: OBFC2A: CHMP4A: MDP-1: PPTC7: 
CLK4: NFKBID: ZBTB43: CCDC49: ZNF460: 
UHRF1BP1L: BRD1: LOC90834: PI4K2A  
rs2193049 12 66833189 C/G IFNG Near-gene-3[NM_000619.2] NPY: TFCP2L1: C16orf33: IL1R2: IFI44L: 
SFRS10  
rs2069727 12 66834490 A/G IFNG Near-gene-3[NM_000619.2] GCLM: GALR3: RP5-1077B9.4: BTN2A3: 
LRRCC1: FBXL4: CASP6: ZAK: CUTA: 
DUSP7: MBOAT2: RAB23: PTPLB: RBPJ: 
ANLN: EMILIN2: TTL: NOD1: 
C1orf112:C6orf145:SLC4A7: CUL7:TIFA: 
UPK2: C6orf26: MSH5: B3GALTL: EZH2  
rs2107538 17 31231893 C/T CCL5 Near-gene-5[NM_002985.2] HYOU1: ANG: RNASE4  
rs767455 12 6321206 C/T TNFRSF1A Reference[NM_001065.2] MFSD7  
rs1061622 1 12175542 G/T TNFRSF1B Missense[NM_001066.2] PXN YRI: GPR146: LOC100130456: 
LOC100134611: CA9  
rs1061624 1 12189852 A/G TNFRSF1B UTR-3[NM_001066.2] RAB9B  
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rs3397 1 12189879 C/T TNFRSF1B UTR-3[NM_001066.2] LOC100130157: PIGT: RAD51AP1: TCF4: 
NFS1: LOC728543: TMEM116: PIP4K2B: 
C21orf45: OIP5: NUP37: CDKN3: TMEM169: 
RBM10  
rs496888 1 12155393 A/G TNFRSF1B Intron[NM_001066.2] SPTAN1: ALKBH3: ACLY: FLJ14154: GNG7 
rs1061631 1 12191086 A/G TNFRSF1B UTR-3[NM_001066.2] FCRL4: LOC100128968: MIB2: C5orf29  
rs2228139 2 1.02E+08 C/G IL1R1 Reference[NM_000877.2] SLC37A1  
rs7749390 6 1.38E+08 A/G IFNGR1 Intron[NM_000416.2] RHBDF2: CPSF1: LMF2: HIST1H1B: HLA-B: 
HLA-C: MICA: MICB: XXbac-BPG181B23.1: 
HIST1H1E: VIPR1: COX8A: WDR24: 
AMMECR1: SNORD96B: LOC100130790: 
SLC16A3: REEP4: RNPEPL1 
rs1130864 1 1.58E+08 C/T CRP UTR-3[NM_000567.2] CD84  
rs3093066 1 1.58E+08 A/C CRP UTR-3[NM_000567.2] MAP1B: RASSF7  
rs1205 1 1.58E+08 C/T CRP UTR-3[NM_000567.2] TSC2: PURA: PLAUR: ARID3C: DCTN3  
rs3775485 4 74494685 A/T ALB Intron[NM_000477.3] C17orf59  
rs1800849 11 73397813 C/T UCP3 Near-gene-5[NM_022803.1] CLK3: LBXCOR1: PIAS1  
rs972936 12 1.01E+08 A/G IGF1 Intron[NM_000618.3] TAGLN2: ARF6: CCDC85B  
rs11111272 12 1.01E+08 C/G IGF1 Intron[NM_000618.3] C1orf86: FLJ14100: ARF6: OAZ2: KCTD5: 
CCDC85B  
rs2453839 7 45920098 C/T IGFBP3 Intron[NM_000598.4] ZNF793:ZHX3  
rs1801278 2 2.27E+08 A/G IRS1 Missense[NM_005544.1] RBL1: TIMELESS: HSBP1: ZNF558: DPYSL2  
rs2234931 2 2.27E+08 A/G IRS1 Coding-
synonymous[NM_005544.1] 
RBL1: DPYSL2: CHAF1B: HSBP1: ZNF558: 




rs2229765 15 97295748 A/G IGF1R Coding-
synonymous[NM_000875.3] 
WNK1: TAP1: IFI35: GNB2: ENDOG: 
UQCRC1: GUK1: FLJ36031: IFI6: PSMD3: 
IRF1: RRP9: GTF2H4: VARS2: MAP3K11: 
BAT5: PLAC8: HIST1H2AB: 
HIST1H2AE:HIST1H2BN: HIST1H3A: 
HIST1H3B: HIST1H3C: HIST1H3D: 
HIST1H3E: HIST1H3F: HIST1H3G: 
HIST1H3H: HIST1H3I: HIST1H3J: IDH2: 
GRIN1: TUBB2C: GPR172A: GMPR: POLD4: 
SLC9A5 
rs1743966 6 1.35E+08 C/T SGK1 Intron[NM_005627.3] PRKCSH: SLC27A5: APLP2: OAS3: 
UGT2B15: UGT2B17  
rs9402571 6 1.35E+08 G/T SGK1 Near-gene-3[NM_005627.3] CLK3: DOK7: FBXO16: ZNF395: RNF34: 
EFNA3: C1orf113: LOC100127947: MYLIP: 
NR4A1: TGM2: LOC100133227: SEPT9 
rs2236903 1 2.08E+08 A/T HSD11B1 Intron[NM_005525.2] GIPC1: F2RL3: HERC1: FLNB: FKSG43: 
FRMD8 
rs16940665 17 41263677 C/T CRHR1 Coding-
synonymous[NM_004382.3] 
LARP5  
rs17689824 17 41260178 C/T CRHR1 Intron[NM_004382.3] PYY  
rs7209436 17 41225913 C/T CRHR1 Intron[NM_004382.3] TRIM46  
rs110402 17 41235818 C/T CRHR1 Intron[NM_004382.3] TRIM46 
rs780094 2 27594741 A/G GCKR Intron[NM_001486.2] TNFRSF18:C16orf62: XPC: ATRN: NDFIP1: 
PPAPDC1B: RUVBL1: SLC25A4: TDRKH: 
XRRA1  
rs780106 2 27535102 A/C IFT172 Intron[NM_015662.1] TXNDC1:PHF6: CCDC120: FGFR1OP2 
rs1647266 2 27546989 C/T IFT172 Intron[NM_015662.1] TXNDC1: PHF6: CCDC120: FGFR1OP2  
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rs7310409 12 1.2E+08 A/G HNF1A Intron[NM_000545.4] PDE8A: MT1H: MT1P2: LACTB2: MBP: 
C20orf19: OBFC1: UBE2L3: CCNY: STAU1: 
TULP4: HSP90B1: HSP90B2P: LRRC28: 
RAB3IP: RBM41: FAS: AIFM2: 
CAMK2G:PTER:UBE2D1: LOC731788: NF1: 
KPNA3: ANUBL1: SETD3: HNRNPUL1: 
LOC100128562: PTPN9: RFXDC2: BLMH: 
DDX52: DIS3L: TDRD3 
rs1169300 12 1.2E+08 A/G HNF1A Intron[NM_000545.4] NLRC3: TULP4: BLMH: GEN1: LOC284952: 
C1orf19: SRD5A1: ATG10: C20orf19  
rs2464196 12 1.2E+08 C/T HNF1A Missense[NM_000545.4] TULP4: NLRC3: BLMH: GEN1: LOC284952: 
C1orf19: ATG10: SRD5A1: CXorf10: 
EFCAB4B: FLJ33046: LOC100131749: TRIO: 
DIS3L: ELK4: HNRNPUL1: C20orf19 
rs1169302 12 1.2E+08 G/T HNF1A Intron[NM_000545.4] LRRFIP1: GCC2: NLRC3: HIST1H2BC: 
HIST1H2BE: HIST1H2BF: HIST1H2BG: 
HIST1H2BI: CALML4: C11orf47: CCDC35: 
DNHD1: C14orf65: LOC100128667  
rs1815739 11 66084671 C/T ACTN3 nonsense[NM_001104.1] TPPP  
rs2239179 12 46544033 A/G VDR Intron[NM_001017535.1] HDAC9  
rs731236 12 46525024 C/T VDR  Coding-
synonymous[NM_000376.2]  
SLC27A1: NUDT9: ZNF524: WIPF1: UBE2K: 
PRPS2: OTUD6B: PRPF38B  
rs4343 17 58919763 A/G ACE Coding-
synonymous[NM_152830.1]  
DENND2D: APOM: B3GALT4: CDC37L1  
rs4329 17 58917190 A/G ACE Intron[NM_152830.1] FXYD2: BLK: CLU: SHROOM3: HEY1  
rs2854464 12 50675158 A/G ACVR1B UTR-3[NM_004302.3] NNT: AFAP1L2: ELK1  
rs16892496 8 1.1E+08 A/C TRHR Intron[NM_003301.2] CAT: BAIAP3  
rs2070802 9 34546453 A/T CNTFR Intron[NM_001842.3] EOMES: OASL: IFITM1: BIN2: SHKBP1: 
PRIC285: MYO18A: TIAF1: LOC399491: 
NPIP: PKD1  
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rs361072 3 1.4E+08 A/G PIK3CB Near-gene-5[NM_006219.1] CCDC94: GTF2F1: LOC100130856: 
MAP3K14 
rs2536 1 11089300 C/T FRAP1 UTR-3[NM_004958.2] PGK1: RAD23A: ASB7: LOC145758: PARVB: 
FRAT2: KIAA0182  




rs744166 17 37767727 C/T STAT3  Intron[NM_213662.1] SAMD10: LOC51149: TLN1: SMO: NDST1: 
MMP11: ABHD6: RAPGEF5 
rs8069645 17 37748428 A/G STAT3  Intron[NM_213662.1]  COMMD5 
rs2293152 17 37735055 C/G STAT3  Intron[NM_213662.1] HLA-DQA1: HLA-DQA2  
rs1053005 17 37719436 A/G STAT3  UTR-3[NM_213662.1]  C3orf59: ENC1: BTG2 
rs2419621 10 1.14E+08 C/T ACSL5  Intron[NM_203379.1]  COCH  
rs2701896 13 40025892 C/G FOXO1 Near-gene-3[NM_002015.3] LAMP1: CCND1: GLTSCR2: SNORD23: ADA: 
PIK3R5: ERAL1: C19orf22: SGTA: PES1: 
DCTN2: MRPL45: MRPL40: VAV1: B3GNTL1: 
TOMM34: PPARD: SIRPA: HPS1: PRMT6: 
HCLS: MRPS7: FBXO46: TH1L: GRAMD1A: 
GRAMD1B: NADSYN1: C11orf24: AP3D1: 
FOXK2: UBTD2: C1orf142: JMJD4: CDH1: 
CLYBL: PHC2  
rs2297627 13 40131931 C/T FOXO1 Intron[NM_002015.3] LRRK1: CD96: LRRK1: PKN3: TLR4: 
MGC39372  
rs2802292 6 1.09E+08 G/T FOXO3 Intron[NM_001455.3] RPL27A: hCG_21078: UHRF2  
rs3791783 2 1.91E+08 C/T MSTN Intron[NM_005259.2] C3orf59  
rs2268757 3 38480857 C/T ACVR2B Intron[NM_001106.3] FKBP2: ZAR1  
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rs947712 1 2.17E+08 A/G TGFB2 Intron[NM_003238.1] PLP2: RAB11FIP2: ERGIC1: LHPP: 
LOC100132892: DNASE2: DTWD2: 
LOC440983: WWTR1: STK40: WBP2: 
LAPTM4A: GTPBP1: TMEM59: ENPP7: 
LRRC33: EFHA1: CUTA: NLRP1: CAPN2: 
MCM9: SAMD14: MED28: RAB7A: TSG101: 
TESK2: KIAA0141: H1FX: C16orf44: IFITM1: 
ANXA5: JAM2: GNPDA1: TMED4: ASB8: 
TMUB1: TEX264: NUDT12: C20orf19: ING3: 
ADCK2: GMPR2: IQGAP2: DYNLRB1: HBP1: 
SRD5A3: CENTA1: C11orf49: EMP3: PIAS3: 
MTX2: MRPS22: NPC2: TMEM90A: 
NIPSNAP3A: NR1D2: NAIF1: PXN: CAPZB: 
LOC100130193: LOC644075: GTPBP10: 
PPAP2C: RNPEPL1: IMPACT 
rs1890995 1 2.17E+08 C/T TGFB2 Intron[NM_003238.1] NUDT4: NUDT4P1: C15orf24: LOC201164: 
ARID3C: DCTN3: TOX4: ARMCX3: CCDC12: 
PWP1  
rs817529 2 33350839 A/G LTBP1 Intron[NM_000627.2] SDF4: FICD: LRRC59: RBM15: DHX30: E4F1: 
PLEKHB2  
rs2577262 2 11856397 C/T LPIN1 Intron[NM_145693.1] CD320:LRDD  
rs1801253 10 1.16E+08 C/G ADRB1 Missense[NM_000684.2] CREBBP: RICH2: ZNF318: MED14: CBX5: 
MAP3K15: SH3KBP1: KIAA1267: 
LOC100132495: NOTCH2: NOTCH2NL: 
SKAP1: TXNDC13: TNFSF12: TNFSF12-
TNFSF13: TNFSF13: RAD23B: TAOK3: 
LOC643475: PIP4K2A: PROK2: CD24: 
COL6A1  
rs1042713 5 1.48E+08 A/G ADRB2 Missense[NM_000024.4] LMF1 CEU 5e-05 
rs1042714 5 1.48E+08 C/G ADRB2 Missense[NM_000024.4] ARPC1B: FHOD1: MYD88: PODXL2: RARG: 
CORO1A: LOC606724  
rs1042717 5 1.48E+08 A/G ADRB2 Coding-
synonymous[NM_000024.4] 
LAPTM4B: DSCR6  
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rs1042719 5 1.48E+08 C/G ADRB2 Coding-
synonymous[NM_000024.4] 
DSCR6  
rs5443 12 6825136 C/T GNB3 Reference[NM_002075.2] SRRM2: C4orf8: RNF4: KIAA0182: ND5: 
UNQ6228  
rs1800590 8 19840951 G/T LPL UTR-5[NM_000237.2] FLJ10232: LY9: FAM102A  
rs326 8 19863719 A/G LPL Intron[NM_000237.2] PAPD5: ARF4  
rs157580 19 50087106 A/G TOMM40 Intron[NM_006114.1] NUDT9: SS18L2: C11orf46  
rs1862513 19 7639793 C/G RETN Near-gene-5[NM_020415.2] CYFIP2: LRP8: CSF3: ZDHHC18  
rs1501299 3 1.88E+08 A/C ADIPOQ Intron[NM_004797.2] TBXAS1: SESTD1: WWP2: PAG1: B3GNT7  
rs16928751 12 1760460 A/G ADIPOR2 Coding-
synonymous[NM_024551.2] 
EMR2: CTSW  
rs1137101 1 65831101 A/G LEPR Reference[NM_002303.3]  FAM128A: FAM128B: LOC646836 
rs1137100 1 65809029 A/G LEPR  Reference[NM_002303.3]  C16orf74: CKB: TRAF2: PTPRS: MAN1B1: 
MAP2K6  
rs8179183 1 65848540 C/G LEPR Missense[NM_002303.3]  RAB11FIP3: ZNF416: TRAF7: IRF2BP1: 
HPS6: PI4K2A: INPP5E: TOB1: GSTM1: 
GSTM2: GSTM4: TM9SF4  
rs12409877 1 65716460 A/G LEPR  Intron[NM_002303.3]  GSTM1: GSTM2: GSTM4: APOA2  
rs696217 3 10306457 G/T GHRL Missense[NM_016362.2] ASB3: LOC728653: MECP2: RRAS2: ACBD3: 
OBFC2A: SRPRB  
rs35681 3 10304377 A/G GHRL Intron[NM_016362.2] PTGIR  
rs3746619 20 54257212 A/C MC3R Missense[NM_019888.2] POU5F1: POU5F1P1: POU5F1P3: 
POU5F1P4: SNRP70: KLF9: SPIB  
rs3827103 20 54257436 A/G MC3R Missense[NM_019888.2] SNRP70: POU5F1: POU5F1P1: POU5F1P3: 
POU5F1P4: SPIB: KLF9  
rs1875233 16 55244205 A/G MT1B Intron[NM_005947.2] ZC3H3: ZNF696: NAPRT1: TAF5: CRLF3: 
NFYB: TM9SF3: HTRA1: GMCL1: GMCL1L: 




rs10636 16 55200844 C/G MT2A UTR-3[NM_005953.2] HIP1: KCNK1  
rs3745601 19 10085548 A/G P2RY11  Missense[NM_002566.4]  ARSA: PNPLA2  
rs10183022 2 2.37E+08 A/G CXCR7 Intron[NM_020311.2] SSR2: IK: ATP6V0E1: SNORA74B: PFDN6: 
EIF4E2: VAMP8  
rs1045879 2 2.37E+08 C/T CXCR7  Reference[NM_020311.2] 
Coding-
synonymous[XM_001714208.1]  
IK: H3F3A: H3F3B: LOC440093: MRPL27: 
EEF1A1: EEF1AL3: EEF1AL7: CSAD: 
PARD6B: HNRNPH1: FOXK2: VASP: 
HNRNPH3: GPR44: EIF4E2: TARDBP  
rs6805421 3 42703148 A/G KBTBD5 Reference[NM_152393.2] CMBL  
rs123509 3 42708472 A/G KBTBD5  Missense[NM_152393.2]  RIMS4  
rs4855881 3 49690450 C/T APEH Intron[NM_001640.3] FLJ34077  
rs2142234 6 31747108 C/T LY6G5B Intron[NM_021221.2] FCN1: TMEM170: ERH  
rs1266076 6 31748497 A/C LY6G5B Near-gene-3[NM_021221.2] B3GNT7:CMPK2: PRIC285: TTYH3: CRIM1: 
IFIT3: ALDH2: HOXB3: CRIP3: CCR6: CD72: 
OAS3: C1orf161: ZNF318: OASL: A4GALT: 
BLVRB: NME4: SLC45A3: SDC4: HOOK1: 
LOC399491: NPIP: PKD1: RTKN: EPHB1: 
SYS1: SYS1-DBNDD2: SPIB: PLCB2: GLIS2: 
DDX60: CHDH: HNRPLL: BIN1: DBN1: 
PLA1A: GMPR: LCK: MOBKL2B: HNF1B: 
CACNB3: SOX4: ISG15: DUSP4: MARCKSL1: 
LOC100128950: PIGZ: PARD3: 
LOC100134130: LOC440456: PLEKHM1: 
KIAA0746: SERINC2: GSTP1: ETV4: CHL1: 
PHLDA1: SLCO4C1: APLP2: GPER: 
C20orf59: CLCF1: MAP1B: CHST11: PARP12 
rs3802427 9 34608641 A/G DCTN3 Intron[NM_024348.2] GARNL4:C10orf10 
rs3088241 11 1.25E+08 C/G HYLS1  Intron[NM_145014.1] NCOA3  
rs3848017 13 97828590 C/T FARP1 Intron[NM_005766.2] C9orf148: TTLL11 
rs584800 13 97836088 A/G FARP1 Intron[NM_005766.2] SLAMF1: ABCC4 
rs4969484 17 77608150 G/T GPS1  Intron[NM_212492.1]  C20orf149  
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rs3826785 19 10088149 C/T EIF3G Intron[NM_003755.3] ARSA: PNPLA2: BNIP3L 
rs11085824 19 12862547 A/G GCDH Near-gene-5[NM_013976.2] DHRS1: TADA3L: RICH2: SF3B4: 
C1GALT1C1: TOR3A  
rs9384 19 12871643 G/T SYCE2 Intron[NM_001105578.1]  TADA3L: SF3B4  
rs163781 20 56997160 A/G TH1L Intron[NM_198976.1] TNNT2: FBXL8: C6orf192: MSH3: GPR27: 
ZBED4: GJA4: ZNF131: ZNF184: ZNF204: 
NFXL1: MTMR15: C4orf30: C10orf28: 
MANBAL: CDC42BPG: RARRES3:KCTD20: 
C4orf1405:CHD1L  
rs2284890 3 1.97E+08 A/G TFRC Intron[NM_003234.1] MGMT  
rs3817672 3 1.97E+08 A/G TFRC Missense[NM_003234.1] MGMT  
              





Even with the same tumour type and burden, one individual may become cachectic 
whereas another will not. One mechanism for such variation may relate to host 
genotype. Genetic variation in immunity and associated signaling pathways is known 
to relate to outcomes in major sepsis (742), and recent findings suggest a similar 
pattern in cancer cachexia (207). Single-nucleotide polymorphisms in the IL-1, IL-6, 
and IL-10 genes that are linked to production rates of these cytokines have been 
associated with the prevalence of cachexia in gastric or pancreatic cancer (743). For 
example, the 1082G allele in the IL-10 promoter has been validated as a procachectic 
genotype in an independent cohort (200, 208). IL-10 has been shown to be elevated 
in a Myc/mTOR-driven murine model of cancer cachexia (744), as well as in cachectic 
patients with colorectal cancer (745). Others have identified associations with 
cachexia defined as >10% weight loss and polymorphisms in cytokine genes such as 
the IL1-B 3954C/T polymorphism (rs1143634) in patients with gastric cancer (209). 
Cancer related anorexia has been associated with the TNF-308G/A polymorphism 
(rs1800629) in patients with non-small cell lung cancer (198). Most recently, the C 
allele of the rs6136 polymorphism in the P-selectin gene has recently been associated 
with weight loss in a large heterogenous group of cancer patients and validated in an 
independent cohort (207). Taken together, these findings are consistent with a key 
role for the immune system in the variable presentation of cachexia. However, cancer 
cachexia has been defined in a number of ways (6-10), mainly focused on weight loss 
and the presence of systemic inflammation. This has lead to phenotyping in many of 
the existing studies on genetic association relying wholey on a degree of weight loss 
and inflammation. However, one recent definition described cancer cachexia with a 
more musculocentric view (11). This definintion highlights the importance of skeletal 
muscle loss as one of the most significant event in cachexia and is associated with a 
poor outcome (11, 12). In genetic studies of common diseases, the capacity to define 
genotypes is often far better than the capacity to define phenotypes, therefore more 
robust classifications of phenotypes need to be sought. With the existing studies 
focusing mainly on weight loss and CRP to define cancer cachexia phenotypes this 
may have lead to the discovery of associated SNPs exclusively involved in mediating 
the immune response. Recent advances in the use of routine CT scans in cancer 
patient’s care have lead to unmasking of detailed body composition analysis for 
accurate measurements of skeletal muscle and adipose tissue mass (746). Taking 
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into account a level of skeletal muscle mass alongside degrees of weight loss and 
inflammation will improve accuracy of phenotyping and may open up the analysis to 
include genetic variants in muscle specific genes.  
The published studies linking genetic variation to cancer cachexia are listed in Table 
5.1, the definitions of the cancer cachexia phenotype vary greatly from weight loss cut 
offs and inclusion of systemic inflammation, to performance status assessment and 
quality of life scores. The only study to directly state and include an independent 
validation cohort to confirm the presence of a significant SNP is the detection of the 
p-selectin genotype from our group (207). In the discovery cohort a further 20 
significant SNPs were found however these did not reach significance in the validation 
cohort. It may be these SNPs are significant but due to the size of the independent 
validation cohort they failed to reach significance.   
In the current review, associated polymorphisms in genes with a possible role in 
cachexia have been recorded as well as polymorphisms with clinical associations 
related to cachexia such as inflammation, weight/body composition changes and 
cancer survival. Because cancer cachexia is a multifactorial disease involving a 
variety of biological pathways it can be assumed that analysis of combinations of gene 
variants encoding interacting factors within a biological chain or cascade, rather than 
isolated investigation of its single components, may have more chances to reveal real 
causative connections between gene polymorphisms and phenotypes. Of the 80 
polymorphisms with a potential role in the development of cachexia that have been 
independently verified in at least one repeat study, 24 polymorphisms have been 
shown to have more than one association on clinical features associated with cancer 
cachexia. These 24 polymorphisms are likely to be the most promising candidates in 
terms of susceptibility biomarkers of cancer cachexia and have investigated in 
Chapter 6.  
Eighty eight newly identified genes with a potential role in cancer cachexia were 
included since the last review, however the main limitation to identifying new SNPs in 
these genes was the lack of studies to date into functional polymorphisms within them. 
Undertaking a genome wide association study (GWAS) would be one way to 
overcome this potential limitation and in the future would be preferable to repeating 
candidate gene selection studies. However, without an adequate sample size and 
highly accurate phenotyping, coupled with lack of government funding to complete 
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the project, candidate gene association studies will continue to provide novel insights 
in to the genetic of cancer cachexia.  
In conclusion, the current review has expanded on an initial framework to further 
enhance the possibility of identifying functional polymorphisms involved in cancer 
cachexia. Based on the expansion of the definition of cancer cachexia along with an 
inclusion of skeletal muscle mass and not just weight loss and systemic inflammation, 
new muscle specific SNPs may provide novel biomarkers in the early detection of 
individuals at risk of developing cancer cachexia. These SNPs are explored in an 
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Cancer cachexia is characterised by loss of weight (WL), muscle and fat. This Chapter 
aimed to (i) replicate SELP rs6136 and other genes previously associated with WL (ii) 
explore associations with 92 predefined new candidate single nucleotide 
polymorphisms (SNPs) and (iii) explore a panel of candidate SNPs (i and ii) for 
association with CT-defined low muscularity (LM) +/- WL. Whether the transcription 
in muscle (n=134 cancer patients) of identified genes was altered according to 
cachexia phenotype was also explored.  
 
6.1.2 Methods 
The replication study included 545 new cases. Combined analysis of prior and new 
cohorts (n=1276) explored associations of new candidate SNPs with WL and LM. 
Human muscle transcriptome was analysed using Agilent platform. 
  
6.1.3 Results 
SNPs rs6136 (SELP) and rs4149570 (TNFRSF1A) shown in a prior study to associate 
with WL, were replicated. New candidate SNPs in the following genes showed 
association with WL: IFT172, ACVR2B, TLR4, FOXO3, IGF1, LEPR, FOXO1, 
TOMM40, and CPN1. SNPs in ACE, MT2A, WDR20, PPARG, LPIN2 and LEPR, 
ACVR2B, TNF, ACE were associated with LM and concurrent LM + WL, respectively. 
There was concordance between muscle-specific expression for ACVR2B, FOXO1 




rs6136 in the SELP gene is the leading replicated SNP to associate with WL. New 
SNP associations for cachexia phenotypes that include an index of muscle mass and 
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muscle specific gene expression signatures for WL or LM provide insights into 
potential risk factors/biomarkers for muscle loss in cancer cachexia. 
 
6.2 Introduction 
As previously stated, cachexia affects the majority of patients with advanced cancer 
and is associated with a reduction in treatment tolerance, response to therapy, quality 
of life and duration of survival (747). Cachexia is a complex multifactorial syndrome 
characterized by weight loss (WL), and specific losses of muscle and/or adipose 
tissue (748). Based on current knowledge of demographic and clinical factors 
including cancer type, it is not possible to predict, for any given cohort of patients, who 
will develop cancer cachexia and who will not. Such variation may, in part, be due to 
the patient’s genotype. Knowledge of genotypic variation associated with cachexia 
could contribute to early identification of patients at risk and allow institution of 
prophylactic measures. 
Using a candidate gene approach, prior research has identified an association with 
cancer cachexia and several single nucleotide polymorphisms (SNPs) on different 
genes/chromosomes; among these, a variant from the SELP gene (that encodes for 
the cell adhesion molecule P-selectin (207)) was investigated in depth for functional 
significance. Since that study, many new target genes that might potentially influence 
the development of cancer cachexia have been reported (89, 103, 145, 283, 286, 329, 
749). Chapter 5 details a comprehensive and contemporary review of candidate 
genes and polymorphisms to aid association studies for the identification and 
characterisation of genetic determinants of the different phenotypic domains 
described in cachexia (193, 750). Candidate genes and their polymorphisms 
considered in the present study are from pro/anti-inflammatory pathways, neuronal 
melanocortin signalling pathways, energy regulation, appetite regulation, muscle, and 
adipose tissue catabolic pathways.  
Although there is depletion of both adipose tissue and lean body mass in cancer 
cachexia, WL per se has long been used as the diagnostic criterion for the syndrome 
(751) and this remains the case in current classification systems (11). Validity for the 
use of WL in the diagnostic phenotype is provided by the observation that it is an 
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independent predictor of shortened survival, with increasing WL carrying a 
progressively worse prognosis (23, 396). 
However, it could be argued that it is skeletal muscle loss that has the greatest impact 
on patients’ function and quality of life. It has recently been possible to specifically 
quantify muscle mass in cancer patients’ diagnostic CT scans and low muscularity 
(LM) identified by such means is clearly associated with a poor outcome in advanced 
cancer (11, 12, 69). One limitation of this approach is that due to the absence of pre-
illness scans, it is not possible to document a state of active muscle loss but rather 
one of LM determined by pre-determined cut-offs. In the present study the term LM is 
used in a manner synonymous with that of sarcopenia defined by cut-offs in relation 
to excess mortality (28, 396). The combination of LM and WL has been suggested to 
combine a focus on muscle mass with a dynamic process of active loss (11). 
Interestingly, such a combined definition proved superior to its individual components 
in terms of identification of cancer patients with histological evidence of skeletal 
muscle fibre atrophy (Chapter 4) (752). Therefore both WL, LM and a combination of 
the two were used in the characterisation of the cachexia phenotype.  
A candidate gene approach was used to evaluate the association between genetic 
polymorphisms and the presence of cancer cachexia in patients from Europe and 
Canada. The hypothesis was that inter-individual variations in the susceptibility to 
cachexia are in part due to inherited genetic variations (host); remaining phenotypic 
variance may be ascribed to the contribution of the tumour or other comorbidity. The 
premise that susceptibility variants may show a certain degree of overlap with related 
sub-phenotypes was also tested (e.g., WL cut-offs adopted to describe severity of 
cachexia). The latter is an expected consequence for a polygenic trait such as 
cachexia and the underlying cross-talk from the biological networks involved (18). The 
primary objective of the present study was to further replicate findings from a previous 
association study which identified the SNP rs6136 in the SELP gene and a number of 
other polymorphisms as promising candidates influencing genetic predisposition to 
cachexia. The second objective was to explore the association with 92 predefined 
new candidate SNPs and WL. The third objective was to compare our entire panel of 
candidate SNPs and their association with LM with and without WL. Lastly, it was 
investigated whether genes demonstrating significant associations with the cachexia 
phenotypes had altered transcript expression in muscle from cancer patients with or 




6.3 Patients and Methods 
(Detailed methodology is found in Chapter 3) 
 
6.3.1 Genotyped cancer patients: new and prior study cohorts 
Study subjects were recruited between 2004 to 2012 from the National Health Service 
Lothian, UK; Cross Cancer Institute, Edmonton, Canada; McGill University Health 
Centre, Montreal, Canada; Palliative Research Centre, Norwegian University of 
Science and Technology (NTNU), Norway; Cantonal Hospital, St Gallen, Switzerland; 
and Department of Medical Oncology, University Hospital of Larissa, Greece. All 
subjects participated in clinical or research studies on cancer cachexia at the host 
institutions under ethically approved protocols allowing for analysis of patients’ DNA. 
Recruitment was conducted at first presentation (treatment naive) to surgical, 
oncology or palliative care clinics at each institution. Recruitment was performed 
sequentially with the following exclusion criteria: (i) under 18 years of age; (ii) cognitive 
impairment; (iii) inability to give written, informed consent; (iv) presence of underlying 
infection; (v) on corticosteroids. Patients recruited generally had cancer types with 
propensity to develop cachexia (e.g. gastric/oesophageal, pancreatic, lung). Overall, 
1276 patients were included: 731 from our prior study and 545 new patients. More 
than 98% of the patients were of European descent. Information collected on each 
patient included date of birth, date of diagnosis, type and stage of cancer. All patients 
underwent measurements of height and weight at the time of recruitment. Pre-morbid 
weight was recalled by the patient and verified where possible from the medical notes. 
WL was calculated and expressed as percentage of pre-morbid body weight lost. The 
documentation of WL (current minus previous recalled stable weight) is dependent on 
the accurate recall of previous weight. Studies in healthy populations suggest a strong 
correlation between current recalled and measured weight (753). Height and weight 
were used to compute BMI (kg/m2); this was calculated for time of recruitment (at time 
of diagnosis of cancer). Diagnostic or staging CT scans closest to the time of 
diagnosis (within 30 days on average) were selected to determine the level of 
muscularity. Stage of disease was based on the American Joint Committee on Cancer 
stage groupings I, II, III and IV. All patients provided written informed consent to allow 




6.3.2 Skeletal muscle transcriptome study 
Description of the patients who contributed to the muscle transcriptomic biobank has 
been described recently (754). Briefly, rectus abdominis muscle (0.5 – 1 g) from adult 
cancer patients were obtained during open abdominal surgery. Review of medical 
charts and CT images was used to identify WL status and muscularity. 
 
6.3.4 Phenotypes 
 WL >5%, >10%, >15%. A range of weight loss was used to provide a 
subgroup analysis that would help identify associations that would have been 
missed with a single cut-off as the interest is to detect all potential 
associations in a polygenic model of inheritance where the variants are likely 
to be of lower penetrance, yet conferring finite effects.  
 LM: analysis of CT scans allows patients to be classified as having LM or not. 
Cut offs for LM were defined in relation to the duration of survival of advanced 
cancer patients (396). 
 LM with any degree of WL (>2%)  
 
6.3.5 CT Analysis 
Digitally stored CT images completed with a spiral CT were analysed as described 
previously. A transverse CT image from the third lumbar vertebrae (L3) was assessed 
for each scan date and tissue cross-sectional area (cm2) quantified (395). All CT 
images were analysed by a single trained observer. Cross-sectional area for muscle 
was normalized for stature (cm2/m2) and a lumbar skeletal muscle index (SMI) 
computed as described previously (28, 397). SMI cut offs for LM were based on a CT-
based study of cancer patients by Martin et al. (396). 
 
6.3.6 Candidate gene and SNP selection 
All candidate genes and SNP selections were based on the systematic literature 
review presented in Chapter 5 (193, 750). Candidate SNPs met one or more of the 
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following criteria: previously published association with cancer cachexia (197, 200, 
209), statistically significant association with cancer cachexia in our prior study but 
still requiring validation (207), likely role in cancer cachexia based on functional or 
clinical relevance in more than one study (193, 750), significant SNPs identified in a 
preliminary study (755), and finally those SNPs which had been identified in relation 
to pro/anti-inflammatory pathways, neuronal melanocortin signalling pathways, 
energy regulation, appetite regulation, muscle, and adipose tissue catabolic pathways 
since the prior systematic review (193, 750). 
 
6.3.7 Genotyping  
Genotyping of the samples were performed on the Sequenom iPLEX Gold platform 
(San Diego, CA, USA) or TaqMan assay (for rs4280262) using services from the 
McGill University and Genome Quebec Innovation Center, Montreal, Quebec, 
Canada. Polymorphisms selected were validated for assay feasibility using DNA from 
apparently healthy Caucasian subjects (n=92) from Coriell Institute (Coriell Panel, 
Coriell Institute of Medicine, CA, USA) (398).  
 
6.3.8 Microarray analysis 
Microarray analysis was conducted as previously described(754). Briefly, total RNA 
was isolated, purified and subsequently quantified. RNA samples with RNA Integrity 
Numbers (RIN) greater than 7.0 were used. RNA was subjected to linear amplification 
and Cy3 labeling and Hybridization to Agilent Whole Human Genome Arrays using 
Agilent kits (One Color Low RNA Input Linear Amplification Kit Plus, One Color RNA 
Spike-In Kit and Gene Expression Hybridization Kit) according to the manufacturer’s 
protocols. The arrays were scanned using an Agilent Scanner, the data was extracted 
and quality was evaluated using Feature Extraction Software 10.5.1 (Agilent). The 
data were normalized using GeneSpring GX 11.5.1 (Agilent). The data used in this 
publication have been deposited in the U.S. National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus25 and are accessible through GEO 






6.3.9 Power calculations 
Power calculations were performed using Quanto. For the most prevalent cachexia 
phenotype (i.e. >5% WL, 50% affected), the present study has 87% power to detect 
an OR of 1.5 for SNPs with a MAF of >0.05. For the least prevalent cachexia 
phenotype (i.e. >15% WL, 16% affected), the present study has 35% power to detect 
an OR of 1.5 for SNPs with a MAF of >0.05. 
 
6.3.10 Statistical analysis 
6.3.10.1 Gene association study 
Statistical analyses were performed using PLINK (version 1.06) (399). Unconditional 
logistic regression was employed to calculate ORs and their 95% CI for the minor 
allele of individual SNPs and its association with each proposed cachexia phenotype. 
All analyses were adjusted for covariates that may affect WL: age at diagnosis, sex, 
pre-diagnosis BMI, tumour type and stage.  
Patients meeting the criteria for each of the proposed cachexia phenotypes were 
compared with patients who had lost <5% body weight as control.  
To account for multiple testing, permutation testing was performed by running the 
adaptive permutation test in PLINK within each proposed phenotype. Permutation 
tests are often employed to adjust groups of correlated tests for multiple testing, since 
conventional methods such as Bonferroni correction are overly conservative when 
tests are correlated (400). The adaptive permutation test in PLINK gives up permuting 
SNPs that are clearly not going to be significant. This greatly speeds up the 
permutation procedure, as SNPs that are not significant will drop out quickly, making 
it possible to evaluate properly the significance of the handful of SNPs that require 
millions of permutations.  
Finally, candidate genes (and the SNPs in the corresponding gene regions) were 
grouped based on known functional similarity according to gene ontology using 
AmiGO (Table 6.1). The set-based test in PLINK was used to analyse association 
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between grouped SNPs and cachexia = phenotypes. The set-based test selects the 
best set of SNPs whose mean of these single SNP statistics is significant after 
permutation, which is particularly suited to large scale candidate gene studies (401). 
The empirical p-values of the set-based test were obtained by a permutation of 10 
000 times of phenotype labels. 
 
Table 6.1 - Candidate genes groupings based on known functional similarity 
according to gene ontology 
 
Regulation of MAPK activity 
GHRL IL1B TNF 
PIK3CB IGF1 SGK1 
SELP TLR4 IGF1R 
FOXO1 TRAF6 IRS1 
FOXO3   
   
Regulation of apoptosis 
TOMM40 IGF1 PPARG 
VDR CNR1 IGF1R 
TLR2 CNTFR IKKA 
TNF DIO1 FOXO3 
IL10 TNFRSF1A IL1B 
IL6R TRAF6 VCAM1 
   
Regulation of NF-KB activity 
IL1B TNF TLR4 
IL10 TLR2 TNFRSF1A 
IKKA IL6R TRAF6 
   
Inflammatory response 
GHRL CRP TNF 
TNFRSF1A TRAF6 IL10 
IL1B AGER TOMM40 
CNR1 FOXO3 IL6R 
LRRFIP1 PPARG RUNX1 
SELP STAT3 TLR1 
TLR2 TLR4 TNFRSF1B 
   
Lipid metabolism 
PPARG CRP TNF 
ADIPOR2 LPL IRS1 
IL1B TOMM40 CNR1 
FTO LEPR LIPE 
LPIN2 TRAF6 VDR 
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Appetite regulation   
GHRL LEPR CNR1 
MC3R MC4R NPY 
STAT3 VDR  
   
Cell adhesion 
IL18 ICAM1 VCAM1 
TNF SELP TNF 
AKT2 AZGP1 IL10 
NPY PIK3CB STAT3 
   
Protein metabolism 
TNF ACE TRAF6 
TSC2 VCAM1 VDR 
IGF1 IL10 RUNX1 
PIK3CB PPARG ACSL5 
APEH IL1B CPN1 
MC4R CNTFR TNFRSF1A 
TNFRSF1B MSTN IGF1R 
IL6R GHRL  
   
Immune response 
IL10 TNF RUNX1 
SELP STAT3 TLR1 
TLR2 TLR4 PPARG 
TNFRSF1A TRAF6 VCAM1 
TOMM40 FOXO1 FOXO3 
AZGP1 CNTFR CRP 
ICAM1 IGF1 IGF1R 
IKKA IL1B IL6R 
IRS1 LPL LRRFIP1 
MT2A PIK3CB IL18 
   
ATP Binding 
AKT2 CAMK2B IGF1R 
PIK3CB RUNX1 STAT3 
   
Calcium signalling 
STAT3 PIK3CB RUNX1 
TOMM40 CRP GHRL 
LTBP1 NPY VDR 
TNF   
   
Cell membrane structure and function 
ACE ADIPOR2 AGER 
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APEH TOMM40 AZGP1 
CNR1 CNTFR CRHR1 
FOXO3 HYLS1 ICAM1 
IGF1R IL6R IRS1 
LEPR LPL LRRFIP1 
MC3R MC4R PIK3CB 
SELP STAT3 TLR1 
TLR2 TLR4 TNF 
TNFRSF1A TNFRSF1B TRAF6 
TRHR VCAM1  
   
Signal Transduction 
CAMK2B IL1B IRS1 
NR3C1 MSTN MT2A 
NPY PIK3CB RUNX1 
SELP IGF1 TLR1 
TLR2 TLR4 SGK1 
STAT3 TNF TNFRSF1A 
TNFRSF1B TRAF6 TRHR 
TSC2 VCAM1 VDR 
AGER PPARG LEPR 
ACSL5 ADIPOR2 AKT2 
TOMM40 AZGP1 CNTFR 
CRHR1 CRP FOXO1 
FOXO3 FTO GHRL 
HNF1A ICAM1 IGF1R 
IKKA IL10 IL6R 
INHBC LIPE LRRFIP1 
LTBP1 MC3R MC4R 
   
Metal ion regulation 
ACE CPN1 CRP 
FTO MT2A NR3C1 
PPARG VDR  
   
   
Insulin signalling 
GHRL IRS1 TNF 
IGF1 TSC2 STAT3 
TNF PPARG IL1B 
AKT2 TOMM40 AZGP1 
CNR1 FOXO3 IFT172 
IGF1R HNF1A PIK3CB 
   
Transcription Regulation 
AZGP1 FOXO3 HNF1A 
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IL10 IL1B LPIN2 
LRRFIP1 MSTN NR3C1 
PPARG RUNX1 STAT3 
TLR2 TLR4 TNF 
TNFRSF1A TRAF6 VDR 
   
Glucocorticoid signalling 
CPN1 IL10 TNF 
GHRL   
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6.3.10.2 Transcriptomic study 
Pearson correlation analysis was conducted to assess the linear relationship between 
the considered phenotypes independently (SMI or WL) with the expression of 
transcripts from select candidate genes. T-test analysis was conducted to compare 
how SMI (or WL) values differed for patients with high expression versus those with 
low expression for each of the candidate genes. The high and low expression groups 
for each gene transcript were determined by sorting patients by expression intensity 
and subsequently splitting the patients into three equally sized groups: those with high 
expression, mid- expression and low expression. The extremes of gene expression 
were compared while leaving out middle values. Comparison of the distal ends of 
gene expression maximizes the chance of detecting differences. Given the inherent 
variation in measures of gene expression, separation of the compared categories in 
this fashion also limits potential classification error. The cases considered for SMI and 
WL phenotypes for gene expression were based on sorting of transcript expression 
in all of the samples and binning based on extremes of gene expression as described 
above. The samples used for SNP studies (based on WL or muscularity) are non-
matched as these two were independently designed studies. Transcriptome profiles 
were obtained from a single biopsy specimen along the disease trajectory of patients 
(static but not a dynamic read-out). Caution was exercised in over-interpreting the 
data with the emphasis to seek nominal relationships as it was not possible to 
delineate the expression from early vs. late response genes. A mechanistic 
understanding of the role of early and late response genes and their spatiotemporal 
relationships could be clearly discerned in animal models of cachexia(207), as 




Of the 148 SNPs selected initially (21 SNPs from a previous association study and 
127 newly selected SNPs for this study), for Sequenom platform, 15 SNPs failed at 
the multiplex assay design stage, and 15 SNPs were non polymorphic, leaving 118 
SNPs for genotyping in the present study population. Assay duplicates for 154 
samples were included and genotyped for all 118 SNPs; 100% concordance of 
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genotype calls for replicates were obtained. Of the 1452 patients samples available 
for the study, detailed clinical annotations for the study end points were available for 
only 1276 patients. Therefore, germline DNA isolated from buffy coat cells from these 
1276 individuals were interrogated for the 118 SNPs. SNP call rates in the study 
population with >90% were retained for all subsequent analysis (2 SNPs did not meet 
this criteria; rs4280262 and rs1544410 and these showed call rates of 80 and 86% 
respectively). Three SNPs showed a minor allele frequency of <5% and these were 
excluded (rs1805086; rs2536; and rs16139) leaving 113 SNPs from a total of 62 
genes (Table 6.2) amenable for association analysis. Deviations from Hardy-
Weinberg equilibrium (HWE) were assessed in the Coriell panel of control population 
2 test with 1 degree of freedom (df); a p-value of <0.001 was considered 
as a significant deviation from the HWE proportions.  None of the 118 SNPs 
considered for association analysis showed deviations from HWE in the control Coriell 
samples or in the study subjects. 
292 
 
Table 6.2 - List of polymorphisms considered for association analysis 




HWE P in 
cases 
Gene Position of SNP Source of SNP 
rs1025333 0.98 A F 0.08 1.04E-02 IRS1 Intron Previous association 
rs10441113 0.99 T R 0.37 7.96E-01 CAMK2B Intron Previous association 
rs1049353 1.00 A F 0.26 9.65E-01 CNR1 UK Previous association 
rs1053005 1.00 C R 0.19 6.67E-02 STAT3 UTR-3 Current study 
rs10636 0.99 C F 0.26 5.47E-01 MT2A UTR-3 Preliminary study 
rs110402 0.99 A R 0.45 2.36E-01 CRHR1 Intron Current study 
rs11111272 0.97 G F 0.29 1.48E-01 IGF1 Intron Current study 
rs11206244 0.99 T F 0.32 2.78E-01 DIO1 UTR-3 Previous association 
rs1137100 1.00 C R 0.28 5.17E-01 LEPR Missense Previous association 
rs1143627 0.99 G R 0.33 3.75E-01 IL1B 5'UTR Previous association 
rs1143634 0.99 T F 0.23 2.18E-01 IL1B Cds - Syn Published association 
rs11591741 1.00 G R 0.41 6.22E-02 IKKA Intron Current study 
rs11597086 1.00 C F 0.41 2.76E-02 IKKA Intron Current study 
rs11597390 1.00 A F 0.35 3.74E-02 CPN1 UK Current study 
rs11669332 0.97 T F 0.07 2.73E-01 AKT2 Intron Current study 
rs11680012 1.00 G R 0.05 6.25E-01 LRRFIP Missense Current study 
rs1169300 0.98 A F 0.32 4.24E-02 HNF1A Intron Current study 
rs1169302 0.98 C R 0.45 6.11E-01 HNF1A Intron Current study 
rs11749561 0.98 T F 0.47 5.99E-01 NR3C1 UK Current study 
rs1190584 0.99 C F 0.23 2.35E-01 WDR20 Intron Current study 
rs1205 0.99 T F 0.33 9.71E-01 CRP UTR-3 Current study 
rs1206034 1.00 A R 0.34 8.53E-01 LIPE Intron Current study 
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rs12409877 1.00 A F 0.41 1.35E-01 LEPR Intron Current study 
rs12626613 1.00 C R 0.14 9.91E-01 RUNX1 nearGene 5 Current study 
rs12750774 0.99 A F 0.28 4.21E-01 IL6R Missense Current study 
rs12753193 1.00 G F 0.40 1.91E-02 LEPR UK Current study 
rs1417938 1.00 T R 0.31 1.12E-01 CRP Intron Current study 
rs1554973 1.00 C F 0.25 5.86E-01 TLR4 Intron Current study 
rs157580 0.99 C R 0.40 9.18E-01 TOMM40 UK Current study 
rs16147 0.93 G F 0.50 1.57E-01 NPY nearGene 5 Current study 
rs1647266 0.99 G R 0.39 8.25E-03 IFT172 Intron Current study 
rs16892496 0.99 G R 0.30 6.49E-01 TRHR UTR-3 Current study 
rs16928751 1.00 A F 0.12 8.16E-01 ADIPOR2 Cds - Syn Previous association 
rs17295356 1.00 T F 0.41 6.45E-01 AZGP1 UK Current study 
rs17411031 0.99 G F 0.27 6.29E-01 LPL UK Current study 
rs17446593 0.98 G F 0.17 3.45E-01 FOXO1 UK Previous association 
rs17446614 1.00 T R 0.15 8.13E-01 FOXO1 Intron Current study 
rs17689824 1.00 A R 0.19 8.20E-01 CRHR1 Intron Current study 
rs17700633 1.00 A F 0.30 2.48E-01 MC4R UK Current study 
rs17782313 1.00 C F 0.25 7.79E-01 MC4R UK Current study 
rs1799964 0.99 C F 0.20 9.03E-01 TNF nearGene 5 Current study 
rs1800624 0.98 T R 0.25 3.05E-02 AGER nearGene 5 Current study 
rs1800625 1.00 G R 0.19 9.84E-01 AGER nearGene 5 Current study 
rs1800896 1.00 G F 0.45 5.65E-01 IL10 nearGene 5 Published association 
rs1801282 1.00 G F 0.13 1.04E-01 PPARG Intron Previous association 
rs1892534 0.99 A F 0.40 2.22E-01 LEPR Rev Current study 
rs1935949 0.99 A R 0.31 9.97E-01 FOXO3 Intron Current study 
rs1946519 0.99 T R 0.40 8.45E-01 IL18 nearGene 5 Previous association 
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rs2070802 1.00 A F 0.14 3.85E-01 CNTFR UK Current study 
rs2071029 0.99 T R 0.15 7.42E-01 RUNX1 nearGene 5 Current study 
rs2229765 0.98 T R 0.44 8.91E-01 IGFR1 Missense Current study 
rs2239179 0.99 G F 0.44 8.69E-01 VDR Intron Current study 
rs2268757 0.99 G R 0.44 9.74E-02 ACVR2B Intron Current study 
rs2293152 0.98 C F 0.40 2.05E-01 STAT3 Intron Current study 
rs2297627 0.99 G R 0.32 2.63E-01 FOXO1 Intron Current study 
rs2419621 1.00 A R 0.23 4.68E-01 ACSL5 nearGene 5 Current study 
rs2464196 1.00 T F 0.32 2.59E-02 HNF1A Missense Current study 
rs2721068 0.99 C F 0.26 2.35E-01 FOXO1 Intron Current study 
rs2794520 0.99 T F 0.33 9.82E-01 CRP UK Current study 
rs2802292 0.99 G F 0.40 4.38E-01 FOXO3 Intron Current study 
rs2808629 1.00 T R 0.33 8.95E-01 CRP UK Current study 
rs281432 0.99 G F 0.47 7.09E-02 ICAM1 Intron Previous association 
rs2834650 1.00 A R 0.10 4.19E-01 RUNX1 Intron Current study 
rs2854464 0.96 G F 0.28 4.74E-01 INHBC UTR-3 Current study 
rs2960548 0.95 C R 0.43 1.89E-01 APEH Intron Previous association 
rs3088241 0.98 C F 0.50 3.10E-01 HYLS Missense Previous association 
rs3093068 1.00 G F 0.07 4.69E-01 CRP UK Current study 
rs3116654 1.00 G R 0.13 6.78E-01 CRP UK Current study 
rs3122012 1.00 C F 0.31 5.12E-02 CRP UK Current study 
rs3176860 0.98 C R 0.38 7.04E-01 VCAM1 Intron Preliminary study 
rs331457 1.00 A F 0.14 5.73E-01 TRAF6 Intron Current study 
rs3397 0.98 G R 0.37 5.91E-01 TNFRSF1B UTR-3 Previous association 
rs35767 1.00 T F 0.16 4.91E-01 IGF1 nearGene 5 Current study 
rs35854772 0.99 T F 0.12 8.20E-01 ADIPOR2 Cds - Syn Previous association 
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rs361072 0.92 G F 0.46 3.34E-02 PIK3CB nearGene 5 Current study 
rs3745012 1.00 A R 0.26 9.37E-01 LPIN2 UK Preliminary study 
rs3746619 1.00 T R 0.09 1.18E-01 MC3R Missense Current study 
rs3791783 0.99 G R 0.21 6.04E-01 MSTN Intron Current study 
rs3804099 0.99 C F 0.45 4.54E-01 TLR2 Cds - Syn Preliminary study 
rs3856806 1.00 A R 0.13 4.29E-02 PPARG Syn His449His Previous association 
rs4129267 1.00 T F 0.40 1.81E-01 IL6R Intron Current study 
rs4131568 1.00 T R 0.34 1.60E-01 CRP UK Current study 
rs41423247 0.99 G R 0.37 5.53E-01 NR3C1 Intron Current study 
rs4149570 1.00 A R 0.41 1.33E-02 TNFRSF1A Intron Previous association 
rs42451 1.00 A R 0.27 4.08E-01 GHRL Intron Previous association 
rs4291 0.96 A R 0.37 1.86E-01 ACE nearGene 5 Current study 
rs4343 1.00 T R 0.49 1.48E-01 ACE Cds - Syn Current study 
rs1544410 0.86 T R 0.27 UK VDR Intron Current study 
rs4855881 0.99 G R 0.46 5.44E-01 APEH Intron Previous association 
rs4946935 0.99 T R 0.31 7.75E-01 FOXO3 Intron Current study 
rs5010905 0.99 C F 0.24 9.31E-01 LEPR UK Current study 
rs4280262 0.80 C F 0.12 UK LITAF Missense Preliminary study 
rs6136 0.97 G R 0.09 2.69E-01 SELP Missense Previous association 
rs6198 1.00 C R 0.17 6.14E-01 NR3C1 UTR-3 Current study 
rs6220 0.97 C R 0.29 1.56E-01 IGF1 UTR-3 Current study 
rs7136446 0.97 G R 0.39 2.41E-02 IGF1 Intron Current study 
rs7187438 0.98 G R 0.36 9.88E-02 TSC2 Intron Previous association 
rs7209436 0.97 A R 0.43 2.69E-01 CRHR1 Intron Current study 
rs7310409 0.99 T R 0.41 3.60E-03 HNF1A Intron Current study 
rs731236 0.99 C F 0.40 2.96E-01 VDR Cds - Syn Current study 
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rs744166 1.00 G R 0.41 4.52E-01 STAT3 Intron Current study 
rs7539471 0.98 A F 0.31 1.09E-02 LEPR UK Current study 
rs767455 0.98 C F 0.42 7.08E-02 TNFRSF1A Cds - Syn Previous association 
rs767870 1.00 C F 0.15 9.15E-01 ADIPOR2 Intron Current study 
rs769449 0.99 A F 0.11 6.48E-01 TOMM40 Intron Current study 
rs780106 1.00 C F 0.39 1.15E-02 IFT172 Intron Current study 
rs7832552 0.98 A R 0.30 6.17E-01 TRHR Intron Current study 
rs8069645 1.00 G F 0.27 8.79E-01 STAT3 Intron Current study 
rs817529 1.00 C R 0.38 7.83E-01 LTBP1 Intron Previous association 
rs863013 0.98 A R 0.32 3.93E-01 CRP UK Current study 
rs9402571 0.98 G F 0.18 9.75E-01 SGK1 Intron Current study 
rs972936 1.00 T R 0.27 1.07E-01 IGF1 Intron Current study 
rs976881 0.97 T R 0.32 2.57E-01 TNFRSF1B Intron Previous association 
Table legend: List of polymorphisms following data pruning strategies as mentioned in methods section are retained for 
association analysis. CR, SNP call rate; MA, minor allele; MAF, minor allele frequency; Gene, gene symbol; Source of SNP, 
the SNPs (rs#) considered from a previous association study(207), published association(197, 200, 209) and a preliminary 
study(755) are replicated and shown in bold. The remaining SNPs are newly reported in this study. The sequencing strand 
for genotyping is indicated and the minor allele shown is based on the measured frequencies in our study population 




6.4.2 Patient demographics 
General characteristics of the genotyped patient population are presented (Table 6.3). 
Average age of the cohort at diagnosis was 65 ± 13 years (mean ± SD). The majority 
were diagnosed with stage III or IV cancer. At diagnosis, average WL was 6 ± 9% with 
a mean body mass index (BMI) of 25 ± 5. Of the 751 patients with CT scans for the 
assessment of muscularity 47% had LM defined by the specified cut offs. There were 
no significant differences in age, stage of disease, pre-diagnosis BMI and percentage 
WL between patients who had CT scans suitable for the measurement of muscularity 








































Table 6.3 - Patient demographics 
 
Patients were recruited (2004 – 2012) from: NHS Lothian, UK; Cross Cancer Institute, 
Edmonton, Canada; McGill University Health Centre, Montreal, Canada; Palliative 
Research Centre, Norwegian University of Science and Technology (NTNU), Norway; 
Cantonal Hospital, St Gallen, Switzerland; and Department of Medical Oncology, 
University Hospital of Larissa. 
 
 New n=545 Old n=731 All n=1276 
Age (years) † 
Range 
66 ± 11 
(22-91) 
66 ± 11 
(27-97) 






















































Body mass index (kg/m2)† 
Range 
25 ± 5 
(14-59) 
24 ± 7 
(13-47) 
25 ± 5 
(13 – 59) 
Percentage weight loss† 5 ± 7 7 ± 10 6 ± 9 
Patients with CT scans 













49 ± 9 
41 ± 7 
 
Values are number of patients with percentages in parentheses unless indicated otherwise; 
†values are mean ± SD. Characteristics were measured at first presentation to a surgical or 
oncology clinic. 
§Skeletal muscle index calculated as lumbar total muscle cross-sectional area (cm2)/height 
(m)2. 
 
6.4.3 Weight loss phenotype: Stage 2 analysis of previously 
identified SNPs in newly recruited cohort (n=545) 
Table 6.4 lists the detailed results for previously identified SNPs significantly 
associated with cancer cachexia in the newly recruited patients classified according 
to WL alone. Two SNPs were validated in this new cohort, one being found on 
chromosome 1 in the SELP gene and was present at all levels of WL (rs6136). The 
SELP gene encodes for p-selectin, a molecule which functions as a cell adhesion 
molecule (CAM) in response to inflammation on the surfaces of activated endothelial 
cells (756). The second SNP (rs4149570), found in the TNFRSF1A gene on 
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chromosome 12 was found to be significant at >15% WL. This gene encodes for one 
of the major receptors for tumour necrosis factor-α. The downstream effects of this 
receptor are activation of the transcription factor NF-κB to mediate apoptosis, and 
function as a regulator of inflammation (757). 
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Table 6.4a - Genes with variants significantly associated with cancer cachexia from previous stage 1 analysis in newly recruited 
patients classified according to weight loss alone 
Weight loss >15%. Number affected: 62/545 (11.3%) 
Gene SNP Risk allele OR (95%CI) p-Value Permutated p 
TNFRSF1A rs4149570 T 
0.628 (0.402-
0.980) 0.041 0.044 
SELP rs6136 C 
0.331 (0.117-
0.933) 0.036 0.054 
Table 6.4b - Weight loss >10%. Number affected: 129/545 (23.6%) 
Gene SNP Risk allele OR (95%CI) p-Value Permutated p 
SELP rs6136 C 
0.332 (0.160-
0.692) 0.003 0.003 
Table 6.4c - Weight loss >5%. Number affected: 239/545 (43.7%) 
Gene SNP Risk allele OR (95%CI) p-Value Permutated p 
SELP rs6136 C 
0.543 (0.334-




6.4.4 Weight loss phenotype: Stage 1 analysis with new candidate 
SNPs in combined cohort (n=1276) 
Table 6.5 lists the detailed results for newly identified SNPs significantly associated 
with cancer cachexia in all patients classified according to WL alone. In total, 12 SNPs 
had significant associations with various cachexia phenotypes based on increasing 
severity of WL. Two of these SNPs (rs1935949 and rs4946935) found within 
chromosome 6 in the Forkhead box O3 (FOXO3) gene were associated with WL of 
increasing severity (>5% and >10%) and one SNP (rs2297627) found in the Forkhead 
box O1 (FOXO1) gene was associated with WL>10%. FOXO1 and FOXO3 belong to 
the forkhead family of transcription factors. These transcription factors share the 
ability to be inhibited and translocated out of the nucleus on phosphorylation by 
proteins such as Akt/PKB in the PI3K signalling pathway (758). The FOXO proteins 
influence apoptosis through upregulation of genes necessary for cell death (759). 
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Table 6.5a - Genes with variants significantly associated with cancer cachexia in patients classified according to weight loss alone 
Weight loss >15%. Number affected: 199/1276 (15.6%) 
Gene SNP Risk allele OR (95%CI) p-Value Permutated p 
LEPR rs5010905 C 1.547(1.136-2.108) 0.006 0.003 
IGF1 rs35767 T 0.621 (0.426-0.905) 0.013 0.014 
CPN1 rs11597390 A 1.309 (1.009-1.698) 0.042 0.038 
Table 6.5b - Weight loss >10%. Number affected: 382/1276 (29.9%) 
Gene SNP Risk allele OR (95%CI) p-Value Permutated p 
IGF1 rs35767 T 0.677 (0.507-0.905) 0.008 0.008 
FOXO3 rs1935949 T 1.31 (1.05-1.635) 0.017 0.012 
FOXO3 rs4946935 A 1.281 (1.026-1.599) 0.029 0.027 
LEPR rs12409877 A 0.796 (0.641- 0.988) 0.038 0.040 
FOXO1 rs2297627 C 0.795 (0.638-0.990) 0.040 0.049 
TOMM40 rs157580 G 1.24 (1.006-1.529) 0.044 0.050 
Table 6.5c - Weight loss >5%. Number affected: 633/1276 (49.6%) 
Gene SNP Risk allele OR (95%CI) p-Value Permutated p 
IFT172 rs1647266 C 0.788 (0.665-0.933) 0.006 0.006 
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IFT172 rs780106 C 0.803 (0.679-0.950) 0.011 0.009 
FOXO3 rs1935949 T 1.244 (1.035-1.495) 0.012 0.022 
ACVR2B rs2268757 C 1.219 (1.032-1.44) 0.020 0.024 
TLR4 rs1554973 C 1.238 (1.014-1.512) 0.036 0.028 
FOXO3 rs4946935 A 1.227 (1.021-1.474) 0.029 0.034 
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6.4.5 Low muscularity phenotype: Stage 1 analysis with all 
candidate SNPs in combined cohort with CT scans (n=751) 
Table 6.6a lists the detailed results for all SNPs significantly associated with cancer 
cachexia in all recruited patients (n=751) classified according to LM alone. In total, 5 
SNPs were associated significantly with the cachexia phenotype based on levels of 
muscularity: (i) rs4291 in chromosome 17 in the angiotensin converting enzyme 
(ACE) gene; this gene has been associated with muscle function and 
metabolism(172); (ii) rs10636 in chromosome 16 in the metallothionein 2a gene; this 
gene has been shown to be involved in zinc dyshomeostasis which may contribute to 
cancer cachexia(703); (iii) rs1190584 in chromosome 14 in the WDR20 gene; this 
gene encodes a WD repeat-containing protein that functions to preserve and regulate 
the activity of the USP12-UAF1 deubiquitinating enzyme complex; (iv) rs3856806 in 
the peroxisome proliferator-activated receptor gamma (PPARG) gene in chromosome 
3 which has been demonstrated to be involved in fatty acid and glucose 
metabolism(760); and (v) rs3745012 in chromosome 18 in the lipin 2 (LPIN2) gene; 
this gene represents a candidate gene for human lipodystrophy, characterised by loss 
of body fat, fatty liver, hypertriglyceridemia, and insulin resistance. 
 
6.4.6 Low muscularity plus weight loss phenotype: Stage 1 analysis 
with all candidate SNPs in combined cohort (n=943) 
Table 6.6b lists the detailed results for all SNPs associated significantly with cancer 
cachexia classified according to LM + WL >2% in all recruited patients. The analysis 
compared those with the LM + WL >2% phenotype against those without in the entire 
cohort. rs12409877 is in the leptin receptor (LEPR) located on chromosome 3, LEPR 
binds leptin and is involved in adipose tissue regulation(761). rs2268757 is located in 
the activin receptor type-2B (ACVR2B) gene on chromosome 3, ACVR2B is a high 
affinity activin type 2 receptor which mediates signalling by a subset of TGF-β family 
ligands including myostatin, activin, GDF11 and others(762). SNPs in the tumour 
necrosis factor (TNF) (rs1799964) and ACE (rs4291) genes were also significantly 
associated with the phenotype.  
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Table 6.6a - Genes with variants significantly associated with cancer cachexia in patients classified according to low muscularity alone 
LM. Number affected: 356/751 (47.4%) 
Gene SNP Risk allele OR (95%CI) p-Value Permutated p 
ACE rs4291 T 
1.326 (1.058-
1.662) 0.01431 0.017 
MT2A rs10636 C 
1.342 (1.053-
1.711) 0.01736 0.018 
WDR20 rs1190584 C 
0.729 (0.563-
0.943) 0.01621 0.023 
PPARG rs3856806 T 
1.353 (1.003-
1.824) 0.04782 0.046 
LPIN2 rs3745012 T 
0.776 (0.604-
0.996) 0.04646 0.047 
Table 6.6b - Genes with variants significantly associated with cancer cachexia in patients classified according to low muscularity and 
weight loss >2% compared with those who do not 
LM and weight loss >2%. Number affected: 214/943 (22.7%) 
Gene SNP Risk allele OR (95%CI) p-Value Permutated p 
LEPR rs12409877 A 
0.674 (0.526-
0.865) 0.002 0.002 
ACVR2B rs2268757 C 
1.406 (1.126-
1.757) 0.003 0.002 
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TNF rs1799964 C 
1.435 (1.093-
1.885) 0.010 0.010 
ACE rs4291 T 
1.313 (1.039-
1.659) 0.022 0.025 
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6.4.7 Combining genes with functional similarity according to gene 
ontology 
Table 6.7 lists the phenotypes for which candidate gene groups associated with 
specific cancer cachexia phenotypes. SNPs in groups of genes involved in appetite 
regulation, cell adhesion, cell membrane structure and function, and signal 
transduction were associated with the phenotype WL >10%. Only SNPs in the group 
of genes involved in cell adhesion were significant with increasing WL. SNPs in 
groups of genes involved in lipid metabolism, appetite regulation, signal transduction 
and glucocorticoid signalling were associated with the phenotype LM and WL >2%. 
No SNPs in groups of genes were found to be significant with all other phenotypes.  
 
Table 6.7 - Candidate gene groups associated with cancer cachexia phenotypes 







Weight loss >5% N/A N/A N/A N/S 
Weight loss >10% Appetite regulation 
Cell adhesion 
Cell membrane 

















Weight loss >15% Cell adhesion 12 17 0.0193 
LM N/A N/A N/A N/S 

















*The genes in each candidate gene group are listed in Table 6.1 
N/A = Not applicable 
N/S = Not significant 
 
6.4.8 Transcriptomic analysis 
Table 6.8 lists the results from correlation and t-test analysis between phenotypes 
and gene transcript level for the genes that showed significant associations with any 
of the cachexia phenotypes. Expression of ACVR2B, FOXO1 and 3, LEPR, PPARG, 
TLR4, and TOMM40 transcripts was significantly associated with different levels of 
SMI or WL (P<0.05). Specifically, these were all negatively correlated with muscularity 
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(Figure 6.1). FOXO1 and 3 and TOMM40 were the only genes significantly correlated 




Table 6.8 - Results from correlation and t-test analysis between patient characteristics and rectus abdominis muscle gene transcripts for 
selected genes¹ 
 
















FD4  T-test of SMI 
values for patients 
with high vs. low 
probe expressionp-
value5 
T-test of % weight 
loss/100d values for 
patients with high vs. 
low probe expression 
p-value5 
A_23_P109950 ACVR2B 0.94 -0.21a -0.03 3.9 0.04 0.86 
A_24_P231132 ACVR2B  -0.24 a -0.09 3.0 0.03 0.17 
A_23_P151426 FOXO1 0.71 -0.22 a -0.23 a 4.2 0.01 0.04 
A_24_P22079 FOXO1  -0.39 a -0.43 a 3.5 < 0.01 < 0.0 
A_23_P345575 FOXO3 0.97 -0.31 a -0.29 a 2.9 < 0.01 0.01 
A_32_P102062 FOXO3  -0.33 a -0.28 a 3.1 < 0.01 0.01 
A_23_P161135 LEPR  -0.26 a 0.00 3.5 < 0.01 0.31 
A_23_P252062 PPARG  -0.16 0.02 3.8 0.03 0.49 
A_23_P60306 TLR4 0.60 to 0.85 -0.18 -0.07 2.1 0.02 0.19 
A_24_P69538 TLR4  -0.10 -0.01 2.1 0.03 0.95 
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A_32_P66881 TLR4  -0.19 -0.15 2.0 0.04 0.29 
A_23_P153266 TOMM40  -0.30 a -0.26 a 1.8 < 0.01 < 0.01 
SMI, skeletal muscle index; FD, fold difference.  
 
¹The following gene probes did not show significant Pearson correlation or significance for the t-test analysis: ACE probes 
(A_23_P371777, A_23_P38235, A_24_P365129), ACVR2B probe (A_32_P134209), CPN1 probe (A_23_P98147), IFT172 probe 
(A_23_P406135), IGF1 probes (A_23_P13907, A_24_P304419, A_24_P304423, A_24_P398572), LEPR probe (A_24_P231104), LPIN2 
probes (A_23_P208055, 
A_24_P301557), MT2A probes (A_23_P106844, A_23_P252413, A_24_P361896), SELP probe (A_23_P137697), TNF probes 
(A_23_P376488, A_24_P50759), TNFRSF1A probes (A_23_P139722, A_24_P364363), TOMM40 probes (A_24_P15754, 
A_24_P178093), WDR20 probes (A_23_P205255, A_24_P184769, A_24_P162412) 
 
2Pearson correlation analysis was conducted only for genes with multiple probes.  
3 Pearson correlation analyses were conducted to identify linear relationships between gene probe intensities and SMI or weight loss. 
Note that not all 134 patients had both SMI and weight loss information available and therefore the number of patients for the SMI and 
weight loss correlation analysis were 102 and 86, respectively. aPearson correlation p-value < 0.05 
4 Fold change = average high expressors / average low expressors  
5 The average sample size for the T-test comparing the SMI values for patients with high versus low probe expression was 35 and 33, 
respectively. The average sample size for the T-test comparing the % weight loss/100d values for patients with high versus low probe 
expression was 30 and 29, respectively. These sample sizes differed slightly from test to test as not all patients had computing 








Figure 6.1 – Graphical representation of the FOXO1 and FOXO3 gene expression 
compared to SMI (A) and % WL (B). Expression FOXO1 and FOXO3 transcripts was 
significantly associated with different levels of SMI or WL (P<0.05). Specifically, these 




6.5.1 Associations with different cachexia phenotypes 
In keeping with the prior study (207), this Chapter has confirmed in a more adequately 
sized validation cohort (Stage 2, n=545) that patients who carry the C allele of the rs6136 
SNP in the SELP gene are at a reduced risk of developing cachexia defined by WL (>5%, 
>10% or >15%), (Table 6.4). This was also confirmed recently in a study of chemo-naïve 
patients with locally advanced or metastatic pancreatic cancer where the presence of the 
C allele of rs6136 was associated with a reduced risk of developing cachexia (as defined 
by WL >5% or >2% in those with a BMI <20kg/m2 (207)) in both the discovery (n=151) 
and validation (n=152) cohorts (206). It is interesting that the same study identified 
patients with the GG allele of rs1130233 on the AKT1 gene to also be at reduced risk of 
cancer cachexia. In our prior study with a larger sample size, a different SNP on the AKT1 
gene (rs1130214) was evaluated and found not to associate with the WL phenotype 
(207). The G-allele of the rs1800796 polymorphism in the IL6 gene has been shown to 
be associated with increased susceptibility to cachexia and decreased survival time of 
stage II and III Chinese pancreatic cancer patients (202). There was not an association 
with rs1800795, which shows a weak linkage disequilibrium with the rs1800796 and 
neither did the aforementioned recent study of chemo-naïve patients with locally 
advanced or metastatic pancreatic cancer (206). In the present study, a number of other 
IL6 polymorphisms were included that also failed to show association. These differing 
findings may, in part, be due to insufficient representation of pancreatic cancer patients 
in our cohort or the differences in ethnicity.  
For the WL phenotype, the present study examined 92 new SNPs in a stage 1 analysis 
that included 1276 cancer patients, the largest sample size to date in an association study 
for cancer cachexia. Twelve new candidate SNPs were identified (Table 6.5). Six of these 
SNPs are associated with muscle metabolism in five genes (IGF1, CPN1, FOXO1, 
FOXO3, and ACVR2B), three are associated with adipose tissue metabolism in two 
genes (LEPR and TOMM40 (APOE on the reverse strand)), two with corticosteroid 
signalling in one gene (IFT172 (GCKR on the reverse strand)) and one with the immune 
response in one gene (TLR4). Two polymorphisms (rs1935949 and rs4946935) in the 
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gene encoding for FOXO3 were consistently associated with WL of increasing severity 
(Table 6.5). On the basis that WL is a continuum in the cachectic process, the observation 
that both SELP and FOXO3 associate with the highest degrees of WL suggests that these 
genetic signatures may be of particular significance. 
For the phenotype based on LM alone, five SNPs were identified (Table 6.6a). Two of 
these SNPs are associated with muscle metabolism in two genes (ACE and WDR20), 
two with adipose tissue metabolism in two genes (PPARG and LPIN2), and one with 
metallic ion metabolism in one gene (MT2A). In the present study, when patients were 
classified as cachectic according to WL and LM, four SNPs were identified (Table 6.6b). 
Two of these SNPs are associated with muscle metabolism in two genes (ACVR2B and 
ACE), one with fat metabolism in one gene (LEPR), and one with cytokine production in 
one gene (TNF). The observation that most of the identified genes are associated with 
muscle and adipose tissue metabolism highlights the importance of these processes in 
the progression of cancer cachexia. Skeletal muscle wasting is a signature event in 
cancer cachexia and could be associated with increased fatty infiltration (396, 763), 
therefore mechanisms effecting the functions of these genes may be of particular 
significance. It would be attractive to assign specific functional significance to some of 
the genetic signatures so identified. For example ACVR2B decoy receptors have been 
shown to abrogate muscle loss and prolong survival in several murine models of cancer 
cachexia (145). However, replication of the present findings along with a genome-wide 
approach would be needed in parallel with functional studies (see below) to resolve this 
issue further. 
 
6.5.2 Gene group analysis 
The two dominant mechanisms of weight loss in cancer patients are anorexia leading to 
reduced food intake and abnormal metabolism (11). Appetite regulation was found to be 
most significantly associated with the cachexia trait WL >10% (p=0.0041). There has 
been some evidence to date that negative regulators of appetite such as PYY are 
elevated in cachexia(764). Regarding metabolic change, lipid metabolism was 
significantly associated with the cachexia trait LM and WL >2% (p=0.0138). Fatty 
infiltration (myosteatosis) has been associated with cancer cachexia and reduced survival 
314 
 
(396, 763). The glucocorticoid signalling pathway was also found to be associated with 
cachexia trait LM and WL >2% (p=0.0337). Glucocorticoids and associated signalling 
pathways have been implicated in accelerating protein degradation in muscle (765). 
Glucocorticoids are thought to act through a permissive effect on the upregulation of 
messenger RNA and the subsequent synthesis of components of the ubiquitin 
proteasome pathway in muscle. Glucocorticoids may also inhibit protein synthesis and 
promote gluconeogenesis, and suppress glucose and amino acid muscle uptake by 
inhibiting cellular transporters(766).  
 
6.5.3 Differential gene expression signatures in human muscle and 
their association with the phenotypes of cachexia 
It has been shown previously that the presence of cancer cachexia is associated with the 
transcriptional regulation of about 1800 genes in human skeletal muscle (89). It was 
therefore of interest to see if the transcript level of the genes associated with cachexia in 
the present study were altered in a separate cohort of cancer patients with or without 
cachexia. Indeed, there was a strong concordance between a proportion of the selected 
genes and either the level of WL or muscularity (Table 6.8). FOXO1 and FOXO3 are good 
examples: SNPs in both genes were identified to associate with the WL phenotype 
(Tables 6.5b and c) and transcript levels of both showed a correlation with WL (Table 
6.8). These transcription factors are key in the pro-inflammatory driven up-regulation of 
the ubiquitin-proteasome pathway, but also act as a negative regulator of the anabolic 
Akt-mTOR pathway (329, 758). Inhibition of FOXO transcriptional activity prevents 
muscle fibre atrophy during cancer cachexia and induces hypertrophy (95). It is therefore 
plausible that variants of the FOXO genes are key determinants of the muscle loss 
component of cachexia syndrome.  
The present analysis was not of a genome-wide nature and therefore genetic variants 
with much greater functional significance may have not have been examined. Equally, 
the true functional significance of any individual SNP for cancer patients is mostly 
unknown. It may, therefore, be better to consider the genetic associations identified in the 
present analysis as genetic signatures or biomarkers associated with the cachexia 
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syndrome. Interestingly, 17 of the 19 SNPs reported as showing significant associations 
with the cachexia phenotypes are in intronic, 3’, or 5’ UTRs. The purpose was to explore 
the trends and probe into the potential functional impact of the loci as SNPs in this study 
are potentially proxy to the more causal variants (not yet captured in the region) which 
may also have an influence on gene expression; as such the probe position in the 
expression array and the SNP position are not the same. Extrapolation to a SNP under 
investigation being an expression quantitative loci (eQTL) is premature. The SNP 
identified may in some cases also affect gene expression signatures not addressed 
herein (as in cis- and trans acting eQTLs). The correlation pattern (albeit, low to modest) 
observed is still encouraging since the trends reported here for a SNP loci and gene 
expression are within the scope of known cachexia literature. Further replication of the 
present findings and fine mapping of the loci may offer insights. Independent of the 
functional significance of the polymorphisms, the SNP signatures serve as heritable 
determinants for cancer cachexia; the polygenic nature of the phenotype warrants 
identification of more susceptibility variants to enable stratification of patients for cancer 
cachexia risk.  
Equally, for those genes for which no strong relationship was found between gene 
expression and patient characteristics it is important to consider that these may not be 
transcriptionally regulated. For the various humoral mediators (ACE, TNF, IGF1), it may 
be that the concentration in blood is important rather than local expression in tissues 
since tissue-specific expression may be transient for some genes but the activation of the 
signal transduction cascade could be the largest prevailing effect. For instance local 
expression of the ligand may be a small part of a bigger picture where several tissue 
sources of ligand, a variety of receptors, soluble receptors and binding proteins may play 
in to the actual response (e.g., TNF and IGF-1).  
  
6.5.4 Limitations 
The present investigation is part of a series undertaken by our international consortium 
which has over time expanded DNA biobanking and cachexia phenotyping from 775 to 
1276 patients. While these represent the largest candidate gene association studies done 
to date in relation to cancer cachexia, they have the general limitation of the candidate 
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gene approach. The assembly of much larger data sets and samples in order to conduct 
genome wide association studies is awaited. The current study combined different tumour 
types in the analysis. As the hypothesis states, for any given cohort it is impossible to 
predict who will develop cancer cachexia and who will not, therefore two different patients 
with the same stage of tumour may have vastly different clinical presentations in terms of 
cachexia, based on this the tumour types were combined. With the recruitment of more 
patients it may be possible to reduce this heterogeneity.    
It is important to establish that the prevalence of LM in the present cancer cohort is in 
excess of that which would be observed in the normal age-matched population. The 
prevalence of LM/sarcopenia in age-matched subjects living in the community varies 
according to the precise definition and methodology used, but is reported to be between 
1-29% (767). The prevalence of LM that was observed in the cancer cohort in this study 
was 44% for males and 52% for females. Thus, the gene associations established with 
LM represent associations with a level of muscularity at least partly independent of age, 
sex or stature. 
Selection of the genes and SNPs may be biased towards genes with a known potential 
influence on WL. Therefore genes used for other processes associated with cachexia 
such as muscle and lipid regulation are under-represented and potential associations 
may have been missed in these key regulatory pathways. As many of these genes have 
been recently discovered there is paucity of functional significance. As far as the muscle 
and lipid regulation phenotypes are concerned, the present study begins a journey into 
defining phenotypes based on these novel measurements. Other independent studies 
need to be conducted to address the muscle loss phenotype and its associated genes 
and pathways. It is also important to recognise that the understanding of the biology of 
cachexia is evolving rapidly and that factors such as GDF-15 (MIC-1) that might now be 
considered as potentially important(768), were not included in the present study. 
 
6.5.5 Conclusions 
The candidate gene SNP analysis offers the advantage that it is hypothesis driven and 
the identified associations are easily explained due to compelling biological rationale. 
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However, the limitations of this approach are that the role of hitherto unexplored genes 
and pathways that otherwise contribute to the trait under investigation are missed. Issues 
surrounding phenotype complexity are addressed in part in this study and conducting a 
genome wide association study (GWAS) using high density of markers on the genome 
would help relate the overlap of SNPs/pathways to the phenotypes of interest. The 
consensus definitions for phenotypes may evolve in an iterative manner from the 











































Cancer cachexia significantly impairs quality of life and response to treatment and is 
associated with increasing morbidity and mortality. This thesis set out to clinically classify 
cancer cachexia based on phenotypic correlates in human skeletal muscle to provide 
accurate phenotyping for a genetic study into the potential predisposition to developing 
cancer cachexia to aid with identification of biomarkers to screen for the syndrome. 
 
7.1 Application of CT scanning for body 
composition analysis 
One of the main themes running through this thesis is the use of CT scan imaging to 
derive measures of body composition to aid with accurate phenotyping. CT scans are 
increasingly used as research tools for body composition analysis in a number of 
conditions including cachexia (396, 397, 746). CT scans allow segmentation of specific 
tissues and provide direct measures of tissue cross sectional area (CSA) (cm2). Single 
slice quantification of muscle and adipose tissue and specific muscle groups using CT 
has been shown to be representative of true muscle and adipose CSA of cadaver axial 
sections (393, 769). Research utilising CT scans has revealed that variation in individual 
tissue compartments may confer specific risks upon particular patient groups. Sarcopenia 
(generally defined as an absolute muscle mass > 2 standard deviations below expected 
for young adults) is associated with functional impairment, disability and survival (350, 
770-773). It has been shown that sarcopenic obesity is an adverse prognostic factor 
associated with reduced survival in several cancer types (12, 28). This has led to 
suggestion that cancer cachexia should be defined by incorporating a level of muscularity 
in the diagnostic algorithm. CT scanning is useful as it forms part of a patient’s standard 
of care therefore making it readily accessible. A number of studies address the 
repeatability of cross sectional imaging in body composition (774-778) and report good 
agreement between repeated measurements using CT for both fat and muscle. 
Segmentation of different tissue types using CT is achieved using defined Hounsfield 
Units (HU) for specific tissues in conjunction with manual correction. In this context 
variations in the image analysis software appear to exert little influence on measurements 
of CSA (779, 780). In many publications data are reported using directly determined units 
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of tissue cross-sectional area (cm2) from a single image (781, 782).   However, several 
authors have worked to find the single image which is most representative of whole-body 
organ volumes (i.e. for muscle and adipose tissues) (783, 784). The intention of this has 
been to estimate values for total body fat, fat free mass, skeletal muscle mass or regional 
volumes such as thigh muscle or visceral adipose, while limiting the time taken for 
analysis. As a result cross sectional data are often used as a surrogate for these 
measures, since they are linearly related to whole body or regional measures. Regional 
analysis of fat and lean tissue (e.g. L3 level) are highly correlated to corresponding whole 
body compartments and can provide precise quantification of specific adipose tissues, 
skeletal muscles and organs (28, 393, 395, 397, 746, 785).  
CT scanning for body composition has its limitations. CT scans involve ionising radiation 
in addition to the accessibility of the measurements to the researcher and clinician. 
Patient positioning, technical errors, movement, slice selection and image interpretation 
including identification of specific muscles (previously described) and also within the 
abdominal cavity where the peritoneum may be incorrectly marked (786) or intestinal 
contents identified as anatomical adipose (787) all are factors when using CT scans to 
quantify body composition. However by understanding the limitations and potential 
sources of error when using CT imaging for measurement of body composition the 
technique can reliably measure muscle and fat distribution in the trunk and can 
discriminate between the intra-abdominal organ and muscle component of fat free mass. 
Using CT imaging compares well with other body composition measures and has the 
significant advantage of being readily available in patients with cancer.  
One of the main findings of this thesis, outlined in the study in Chapter 4, is for the first 
time, the muscle protein content of analysed CT scans has been measured and has 
shown to be reduced. In the study reported in Chapter 4, when compared with non-
cachectic patients, muscle protein content was reduced significantly (approximately 13%) 
if patients were classified as cachectic by either >5% WL (p=0.015) or LM + >2%WL 
(p=0.035), and by 10% in patients with >10% WL. Protein content expressed in relation 
to wet weight of muscle has been shown to decrease progressively (in excess of 50%) in 
the gastrocnemius muscle of mice bearing the MAC-16 tumour (257). This suggests that 
not only is there loss of fibre diameter, but that the quality of the fibre is altered with loss 
of either sarcoplasmic or myofibrillar protein. Such changes in fibre composition may 
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contribute to the reduced muscle mechanical quality (force per unit cross-sectional area) 
observed in human cancer cachexia (213). Whist using CT scans to derive measures of 
body composition is useful, caution has to be exercised because these are only volume 
measures. 
 
7.2 Clinical Classification of Cancer Cachexia by 
deriving Phenotypic Correlates in Human 
Skeletal Muscle 
The international consensus on the classification of cancer cachexia (11) suggested that 
diagnostic criteria should take into account not only that weight loss is a signal event of 
the cachectic process but that the initial reserve of the patient should also be considered 
(either low BMI or low level of muscularity). Although the latter concept has some 
validation in terms of clinical risk, there has been no evaluation of the biological correlates 
in terms of changes within skeletal muscle itself. The study reported in Chapter 4 
demonstrated when patients were classified as cachectic or not according to ≥ 5% weight 
loss there was no significant difference in whole body muscularity (FFMI) or muscle fibre 
CSA. In contrast, when patients were classified according to low muscularity and ≥ 2% 
weight loss, FFMI was decreased and fibre cross sectional area was also significantly 
reduced. Such findings demonstrate that heterogeneity in relation to low muscularity and 
fibre atrophy may be reduced according to the clinical definition of cachexia. This finding 
may be important especially when considering inclusion criteria for clinical trials that aim 
to test the efficacy of drugs targeted at reversal of muscle wasting (fibre atrophy) in cancer 
patients. In cachexia there is conflicting evidence as to whether there is selective loss of 
fibre type. No evidence for selective loss of fibre type was found in the study reported in 
Chapter 4. This is consistent with the literature as it is currently not entirely clear which 
type of fibres are affected in human cancer cachexia. However, in patients with 
oesophago-gastric cancer cachexia early loss of all MyHC isoforms has been reported. 
The activity patterns of a muscle are also key in determining phenotype. If muscle cells 
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are recruited infrequently they develop into fast/glycolytic units whereas if they are 
recruited more often, they form slow/oxidative units. One limitation of the study reported 
in Chapter 4 is that there is no functional data included which is clearly an important 
variable in the development of cancer cachexia. 
The study reported in Chapter 4 looked at muscle protein, DNA, and RNA content in 
cancer cachexia which has seldom been studied in humans before. When compared with 
non-cachectic patients, muscle protein content was reduced significantly (approximately 
13%) if patients were classified as cachectic by either >5% WL (p=0.015) or LM + >2%WL 
(p=0.035), and by 10% in patients with >10% WL. This suggests that not only is there 
loss of fibre diameter, but that the quality of the fibre is altered with loss of either 
sarcoplasmic or myofibrillar protein. Such changes in fibre composition may contribute to 
the reduced muscle mechanical quality (force per unit cross-sectional area) observed in 
human cancer cachexia (213). In Chapter 4, RNA content was unaltered in cachectic 
patients (classified either with >5% WL or LM + >2% WL) compared with non-cachectic 
patients. This is consistent with a recent observation that protein synthesis is unaltered 
(80). The study reported in Chapter 4 demonstrated DNA content was increased by >50% 
with >5% WL but decreased by 40% in patients with LM. Because mature myofibre nuclei 
are thought to be mitotically inactive, increased DNA content in skeletal muscle cells 
suggests activation of satellite cells or infiltration by other cell types such as inflammatory 
cells or adipocytes. In the LM group, the decrease in DNA may be due to pre-existing 
age-related sarcopenia or other causes of muscle atrophy (e.g. immobilisation) and may 
relate to muscle specific apoptosis and reduction in cell number in keeping with a 
reduction in muscle mass on CT scanning. The diametrically opposite changes in muscle 
DNA content dependent on whether patients are classified according to weight-loss or 
low muscularity again underpin the potential diverse mechanisms whereby older cancer 
patients may develop a low level of muscularity. The issue of whether nuclear domain 
size is reduced in cancer cachexia remains to be resolved. In particular, whether 
apoptosis in skeletal muscle is increased in cancer cachexia and the degree to which 
DNA content is maintained or not via a compensatory increase in myonuclear number 
(possibly via satellite cell nuclei incorporation) is not known. Features of cachexia such 
as hypogonadism (resulting in low testosterone) or systemic inflammation (associated 
with high IL-6) could influence such regenerative capacity. In Chapter 4 RNA / DNA was 
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shown to be altered in the cachectic patients (independent of definition) compared with 
the non- cachectic patients. This may be due to the interplay of the mechanisms 
described above. Autophagy proteins (ATG) 5, 7, 12, and beclin 1 were also studied. 
These proteins are necessary for autophagy due to their role in autophagosome 
elongation. When patients were classified according to >10% WL, Beclin and ATG5 
protein levels were significantly increased in cachectic patients when compared with non-
cachectic patients. Further research needs to be done to validate these findings as the 
autophagy pathway may be an important mechanism in the development of cancer 
cachexia. Systemic inflammation is thought to be a major mediator of cancer cachexia. 
However, the relationship between inflammation in the systemic compartment versus 
muscle and the relationship of either to muscle loss in humans is not clear. Although The 
study reported in Chapter 4 presented evidence for systemic inflammation in a proportion 
of patients, no significant difference was found in the levels of phospho-NFkB or phospho-
STAT3 across any of the definitions of cachexia or in those with or without evidence of 
systemic inflammation.  
It is possible that inflammatory mediators have their main effects on muscle atrophy via 
central mechanisms mediated via the CNS. It has been suggested that binding of 
myostatin to the ACVR2B receptor results in the phosphorylation of two serine residues 
of SMAD2 or SMAD3. This leads to the assembly of SMAD2/3 with SMAD4 to the 
heterodimer that is able to translocate to the nucleus and activate transcription of target 
genes. One of the known downstream targets of SMAD signalling is MyoD, a 
transcriptional factor that is involved in skeletal muscle development and takes part in the 
repair of damaged skeletal muscle. When patients were classified as cachectic according 
to >5% WL, SMAD3 protein levels were significantly increased in cachectic patients when 
compared with non-cachectic patients. Equally there was a similar (but not significant) 
increase in phospho-SMAD3 associated with >5% weight loss. It is not known whether 
such increased protein levels indicate increased pathway activity independent of any 
alteration in the ratio of phospho-SMAD3/SMAD3.   
It is important to appreciate that the majority of patients in Chapter 4 will have had some 
degree of age-related sarcopenia, that this will necessarily co-exist with any cancer-
specific loss of skeletal muscle mass and that the diagnostic criteria used in the present 
study will not necessarily separate one from the other. The study reported in Chapter 4 
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was not longitudinal and it was therefore not possible to document active muscle loss. It 
is also important to recognise that when patients were divided into different diagnostic 
categories the sample size in individual categories may have limited the ability to detect 
a statistical difference or not. This was an exploratory study and provides the basis for a 
larger study with adequate statistical power for definitive analysis. However, it has 
demonstrated when the diagnostic criteria for cachexia include both a measure of low 
muscularity and weight loss, muscle fibre size, protein content and RNA/DNA content are 
all reduced. Such consistent findings were not observed when cachexia was diagnosed 
based on weight-loss or low muscularity alone. Whereas fibre type is not targeted 
selectively, muscle fibre size, biochemical composition and pathway phenotype can vary 
according to whether the criteria for cachexia include both a measure of low muscularity 
and weight loss. Such findings suggest that current diagnostic criteria identify groups of 
patients with different skeletal muscle phenotypes. Identification of a more homogeneous 
patient cohort for musculo-centric intervention trials may require use of such combined 
criteria. The findings in Chapter 4 lead on to accurate phenotyping of patients suffering 
from cancer cachexia and provides novel insights into genetic targets potentially 
associated with the condition. 
 
7.3 Genetic basis of inter individual susceptibility 
to cancer cachexia: selection of potential 
candidate gene polymorphisms for association 
studies 
Following the successful identification of the SNP rs6136 in the SELP gene, a 
contemporary review of the literature was needed as a greater understanding of the 
processes involved in cancer cachexia are now available. To enable further candidate 
gene selection studies with larger cohorts, new targets were identified to maximise the 
potential for novel associations. To accommodate the evolving phenotype definitions and 
the current state of the understanding of cachexia, a search was undertaken for candidate 
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genes or pathways related to the biology of muscle, inflammation, adipose tissue, obesity, 
diabetes and molecular mechanisms of cancer in general, as well as factors affecting 
survival and prediction of outcomes following treatments. In view of the increased 
understanding of the biology of cancer cachexia, the search terms were amended to 
reflect the evolving biology and classification of cancer cachexia. Such an approach 
would likely strengthen the premise for hypothesis driven association studies for 
polygenic diseases/traits, vis-à-vis the potential to identify variants with higher effect size 
and hence the heritable component of the cachexia risk in individuals.  
In Chapter 5 a total of 154 genes associated with cancer cachexia were identified and 
explored for functional polymorphisms. Of these 154 genes, 119 had a combined total of 
281 polymorphisms with functional and/or clinical significance in terms of cachexia. Of 
these, 80 polymorphisms (in 51 genes) were replicated in more than one study with 24 
polymorphisms found to influence two or more hallmarks of cachexia (i.e. inflammation, 
loss of fat mass and/or lean mass and reduced survival). These 24 polymorphisms are 
likely to be the most promising candidates in terms of susceptibility biomarkers for cancer 
cachexia. Since this updated systematic review, one paper has published an association 
with two SNPs which feature in the review, one being rs6136, further vindicating this 
candidate gene approach (206). The understanding of cancer cachexia mechanisms is 
vast as discussed in Chapter 2, by understanding these processes a robust candidate 
gene analysis can be performed s which makes detection of on meaningful SNPs a likely 
outcome. Chapter 5 provides a comprehensive framework for the detection of new SNPs 
in the newly discovered genes regulating the biological processes involved in cancer 
cachexia since the last one. 
Biotechnology is progressing at an unprecedented rate and genome wide association 
studies (GWAS) are common place. Conducting a GWAS study for cancer cachexia 
would seem to be the next logical step as they provide a relatively unbiased examination 
of the entire genome for common risk variants. However in doing so there is potential to 
dampen the signal from true risk variants with statistical noise from the vast numbers of 
markers that are not associated with disease. To determine true significance, researchers 
need a much larger cohort of patients and have to set extremely high significance values. 
By achieving high significance values the problem of false positives is reduced, but it also 
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7.4 Genetic signatures associated with 
susceptibility to cancer cachexia vary according 
to weight-loss or low muscle mass phenotype 
In the study reported in Chapter 6 1276 patients were studied in order to (i) replicate 
SELP rs6136 and other genes previously associated with WL (ii) explore associations 
with 92 predefined new candidate single nucleotide polymorphisms (SNPs) and (iii) 
explore our panel of candidate SNPs (i and ii) for association with CT-defined low 
muscularity (LM) +/- WL. Also explored was whether the transcription in muscle (n=134 
cancer patients) of identified genes was altered according to cachexia phenotype. 
 
7.4.1 Weight loss phenotype: Stage 2 analysis of previously 
identified SNPs in newly recruited cohort (n=545) 
One of the major criticisms from the previous study reported from our group (207) that 
needed to be addressed was the relatively small size of the validation cohort (n=101). 
The study reported in Chapter 6 recruited 545 new patients to perform and validate the 
candidate gene analysis and found two SNPs were validated in this new, larger validation 
cohort, one being rs6136 found on chromosome 1 in the SELP gene had a significant 
association with all levels of WL. The SELP gene encodes for p-selectin, a molecule 
which functions as a cell adhesion molecule (CAM) in response to inflammation on the 
surfaces of activated endothelial cells. The second SNP (rs4149570), found in the 
TNFRSF1A gene on chromosome 12 was found to have a significant association with 
>15% WL. This gene encodes for one of the major receptors for tumour necrosis factor-
α. The downstream effects of this receptor are activation of the transcription factor NF-
κB to mediate apoptosis, and thus it functions as a regulator of inflammation. These 




7.4.2 Weight loss phenotype: Stage 1 analysis with new candidate 
SNPs in combined cohort (n=1276) 
A key issue of any gene association study is the power to detect associations with the 
rarest phenotype. The study reported in Chapter 6 examined 92 new SNPs in a stage 1 
analysis that included 1276 cancer patients, the largest sample size to date in an 
association study for cancer cachexia. In total, 12 SNPs had significant associations with 
various cachexia phenotypes based on increasing severity of WL. Six of these SNPs are 
associated with muscle metabolism in five genes (IGF1, CPN1, FOXO1, FOXO3, and 
ACVR2B), three are associated with adipose tissue metabolism in two genes (LEPR and 
TOMM40 (APOE on the reverse strand)), two with corticosteroid signalling in one gene 
(IFT172 (GCKR on the reverse strand)) and one with the immune response in one gene 
(TLR4). Two polymorphisms (rs1935949 and rs4946935) in the gene encoding for 
FOXO3 were consistently associated with WL of increasing severity. On the basis that 
WL is a continuum in the cachectic process, the observation that both SELP and FOXO3 
associate with all degrees of WL suggests that these genetic signatures may be of 
particular significance. All of these new targets in this stage one analysis represent new 
SNPs from various different domains discovered by the updated systematic review. This 
gives potential new insight into the recent mechanisms associated with cancer cachexia. 
 
7.4.3 Low muscularity phenotype: Stage 1 analysis with all candidate 
SNPs in combined cohort with CT scans (n=751) 
One of the main difficulties in research involving cachexia is the lack of a specific 
phenotype. Chapter 3 has reported that CT scans can be used to derive an index of 
muscle mass to classify patients with low muscularity or not using established cut-offs for 
their skeletal muscle index. Moreover the latter can be related to a change in muscle fibre 
diameter indicating active muscle atrophy associated with cachexia. The study reported 
in Chapter 6 also investigated the potential relationship between patients’ genotype and 
the propensity to low muscularity in cancer cachexia. In total, 5 SNPs were associated 
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significantly with the cachexia phenotype based on levels of muscularity: (i) rs4291 in 
chromosome 17 in the angiotensin converting enzyme (ACE) gene; this gene has been 
associated with muscle function and metabolism; (ii) rs10636 in chromosome 16 in the 
metallothionein 2a gene; this gene has been shown to be involved in zinc 
dyshomeostasis which may contribute to cancer cachexia; (iii) rs1190584 in chromosome 
14 in the WDR20 gene; this gene encodes a WD repeat-containing protein that functions 
to preserve and regulate the activity of the USP12-UAF1 deubiquitinating enzyme 
complex; (iv) rs3856806 in the peroxisome proliferator-activated receptor gamma 
(PPARG) gene in chromosome 3 which has been demonstrated to be involved in fatty 
acid and glucose metabolism; and (v) rs3745012 in chromosome 18 in the lipin 2 (LPIN2) 
gene; this gene represents a candidate gene for human lipodystrophy, characterised by 
loss of body fat, fatty liver, hypertriglyceridemia, and insulin resistance.  
 
7.4.4 Low muscularity plus weight loss phenotype: Stage 1 analysis 
with all candidate SNPs in combined cohort (n=1276) 
In the study reported in Chapter 6, when patients were classified as cachectic according 
to both WL and LM, four SNPs were identified. Two of these SNPs are associated with 
muscle metabolism in two genes (ACVR2B and ACE), one with fat metabolism in one 
gene (LEPR), and one with cytokine production in one gene (TNF). The observation that 
most of the identified genes are associated with muscle and adipose tissue metabolism 
highlights the importance of these processes in the progression of cancer cachexia. 
Skeletal muscle wasting is a signature event in cancer cachexia and can be associated 
with increased fatty infiltration (763), therefore mechanisms effecting the functions of 
these genes may be of particular significance. It would be attractive to assign specific 
functional significance to some of the genetic signatures so identified. For example 
ACVR2B decoy receptors have been shown to abrogate muscle loss and prolong survival 





7.4.5 Combining genes with functional similarity according to gene 
ontology 
Candidate genes (and the SNPs in the corresponding gene regions) were grouped based 
on known functional similarity according to gene ontology and the association between 
grouped SNPs and cachexia was analysed using subjects in the main study cohort. Gene 
group analysis provides one way of summarising the evidence between cachexia traits 
and multiple genetic variants across groups of genes that share functional similarity. 
SNPs in groups of genes involved in appetite regulation, cell adhesion, cell membrane 
structure and function, and signal transduction were associated with the phenotype WL 
>10%. Only SNPs in the group of genes involved in cell adhesion were significant with 
increasing severity of WL. SNPs in groups of genes involved in lipid metabolism, appetite 
regulation, signal transduction and glucocorticoid signalling were associated with the 
phenotype LM and WL >2%. No SNPs in groups of genes were found to be significant 
with all other phenotypes.  
There is some evidence that negative regulators of appetite are elevated in cancer 
cachexia (13, 688, 690, 691). Lipid metabolism was significantly associated with the 
cachexia trait low muscle mass and WL >2% (p=0.0138). Fatty infiltration resulting in 
reduced muscle quality (myosteatosis) has been associated with cancer cachexia and 
reduced survival (396, 763). The glucocorticoid signalling pathway was also found to be 
associated with the cachexia trait LM and WL >2% (p=0.0337). Glucocorticoids and 
associated signalling pathways have been implicated in accelerating protein degradation 
in muscle, which results in loss of lean body mass in cachexia (100). Glucocorticoids are 
thought to act through a permissive effect on the upregulation of messenger RNA and 
the subsequent synthesis of components of the ubiquitin– proteasome system in muscle. 
Glucocorticoids may also inhibit protein synthesis and promote gluconeogenesis, and 





7.4.6 Differential gene expression signatures in human muscle and 
their association with the phenotypes of cachexia 
Transcriptomic analysis for gene transcript level for the genes that showed significant 
associations with any of the cachexia phenotypes was undertaken. Expression of 
ACVR2B, FOXO1 and 3, LEPR, PPARG, TLR4, and TOMM40 transcripts was 
significantly associated with different levels of SMI or WL (P<0.05). Specifically, these 
were all negatively correlated with muscularity. FOXO1 and 3 and TOMM40 were the 
only genes significantly correlated with WL; these were correlated negatively with WL. It 
has previously been shown that the presence of cancer cachexia is associated with the 
transcriptional regulation of about 1800 genes in human skeletal muscle (177). It was 
therefore of interest to see if the transcript level of the genes associated with cachexia in 
Chapter 6 were altered in a separate cohort of cancer patients with or without cachexia. 
Indeed, there was a strong concordance between a proportion of the selected genes and 
either the level of WL or muscularity. FOXO1 and FOXO3 are good examples: SNPs in 
both genes were identified to associate with the WL phenotype and transcript levels of 
both showed a correlation with WL. These transcription factors are key in the pro-
inflammatory driven up-regulation of the ubiquitin-proteasome pathway, but also act as a 
negative regulator of the anabolic Akt-mTOR pathway (95). Inhibition of FOXO 
transcriptional activity prevents muscle fibre atrophy during cancer cachexia and induces 
hypertrophy (95). It is therefore plausible that variants of the FOXO genes are key 
determinants of the muscle loss component of cachexia syndrome. 
 
7.4.7 Limitations 
In the study reported in Chapter 4 it is important to appreciate that the majority of patients 
in the present series will have had some degree of age-related sarcopenia, that this will 
necessarily co-exist with any cancer specific loss of skeletal muscle mass and that the 
diagnostic criteria used in the present study will not necessarily separate one from the 
other. The study reported in Chapter 4 was not longitudinal and it was therefore not 
possible to document active muscle loss. It is also important to recognise that when 
patients were divided into different diagnostic categories the sample size in individual 
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categories may have limited the ability to detect a statistical difference or not. This was 
an exploratory study and provides the basis for a larger study with adequate statistical 
power for definitive analysis.  
In the study reported in Chapter 5 eighty eight newly identified genes with a potential role 
in cancer cachexia were included since the last review, however the main limitation to 
identifying new SNPs in these genes was the lack of studies to date into functional 
polymorphisms within them. Undertaking a genome wide association study (GWAS) 
would be one way to overcome this potential limitation and in the future would be 
preferable to repeating candidate gene selection studies. However, without an adequate 
sample size and highly accurate phenotyping, coupled with lack of government funding 
to complete the project, candidate gene association studies will continue to provide novel 
insights in to the genetic of cancer cachexia.  
The analyses in the study reported in Chapter 6 was not of a genome-wide nature and 
therefore genetic variants with much greater functional significance may have not have 
been discovered. Equally, the true functional significance of any individual SNP for cancer 
patients is mostly unknown. It may, therefore, be better to consider the genetic 
associations identified in the present analysis as genetic signatures or biomarkers 
associated with the cachexia syndrome. Interestingly, 17 of the 19 SNPs reported as 
showing significant associations with the cachexia phenotypes are in intronic, 3’, or 5’ 
UTRs. The purpose was to explore the trends and probe into the potential functional 
impact of the loci as SNPs in this study are potentially proxy to the more causal variants 
(not yet captured in the region) which may also have an influence on gene expression; 
as such the probe position in the expression array and the SNP position are not the same. 
Extrapolation to a SNP under investigation being an expression quantitative loci (eQTL) 
is premature. The SNP identified may in some cases also affect gene expression 
signatures not addressed herein (as in cis- and trans acting eQTLs). The correlation 
pattern (albeit, low to modest) observed is still encouraging since the trends reported 
here for a SNP loci and gene expression are within the scope of known cachexia 
literature. Further replication of the present findings and fine mapping of the loci may offer 
insights. Independent of the functional significance of the polymorphisms, the SNP 
signatures identified herein serve as heritable determinants for cancer cachexia; the 
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polygenic nature of the phenotype warrants identification of more susceptibility variants 
to enable stratification of patients for cancer cachexia risk.  
Equally, for those genes for which no strong relationship was found between gene 
expression and patient characteristics it is important to consider that these may not be 
transcriptionally regulated. For the various humoral mediators (ACE, TNF, IGF1), it may 
be that the concentration in blood is more important rather than local expression in tissues 
since tissue-specific expression may be transient for some genes but the activation of the 
signal transduction cascade could be the largest prevailing effect. For instance local 
expression of the ligand may be a small part of a bigger picture where several tissue 
sources of ligand, a variety of receptors, soluble receptors and binding proteins may play 
a role in the actual response (e.g., TNF and IGF-1).  
The study reported in Chapter 6 is part of a series of studies undertaken by our 
international consortium which over time has expanded DNA biobanking and cachexia 
phenotyping from 775 to 1276 patients. While these represent the largest candidate gene 
association studies done to date in relation to cancer cachexia, they have the general 
limitation of the candidate gene approach. The assembly of much larger data sets and 
samples in order to conduct genome wide association studies is awaited.  
It is important to establish that the prevalence of LM in the present cancer cohort is in 
excess of that which would be observed in the normal age-matched population. The 
prevalence of LM/sarcopenia in age-matched subjects living in the community varies 
according to the precise definition and methodology used, but is reported to be between 
1-29%. The prevalence of LM that was observed in the cancer cohort in Chapter 6 was 
44% for males and 52% for females. Thus, the gene associations established with LM 
represent associations with a level of muscularity at least partly independent of age, sex 
or stature. 
Selection of the genes and SNPs may be biased towards genes with known potential to 
influence on WL. Therefore genes used for other processes associated with cachexia 
such as muscle and lipid regulation are under-represented and potential associations 
may have been missed in these key regulatory pathways. As many of these genes have 
been recently discovered there is paucity of functional significance. As far as the muscle 
and lipid regulation phenotypes are concerned, the present study begins a journey into 
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defining phenotypes based on these novel measurements. Other independent studies 
need to be conducted to address the muscle loss phenotype and its associated genes 
and pathways. It is also important to recognise that the understanding of the biology of 
cachexia is evolving rapidly and that factors such as GDF-15 (MIC-1) that might now be 
considered as potentially important (789), were not included in the present study. 
The candidate gene SNP analysis offers the advantage that it is hypothesis driven and 
the identified associations are easily explained due to compelling biological rationale. 
However, the limitations of this approach are that the role of hitherto unexplored genes 
and pathways that otherwise contribute to the trait under investigation are missed. Issues 
surrounding phenotype complexity are addressed in part in this study and conducting a 
genome wide association study (GWAS) using high density of markers on the genome 
would help relate the overlap of SNPs/pathways to the phenotypes of interest. The 
consensus definitions for phenotypes may evolve in an iterative manner from the 
cumulative wisdom from candidate SNPs, GWAS and the current definitions available for 
cachexia. 
 
7.5 Future work and direction 
Chapter 2 looked at the vast amount of research conducted on cachectic muscle in both 
animal models and clinical studies. The heterogeneity between morphology, mediators, 
and mechanisms of animal models and human cancer cachexia is considerable. There 
are some comparisons that can be drawn from the two but it must be realised that these 
may represent distinct disease processes. The relatively acute wasting seen in young, 
metabolically active animal models may have little bearing on the chronic disease patho 
- physiology seen in aged cancer patients with chronic wasting. Progress in treating the 
human form of cancer cachexia can only move forwards through carefully designed large 
randomised controlled clinical trials of specific therapies with validated biomarkers of 
relevance to underlying mechanisms. This thesis sought to identify SNPs as biomarkers 
for such trials. From the results in Chapter 6 it can be assumed that rs6136 in the SELP 
gene is a novel biomarker in the development of cancer cachexia as defined by 
increasing weight loss. It could also be assumed that rs2268757 in the ACVR2B gene 
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has the potential to be a novel biomarker in the development of cancer cachexia as 
defined as increasing muscle and weight loss. The observation that many of the 
significant SNPs in each phenotype were from genes directly associated with the 
pathophysiology of that same phenotype only confirms the need for accurate phenotyping 
which was demonstrated in muscle in Chapter 4. The latter chapter demonstrated that a 
reduction in fibre diameter was seen when an element of muscularity was introduced to 
phenotyping based on weight loss alone. Further work is needed to validate these 
findings in a larger cohort as this was an exploratory study. Nonetheless Chapter 4 
validates the definition proposed by the international consensus that any weight loss 
(>2%) in the presence of low muscularity will have biological significance (11). Of the new 
significant SNPs identified in Chapter 6, the SCAN database highlights some of the genes 
whose expression may be altered. It would be of interest to look at the transcript levels 
of some of the potentially more influential genes in terms of cancer cachexia in the current 
cohort. Clearly a GWAS study is needed in the future to take forward the genetics of 
cancer cachexia, however for the reasons outlined in the present Chapter it needs to be 
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THE IDENTIFICATION OF GENETIC MARKERS OF 
CANCER- ASSOCIATED WASTING 
 
You are being invited to take part in a research study. Before you decide, 
it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information 
carefully.  Talk to others about the study if you wish. 
• Part 1 tells you the purpose of this study and what will happen to you if 
you take part. 
• Part 2 gives you more detailed information about the conduct of the 
study. 
 
Ask us if there is anything that is not clear or if you would like more 







What is the purpose of the 
study? 
The purpose of this research study is to find out if there is a genetic basis 
for people who have cancer to become wasted, lose weight and feel tired. 
This wasting is a significant problem for patients as it causes a reduction 
in both quality and quantity of life. In order to find out if there is any way to 
predict its development, we would like to see if wasting in cancer is related 
to the presence or absence of certain genetic markers. 
 
Why have I been chosen? 
 
You have been chosen because you have been diagnosed with 
oesophageal, gastric or pancreatic cancer  
 
Do I have to take part? 
 
No. It is up to you to decide whether or not to take part. If you do, you will 
be given this information sheet to keep and be asked to sign a consent 
form. You will still be free to withdraw at any time in the future and without 
giving a reason. A decision to withdraw at any time, or a decision not to take 
part, will not affect the standard of care that you receive. 
 
What will happen to me if I take part? 
 
If you take part, you will be asked to undergo a single blood test and have your 
weight and height measured. This will take place during a routine outpatient 
clinic appointment with your consultant. No extra appointments are required if 
you choose to take part in this study.  We will also ask your permission for 
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access to your clinical case notes and any CT scan images that are performed 
as part of your routine treatment. 
 
• Blood test: The amount of blood taken is approximately the same as 




What do I have to do? 
 
Apart from attendance at the initial appointment, no other responsibilities are 
required from your participation. 
 
 
What are the possible disadvantages and risks of taking part? 
 
There are negligible disadvantages and risks of taking part. Minor discomfort 
may occur during blood sampling. 
 
What are the possible benefits of taking part? 
 
We cannot promise that the study will help you, but the information we receive 
might help improve the treatment of patients with cancer and cancer-associated 
weight loss. 
 What happens when the research study stops? 
 
Following  your  initial  appointment,  no  further  appointments  are  required. 
However, if any of your blood, or DNA samples remain, we would ask your 
permission to store these samples (in anonymised form) in the University of 
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Edinburgh so that we can consider them for use in future research studies 




What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information 
on this, including contact details, is given in Part 2. 
 
 
Will my taking part in the study be kept confidential? 
 
Yes. All the information about your participation in this study will be kept 





What if relevant new information becomes available? 
 
If any new treatment for cancer or cancer-associated wasting becomes 
available during the time of the study, it will not be withheld from you because 
of your participation in this study. Furthermore, if you require any other 
treatment for cancer during the course of the study (e.g. chemotherapy or 






What will happen if I don’t want to carry on with the 
study? 
 
You can withdraw from the study at any time. All information that was collected 
during the time of your participation in the study will be destroyed. Any stored 
blood or DNA samples that are identified as yours will also be destroyed 
 
What if there is a problem? 
 
•       Complaints: If you have a concern about any aspect of this study, you 
should ask to speak with the researchers who will do their best to answer your 
questions. If you remain unhappy and wish to complain formally, you can do 
this through the NHS Complaints Procedure. Details can be obtained from the 
hospital. 
•       Harm: In the event that something does go wrong and you are harmed 
during the research study, there are no special compensation arrangements. If 
you are harmed and this is due to someone’s negligence, then you may have 
grounds for a legal action for compensation against the University of Edinburgh 
but you may have to pay for your legal costs. The normal National Health 
Service complaints mechanism will still be available to you. 
 
 
Will my taking part in this study be kept confidential? 
 
Yes.  All  information  which  is  collected  about  you  during  the  course  of  
the research will be kept strictly confidential. However, we would like to inform 
your GP of your involvement in this study but we will require your permission 
to do this.  All  other  information  about  you  which  leaves  the  Royal  Infirmary  
of Edinburgh will have your name and address removed so that you cannot be 
recognised from it. 
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Blood and DNA samples collected during the study may be transferred for the 
purpose of analysis to associated researchers within the European Economic 
Area. However, all samples will be anonymised prior to sending and 
therefore you will not be identifiable. 
 
 
What will happen to any samples I give? 
 
A portion of the blood sample will be immediately analysed by the Department 
of Biochemistry at the Royal Infirmary of Edinburgh or Western General 
Hospital. The remainder of the blood sample will be transferred to the University 
of Edinburgh for analysis. The only individuals who will have direct access to 
these samples will be the members of the study research team. DNA will be 
extracted from the blood sample at the University of Edinburgh. A small portion 
of the DNA will  be  sent  from  the  University  of  Edinburgh  to  our  collaborators  
at  the University of Alberta, Canada, for genetic analysis. The samples that 
are sent to Canada will already be anonymised so that you will not be 
identifiable from them. 
 
 
Following all of these different analyses, if any of the samples remain, we would 
ask  your  permission  to  store  these  samples  (in  anonymised  form)  in  the 
University of Edinburgh so that we can consider them for future research studies 
(if a local Ethics Committee deems the studies appropriate). Professor Kenneth 
Fearon, Professor of Surgical Oncology, will act as custodian for any stored 
samples. The only other individuals who will have direct access to the stored 






Will any genetic tests be done on the samples that I give? 
 
Yes. There will not be any implications, healthcare or otherwise, from the genetic 
study. The genetic markers that we aim to test for have not been shown to be 
linked with or have any association with inheritable risk for any known diseases. 
Therefore, we will not normally feedback any results to you. 
 
 
What will happen to the results of the current research study? 
 
The results of this study will be published in medical journals, reports and 
textbooks. You will not be identifiable in any report/publication or report unless 
you have specifically consented to release such information. 
 
 
Who is organising and funding the research? 
 
The research is being organised and sponsored by the University of Edinburgh. 
The research is being funded by the European Commission. 
 Who has reviewed the study? 
 
This study was given a favourable ethical opinion for conduct in the NHS by 
Lothian Research Ethics Committee.  This study has also been reviewed by 











You may contact our research team directly by telephoning 0131 242 
6520 for further information at any time. Alternatively, you may contact Prof. 
Stephen Wigmore, Consultant Surgeon in the Department of Surgery, who is 
acting as an independent advisor – contact 0131 242 3615. 




























THE IDENTIFICATION OF EARLY BIOCHEMICAL AND 
CLINICAL MARKERS OF CANCER-ASSOCIATED 
WASTING 
 
You are being invited to take part in a research study. Before you decide, it is important 
for you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully. Talk to others about the study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you take part. 
 Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
Part 1 
What is the purpose of the study? 
The purpose of this research study is to find out what causes people who have cancer to 
become wasted, lose weight and feel tired. This wasting is a significant problem for 
patients as it causes a reduction in both quality and quantity of life. In order to find out 
what causes this problem and if there is any way to predict its development, we are asking 
patients with cancer if they would undergo a variety of tests around diagnosis, and 6 
months, 12 months and 18 months afterwards. These tests are mainly to measure 
changes in muscle size, muscle strength and power. We would like to see if any of these 
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changes are related to the activity of certain ‘markers’ of wasting which we will measure 
in samples of muscle, blood and urine. These tests are designed to cause the minimum 
of discomfort or inconvenience for anyone involved. 
 
Why have I been chosen? 
You have been chosen because you are undergoing treatment for cancer. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You will still be free to 
withdraw at any time in the future and without giving a reason. A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care that you receive. 
 
What will happen to me if I take part? 
If you take part, you will be asked to undergo certain tests around the time of diagnosis, 
and at appointments 6 months, 12 months and 18 months afterwards. The appointments 
will be timed to coincide with the normal clinic appointments where possible. Therefore, 
no extra visits to hospital are required if you choose to take part in this study. However, 
if for any reason we are unable to coincide your study appointments with your normal 
clinic appointments, we will provide taxi transport to and from the Royal Infirmary of 
Edinburgh’s Clinical Research Facility. The tests will include: 
 
 A blood test: The amount of blood taken is approximately the same as one teaspoonful 
(5ml), and it will be taken from your arm in the usual fashion.   
 





 Tests of muscle strength and power: These tests will involve you sitting in 
specialised chairs and extending your leg as fast and as hard as you can. These tests 
will take about 20 minutes. 
 
 Test of functional ability (timed up-and-go): This test will measure your ability to get 
up out of a chair and walk a few metres then turn around and go back to your chair. It 
will only take a few minutes. 
 
 An MRI scan of your legs: This test will be carried out in the Department of Radiology. 
It involves you lying flat within the scanner and will take approximately 20 minutes to 
perform. There are no X-rays or injections involved.  
 
 A questionnaire: This will take approximately 15 minutes to complete but can be taken 
home to do. We can provide a stamped-addressed envelope to post it to us if you take it 
home. 
  
We would initially plan to carry out all of the above tests at one appointment. If, after 
carrying them out, you found that these tests were acceptable to perform (as we would 
hope), we would ask you to repeat the same tests at appointments dated 6 months, 12 
months and 18 months afterwards. 
 
Apart from the above-described tests, the only other test will be to take a muscle biopsy: 
 
 A muscle biopsy:  We plan to biopsy the muscle on the front of your thigh.  The amount 
of muscle removed is small and is taken via a tiny incision (a few millimeters long) through 
which a needle is introduced. The procedure is performed under local anaesthetic so you 
will not feel any pain.  This incision will be closed by paper stitches and will leave a small 




If at one of the appointments dated 6 months, 12 months and 18 months after the initial 
assessment you are noticed to have lost a significant amount of weight (e.g. more than 
15% of your normal weight), we would ask that you give us permission for a further thigh 
muscle biopsy at that time. This will again be performed under a local anaesthetic 
injection. Obviously we will re-confirm your permission to perform this test at that time. 
 
What do I have to do? 
Apart from attendance at the initial appointment and at 6, 12 and 18 months afterwards, 
no other responsibilities are required from your participation. 
 
What are the possible disadvantages and risks of taking part? 
We have taken every step in the design of this study to minimise any possible 
disadvantages and risks. Regarding the thigh muscle biopsy, you may experience some 
mild discomfort and stiffness in the leg following the procedure, but this should wear off 
after a few hours. This biopsy will be performed under a local anaesthetic injection. The 
anesthetic agent may sting for a few seconds as it is being administered. Also, 
approximately 1 in 200 people suffer with bruising following the procedure. Regarding the 
MRI scans, some people may occasionally feel claustrophobic within the scan machine. 
However, the machine is smaller than other scan machines you may have been in (e.g. 
CT) and the radiographer remains present with you throughout the scan. The MRI scan 
does not involve X-rays. 
 
What are the possible benefits of taking part? 
We cannot promise that the study will help you, but the information we receive might help 





What happens when the research study stops? 
Following your appointment at 18 months, no further appointments are required. 
However, if any of your blood, muscle or urine samples remain, we would ask your 
permission to store these samples (in anonymised form) in the University of Edinburgh 
so that we can consider them for use in future research studies that we may carry out (if 
a local Ethics Committee deems the studies appropriate).  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this, including 
contact details, is given in Part 2.   
 
Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential.  
The details are included in Part 2. 
 
Part 2 
What if relevant new information becomes available? 
If any new treatment for cancer or cancer-associated wasting becomes available during 
the time of the study, it will not be withheld from you because of your participation in this 
study. Furthermore, if you require any other treatment for cancer during the course of the 
study (e.g. chemotherapy or radiotherapy), it will not be withheld from you because of 






What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time. However, we would ask your permission to 
keep in contact with you to monitor your progress. In this way, any information that was 
collected during the time of your participation in the study may still be used for research 
purposes. Any stored blood or tissue samples that can still be identified as yours will be 
destroyed if you wish. 
 
What if there is a problem? 
 Complaints: If you have a concern about any aspect of this study, you should 
ask to speak with the researchers who will do their best to answer your questions. If you 
remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from the hospital. 
 Harm: In the event that something does go wrong and you are harmed during the 
research study, there are no special compensation arrangements. If you are harmed and 
this is due to someone’s negligence, then you may have grounds for a legal action for 
compensation against the University of Edinburgh but you may have to pay for your legal 
costs. The normal National Health Service complaints mechanism will still be available to 
you. 
 
Will my taking part in this study be kept confidential? 
Yes. All information which is collected about you during the course of the 
research will be kept strictly confidential. However, we would like to inform your 
GP of your involvement in this study but we will require your permission to do 
this. All other information about you which leaves the Royal Infirmary of 
Edinburgh will have your name and address removed so that you cannot be 
recognised from it. 
Muscle and blood samples collected during the study may be transferred for the 
purpose of analysis to associated researchers within and outside the European 
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Economic Area. However, all samples will be anonymised prior to sending and 
therefore you will not be identifiable. 
 
What will happen to any samples I give? 
A portion of the blood samples will be immediately analysed by the Department of 
Biochemistry at the Royal Infirmary of Edinburgh. The remainder of the blood samples, 
along with the muscle and urine samples, will be transferred to the University of 
Edinburgh for analysis. The only individuals who will have direct access to these samples 
will be the members of the research team behind this study. The samples will be analysed 
in the University of Edinburgh by various biochemical techniques in order to measure the 
levels of certain ‘markers’ of wasting within the various tissues. Also, small portions of the 
samples may be sent from the University of Edinburgh to our collaborators at the 
University of Ohio, USA, for other biochemical analyses which examine different 
‘markers’ of wasting. The samples that are sent to the USA will already be anonymised 
so that you will not be identifiable from them. Furthermore, all of these samples will be 
‘used up’ in the USA, and therefore, there will be none left over which will require storage 
overseas. 
Following all of these different analyses, if any of the samples remain, we would ask your 
permission to store these samples (in anonymised form) in the University of Edinburgh 
so that we can consider them for future research studies (if a local Ethics Committee 
deems the studies appropriate). Professor Kenneth Fearon, Professor of Surgical 
Oncology, will act as custodian for any stored samples. The only other individuals who 
will have direct access to the stored samples will be the members of the research team 
behind the current study. 
Will any genetic tests be done on the samples that I give? 
We have no plans to perform genetic analysis within the remit of this current study. 
However, following this current study, we would ask your permission to store any 
remaining samples so that we may consider them for use in future research studies that 
we may carry out (if a local Ethics Committee deems the study appropriate). Future 
studies could potentially involve genetic analysis, but such studies are at a very early 
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stage of planning and not yet in progress. Any results from future genetic studies will not 
have any healthcare implications for you and hence we would not normally feed these 
results back to you. 
 
 
What will happen to the results of the current research study?  
The results of this study will be published in medical journals, reports and textbooks. 
Results will be made available to study participants through the Cancer Research UK 
website. You will not be identifiable in any report/publication or report unless you have 
specifically consented to release such information. 
 
Who is organising and funding the research? 
The research is being organised and sponsored by the University of Edinburgh. The 
research is being funded by Cancer Research UK. 
 
Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by Lothian 
Research Ethics Committee. This study has also been reviewed by members of the 
scientific committee of Cancer Research UK. 
 
Contact details 
You may contact the research team directly by telephoning 0131 242 6520 for further 
information at any time. Alternatively, you may contact Mr. Rowan Parks, Senior Lecturer 
and Consultant Surgeon in the Department of Surgery, who is acting as an independent 
advisor – contact 0131 242 3615.  








THE IDENTIFICATION OF GENETIC MARKERS OF 
CANCER- ASSOCIATED WASTING 
 
1.         I agree to take part in the 
above-titled study. 
2.         I agree for my blood to be taken for the purpose of 
DNA analysis. 
3.         I  confirm  that  I  have  read  and  understand  the  information  sheet  dated  
June  2008 (version 2.1) for the above study. I have had the opportunity to consider 
the information and ask questions, and I have had these answered satisfactorily. 
4.         I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected. 
5.         I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals from regulatory 
authorities or from Lothian NHS Trust University Hospitals Division, where it is relevant 
to my taking part in this research. I give permission for these individuals to have access 
to my records. 
6.         I agree to my GP being informed of my participation 
in the study. 
7.         I agree to the storage of samples taken during the course of this study so that 
they may be considered for use in future research studies (pending a favourable ethical 
opinion by Lothian Local Research Ethics Committee). 
 
Name of Patient                                             Date                                            Signature 
 








THE IDENTIFICATION OF EARLY BIOCHEMICAL AND 
CLINICAL MARKERS OF CANCER-ASSOCIATED 
WASTING 
1. I agree to take part in the above-titled study.  
 
2. I confirm that I have read and understand the information sheet dated 
Feb 2008 (version 4.1) for the above study. I have had the opportunity to 
consider the information and ask questions, and I have had these answered 
satisfactorily. 
 
3. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected. 
 
4. I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals from 
regulatory authorities or from Lothian NHS Trust University Hospitals 
Division, where it is relevant to my taking part in this research. I give 
permission for these individuals to have access to my records. 
 
5. I agree to my GP being informed of my participation in the study.  
 
6. I agree to the storage of samples taken during the course of this study so 
that they may be considered for use in future research studies (pending a 
favourable ethical opinion by Lothian Local Research Ethics Committee). 
 
7. I agree to the use of samples taken during the course of this study in 
possible future genetic studies (pending a favourable ethical opinion by 
Lothian Local Research Ethics Committee). 
 
Name of Patient Date  Signature 
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Abstract
Cancer cachexia is a complex and multifactorial disease. Evolving definitions highlight the fact that a diverse range of bio-
logical processes contribute to cancer cachexia. Part of the variation in who will and who will not develop cancer cachexia
may be genetically determined. As new definitions, classifications and biological targets continue to evolve, there is a need
for reappraisal of the literature for future candidate association studies. This review summarizes genes identified or impli-
cated as well as putative candidate genes contributing to cachexia, identified through diverse technology platforms and model
systems to further guide association studies. A systematic search covering 1986–2012 was performed for potential candidate
genes / genetic polymorphisms relating to cancer cachexia. All candidate genes were reviewed for functional polymorphisms
or clinically significant polymorphisms associated with cachexia using the OMIM and GeneRIF databases. Pathway analysis
software was used to reveal possible network associations between genes. Functionality of SNPs/genes was explored based
on published literature, algorithms for detecting putative deleterious SNPs and interrogating the database for expression of
quantitative trait loci (eQTLs). A total of 154 genes associated with cancer cachexia were identified and explored for func-
tional polymorphisms. Of these 154 genes, 119 had a combined total of 281 polymorphisms with functional and/or clinical
significance in terms of cachexia associated with them. Of these, 80 polymorphisms (in 51 genes) were replicated in more
than one study with 24 polymorphisms found to influence two or more hallmarks of cachexia (i.e., inflammation, loss of fat
mass and/or lean mass and reduced survival). Selection of candidate genes and polymorphisms is a key element of multigene
study design. The present study provides a contemporary basis to select genes and/or polymorphisms for further association
studies in cancer cachexia, and to develop their potential as susceptibility biomarkers of cachexia.
[Johns N., Tan B. H., MacMillan M., Solheim T. S., Ross J. A., Baracos V. E., Damaraju S. and Fearon K. C. H. 2014 Genetic basis of
interindividual susceptibility to cancer cachexia: selection of potential candidate gene polymorphisms for association studies. J. Genet. 93,
893–916]
Introduction
Cachexia affects the majority of patients with advanced cancer
and is associated with a reduction in treatment tolerance,
response to therapy, quality of life and duration of survival.
Cancer cachexia has recently been defined as a multifactorial
syndrome characterized by an ongoing loss of skeletal muscle
mass (with or without loss of fat mass) that cannot be fully
∗For correspondence. E-mail: k.fearon@ed.ac.uk.
reversed by conventional nutritional support and leads to pro-
gressive functional impairment (Fearon et al. 2011). Depend-
ing on the tumour type, weight loss occurs in 30–80% of
cancer patients and is severe (with loss of >10% of the ini-
tial body weight) in 15% (Dewys et al. 1980). The degree
of cancer cachexia is variable depending on the phenotype
and genotype of both patient and tumour. It is likely, there
may be cachexia prone genotypes as well as cachexia resis-
tant genotypes. A recent longitudinal study of patients with
a variety of cancers has demonstrated that some will remain
Keywords. cancer; cachexia; genetics; polymorphism.
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stable, lose or gain skeletal muscle or adipose tissue (Prado
et al. 2013), further strengthening the concept of a genetic
predisposition to wasting in the presence of cancer.
Pathophysiology of cancer cachexia is characterized by
a negative protein and energy balance driven by a variable
combination of reduced food intake and abnormal meta-
bolism (Fearon et al. 2011). Skeletal muscle loss appears
to be the most significant event in cachexia leading to
poor treatment outcomes (Tan et al. 2009; Fearon et al.
2011). While malnutrition is reversible with nutrient intake,
cachexia is not completely reversible by this approach.
Indeed, cachectic patients usually present with progressive
weight loss along with body composition alterations and dis-
turbed homeostasis of many body systems, particularly of fat
tissue and muscle (Tisdale 2002; von Haehling et al. 2009).
Single nucleotide polymorphisms (SNPs) are the most
common type of heritable and evolutionarily stable genetic
variations in the population (Brookes 1999); other genetic
polymorphisms include copy number aberrations, insertion,
deletions and tandem repeats. SNPs may exert differing
effects on genes leading to an aberrant gene product. Poly-
morphisms in promoter regions potentially contribute to dif-
ferential gene expression, presumably affecting the binding
of transcription factors to DNA. Sequence variation in the
5′ untranslated region (UTR) could disrupt mRNA transla-
tion; mutations in the 3′ UTR could affect mRNA through
posttranscriptional mechanisms such as splicing, maturation,
stability and export. Polymorphisms in intronic regions may
result in cis regulation or trans regulation of genes, unmask
cryptic splice sites or promoters leading to alternative tran-
scripts. Synonymous and nonsynonymous SNPs in exons
could alter protein function or activity and may introduce
codon bias contributing to the relative abundance of the pro-
teins, respectively. Finally, nonsense mutations cause a stop
altogether in the translation of mRNA (Wjst 2004). Genomic
distribution of SNPs is not homogenous, SNPs usually occur
in noncoding regions more frequently than in coding regions
(Barreiro et al. 2008). It has been estimated that 10% of
all SNPs in the genome are functional, thereby having the
potential of altering some biological process.
The case to support a genetic predisposition to cachexia
is strengthened from the known genetic contribution to the
activity of a variety of key mechanisms that underlie the
cachexia syndrome. In a previous systematic review on the
identification of possible genetic polymorphisms involved in
cancer cachexia, a total of 184 polymorphisms with func-
tional or clinical relevance to cancer cachexia were identi-
fied in 92 candidate genes (Tan et al. 2011). Following this
approach here, we were able to identify 23 significant SNPs
associated with cachexia based on definitions of weight loss
and systemic inflammation (measured with C-reactive pro-
tein (CRP)) and validated a SNP in the SELP gene encod-
ing for p-selectin in an independent cohort. P-selectin binds
to leucocytes and in certain inflammatory conditions, the
plasma concentration of soluble p-selectin is highly elevated
(Dunlop et al. 1992). By incorporating a definition based on
systemic inflammation, we identified a SNP involved in the
innate immune response. To date most of the studies on iden-
tification of SNPs involved in cancer cachexia has led to the
discovery of other SNPs involved in the innate immune sys-
tem, mainly in the interleukin family of cytokines (Jatoi et al.
2007, 2010; Knoll et al. 2008; Zhang et al. 2008; Deans et al.
2009; Bo et al. 2010; Rausch et al. 2010; Sun et al. 2010a, b)
(table 1). SNPs in other biological processes have also been
studied for their association with cancer cachexia (Solheim
2011, 2012; Punzi et al. 2012) (table 1). By altering the phe-
notype for a degree of skeletal muscle quantification, it may
be possible to identify SNPs associated with muscle tissue
biology.
A contemporary review of the literature is now needed as
a greater understanding of the processes involved in cancer
cachexia are increasingly sought. To enable further candi-
date gene selection studies with larger cohorts, new targets
need to be identified to maximise the potential for associ-
ations. An increase in earlier sample size will increase the
power of further studies to identify novel SNPs. To accom-
modate the evolving phenotype definitions and the current
state of the understanding of cachexia, we searched for can-
didate genes or pathways related to the biology of muscle,
inflammation, adipose tissue, obesity, diabetes and molecular
mechanisms of cancer in general, as well as factors affect-
ing survival and prediction of outcomes following treat-
ments. There is an express need to restrategize the selection
of candidate genes to drive association studies since ‘omics’
approaches uncovered the hitherto unexplored biological
pathways in the last five years in the realm of cancer and
genetic predisposition markers for a host of diseases and
traits. In view of the increased understanding of the biology
of cancer cachexia, we have amended the search terms used
as both biology and classification of cancer cachexia continues
to evolve. We reasoned that insights into functional signi-
ficance of the candidate gene SNPs will help explore puta-
tive causality of the SNPs. These approaches would likely
strengthen the premise for hypothesis driven phenotype–
genotype association studies for polygenic diseases/traits,
vis-à-vis potential to identify variants with higher effect size
and hence heritable component of the cachexia risk in indi-
viduals. Functionality of SNPs/genes was explored based on
published literature, algorithms for detecting putative dele-
terious SNPs and databases for expression quantitative trait
loci (eQTLs) (Hunter and Crawford 2008; Schadt et al. 2008;
Fehrmann et al. 2011; Hao et al. 2012; He et al. 2013).
Interindividual variations in susceptibility to cancer induced
cachexia and the heritable component of the genome when
fully delineated would help identify possible interventions
for those at risk well before the onset of clinical symptoms.
Methods
The US National Library of Medicine database, Medline; the
Excerpta Medica database, Embase; Cochrane Central Reg-
ister of Controlled Trials, Central; and the database of the
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Table 1. Published associations of genetic variants in cancer cachexia.
Reference SNP Gene Patients included Phenotype
Solheim (2012) No associations N/A Patients 1853, with cancer EORTC QLQ-C30 questionnaire, question 13:
at different sites, stages ‘have you lacked appetite’
and with different
performance status
Punzi (2012) rs1544410 VDR Patients 43, with cancer Guidelines for diagnosis of cancer associated
(BsmI) from various sites and cachexia provided by the Italian Association of
rs731236 (TaqI) stages Medical Oncology
Tan (2012) rs6136 SELP Patients 775, with Six phenotypes
upper gastrointestinal cancers (1) >5% weight loss
(UGI) and pancreatic cancers (2) >10% weight loss
(3) >15% weight loss
(4 – 6) The above with CRP concentration of
>10 mg/l −1
Solheim (2011) No associations N/A Patients 1797, with cancer • BMI: <20 kgm−2
at different sites, stages • Karnofsky score: <80
and with different • CRP: <10 mg l−1
performance status • Appetite loss: a response of little or
greater on EORTC QLQ-C30 item ‘have
you lacked appetite?’
>3 features = severe cachexia
2 or 3 features = mild cachexia
<2 = no cachexia
Sun et al. (2010a, b) rs1800896 IL-10 Two hundred and twenty-three
gastric cancer
Bo et al. (2010) rs2227306 IL-8 + 781 Gastric cancer
Jatoi et al. (2010) rs1800629 TNF Patients 471, with non >10% Weight loss
small cell lung cancer
Rausch et al. (2010) rs3024498 IL-10 Caucasian lung cancer Lung cancer symptom scale
survivors 1149 How much loss
appetite are you experiencing?
Deans et al. (2009) rs1800896 IL-10 (-1082) Patients 203, with UGI >10% Weight loss
cancers
Knoll et al. (2008) rs2229616 MC4R Patients 509, with various (1) >10% weight loss (exclusively cancer)
Val103Ile cancers (including (2) >10% weight loss (treatment influenced)
haematological (3) >5% weight loss
malignancies) at various (4) >1% weight loss (cancer specific) or >5%
stages treatment induced
(5) No weight loss
Zhang et al. (2007) rs1143634 IL-1β (+ 3954) Patients 214, with locally >10% Weight loss
advanced gastric cancer
Jatoi et al. (2007) rs1143634 IL-1β (+ 3954) Patients 44, with metastatic Phenotype is greater improvement
gastric and gastrooesophagal in weight registered once in every three weeks
cancer during chemotherapy
BMI, body mass index.
Cumulative Index to Nursing and Allied Health Literature,
Cinahl, were searched through the National Library of Health
website, the Cochrane library, Pubmed (free citation database
of Medline) and Grey literature online.
The first aim was to identify articles with new potential
candidate genes involved in the development of cancer
cachexia using the keyword search ‘genes/genetics and
inflammation or cancer or cachexia or weight loss or body
composition or survival or muscle or adipose to provide
an update on the existing database. Following the initial
retrieval of possible new candidate genes, selected genes
were entered into a pathway functional analysis software
(ingenuity pathways analysis (IPA), ingenuity systems,
Redwood, USA) to further identify related genes.
The second and third aims were to find genetic poly-
morphisms with known functional or clinical significance
in each of these new and existing genes using the keyword
search (gene of interest) and polymorphism(s). All identi-
fied candidate genes were reviewed for functional polymor-
phisms or clinically significant polymorphisms in terms of
cachexia using OMIM, dbSNP and GeneRIF databases. The
search was limited to reports within English language and a
manual search of reference lists and conference proceedings
followed with all cross references screened.
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Study selection
Published papers and or abstracts were screened after remov-
ing duplicates. Inclusion criteria were set as any study either
involving genes in the selected domains or any study show-
ing functional SNPs influencing these genes. Reasons for
exclusion included studies of irrelevance to cancer cachexia,
studies with no genes or functional polymorphisms identi-
fied, and complex polygenic phenotypes analysing random
SNPs for association. The remaining papers were reviewed
in full and only those involving genes in the development
of cancer cachexia or any study showing functional SNPs
influencing these genes, were included in the final analysis.
In accordance with the previous review, candidate genes
were grouped based on the role their product is postulated to
have in the development of cancer cachexia (Tan et al. 2011),
these being the domains of:
(i) Inflammation:
(a) innate immune receptors and mediators of the
immune response; (b) cytokines; (c) cytokine receptors
and related binding proteins; (d) acute phase protein
reactants.
(ii) Central homeostasis
(a) energy production; (b) insulin-like growth fac-
tors and related proteins; (c) corticosteroid signalling
proteins.
(iii) Muscle:
(a) muscle function and structure; (b) muscle synthesis;
(c) muscle proteolysis and degradation.
(iv) Adipose tissue:
(a) adipogenesis; (b) lipid turnover and transport; (c)
adipokines and adipokine receptors.
(v) Appetite.
(vi) Others.
The updated summary tables of polymorphisms are pre-
sented according to each category with ‘easy to see’ boxes
that denote whether a polymorphism has any effect on
inflammation, weight/body composition (i.e. lean mass / fat
mass) and cancer survival. Also added is information on
ancestral allele, SNP allele, type of SNP, polymorphism
reference number (rs number), and mean allele frequency
(MAF) based on a population with European ancestry
derived from the HapMap or dbSNP databases.
Pathway analysis
Multiple genes within a single pathway are likely to influ-
ence the development of cancer cachexia. To provide a more
comprehensive assessment in terms of pathway involvement
in cancer cachexia, we performed pathway-based analyses
using the IPA software. Focus genes were defined as func-
tional SNPs which had been validated in at least one study
and these were entered into the IPA analysis tool. The IPA
software was used to measure associations of these genes
with other molecules, their network interactions, and bio-
logical functions stored in its knowledge base. Our focus
genes served as seeds for the IPA algorithm, which rec-
ognizes functional networks by identifying interconnected
molecules, including molecules not among the focus genes
from the IPA knowledge base. The software illustrates
networks graphically and calculates a score for each net-
work, which represents the approximate ‘fit’ between the eli-
gible focus molecules and each network. The network score
is based on the hypergeometric distribution and is reported
as the −log (Fisher’s exact test result).
Putative functions
To identify the likely effect of individual SNPs on nearby
genes the sorting intolerant from tolerant (SIFT; http://sift.
bii.a-star.edu.sg/) program was used for nonsynonymous
SNPs (Ng and Henikoff 2003), SIFT is a program that pre-
dicts whether a nonsynonymous SNP leading to an amino
acid substitution affects protein function or not (Ng and
Henikoff 2003). To predict whether an amino acid substi-
tution in a protein will affect protein function, SIFT con-
siders the position at which the change occurred and the
type of amino acid change. Given a protein sequence, SIFT
chooses related evolutionarily conserved proteins and amino
acid residues likely critical for structure or function and
obtains an alignment of these proteins with the query. Based
on the amino acids appearing at each position in the align-
ment, SIFT calculates the probability that an amino acid at a
position is tolerated conditional on the most frequent amino
acid being tolerated. If this normalized value is less than a
cut-off, the substitution is predicted to be deleterious (Ng and
Henikoff 2001). Many of the amino acid substitutions are
well tolerated since the SNPs tend to capture subtle effects,
and the ones with drastically altered functions are not to the
survival advantage of the species, hence are eliminated dur-
ing the course of evolution. A limitation of SIFT program is
that only nonsynonymous substitutions are interrogated and
those in the regulatory and intronic regions (>95% of the
genome) are not considered.
The SNP and copy number annotation (SCAN) database
(http://www.scandb.org/newinterface/about.html) is a large-
scale database providing a web interface for easy search
with a gene name or an input of SNP ID (rs#) (Gamazon
et al. 2010). This database can use SNPs from 5′ or 3′ and
intronic SNPs and their potential influence on the gene
expression for nearby genes; gene expression if regulated
on the same chromosome and within 100 Mb distance from
the SNP could be categorized as cis regulatory SNPs, if not
they are called trans SNPs. The SNPs are classified accord-
ing to their effects on expression levels, i.e. eQTLs using
scan database. Gene expression data and polymorphism
data from HapMap population-derived lymphoblastoid cell
lines (Caucasian, Yoruba and Han Chinese/Japanese) are
used to interrogate the cis effects and trans effects from
SNPs/genes. We have therefore summarized our findings
for the selected SNPs for possible functional significance
using this approach as well. Generalizability of observations
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from genotype to expression from lymphoblastoid cell lines
is not the same as correlations made with tissue specific
expression, and therefore, one should exercise caution in
the interpretations of findings. However, several published
studies attest to the utility of this approach to extrapolating
genotype–phenotype correlations to be valid even to specific
tissues, albeit for select candidate SNPs.
Results
A total of 281 polymorphisms in 154 genes were identified
and explored for relevance to cancer cachexia (see tables
1–15 in electronic supplementary material at http://www/
ias.ac.in/jgenet/). Of these genes, 88 were newly identified
and 66 were from the previous review by our group (Tan
et al. 2011). The 281 functional polymorphismswith or with-
out clinical significance to cancer cachexia (i.e. inflamma-
tion, loss of fat mass and/or lean mass and reduced survival)
were found in 119 genes with no SNPs of interest found in
the remaining 35 genes. A pathway-based analysis for rel-
evance to cachexia and SNPs selected from these pathways
are summarized (table 3; figures 1 & 2).
Inflammation
Inflammation is widely accepted to play a dominant role in
the host’s response to cancer and mediators regulating skele-
tal muscle atrophy in cachexia are thought to derive from
immune or tumour cells, or the targeted tissues undergo-
ing wasting (both adipose tissue and skeletal muscle) (Stew-
art et al. 2006). Cancer cells rely on production of proin-
flammatory mediators for growth, protection from apoptosis,
and promotion of angiogenesis/metastasis. The tumour may
consequently initiate a cytokine cascade that has multiple,
direct, and distant effects including the initiation of skeletal
muscle protein degradation. Host immunological response to
proinflammatory and antiinflammatory cytokines dictates to
what degree the metabolic rates are altered. In experimen-
tal models, proinflammatory cytokines lead to an acute phase
response and tissue catabolism (Argiles et al. 2003).
Innate immune receptors and mediators of immune response:
Electronic supplementary table 1 shows the genes involved
in the regulation of the innate immune response and how
they may generate or suppress the inflammatory response to
influence the rate of cancer cachexia. Variants of these genes
which may influence their function are also listed. Since
the previous review, focus has spread to include new genes
(AKT2, AKT3 andCOX2) (Bonetto et al. 2011; Ol et al. 2011)
which act via signalling pathways to alter the innate immune
response. AKT regulates cellular survival and metabolism by
binding and regulating many downstream effectors, e.g. NF-
κB and Bcl-2 family proteins (Song et al. 2005). IGF-1-
induced AKT signalling is important in both the suppression
of degradation and induction of protein synthesis (Rommel
et al. 2001). AKT2 has been shown to induce glucose
transport, a mouse model null for AKT2 demonstrated
marked growth deficiency and displayed a diabetic pheno-
type (Garofalo et al. 2003); the role of AKT3 is less clear.
Also of interest are variants coding forCOX2, it is found in
low levels in most cells under normal conditions but has been
shown to be elevated during periods of inflammation. COX2
mediates the formation of prostaglandins from arachidonate
and may play a role as a major mediator of inflammation
and/or a role for prostanoid signalling (Kim et al. 2005).
New variants in the genes coding for the toll-like receptor
(TLR) family and CAMs have been found. These genes play
an instructive role in innate immune responses as well as the
subsequent induction of adaptive immune responses. TLRs
are involved in triggering intracellular signals, culminating
in the activation of nuclear factor (NF)-κB, where it par-
ticipates in enhancing expression of other immuneregula-
tory substances (Kawai and Akira 2006), whereas CAMs are
known to mediate migration of cells to sites of inflammation.
Cytokines and cytokine receptors: Mediators regulating cancer
cachexia are thought to be derived from immune or tumour
cells, or the targeted tissues undergoing wasting (both adi-
pose tissue and skeletal muscle). All cytokines play a role in
the induction of immune and inflammatory responses. Con-
sequences on cellular function are vast including, prolifera-
tion, mediating intracellular tissue cross talk, chemotaxis and
killing. Genetic variants of genes encoding proinflammatory
and antiinflammatory cytokines are presented in table 2 in
electronic supplementary material.
Cytokines bind to their appropriate receptor to initiate a
downstream cascade of intracellular signalling. Signalling
leads to either potentiation of the signal and to production
of similar or other cytokines and their receptors or to a sup-
pression of the signal (Ihle et al. 1995). Since the last review,
the gene encoding the IL-6R protein has been shown to
play an important role in the mediation of IL-6 signalling,
and a genetic variant in this gene has been shown to influ-
ence the C-reactive protein (CRP) level (Ridker et al. 2008).
Genetic variants of genes encoding cytokine receptors and
related binding proteins are presented in table 3 in electronic
supplementary material.
Acute phase protein reactants: An organism responds to the
presence of acute infection, tissue injury, trauma or surgery
by mounting an acute phase response (APR); this is designed
to help limit tissue injury by the increased synthesis of key
defence / repair proteins by the liver. However, in certain cir-
cumstances, when dietary protein intake is limited and the
APR is prolonged or severe, an APR can exacerbate muscle
wasting by increasing the demands for certain amino acids
to support increased hepatic export protein synthesis. They
have also been shown to be predictors of adverse outcomes
in cancer patients (Stephens et al. 2008). Some acute phase
proteins also have roles in modulating immune response such
as CRP. CRP genetic variants have been increasingly studied
since the last review and some of these have been replicated
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in other studies. These represent promising targets for future
genetic studies on links with degrees of cachexia. Variants
in genes coding for APPR are shown in table 4 in electronic
supplementary material.
Central homeostasis
Energy production: The human body responds to stress with
dramatic resilience and ultimately aims to maintain home-
ostasis. The mechanisms to respond to injury can ultimately
prove detrimental to the host. For example, although the hep-
atic acute phase protein response is useful in acute injury
(e.g. haemostasis and wound healing), if the response is
prolonged and potentially futile (as in advanced cancer),
then what results is an accelerated loss of skeletal mus-
cle and excess morbidity and mortality. In certain forms of
cancer, patients with cachexia have been observed to have
much higher resting energy expenditure (REE) (Fredrix et al.
1991). Gene polymorphisms in the regulatory pathways con-
trolling energy intake and expenditure are discussed here.
The following section also explores genes involved in growth
and development, and metabolic pathways common to both
muscle and adipose tissues.
Electronic supplementary table 5 shows the genes
involved in energy production, these consist mainly the
uncoupling proteins. These are transporters present in the
mitochondrial inner membrane that mediate a regulated dis-
charge of the protein gradient that is generated by the respi-
ratory chain. This serves to regulate functions such as ther-
mogenesis, maintenance of the redox balance, or reduction
in the production of reactive oxygen species (Ledesma et al.
2002). No new functional SNPs were found in this group
during this review.
Insulin-like growth factors and related proteins: The IGF sig-
nalling pathway consists of two main ligands (IGF-1 and
IGF-2), two cell surface receptors (IGFR1 and IGFR2), and
six high affinity IGF-binding proteins (IGFBP1–6) (Jones
and Clemmons 1995). The predominant regulator of skeletal
muscle hypertrophy is through stimulation of the PI3K/AKT
pathway by insulin or IGF-1 (Bodine et al. 2001a, b; Rommel
et al. 2001; Glass 2010). Mice in which AKT is trans-
genically expressed and inducibly activated in skeletal mus-
cle demonstrate dramatic hypertrophy upon the activation
signal (Pallafacchina et al. 2002; Lai et al. 2004; Izumiya
et al. 2008), helping to prove that AKT is the pathway that
is sufficient to mediate hypertrophy downstream of IGF1
upregulation. Activation of AKT leads to an increase in the
mTOR/p70S6K pathways and a rise in protein synthesis. As
well as inducing protein synthesis, IGF1 can inhibit skeletal
muscle atrophy. In the presence of upregulated IGF1 sig-
nalling, the atrophy genes MuRF-1 and MAFbx/atrogin-1
are actively inhibited (Bodine et al. 2001a, b). A number
of new genetic variants for IGF-1 and IGF-1R have been
discovered recently and are included (table 6 in electronic
supplementary material).
Corticosteroid signalling proteins: Corticosteroids are essen-
tial steroid hormones that are secreted by the adrenal
cortex and affect multiple organ systems. Corticosteroids
are involved in a wide range of physiologic systems
such as stress response, immune response and regula-
tion of inflammation, carbohydrate metabolism and protein
catabolism. A number of new genes have been included,
the corticotropin-releasing hormone receptor 1 (CRHR1)
binds to corticotropin-releasing hormone, a potent medi-
ator of endocrine, autonomic, behavioural and immune
responses to stress. A number of polymorphisms in this gene
have been shown to effect circulating levels of CRP and
ICAM-1 (Wilker et al. 2009). The glucokinase regulatory
protein (GCKR) binds and moves glucokinase (GK);
thereby, controlling both activity and intracellular location
(Van Schaftingen 1994) of this key enzyme of glucose
metabolism (Iynedjian 2009). Genetic variants of this pro-
tein have also been linked with alterations in circulating
CRP levels (Ridker et al. 2008). The genetic variants of
the components in the mechanism of corticosteroid sig-
nalling are examined in table 7 in electronic supplementary
material.
Muscle
In healthy adults, skeletal muscle mass is maintained
within relatively narrow limits, reflecting a dynamic balance
between protein synthesis and degradation. A predominance
of either will result in muscle hypertrophy or atrophy. Even
small changes in protein synthesis or degradation will lead
to large protein deficits over time due to the continuous pro-
cess of protein turnover. In cancer cachexia, there is ongo-
ing debate as to whether a reduction in protein synthesis, an
increase in protein degradation or a combination of both is
more relevant. Although there is depletion of both adipose
tissue and lean body mass, it is skeletal muscle loss that has
the greatest impact on patients’ function and quality of life
and is clearly associated with a poor outcome (Tan et al.
2009; Fearon et al. 2011; Miller et al. 2012). Highlighted
here are genetic variations that affect the structure and func-
tion of muscle as well as those that regulate muscle synthesis
and degradation.
Muscle structure and function: IL-15 signals through IL-15
receptor alpha (IL-15RA) and is found in abundance in skele-
tal muscle. IL-15 is shown to be anabolic, marked by an
increase in myosin heavy chain accumulation (Quinn et al.
2002). ACTN3 (alpha-actinin 3) binds to actin at the Z-line
within muscle fibres and acts to anchor actin filaments. Poly-
morphisms in ACTN3, IL15 and IL15RA are shown in
table 8 in electronic supplementary material.
Recent studies have focussed on polymorphisms associ-
ated with alterations of fat free mass in the gene encoding
the vitamin D receptor (VDR). Promising new variants
encoding for this protein are also included in table 8 in
electronic supplementary material. Inhibin β C (INHBC) is
898 Journal of Genetics, Vol. 93, No. 3, December 2014
Genetic basis of cancer cachexia susceptibility variation
a newly added gene, it is part of the transforming growth
factor β pathway regulating myostatin (a negative regula-
tor of muscle mass). Polymorphisms identified in this gene
are shown in table 8 in electronic supplementary material.
Another significant new addition to the genes implicated in
cancer cachexia is thyrotropin-releasing hormone receptor
(TRHR). Thyrotropin-releasing hormone is released by the
anterior pituitary and acts on a number of tissues, includ-
ing muscle to influence metabolic rates. Genetic variants are
listed in table 8 in electronic supplementary material.
New variants in the ACE gene have also been included.
Alterations in this gene have led to differences in oxygen
carrying capacity of muscles as well as increased vaso-
constriction in blood vessels within the muscle architec-
ture (Costa et al. 2009). Acute and chronic exposure to
angiotensin II in animal models are associated with weight
loss and enhanced protein breakdown in skeletal muscle
(Brink et al. 2001). Genetic variants are listed in table 8 in
electronic supplementary material.
Muscle synthesis: The main signalling pathway for muscle
synthesis is via the IGF-1/PI3K/AKT axis. Polymorphisms
relating to these can be found in the insulin-like growth
factors and related proteins section (table 6 in electronic
supplementary material). mTOR, RUNX1, phosphoinosi-
tide 3-kinase (PIK3) and various isoforms have been impli-
cated in hypertrophy signals of muscle mass (Bonetto
et al. 2011) and have been added to the list of genes. However
very few studies have looked into how variants effect struc-
ture and function of these gene products. A number of genes
from expression arrays were also included as cis acting or
trans acting polymorphisms on the genome may be affecting
their expression. Genetic variants influencing function can be
found in table 9 in electronic supplementary material.
Muscle proteolysis: In atrophying muscles, the ubiquitin lig-
ases, MuRF1/atrogin-1 and MAFbx, are induced and this
response is necessary for rapid atrophy. FOXO isoforms
1 and 3 are known to act on MuRF1 promoter to cause
MuRF1 transcription and this leads to dramatic atrophy of
myotubes andmuscle fibres (Sandri et al. 2004; Bonetto et al.
2011). IKKα also influences the ubiquitin proteasome path-
way (UPP) pathway and a number of functional polymor-
phisms are listed in table 10 in electronic supplementary
material. Another gene encoding for tumour necrosis factor
receptor (TNFR) associated factor 6 (TRAF6) is an impor-
tant adaptor protein involved in receptor mediated activation
of various signalling pathways in response to cytokines and
bacterial products. TRAF6 also possesses E3 ubiquitin ligase
activity causing lysine-63 linked polyubiquitination of target
proteins (Paul and Kumar 2011).
A more recent factor, which has captured the attention
of many investigators, is the TGF-β family member, myo-
statin. Genetic null animals for myostatin, demonstrate dra-
matic muscle hypertrophy (Mosher et al. 2007). Myostatin
is synthesised and secreted mainly from skeletal muscle
cells. Myostatin acts firstly by signalling through the activin
type II receptor (ACTRIIB), which then recruits an Alk
family kinase, resulting in the activation of a SMAD2 and
SMAD3 transcription factor complex (Sartori et al. 2009;
Trendelenburg et al. 2009).
STAT3 has recently been shown to influence muscle wast-
ing by altering the profile of genes expressed and translated
in muscle such that amino acids liberated by increased pro-
teolysis in cachexia are synthesized into acute phase proteins
and exported into the blood (Bonetto et al. 2011).
Peroxisome proliferator activated receptor gamma
(PPARγ) and its response gene, Acyl CoA synthetase 5
(ACSL5), have an important role in fatty acid metabolism
and may affect weight loss in response to caloric restriction.
Genetic polymorphisms have demonstrated reduced ACSL5
mRNA in skeletal muscle biopsies (Adamo et al. 2007).
Polymorphisms in all these genes are presented in table 10
in electronic supplementary material.
Adipose tissue
Incidence of obesity and diabetes continues to increase
worldwide. The obese patient is generating a new chal-
lenge in medicine and treatment. Physiology of obese
patients differs remarkably from a normal weighted indi-
vidual. Recently, patients suffering from advanced cancer
have been found to be overweight rather than underweight
(Irigaray et al. 2007). This has been shown to confound
conventional measurements for risk stratification such as
body mass index (BMI). A recent study of pancreatic can-
cer patients has shown that severe muscle depletion when
combined with obesity to be an independent adverse prog-
nostic indicator in this patient group and should be con-
sidered as an alternative and more powerful means of risk
stratification (Tan et al. 2009). It is however unclear how
muscle depletion combined with overweight/obesity causes
accelerated demise. The adipokines secreted by excess adi-
pose tissue may act as systemic inflammatory mediators,
inducing insulin resistance in skeletal muscle and leading to
a further increase in muscle protein loss. Increased lipoly-
sis appears to be a key factor underlying fat loss, though
decreases in lipid deposition and adipocyte developmentmay
also contribute (Legaspi et al. 1987). The following section
examines polymorphisms in genes regulating adipose tissue
metabolism.
Adipogenesis: Peroxisome proliferator-activated receptors
(PPARs) are a group of nuclear receptor proteins that func-
tion as transcription factors regulating the expression of
genes. PPARα is known to participate in the regulation
of key proteins involved in extracellular lipid metabolism,
fatty acid oxidation and inflammation (Torra et al. 2001).
PPARγ is an important regulator of fat cell function and
involved in differentiation of new adipocytes and by induc-
ing expression of genes promoting uptake of fatty acids,
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triglyceride synthesis and insulin sensitivity (Lehrke and
Lazar 2005). Lipin proteins (lipin-1, lipin-2 and lipin-3) also
act as transcriptional coactivators that regulate expression
of lipid metabolism genes (Reue 2009). Polymorphisms in
these genes are shown in table 11 in electronic supplementary
material.
Lipid turnover and transport: Lipid metabolism protein
apolipoprotein C-III (apoC-III) inhibits triglyceride hydroly-
sis. Genetic variants have been shown to have lower fasting
and postprandial serum triglycerides, higher levels of HDL-
cholesterol and lower levels of LDL-cholesterol (Pollin et al.
2008). A genetic link between lipid metabolism and inflam-
mation has been suggested by the association between vari-
ation in the APOE gene and plasma CRP. A variant in the
LRRFIP1 gene, which has been implicated in TNFa expres-
sion has been shown to be associated with adiposity and
inflammation (Plourde et al. 2012).
A recent experiment in tumour bearing mice demonstrated
during the early and intermediate phases of tumour growth
and cachexia, food intake remained normal while plasma
levels of proinflammatory cytokines and zinc-α2-
glycoprotein rose. The investigators found that genetic
ablation of adipose triglyceride lipase (ATGL) prevented
an increase in lipolysis and the net mobilization of adipose
tissue associated with tumour growth. Unexpectedly, they
also observed that skeletal muscle mass was preserved and
that activation of proteasomal degradation and apoptotic
pathways in muscle was averted. Ablation of hormone sen-
sitive lipase (HSL) had similar but weaker effects. Genetic
variants in both these new genes were explored and are listed
in table 12 in electronic supplementary material.
Zinc-α-2-glycoprotein (ZAG), otherwise known as LMF,
is involved in the specific mobilization of adipose tissue,
with increased oxidation of released fatty acids, possibly
via induction of uncoupling protein (UCP) expression (Bing
et al. 2002). ZAG isolated from the MAC16 murine tumour,
or from the urine of patents with cancer cachexia, stimulates
lipolysis directly through interaction with adenylate cyclase
in a guanosine triphosphate (GTP)-dependent process (Bing
et al. 2004; Bao et al. 2005). A polymorphism associated
with change of function is shown in table 12 in electronic
supplementary material.
Adipokines and adipokine receptors: Adipose tissue, similar to
skeletal muscle is an active metabolic and endocrine organ.
A number of inflammatory cytokines secreted by adipose tis-
sue have been shown with varying effect to influence the
development of diseases such as insulin resistance, diabetes
and cancer cachexia by acting on muscle and fat metabolism
(Fantuzzi and Faggioni 2000). These adipokines act locally
in an autocrine/paracrine manner and/or as endocrine sig-
nals to regulate appetite, energy expenditure and a range
of physiological processes including insulin sensitivity and
inflammatory response which may play an important role
in the pathogenesis of cancer cachexia (Kerem et al. 2008).
Resistin is an adipokine which appears to have effects on
substrate metabolism through impairment of insulin action
and insulin independent pathways (McTernan et al. 2006).
Polymorphisms within the RETN gene which codes for
resistin that may influence the development of cachexia
(table 13 in electronic supplementary material).
Adiponectin is secreted from adipose tissue and binds
to a number of receptors including adiponectin receptors
1 and 2. Adiponectin is produced by the adipocyte and
has been shown to decrease insulin resistance. Unlike
other adipokines associated with chronic inflammation,
adiponectin is inversely related to insulin resistance and
BMI. It appears to have protective metabolic and antiinflam-
matory properties (Marcell et al. 2005).
The adipokine, leptin plays a key role in regulating
energy intake and energy expenditure, including appetite
and metabolism. Leptin acts through the leptin receptor.
Polymorphisms in genes coding for adiponectin, leptin and
their respective receptors are given in table 13 in electronic
supplementary material.
Appetite
Muscle mass is clearly sensitive to food intake. The patho-
genesis of cancer anorexia is multifactorial and reflects the
complexity of the mechanisms controlling energy home-
ostasis under physiological conditions. The main molec-
ular mechanisms regulating the cancer anorexia–cachexia
syndrome include alterations in brain neurochemistry. In par-
ticular, the hypothalamic melanocortin system appears not
to respond appropriately to peripheral inputs, and its activ-
ity is diverted largely towards the promotion of catabolic
stimuli promoting metabolism of carbohydrates, lipids,
and proteins in peripheral tissues leading to insulin resis-
tance, increased lipolysis and accelerated muscle proteolysis
(Tisdale 2002). Ghrelin is produced by the P/D1 cells of
the stomach and acts as the natural counterpart to leptin.
Ghrelin exerts its effects by promoting food intake (via the
orexigenic neuropeptide Y(NPY) system) (Toshinai et al.
2003) and decreases sympathetic nerve activity (Matsumura
et al. 2002). The melanocortin receptors, a family of G-
protein coupled receptors, bind α-melanocyte stimulating
hormone (α-MSH). Melanocortin 3 and 4 receptors have
been found to be involved in feeding behaviour and regula-
tion of metabolism (Fan et al. 1997).
NPY acts as a neurotransmitter in the brain and in the auto-
nomic nervous system. An increase in NPY signalling
leads to increased food intake (Hanson and Dallman 1995).
Genetic variants have been added to this new gene and are
listed in table 14 in electronic supplementary material.
Others
Metallothionein (MT) is a family of cysteine-rich, low
molecular weight proteins. MTs have the capacity to bind
both physiological (such as zinc, copper and selenium) and
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xenobiotic (such as cadmium, mercury, silver and arsenic)
heavy metals through the thiol group of its cysteine residues,
which represents nearly 30% of its amino acidic residues.
Zinc homeostasis is often disrupted in cancer cachexia. It has
been proposed that the acute phase response can mediate zinc
redistribution and accumulation in skeletal muscle tissue and
contribute to the activity of the UPP that regulates protein
catabolism (Siren and Siren 2010).
P2Y-receptors belong to the superfamily of G-protein
coupled receptors and mediate the actions of extracellular
nucleotides in cell to cell signalling. The P2Y11 receptor is
highly expressed in immunocytes and may play a role in the
differentiation of these cells (von Kugelgen 2006). Genetic
variants encoding the proteins discussed above may play a
role in the development of cachexia and are listed in table 15
in electronic supplementary material.
A number of new genes and SNPs are listed in table 15 in
electronic supplementary material, these have evolved from
a recent candidate gene approach study identifying SNPs in
cancer cachexia. Target SNPs identified from the previous
review which could not be genotyped in a cancer popula-
tion due to experimental design were substituted for the near-
est SNP with a linkage disequilibrium of >0.9. These SNPs
have been added to the current review as they have been
genotyped in patients with cancer cachexia.
Analysis of results
Clinical significance
Clinical significance is defined as any SNP affecting more
than one of the recognized hallmarks of cancer cachexia.
Inflammation has been shown to influence the severity of
cancer cachexia and was therefore identified as a clinical
feature. Changes in body composition of muscle and/or fat
mass form the basis of cancer cachexia; therefore, SNPs that
have the potential to alter an individual’s body composi-
tion, whether to increase or decrease these components will
play a significant clinical role in the development of can-
cer cachexia or not. Lastly, any SNPs influencing overall
survival were included in a definition of clinical significance.
Out of 281 candidate polymorphisms that were identified
and summarized here, the functional or clinical significance
of 80 polymorphisms have been verified in more than one
study. Of these 80 polymorphisms, 24 have been shown to
have more than one effect on clinical features associated
with cancer cachexia (i.e. inflammation, changes in lean
and/or fat mass, and overall survival), these are termed
promising SNPs. An indepth analysis of the 24 promising
SNPs as biomarkers for susceptibility of cancer cachexia
(table 2) is presented below.
(i, ii) The G allele of TLR-1 (−7202A/G) (rs5743551)
is associated with elevated TLR1-mediated cytokine pro-
duction (Wurfel et al. 2008; Pino-Yanes et al. 2010).
TLR1 (−7202G) marks a coding SNP that causes higher
TLR1-induced NF-kB activation and higher cell surface
TLR1 expression (Wurfel et al. 2008). Toll-like receptor
(TLR) pathways are critical components of the immune
response to pathogens and disease (Trinchieri and Sher
2007). This particular polymorphism has been shown to
lead to decreased survival in patients with sepsis (Wurfel
et al. 2008) and NSCLC (Dai et al. 2012). In addition to
this SNP in TLR-1, patients carrying the mutant allele T of
TLR4 1196C/T (Thr399Ile, rs4986791) had lower TNF-α
and sTNFR2 levels compared to patients carrying wild-type
alleles (Jermendy et al. 2010). These patients carrying the
mutant phenotype have also been shown to have increased
total body fat, visceral fat, liver fat and decreased insulin
sensitivity (Weyrich et al. 2010).
(iii) Steps in the inflammatory process include accumula-
tion of lipids, recruitment of leucocytes and smooth muscle
cells into vessel walls, and accumulation of extracellular
matrix. Intercellular adhesion molecule-1 (ICAM-1) is
integral in these cellular processes as interactions between
ICAM-1 and activated receptors on the leucocytes result
in firm adhesion and transmigration of leucocytes into the
basement membrane of the vasculature. The T allele of
rs5491 encodes a lysine to methionine substitution in exon 2
in the N-terminal domain of ICAM-1 and results in a pro-
tein that is unable to bind to fibrinogen and has a decreased
affinity for T cells at lower ICAM-1 concentrations com-
pared to wild-type ICAM-1 (Craig et al. 2000). This lead
to increased circulating levels of sICAM-1 and an associ-
ation with insulin resistance and the metabolic syndrome
(Hsu et al. 2010).
(iv) The C allele of the A37674C SELP polymorphism
(rs6136) is associated with decreased serum P selectin levels
(Miller et al. 2004; Volcik et al. 2006). P selectin is required
for efficient recruitment of neutrophils in acute inflamma-
tion and of macrophages in later stages of the inflammatory
response and serum levels of P selectin have been found
to be significant prognostic factors in survival in patients
with gastric and colorectal malignancies (Alexiou et al. 2001,
2003). Patients with cancer who carry the C allele of the
rs6136 polymorphism in SELP gene are at reduced risk
of developing cachexia as defined by weight loss >10%
(Tan et al. 2012).
(v–vii) TNF-α is a cytokine involved in systemic inflam-
mation and is a member of a group of cytokines that stimu-
late the acute phase reaction. The –308A allele (rs1800629)
has been associated with an increased TNF-α production
as well as a six-fold increase in transcription of the TNF
gene (Wilson et al. 1997; Sallakci et al. 2005). Women
carrying the A/A genotype have been linked to increased
fat accumulation (Hoffstedt et al. 2000). The −863A allele
(rs1800630) associated with decreased transcriptional activ-
ity and reduced serum TNF-α levels (Day et al. 1998;
Skoog et al. 1999; Kaluza et al. 2000; Sharma et al. 2006).
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Obese people express 2.5-fold more TNF mRNA in fat
tissue (Hotamisligil 1999). The −238A allele of the SNP
rs361525 has shown decreased transcriptional activity of
TNFα (Kaluza et al. 2000), as well as decreased peripheral
mononuclear blood cells (PMBC) production of TNF-α after
stimulation with T-cell mitogens (Kaluza et al. 2000). It has
also been shown to decrease insulin resistance (Day et al.
1998).
(viii) LTA is part of the tumour necrosis factor family, it
is produced by lymphocytes, and mediates inflammatory
responses, stimulation of immune system, and apoptosis
(Aggarwal et al. 1985). The G allele of the 252 A>G poly-
morphism (rs909253) has been associated with increased
serum TNF-α levels (Stuber et al. 1996; McArthur et al.
2002), and patients who are A/A homozygotes have been
linked with better prognosis in lung cancer and gastric
cancer (Shimura et al. 1994, 1995).
(ix–xi) IL-1β is a product of the IL1B gene and plays a
role in potentiating an inflammatory response. The −31
C>T (rs1143627) and −511 C>T (rs16944) polymorphisms
in the promoter region of the IL1B gene have been linked
with increased transcriptional activity of the IL1B gene and
subsequently increased IL-1β production (Wen et al. 2006).
These two alleles are also linked with poorer progression
free survival and overall survival in advanced gastric cancer
(Graziano et al. 2005). A synonymous C to T polymorphism
at nucleotide position 3953 (rs1143634) has resulted in
Increased IL-1β levels (Hernandez-Guerrero et al. 2003).
The T/T genotype has also been associated with lower
plasma levels of IL-1 receptor antagonist (IL-1RA) (Tolusso
et al. 2006). In addition, the T allele has found to be a major
risk factor for cachexia in gastric cancer (Zhang et al. 2007),
as well as being linked to lower total fat mass (Strandberg
et al. 2006). The T/T genotype was found to be associated
with shorter survival in pancreatic cancer (Barber et al.
2000). All of which lead these three polymorphisms to be of
particular interest in potential candidates for cancer cachexia.
(xii) IL-6 is a well characterized cytokine involved in a
number of cellular functions. IL-6 mediates B cell differen-
tiation and maturation, immunoglobulin secretion, cytotoxic
T cell differentiation and acute-phase protein production
(Kishimoto 2005). The −174 G>C promoter polymorphism
(rs1800795) in the IL6 gene has been associated with lower
serum levels of IL-6 (Fishman et al. 1998). The G allele has
been linked to higher fasting insulin and lower adiponectin
levels which may have a role in the regulation of adiposity
(Yang et al. 2005). In addition, the C/C genotype has been
associated with lower fat free mass and increased waist
circumference (Roth et al. 2003; Berthier et al. 2005).
(xiii) IL-18 is produced by macrophages and functions by
binding to the interleukin 18 receptor inducing cell medi-
ated immunity following infection. After stimulation with
Journal of Genetics, Vol. 93, No. 3, December 2014 905
N. Johns et al.
IL-18, natural killer (NK) cells and certain T cells release
interferon-γ (IFN-γ) that plays an important role in acti-
vating the macrophages. Apart from its physiological role,
IL-18 is also able to induce severe inflammatory reactions.
Individuals with the allele 105AA (rs549908) demonstrated
increased IL-18 production from LPS and A23187 + PMA
stimulated monocytes (Arimitsu et al. 2006). Haplotype
of common alleles have been shown to be associated with
significantly lower IL-18 (Thompson et al. 2007).
(xiv) IGF-1 is one of the most potent natural activators
of the AKT signalling pathway which is the main stimula-
tor of cell growth and multiplication. IGF-1 also mediates
many of the growth-promoting effects of growth hormone
(GH) (Jones and Clemmons 1995). The genotype CC of
rs7136446 associated with higher body fat and increased
maximal force production (Huuskonen et al. 2011), it has
also been shown to be significantly associated with elevated
levels of circulating IGF-I (Verheus et al. 2008).
(xv) The glucocorticoid receptor (GR, or GCR) also
known as NR3C1 (nuclear receptor subfamily 3, group
C, member 1) is the receptor to which cortisol and
other glucocorticoids bind. In the absence of gluco-
corticoids, GR resides in the cytosol complexed with
a variety of proteins including heat shock protein 90
(hsp90), heat shock protein 70 (hsp70) and the pro-
tein FKBP52 (FK506-binding protein 52) (Pratt et al. 2006).
The endogenous glucocorticoid hormone cortisol diffuses
through the cell membrane into the cytoplasm and binds to
the GR resulting in release of heat shock proteins. Activated
GR can bind to the transcription factor NF-κB and prevent it
from upregulating target genes (Ray and Prefontaine 1994).
The mutant allele of the N363S (rs6195) SNP enhances
glucocorticoid sensitivity by increasing gene transcription
(Russcher et al. 2005). Indeed, in various studies, a link was
established between the N363S SNP and characteristics of a
cushingoid phenotype, including increased BMI and waist
circumference, dyslipidaemia and augmented fasting insulin
levels, indicating reduced insulin sensitivity (Roussel et al.
2003; Manenschijn et al. 2009).
(xvi) The glucokinase regulatory protein (GKRP) also
known as glucokinase (hexokinase 4) regulator (GCKR) is
a protein produced in hepatocytes. GKRP binds glucoki-
nase (GK), thereby controlling both activity and intracellular
location of this key enzyme of glucose metabolism (Van
Schaftingen 1994; de la Iglesia et al. 1999). The glucose
increasing major C allele of rs780094 of GCKR has been
shown to be significantly associated with increased insulin
resistance leading to development of T2DM and altered lipid
metabolism (Stancakova et al. 2012; Li et al. 2013).
(xvii) CNTF is involved in the neuroendocrine sig-
nalling of appetite. It leads to marked weight loss through
suppressed food intake without causing hunger or stress
(Lambert et al. 2001). CNTF receptor-α is abundantly
expressed in skeletal muscle (Ip et al. 1993; Fraysse
et al. 2000). As such, recent studies have examined
the roles of CNTF and CNTF genotype on neuromuscular
disease and muscle function. CNTF administration has been
shown to prevent losses of soleus muscle mass and function
after hindlimb suspension in rats (Fraysse et al. 2000). In
humans, the A allele mutation of rs1800169 possesses sig-
nificantly greater muscular strength and muscle quality at
relatively fast contraction speed than the ancestral G allele
individual (Roth et al. 2001). This polymorphism has also
been associated with a global weight gain in healthy humans
(Heidema et al. 2010).
(xviii) Uptake of FFA by skeletal muscle for metabolism
is initiated by transmembrane acyl-CoA synthetase long-
chain (ACSL) proteins that esterify FFAs to acyl-coenzyme
A (acyl-CoA) molecules. Acyl-CoA species are used mainly
in both the synthesis of cellular lipids and the degradation of
fatty acids via β-oxidation. Small increases in the expression
of ACSL5 in skeletal muscle could have profound effects
on FFA utilization (Teng et al. 2009). A strong association
between the common SNP rs2419621 and rapid weight
loss in obese Caucasian females in response to restricted
diet has been demonstrated (Adamo et al. 2007). The SNP
located 12 nucleotides upstream of the second transcription
start site of the ACSL5 gene is characterized by a cyto-
sine (rs2419621) to thymine (rs2419621) transition. This
study also demonstrated that the T allele is associated with
a 2.2-fold increase of ACSL5 transcript level in skeletal
muscle biopsies when compared to noncarriers (Adamo
et al. 2007). In a further study T allele variants were shown to
create a functional cis-regulatory E-box element (CANNTG)
that is recognized by the myogenic regulatory factor MyoD.
The T allele promotedMyoD-dependent activation of a 1089
base pair ACSL5 promoter fragment in nonmuscle CV1 cells.
Differentiation of skeletal myoblasts significantly elevated
expression of the ACSL5 promoter. The T allele variants sus-
tained promoter activity 48 h after differentiation, whereas
the C allele variants showed a significant decline. These
results revealed a mechanism for elevated transcription of
ACSL5 in skeletal muscle of carriers of the rs2419621 (T)
allele, associated with more rapid diet-induced weight loss.
This is the first example of a MyoD-binding polymorphism
conferring differential promoter activity of a metabolic gene
(Teng et al. 2009).
(xix) Lipoprotein lipase (LPL) plays a central role in
the overall lipid metabolism and transport (Mead et al.
2002). The rs328 polymorphism in the LPL gene leads
to a premature stop codon at amino acid 447. The stop
codon results in lower LPL activity (Kozaki et al. 1993;
Groenemeijer et al. 1997), and is associated with lower
levels of IL-8 (Ak et al. 2007). Individuals not in posses-
sion of the stop codon are associated with central obesity
(Huang et al. 2006).
906 Journal of Genetics, Vol. 93, No. 3, December 2014
Genetic basis of cancer cachexia susceptibility variation
(xx) Zinc-α-2-glycoprotein (ZAG), otherwise known as
LMF, is involved in the specific mobilization of adipose
tissue, with increased oxidation of released fatty acids, pos-
sibly via induction of uncoupling protein (UCP) expression
(Bing et al. 2002). LMF isolated from the MAC16 murine
tumour, or from the urine of patents with cancer cachexia,
stimulated lipolysis directly through interaction with adeny-
late cyclase in a guanosine triphosphate (GTP) dependent
process (Bing et al. 2004; Bao et al. 2005). This effect
was also produced by the interaction of LMF with the β3-
adrenoceptor (Russell et al. 2002). Genotypes of rs4215 in
ZAG gene have been suggested to be significantly associ-
ated with obesity. The GG genotype subjects in rs4215 site
have an increased susceptibility to obesity when compared
with the AA+AG genotype subjects (Zhu et al. 2012). In a
separate study variations in the rs4215 genotype have been
linked with changes in circulating levels of total cholesterol
and LDL-C.
(xxi) The adipokine resistin potentiates a proinflamma-
tory state, resistin also appears to have effects on substrate
metabolism through impairment of insulin action and insulin
independent pathways (McTernan et al. 2006). The –420
C>G polymorphism (rs1862513) is shown to be linked to
increased plasma resistin (Cho et al. 2004; Osawa et al.
2007), and individuals with the G/G genotype are asso-
ciated with an increased prevalence of obesity (Norata
et al. 2007). Overall, increased plasma resistin has shown
to correlate with increased CRP and insulin resistance
(Degawa-Yamauchi et al. 2003; Silswal et al. 2005; Nagaev
et al. 2006; Kusminski et al. 2007; Osawa et al. 2007).
(xxii, xxiii) Adiponectin is a protein hormone that
is exclusively secreted from adipose tissue and modu-
lates a number of metabolic processes, including glucose
regulation and fatty acid catabolism (Diez and Iglesias
2003). The ADIPOQ gene, which codes adiponectin, has
a 45 T>G polymorphism (rs2241766) that is associated
with increased plasma adiponectin (Berthier et al. 2005;
Mackevics et al. 2006). Individuals with G/G genotype
have been observed to be leaner with less abdominal fat
(Loos et al. 2007). The adiponectin receptors ADIPOR2,
serves as a receptor for adiponectin and mediates
increased AMPK and PPAR-α ligand activities, as well
as fatty acid oxidation and glucose uptake by adiponectin
(Yamauchi et al. 2003). In peripheral monocytes, carriers
of the major A allele (homozygotes and heterozygotes) of
rs767870 polymorphism had higher levels of ADIPOR2
protein expression compared to homozygotes of the minor
G allele (Halvatsiotis et al. 2010). This same SNP has also
been associated with liver fat content and the incidence
of type II DM (Vaxillaire et al. 2006; Kotronen et al. 2009).
(Inui 1999). The orexigenic neuropeptide Y (NPY) peptide
system appears to be strongly influential in the control of
feeding (Plata-Salaman 2000). The pathway originates in
the hypothalamic arcuate nucleus (ARC) and extends pro-
jections widely over the brain (Plata-Salaman 2000). The
role of cytokines in cancer anorexia may be affected through
influence on the NPY system. The genetic variant rs16139
causing, leucine7 to proline7 in the signal peptide of pre-
proNPY has been associated with increased risk factor for
many cardiovascular diseases such as accelerated atheroscle-
rosis (Niskanen et al. 2000). Further, elevated serum lipid
levels have been associated with the P7 allele in certain pop-
ulations (Karvonen et al. 2001). Additionally, the L7P poly-
morphism has been shown to increase the risk of type II
diabetes as well as earlier onset of the disease and vascular
complications (Jaakkola et al. 2006).
Pathway analysis
The 80 polymorphisms which have been verified in more
than one study were found across 51 genes. These genes
were entered into the IPA algorithm as focus genes and
were found to be significantly interconnected in two major
networks (table 3). The two networks are presented in
figures 1 and 2.
Putative functions
Since gene association studies often identify surrogates for
putative causal SNPs, it is imperative that data from selected
SNPs be subjected to further analysis using prediction tools
to shortlist candidates for finer analysis before causality
could be established. Unless causative SNPs/genes are iden-
tified, development of targeted therapeutics are difficult to
achieve. Of the 42 nonsynonymous polymorphisms entered
into the SIFT algorithm (table 16 in electronic supplemen-
tary material) seven SNPs had a significant score (P < 0.05)
causing an intolerant change of amino acid. Since SIFT
programme only evaluates nonsynonymous SNPs, and the
majority of polymorphisms lie within the regulatory regions
at 3′, 5′ ends and in introns, we interrogated the SNPs
selected using the SCAN database for insights into the
potential contribution of selected SNPs on gene regulatory
functions (cis effects or trans effects, eQTLs) (Hunter
and Crawford 2008; Schadt et al. 2008; Fehrmann et al.
2011; Hao et al. 2012; He et al. 2013). We identified 132
SNPs as potential eQTLs in HapMap study populations
(Caucasian, Yoruban, Han Chinese/Japanese) (table 17 in
electronic supplementarymaterial). Analysis of selected can-
didate SNPs for potential eQTLs revealed several target
genes that are regulated both in cis and trans, as expected.
Fine regulation in complex biological networks by a SNP
may be direct or indirect, and likely influence gene expres-
sion through short or long range interactions. Prediction for
regulation of expression was limited to those showing high
statistical significance (P value< 10−4) and to any one of
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(xxiv) Proinflammatory cytokines (TNFα and IL-1β) and
hypothalamic serotonergic neurons have been implicated in
the dysfunction of the hypothalamic melanocortin system























































































































































































































































































































































































































































































































































































































































the HapMap populations. Promising candidates from SCAN
database should be further validated by independent meth-
ods (RT-PCR) to confirm for direction and magnitude of
expression changes in a tissue-specific manner. In addition
to pathway-based-candidate SNP approaches for cachexia,
genomewide association studies (GWAS) have the poten-
tial to identify promising variants for further interrogation of
the genome for genetic predisposition. International efforts
are underway from our group to conduct large scale asso-
ciation studies using well defined phenotypes of cachexia
and higher sample size to achieve the needed statistical
power.
Discussion
Even with the same tumour type and burden, one indi-
vidual may become cachectic, whereas another will not,
such variation may relate to host genotype. Genetic vari-
ation in immunity and associated signalling pathways
is known to relate to outcomes in major sepsis (Thair
et al. 2011), and recent findings suggest a similar pat-
tern in cancer cachexia (Tan et al. 2012). SNP in the
IL-1, IL-6, and IL-10 genes that are linked to production
rates of these cytokines have been associated with the preva-
lence of cachexia in gastric or pancreatic cancer (Tan and
Fearon 2010). For example, the 1082G allele in the IL-10
promoter has been validated as a procachectic genotype in an
independent cohort (Deans et al. 2009; Sun et al. 2010a, b).
IL-10 has been shown to be elevated in a Myc/mTOR
driven murine model of cancer cachexia (Robert et al. 2012),
as well as in cachectic patients with colorectal cancer
(Shibata et al. 1996). Others have identified associations
with cachexia defined as >10% weight loss and polymor-
phisms in cytokine genes such as the IL1-B 3954C/T poly-
morphism (rs1143634) in patients with gastric cancer (Zhang
et al. 2007). Cancer-related anorexia has been associated
with the TNF-308G/Apolymorphism (rs1800629) in patients
with non-small cell lung cancer (Jatoi et al. 2010). Most
recently, the C allele of the rs6136 polymorphism in the p-
selectin gene has recently been associated with weight loss
in a large heterogenous group of cancer patients and val-
idated in an independent cohort (Tan et al. 2012). Taken
together, these findings are consistent with a key role for
the immune system in the variable presentation of cachexia.
However, cancer cachexia has been defined in a number
of ways (Bozzetti and Mariani 2009; Argiles et al. 2010;
Muscaritoli et al. 2010; Argiles et al. 2011; Baracos 2011),
mainly focussed on weight loss and the presence of systemic
inflammation. This has led to phenotyping in many of the
existing studies on genetic association relying wholly on a
degree of weight loss and inflammation. However, one recent
definition described cancer cachexia with a more musculo-
centric view (Fearon et al. 2011). This definition highlights
the importance of skeletal muscle loss as one of the most
significant events in cachexia and is associated with a poor
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Figure 1. Connection map for first ranked network. Genes with variants that had functional or clinical associations replicated in at least
one study were entered into the ingenuity pathway analysis software for an unsupervized functional analysis to discern regulatory networks
that involved these molecules. Focus genes are shaded in grey. Solid lines show direct interaction (binding/physical contact); dashed lines
show indirect interaction that is supported by the literature but possibly involving ≥1 intermediate molecules that have not been investigated
definitively. Molecular interactions that involved only binding are connected with a line without an arrowhead because directionality cannot
be inferred.
outcome (Tan et al. 2009; Fearon et al. 2011). In genetic
studies of common diseases, the capacity to define genotypes
is often far better than the capacity to define phenotypes;
therefore, more robust classifications of phenotypes need to
be sought. With the existing studies focussing mainly on
weight loss and CRP to define cancer cachexia phenotypes
this may have led to the discovery of associated SNPs exclu-
sively involved in mediating the immune response. Recent
advances in the use of routine CT scans in a cancer patient’s
care have led to unmasking of detailed body composition
analysis for accurate measurements of skeletal muscle and
adipose tissue mass (Prado et al. 2009). Taking into account,
a level of skeletal muscle mass alongside degrees of weight
loss and inflammation will improve accuracy of phenotyping
and may open up the analysis to include genetic variants in
muscle specific genes.
While some genetic variants can predisopose individuals
to develop cancer cachexia, also there will be variants which
may protect against the devlopment of the condition. In
multigene studies, judicious selection of candidate genes and
polymorphismswithin them is a key element of study design.
It is always important to choose genes products which
interact within regulatory or metabolic pathways. In most
cases, it is not realistic to analyse all possible gene variants
and combinations; hence, existing polymorphisms should be
initially prioritized on the basis of their likelihood to affect
function of the encoded product (Tabor et al. 2002). Pub-
lished studies linking genetic variation to cancer cachexia
are listed in table 1, the definitions of the cancer cachexia
phenotype vary greatly from weight loss cut-offs and inclu-
sion of systemic inflammation, to performance status assess-
ment and quality of life scores. The only study to directly
state and include an independent validation cohort to con-
firm the presence of a significant SNP is the detection of
the p-selectin genotype from our group (Tan et al. 2012).
In the discovery cohort, a further 20 significant SNPs were
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Figure 2. Connection map for second ranked network. Genes with variants that had functional or clinical associations replicated in at
least one study were entered into the ingenuity pathway analysis software for an unsupervized functional analysis to discern regulatory
networks that involved these molecules. Focus genes are shaded in grey. Solid lines show direct interaction (binding/physical contact);
dashed lines show indirect interaction that is supported by the literature but possibly involving ≥1 intermediate molecules that have not
been investigated definitively. Molecular interactions that involved only binding are connected with a line without an arrowhead because
directionality cannot be inferred.
found; however, these did not reach significance in the vali-
dation cohort. These SNPs may be significant, but due to the
size of the independent validation cohort, they failed to reach
significance.
In the current review, functional polymorphisms in genes
with a possible role in cachexia have been recorded as
well as polymorphisms with clinical consequences related
to cachexia such as inflammation, weight/body composition
changes and cancer survival. Since cancer cachexia is a mul-
tifactorial disease involving a variety of biological pathways,
it can be assumed that analysis of combinations of gene vari-
ants encoding interacting factors within a biological chain or
cascade, rather than isolated investigation of its single com-
ponents, may have more chances to reveal real causative con-
nections between gene polymorphisms and phenotypes. Of
the 80 polymorphisms with a potential role in the develop-
ment of cachexia that have been independently verified in at
least one repeat study, 24 polymorphisms have been shown
to have more than one effect on clinical features associated
with cancer cachexia. These 24 polymorphisms are likely
to be the most promising candidates in terms of suscepti-
bility biomarkers of cancer cachexia and should be further
investigated.
Eighty-eight newly identified genes with a role in cancer
cachexia were included since the last review. However, the
main limitation to identifying new SNPs in these genes was
the lack of studies to date into functional polymorphisms
within them. Undertaking a GWAS would be one way to
overcome this potential limitation and in the future would
be preferable to repeating candidate gene selection studies,
however without an adequate sample size and highly accu-
rate phenotyping, coupled with lack of government funding
to complete the project, candidate gene association studies
will continue to provide novel insights into the genetics of
cancer cachexia.
In conclusion, the current review has expanded on an ini-
tial framework to further enhance the possibility of identify-
ing functional polymorphisms involved in cancer cachexia.
Based on the expansion of the definition of cancer cachexia
along with an inclusion of skeletal muscle mass and not just
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weight loss and systemic inflammation, new muscle specific
SNPs may provide novel biomarkers in the early detection of
individuals at risk of developing cancer cachexia.
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Abstract
Background: Cachexia affects the majority of patients with advanced cancer and is associated with a reduction in treatment
tolerance, response to therapy, and duration of survival. One impediment towards the effective treatment of cachexia is a
validated classification system.
Methods: 41 patients with resectable upper gastrointestinal (GI) or pancreatic cancer underwent characterisation for
cachexia based on weight-loss (WL) and/or low muscularity (LM). Four diagnostic criteria were used .5%WL, .10%WL, LM,
and LM+.2%WL. All patients underwent biopsy of the rectus muscle. Analysis included immunohistochemistry for fibre size
and type, protein and nucleic acid concentration, Western blots for markers of autophagy, SMAD signalling, and
inflammation.
Findings: Compared with non-cachectic cancer patients, patients with LM or LM+.2%WL, mean muscle fibre diameter was
reduced by about 25% (p = 0.02 and p = 0.001 respectively). No significant difference in fibre diameter was observed if
patients had WL alone. Regardless of classification, there was no difference in fibre number or proportion of fibre type
across all myosin heavy chain isoforms. Mean muscle protein content was reduced and the ratio of RNA/DNA decreased in
patients with either .5%WL or LM+.2%WL. Compared with non-cachectic patients, SMAD3 protein levels were increased
in patients with .5%WL (p = 0.022) and with .10%WL, beclin (p = 0.05) and ATG5 (p = 0.01) protein levels were increased.
There were no differences in phospho-NFkB or phospho-STAT3 levels across any of the groups.
Conclusion: Muscle fibre size, biochemical composition and pathway phenotype can vary according to whether the
diagnostic criteria for cachexia are based on weight loss alone, a measure of low muscularity alone or a combination of the
two. For intervention trials where the primary end-point is a change in muscle mass or function, use of combined diagnostic
criteria may allow identification of a more homogeneous patient cohort, reduce the sample size required and enhance the
time scale within which trials can be conducted.
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Introduction
Cancer cachexia has been defined recently as a multifactorial
syndrome characterised by an ongoing loss of skeletal muscle mass
(with or without loss of fat mass) that cannot be fully reversed by
conventional nutritional support and leads to progressive func-
tional impairment [1]. Cachexia affects the majority of patients
with advanced cancer and is associated with a reduction in
treatment tolerance, response to therapy, quality of life and
duration of survival. Skeletal muscle loss appears to be the most
significant event in cancer cachexia and is associated with a poor
outcome [1,2]. The international consensus on the classification of
cancer cachexia suggested that diagnostic criteria should take into
account not only that weight loss is a signal event of the cachectic
process but that the initial reserve of the patient should also be
considered (either low BMI or low level of muscularity). Although
the latter concept has some validation in terms of clinical risk [2],
there has been no evaluation of the biological correlates in terms of
changes within skeletal muscle itself.
Human skeletal muscle is composed of muscle fibres that are
classified depending on their speed of contraction and predom-
inant type of energy metabolism. Muscle fibres can be classified as
type I (slow-twitch) and type II (fast-twitch) fibres based on their
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predominant myosin heavy chain (MyHC) isoform content.
Generally, type I and type IIa fibres utilise oxidative phosphor-
ylation, whereas type IIx and IIb fibres harness primarily
anaerobic metabolism to generate ATP. Both the percentage
and structural morphology of the fibre type will determine the
phenotypic capacity and functional performance of any given
muscle. Environmental factors in both health and disease have a
direct impact leading to changes in fibre type/morphology and
consequent functionality; such processes include aging, exercise,
chronic disease, and cachexia [3–7]. The change, preservation or
loss of fibres may influence clinical symptoms and there is some
evidence that all types of MyHC is targeted selectively in cancer
cachexia [8]. Ongoing loss of protein in muscle tissue may lead to
muscle fibre shrinkage and a reduction in cross-sectional area
(CSA). Equally, loss of muscle fibre CSA may lead to loss of
aerobic capacity (VO2 max) in healthy subjects as well as cancer
patients [5,9].
Although systemic inflammation is generally thought to be an
important upstream mediator of cancer cachexia [10], the precise
molecular mechanisms that mediate the changes in protein
synthesis and degradation that ultimately lead to atrophy of
muscle fibres in cancer cachexia in humans are not known. For
each animal model that has been studied, different pathways have
been implicated. From such animal models there is a predominant
impression that increased degradation via activation of the
ubiquitin proteasome pathway (UPP) is important [10]. In
contrast, human data is very limited. Activation of protein
degradation via the UPP has not been a consistent finding [11]
[12]. This has led to suggestions that autophagy may be important
or that pathways that may influence both synthesis and
degradation may be important (e.g. TGF-b/SMAD signalling)
[13].
In the present study we chose to evaluate the relationship
between the different cachexia definitions, systemic inflammation
(serum C-reactive protein) and potential inflammatory signalling
pathways within muscle (phospho-STAT3 and phospho-NFkB).
We also examined for potential associations between the various
cachexia definitions and activation of autophagy pathways or
TGF-b/SMAD signalling.
The aim of this study was to investigate the changes in muscle
fibre biology with regards to morphological structure and
composition, to study alteration in various pathways that may
account for altered fibre size and relate these changes to the
different diagnostic criteria that have been proposed as part of the
recent international consensus on the classification of cancer
cachexia [1].
Materials and Methods
Patient Recruitment, Identification, Consent and Ethics
Patients with resectable disease and suitable for the study were
identified via the upper gastrointestinal cancer multi-disciplinary
team (MDT) meetings at the Royal Infirmary, Edinburgh, UK.
Written consent was given prior to entry into the study. All
procedures were approved by the NHS Lothian local research
ethics committee. The study conformed to the standards set by the
Declaration of Helsinki.
Calculation of Weight Loss
Pre-morbid weight was recalled by the patient and verified
where possible from the medical notes. Although there may be
recall bias, evidence to support the reliability of self-reported
weight and weight history [14,15] is well documented. Individual
weight loss was calculated and expressed as percentage of pre-
morbid body weight lost.
Classification of Cancer Cachexia
I. Weight loss .5% over past 6 months (in absence of simple
starvation) (WL.5%)
II. Weight loss .10% over past 6 months (in absence of
simple starvation) (WL.10%)
III. Stature adjusted skeletal muscle index consistent with low
muscularity (LM) (see ‘CT-image analysis’ for cut-offs)
IV. Stature adjusted skeletal muscle index consistent with low
muscularity and any degree of weight loss .2% (LM + .
2%WL)
Rectus Abdominis Muscle Biopsy and Storage For
Biochemical Analysis
All biopsies were taken at the start of open abdominal surgery
under general anaesthesia. Patients had fasted overnight prior to
surgery. The edge of the rectus abdominis was exposed and a
1 cm3 specimen removed using sharp dissection. The biopsy was
cleaned of gross blood contamination. Obvious fat/fibrous tissue
was removed prior to placement in a cryotube and being snap
frozen in liquid nitrogen and stored at 280uC.
Rectus Abdominis Muscle Sample Preparation for Cryo-
Section
A 0.1–0.5 cm3 section of muscle was cut. Liquid nitrogen was
used to cool isopentane solvent in a tube to a temperature of
,2190uC. The section of muscle was stitched onto a segment of
cork. OCT solution was placed at the junction between the cork
base and the muscle. This was then lowered with the cork
uppermost (i.e. muscle first) into cooled solvent and held for
approximately 5 minutes (until the muscle was frozen). Samples
were then stored at 280uC until use.
CT Image Analysis
CT scans used for the analysis were done solely for routine
cancer care. A transverse CT image from the third lumbar
vertebrae (L3) was assessed for each scan date and tissue volumes
estimated [16]. All CT images were analysed by a single trained
observer. Cross-sectional area for muscle and adipose tissue was
normalized for stature (cm2/m2).
Estimates of whole body stores were generated from the raw
data (cm2) using the regression equations by Mourtzakis et al. [17],
which show a close correlation between muscle and fat areas in
CT images at the third lumbar vertebrae and whole body
compartments of fat-free mass (FFM) and fat mass (FM)
respectively.
Total body fat free mass FFMð Þ kgð Þ
~0:3| skeletal muscle at L3 cm2
  
z6:06 r~0:94ð Þ
Total body fat mass FMð Þ kgð Þ
~0:042| total adipose tissue at L3 cm2
  
z11:2 r~0:88ð Þ
The respective indexes for FFM and FM (kg/m2) were calculated.
Cutoffs for low muscularity were based on a CT-based
sarcopenic obesity study of cancer patients by Prado et al. (i.e.,
Clinical Classification of Cancer Cachexia
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L3 skeletal muscle index: #38.5 cm2/m2 for women and
#52.4 cm2/m2 for men) [18].
CT scans used were routine diagnostic staging CT scans which
were performed within 30 days of a diagnosis of cancer and all
were in treatment naive patients. The median time to biopsy after
the CT scan was 18 days.
Immunohistochemistry
The frozen muscle sections were co-stained for laminin (L9393,
Sigma-Aldrich, Buchs, Switzerland) and myosin heavy chain type I
or IIa to distinguish each fibre type (BA-D5 for type I, SC-71 for
type IIa). The paraffin sections were stained for phospho-STAT3
(D3A7, Cell Signaling Technologies, Danvers, MA, USA) with a
Ventana discovery XT (Roche group, Tucson, USA). Images of
the entire tissue section were acquired using a VS120 slide scanner
(Olympus Corporation, Tokyo, Japan). The distribution of myosin
heavy chain fibre types, the cross section area of the individual
fibres in the section, and the phospho-STAT3 positive nuclei and
staining density were analysed using the proprietary image analysis
platform ASTORIA (Automated Stored Image Analysis) devel-
oped by Novartis/Preclinical Safety.
Tissue Preparation for DNA, RNA and Protein Extractions
Skeletal muscle tissue was minced and ground on dry ice.
Aliquots were weighed using an analytical balance (Mettler
Toledo) and stored at 280uC until use.
DNA and RNA Extraction and Linearity of the Extraction
Method
DNA and RNA from human skeletal muscle tissue was
extracted and purified with the automated Maxwell 16 system
(Promega, Duebendorf, Switzerland). To determine the linearity
of the extraction methods using the Maxwell 16 system, DNA and
RNA was extracted from 4 mg, 6 mg, 8 mg, and 10 mg of muscle,
respectively. Calculating the total DNA and RNA content per wet
weight (which in a linear extraction system should be equal for all
aliquots), allowed us to define the linear range of the Maxwell 16
extraction system. Based on these preliminary studies, aliquots of
4–8 mg human skeletal muscle tissue were used for all subsequent
DNA and RNA extractions. Using more starting material
drastically reduced the total DNA and RNA content per wet
weight (data not shown).
For DNA extraction, the Maxwell 16 LEV Blood DNA Kit
(Promega) was used with a slightly adapted protocol compared
with the manual’s instructions. Briefly, 300 ml of Tail Lysis Buffer
from the kit ReliaPrep gDNA Tissue Miniprep System (Promega)
was added to minced and ground human skeletal muscle tissue in
Precellys 24 lysing kit tubes. Tissue was further homogenized using
the high-throughput homogenizer Precellys 24, for 10 s. After
cooling on ice for 5 minutes, 30 ml of the protein K and 5 ml of the
1-Thiolglycerol solution were added. This mixture was incubated
at 56uC for 2 hrs. Afterwards, the lysate was transferred into well 1
of the LEV Blood DNA cartridge, and diluted with 300 ml
nuclease-free water. For the elution, 50 ml of elution buffer was
added into elution tubes. The Maxwell 16 instrument was started
using the DNA Blood program.
For RNA extraction, the Maxwell 16 LEV simplyRNA Tissue
Kit was used (Promega), following the manual’s instructions.
Briefly, minced and ground human muscle tissue was incubated in
200 ml of chilled 1-Thioglycerol/Homogenization solution and
further homogenized using the Precellys 24 system (see DNA).
Afterwards, the samples were heated at 70uC for 2 min, then the
lysates were allowed to cool down. 200 ml of lysis buffer was added
to the cooled-down homogenate, mixed vigorously, followed by
transfer of the total 400 ml into well 1 of the Maxwell 16 LEV
cartridge. 5 ml of DNAse was added to well 4 of the cartridge and,
50 ml RNAse-free water was added to 0.5 ml Elution Tubes and
the RNA extraction program was started at the Maxwell 16
instrument.
Extracted DNA and RNA were measured spectrometrically
using a Trinean DropSense Instrument (Trinean, Gentbrugge,
Belgium) for quantity and quality.
Protein Extractions
To extract proteins, 300 ml of PhosphoSafe Extraction Reagent
(Millipore) was added to a specific amount (between 8 and 18 mg)
of homogenized human skeletal muscle tissue. To further
homogenize the samples, the Precellys 24 system was used (see
section above). After incubation on ice for 5 min, the lysates were
spun at 8006g for 5 min at 4uC. Supernatants were transferred
into new tubes and spun for another 12 min at 16006g at 4uC.
Supernatants were collected and protein concentrations measured
using the BCA Protein Assay Kit (Pierce) with BSA as a standard.
Afterwards, phosphatase inhibitor cocktail (Roche) was added and
the samples were stored at 280uC until further use.
Western Blots
20 mg of human skeletal muscle protein extracts (see above) in
reducing Laemmli SDS sample buffer were boiled for 5 min at
95uC and then separated by SDS-PAGE on 4–20% gradient gels
(Bio-Rad, Cressier, Switzerland), blotted to Nitrocellulose mem-
branes (Bio-Rad) using the Trans-Blot Turbo Transfer System
(Bio-Rad), blocked for 1 h in 5% non-fat milk in Tris-buffered
saline+0.05% Tween-20, incubated overnight with primary
antibody, rinsed, and incubated for 1 h with peroxidase-conjugat-
ed goat anti-rabbit IgG (1:5000) (Santa Cruz, Heidelberg,
Germany) at room temperature. Blots were developed using
ECL (Roche, Rotkreuz, Switzerland) or SuperSignal West Femto
substrate (Thermo Scientific, Wohlen, Switzerland) and exposed to
Kodak film (Kodak, Rochester, NY, USA).
Rabbit monoclonal antibodies used were: Beclin-1 (clone
D40C5), Atg5 (clone D1G9) , Atg7 (clone D12B11), Atg12 (clone
D88H11), SMAD3 (clone C67H9), phospho-NFkB p65 (Ser536)
(clone 93H1) and a-tubulin (clone 11H10) (all from Cell Signaling
Technologies, Danvers, MA, USA), phospho-SMAD3 (Ser423/
Ser425, clone EP823Y) (Millipore, Billerica, MA, USA). Rabbit
polyclonal antibodies used were: Gelsolin (Cell Signaling Tech-
nologies).
Western blots were analyzed densitometrically using ImageJ
software version 1.45 (NIH, Bethesda, MD, USA; http://rsbweb.
nih.gov/ij). Band intensity of each sample was normalised to that
of a-tubulin.
C - Reactive Protein (CRP)
Serum CRP concentration was measured with an automated
immunoturbidimetric assay by clinical chemistry department,
Royal infirmary Edinburgh, using blood collected from patients at
the time of recruitment and before any therapeutic intervention.
Statistical Analysis
Results are expressed as mean (6 SEM). Comparisons between
groups were performed using unpaired Student’s t tests, whereas
possible relationships were evaluated using Pearson’s correlations.
Results were considered significant if p values were less than 0.05.
The program SPSS (version 20, SPSS, Chicago, IL, USA) was
used for all the statistical tests.
Clinical Classification of Cancer Cachexia
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Results
Patient Demographics
A total of 41 cancer patients with resectable UGI or pancreatic
cancer were recruited. In general, patients were over 65 years of
age, predominantly male and had sustained, on average, 5% loss
of weight compared with pre-illness levels (Table 1). Patients were
grouped based upon the concepts of the International Classifica-
tion Framework [1] according to weight loss or weight loss in
association with low muscularity. The specific phenotypes
considered were weight loss .5% (WL.5%), weight loss .10%
(WL.10%), low muscularity (LM), and LM with weight loss .2%
(LM+.2% WL). Although BMI was reduced in all groups
classified as cachectic, only the LM and LM+.2% WL groups
had a significantly lower fat free mass index (Table 1).
Muscle Fibre Size, Number, and Type
If patients were classified as cachectic by LM or LM +
.2%WL, fibre size was reduced significantly (all types of myosin
heavy chain fibre) when compared with non-cachectic patients
and controls (Figure 1A). The association of cachexia with reduced
fibre size was not observed if patients were classified according to
WL alone. Representative immunohistological sections demon-
strating differences in fibre diameter between a healthy control
and an individual in Group II versus Group IV is shown in
Figure 1B. Immunohistology for type I and IIa resulted in
complementary staining in general, whereas fibre type IIb resulted
in very low staining intensity as reported elsewhere [19]; therefore
quantitative analysis was done only with type I and IIa but not
with type IIb (Table 2). As would be expected from a decrease in
fibre size, there was a trend across all groups for fibre density to
increase in those with cachexia. However, due to large variability,
this was not statistically significant. There was no evidence of
selective fibre atrophy across any of the classification groups
(Table 2).
Protein Content
The results for skeletal muscle protein content are shown in
Figure 2(A). When compared with non-cachectic patients, muscle
protein content was reduced significantly (approximately 13%) in
patients with either .5% WL or LM + .2%WL (Figure 2A and
table 3). However if the LM criteria were applied alone no
difference in the protein content was observed. In addition,
patients with .10% WL showed a 10% reduction in protein
content when compared with non-cachectic patients but this
difference did not reach statistical significance (Figure 2A and
table 3).
RNA, DNA, and RNA/DNA Ratio
The results for skeletal muscle DNA and RNA content are also
shown in Figure 2(B,C, and D) and table 3. RNA content was not
significantly different in cachectic patients when compared with
non-cachectic patients according to any of the diagnostic criteria
(Figure 2B and table 3). In contrast, DNA content was increased
by 50% with .5% WL but decreased by ,40% in patients with
LM (Figure 2C). The ratio of RNA/DNA was decreased
(approximately 30%) in patients with .5% WL and LM +
.2%WL (Figure 2D).
Autophagy Pathways
In patients with .10% WL, Beclin and ATG5 protein levels
were increased significantly in cachectic patients when compared
with non-cachectic patients (Figure 3). ATG7 and 12 levels were
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– cachectic patients according to any of the diagnostic criteria
(Table 3).
SMAD Signalling
In patients with .5% WL, SMAD3 protein levels were
significantly increased when compared with non-cachectic patients
(Figure 4). There were no significant differences in phospho-
SMAD3/SMAD3 across any of the groups (Figure 4).
Inflammatory Pathways
Systemic inflammation was estimated using patients’ serum
CRP levels (Table 1). Patients were classified as having systemic
inflammation if their CRP was $10 mg/L. There was no
Figure 1. Fibre type cross sectional area (FCSA) according to different definitions of cachexia. (A) Mean (6 SEM) fibre size for both
MyHC1 and MyHCIIa. A comparison is made between patients with the proposed cachexia definition absent (dark grey) and those with the proposed
cachexia definition present (light grey) for the four definitions set out in Methods (I–IV). (*, P,0.05 and **, P,0.01, by Student’s t test). (B)
Immunohistological sections of muscle for a healthy control, patient with weight loss alone (10.1%) (Group II), and patient with low muscularity and
.2% weight loss (Group IV). Laminin is shown in green, MyHC1 shown in red, and MyHCIIa is shown in blue.
doi:10.1371/journal.pone.0083618.g001
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difference in the proportion of patients with or without systemic
inflammation according to the definition of cachexia. Levels of
phospho-NFkB and phospho-STAT3 were not significantly
different in patients with or without cachexia (using any of the




The diagnostic criterion for cancer cachexia has long been
based on weight loss alone [1] and can reflect loss in either fat or
lean tissue compartments. Given that the key tissue loss in cancer
cachexia is considered to be skeletal muscle, a recent consensus
process suggested that the diagnostic criteria for cachexia should
also take account of low baseline levels of muscularity [1]. In the
present study, when patients were classified as cachectic or not
according to $5% weight loss there was no significant difference
in whole body muscularity (FFMI) or muscle fibre CSA. In
contrast, when patients were classified according to low muscu-
larity and $2% weight loss, FFMI was decreased and fibre cross
sectional area was also significantly reduced (Figure 1). Such
findings demonstrate that heterogeneity in relation to low
muscularity and fibre atrophy may be reduced according to the
clinical definition of cachexia. This finding may be important
especially when considering inclusion criteria for clinical trials that
aim to test the efficacy of drugs targeted at reversal of muscle
wasting in cancer patients. The reduction in fibre size in all MyHC
isoforms observed in the present study is consistent with previous
animal [20] and human studies of cancer cachexia [4–7]. The
rectus muscle of patients with oesophago-gastric cancer cachexia
has been shown to lose all type MyHC content as well as undergo
a reduction in fibre size [4]. Equally, in pancreatic cancer patients
with cachexia, both type I and type II MyHC protein levels were
decreased by 45% when compared with controls [6].
Fibre Type
In order to study differences in muscle fibre morphology and
composition within the different cachexia categories, we per-
formed immunohistochemical analysis of human muscle samples.
For that, we first established and validated the staining methods
for the myosin heavy chain antibodies specific for the different
fibre types (I, IIa, and IIb). Staining for type I and IIa fibres
resulted in strong specific staining specificity, however only weak
Figure 2. Variations in protein and nucleic acid content according to the different definitions of cancer cachexia. A comparison is
made between patients with the proposed cachexia definition absent (dark grey) and those with the proposed cachexia definition present (light
grey) for the four definitions set out in the methods (I–IV). (A) Mean (6 SEM) wet weight protein content. (B) Mean (6 SEM) RNA content. (C) Mean
(6 SEM) DNA content. (C) Mean (6 SEM) RNA/DNA ratio. (*, P,0.05 by Student’s t test).
doi:10.1371/journal.pone.0083618.g002
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PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e83618
staining was observed against type IIb MyHC, this finding has also
been reported elsewhere [19]. The predominant types of MyHC
fibre in rectus abdominis muscle are I and IIa and only ,8% of
type IIb positive fibres have previously been described [21]. Of the
adult skeletal isoforms, each are expressed to varying degrees in
both mouse and human skeletal muscle. However, although
MyHCIIb is highly expressed at both the messenger RNA
(mRNA) and protein level in murine skeletal muscle, evidence to
date suggests that this isoform is effectively only expressed at the
mRNA level in a very small subset of specialised muscles in the
adult human [22]. As mentioned above, MyHCIIb expression is
typically associated with high forces of contraction combined with
rapid contractile characteristics and it has been suggested that the
contractile characteristics of MyHCIIb may be incompatible with
the biomechanical constraints of larger muscles [23], which may
account for the lack of specificity found in the rectus muscle of our
patient population.
In cachexia there is conflicting evidence as to whether there is
selective loss of fibre type. There was no evidence for selective loss
of fibre type in the present study (Table 2). Evidence from animal
models suggests that Type II fibres are targeted selectively [24],
with relative preservation of type I fibres in fasting [25], exposure
to glucocorticoids [26], sepsis [27] and in the gastrocnemius
muscle of the C26 model of cancer cachexia [28,29]. Models of
cardiac cachexia, however have suggested a trend to selective loss
of type I fibres and an increase in type II fibre [30]. Furthermore,
not all groups have demonstrated Type I and II fibre differences
even in animals. Indeed in a recent study of the C26 cachectic
mouse model, both glycolytic and oxidative fibres of (extensor
digitorum longus) EDL muscle underwent wasting [20], whilst in a
previous study using the same mouse model there was a significant
increase in the amount of MyHCIIb and a significant decrease in
the amount of type 1 MyHC in soleus muscle [31]. It is currently
not entirely clear which type of fibres are affected in human cancer
cachexia, however, in patients with oesophago-gastric cancer
cachexia early loss of all MyHC isoforms has been reported [4].
The activity patterns of a muscle are also key in determining
phenotype. If muscle cells are recruited infrequently they develop
into fast/glycolytic units whereas if they are recruited more often,
they form slow/oxidative units. In the C26 mouse model of cancer
cachexia, there have been reports of switching of myosin isoforms
in the soleus muscle of cachectic mice [31]. In pancreatic cancer
patients with cachexia, no difference in the ratio of fast/slow
myosin isoform was demonstrated compared with controls [6].
Muscle RNA, DNA, and Protein Content
In the present study, when compared with non-cachectic
patients, muscle protein content was reduced significantly
(approximately 13%) if patients were classified as cachectic by
either .5% WL (p = 0.015) or LM + .2%WL (p = 0.035), and by
10% in patients with .10% WL. Protein content expressed in
relation to wet weight of muscle has been shown to decrease
progressively (in excess of 50%) in the gastrocnemius muscle of
mice bearing the MAC-16 tumour [32]. This suggests that not
only is there loss of fibre diameter, but that the quality of the fibre
is altered with loss of either sarcoplasmic or myofibrillar protein.
Such changes in fibre composition may contribute to the reduced
muscle mechanical quality (force per unit cross-sectional area)
observed in human cancer cachexia [33].
A reduction in both RNA content and activity in skeletal muscle
has been attributed to a depression of protein synthesis in mice
bearing the MAC16 tumour [32] . In the present study, RNA
content was unaltered in cachectic patients (classified either with
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Figure 3. Skeletal muscle Beclin and ATG5 protein levels in patients with or without .10% weight loss (Group II). Western blot
analysis with indicated antibodies, a-tubulin was used as a loading control. Graph shows the mean (6 SEM) protein level represented in arbitrary
units (A.U). (*, P,0.05 and **, P,0.01, by Student’s t test).
doi:10.1371/journal.pone.0083618.g003
Figure 4. Total SMAD3, phospho-SMAD3 and ratio of phospho-SMAD3/SMAD3 in patients with or without .5% WL (Group I)
levels. Western blot analysis with indicated antibodies, a-tubulin was used as a loading control. Graph shows the mean (6 SEM) protein level
represented in arbitrary units (A.U). (*, P,0.05 by Student’s t test).
doi:10.1371/journal.pone.0083618.g004
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patients. A reduction in the RNA content in the muscle of mice
bearing the Ehrlich ascites tumour has also been reported, but this
occurred later than the observed depression in the rate of protein
synthesis [34]. Whether muscle protein synthesis is depressed in
human cancer cachexia remains to be resolved [10].
In a murine model of cancer cachexia DNA content of the
gastrocnemius muscle has been shown to remain relatively
constant, despite the finding of a decrease in protein and RNA
content [32]. The current study demonstrated DNA content was
increased by .50% with .5% WL but decreased by 40% in
patients with LM (Figure 2C). Because mature myofibre nuclei are
thought to be mitotically inactive, increased DNA content in
skeletal muscle cells suggests activation of satellite cells [35] or
infiltration by other cell types such as inflammatory cells or
adipocytes. In the LM group, the decrease in DNA may be due to
pre-existing age-related sarcopenia or other causes of muscle
atrophy (e.g. immobilisation) and may relate to muscle specific
apoptosis and reduction in cell number in keeping with a reduction
in muscle mass on CT scanning. The diametrically opposite
changes in muscle DNA content dependent on whether patients
are classified according to weight-loss or low muscularity again
underpin the potential diverse mechanisms whereby older cancer
patients may develop a low level of muscularity.
The issue of whether nuclear domain size is reduced in cancer
cachexia remains to be resolved. In particular, whether apoptosis
in skeletal muscle is increased in cancer cachexia and the degree to
which DNA content is maintained or not via a compensatory
increase in myonuclear number (possibly via satellite cell nuclei
incorporation) is not known. Features of cachexia such as
hypogonadism (resulting in low testosterone) or systemic inflam-
mation (associated with high IL-6) could influence such regener-
ative capacity. In the current study RNA/DNA was altered in the
cachectic patients (independent of definition) compared with the
non- cachectic patients. This may be due to the interplay of the
mechanisms described above.
Mechanisms
Skeletal muscle atrophy may occur as a result of decreased
synthesis, increased degradation or both [36]. In mice bearing the
MAC-16 adenocarcinoma, muscle loss is due to the combination
of reduced synthesis and increased degradation [37]. Similarly
Samuels et al demonstrated reduced protein synthesis and
increased degradation in skeletal muscle co-incident with the
onset of cachexia in mice implanted with the C26 murine model
[38].
Degradation Pathways. The majority of signalling pathways
contributing to muscle atrophy in pre-clinical models are mediated
through activation of the ubiquitin-proteasome proteolytic path-
way (UPP) [39]. The muscle-specific E3 ubiquitin ligases, MuRF-1
and MAFbx/atrogin-1 are up regulated in animal models of acute
Figure 5. Inflammatory pathways in patients with (CRP .10 mg/L) and without (CRP #10 mg/L) systemic inflammation. (A) Western
blot analysis in the presence or absence of systemic inflammation with indicated antibodies, a-tubulin was used as a loading control. (B) Graph shows
the mean (6 SEM) protein level of phospho-NF-kB, represented in arbitrary units (A.U). (C) Representative immunohistochemistry and nuclei count of
phospho-STAT3 (area shown is representative of field) of a patient with or without systemic inflammation. (D) Graph shows the staining density of
phospho-STAT3 nuclei (A.U.) (6 SEM) in the presence or absence of systemic inflammation.
doi:10.1371/journal.pone.0083618.g005
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atrophy [40,41], and MuRF1 selectively targets the myofibrillar
protein myosin heavy chain resulting in muscle wasting [8].
However, the role of the E3 ligases in human cachexia is less well
defined. In the current study we chose not to measure directly
these pathways as results from our previous investigation on a
similar cohort of patients found no up regulation using a
transcriptomics approach [42], this has also been validated
recently in a separate cohort of patients with gastric cancer [43].
In the present study autophagy proteins (ATG) 5, 7, 12, and beclin
1 were studied. These proteins are necessary for autophagy due to
their role in autophagosome elongation [44]. When patients were
classified according to .10% WL, Beclin and ATG5 protein levels
were significantly increased in cachectic patients when compared
with non-cachectic patients. In a previous study in a similar cohort
of patients, the autophagy related genes GABRAPL1 and BNIP3
were increased in rectus muscle biopsies from cachectic versus
non-cachectic patients [42]. In normal muscle, low-protein diets
up-regulate autophagy that leads to the loss of muscle mass at least
partially through lysosomal degradation [45]. Intriguingly, under
other circumstances decreased autophagy can also lead to muscle
atrophy.
Systemic Inflammation. Systemic inflammation is thought
to be a major mediator of cancer cachexia [10]. However, the
relationship between inflammation in the systemic compartment
versus muscle and the relationship of either to muscle loss in
humans is not clear. In the systemic compartment, Il-6 is thought
to be a major mediator and may signal within target organs via
STAT-3. Alternatively, both IL-1 and TNF alpha may signal via
NF-kB. NF-kB regulation of muscle atrophy is predominantly
executed by promoting proteasome-mediated degradation [46].
Activation of NF-kB has been detected in both physiological and
pathological atrophic conditions such as denervation, unloading,
aging, cancer, sepsis, diabetes, and such atrophy can be reversed
by pharmacologic or genetic NF-kB inhibition [47]. In the present
study although there was evidence for systemic inflammation in a
proportion of patients, no significant difference was found in the
levels of phospho-NFkB or phospho-STAT3 across any of the
definitions of cachexia or in those with or without evidence of
systemic inflammation. It is possible that inflammatory mediators
have their main effects on muscle atrophy via central mechanisms
mediated via the CNS [48].
SMAD3. It has been suggested that binding of myostatin to
the ActRIIB receptor results in the phosphorylation of two serine
residues of SMAD2 or SMAD3. This leads to the assembly of
SMAD2/3 with SMAD4 to the heterodimer that is able to
translocate to the nucleus and activate transcription of target genes
[49]. One of the known downstream targets of SMAD signalling is
MyoD, a transcriptional factor that is involved in skeletal muscle
development and takes part in the repair of damaged skeletal
muscle [50]. Moreover, SMAD signalling targets other genes such
as myf5 and myogenin, known to be important for myogenesis
[51]. Myostatin is upregulated in cachexia and in states of muscle
paralysis [52]. Myostatin/ActRIIB activates SMAD2/3 signalling
and importantly SMAD2/3 inhibition completely desensitises
ActRIIB-induced muscle atrophy [13]. Inhibition of myostatin by
a dominant negative ActRIIB promotes muscle hypertrophy
independent of muscle satellite cell recruitment consistent with a
direct signalling effect on muscle catabolism [13]. When patients
were classified as cachectic according to .5% WL, SMAD3
protein levels were significantly increased in cachectic patients
when compared with non-cachectic patients. Equally there was a
similar (but not significant) increase in phospho-SMAD3 associ-
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protein levels indicate increased pathway activity independent of
any alteration in the ratio of phospho-SMAD3/SMAD3.
Limitations of Study
It is important to appreciate that the majority of patients in the
present series will have had some degree of age-related sarcopenia,
that this will necessarily co-exist with any cancer specific loss of
skeletal muscle mass and that the diagnostic criteria used in the
present study will not necessarily separate one from the other. The
current study was not longitudinal and it was therefore not possible
to document active muscle loss. It is also important to recognise
that when patients were divided into different diagnostic categories
the sample size in individual categories may have limited the
ability to detect a statistical difference or not. This was an
exploratory study and provides the basis for a larger study with
adequate statistical power for definitive analysis.
Conclusions
In the present study, when the diagnostic criteria for cachexia
included both a measure of low muscularity and weight loss,
muscle fibre size, protein content and RNA/DNA content were all
reduced. Such consistent findings were not observed when
cachexia was diagnosed based on weight-loss or low muscularity
alone. Whereas fibre type is not targeted selectively, muscle fibre
size, biochemical composition and pathway phenotype can vary
according to whether the criteria for cachexia include both a
measure of low muscularity and weight loss. Such findings suggest
that current diagnostic criteria identify groups of patients with
different skeletal muscle phenotypes. Identification of a more
homogeneous patient cohort for musculo-centric intervention
trials may require use of combined criteria.
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Skeletal muscle loss appears  to  be  the  most  significant  clinical  event  in cancer cachexia  and  is  associated
with  a poor outcome.  With  regard to such  muscle  loss,  despite  extensive study in a range  of models,
there is ongoing  debate  as  to whether  a reduction  in protein synthesis, an increase  in degradation  or  a
combination of both is the  more  relevant.  Each model  differs  in terms  of key  mediators and the  path-
ways  activated  in skeletal  muscle. Certain  models  do suggest  that  decreased  synthesis  accompanied  by




tend to involve  rapid  development  of cachexia  and  may  represent  more  acute muscle atrophy  rather  than
the  chronic  wasting observed  in  humans. There  is  a paucity  of human  data  both at a  basic descriptive  level
and at a molecular/mechanism  level.  Progress  in treating  the  human  form  of cancer cachexia  can  only
move forwards  through  carefully designed  large randomised  controlled  clinical  trials  of specific  therapiesegradation with  validated biomarkers  of relevance  to underlying mechanisms.
This  article  is part  of a  Directed  Issue entitled: Molecular basis  of muscle wasting.
© 2013 Elsevier Ltd. All rights reserved.
ontents
1. Introduction  . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . .  .  . . . . . .  . . . . . .  . . . . . .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . . . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . . . . 2216
2. Heterogeneity . . . .  . . . . .  .  . . . . .  .  . . . .  .  . . . . . .  . . . . . .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . . . .  . . . . .  . . . . .  .  . . . .  .  . . . . .  .  . . . . . 2216
3. Skeletal  muscle morphology  in cancer  associated  myopenia:  murine models  . . .  .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . . . . . . .  . . . . .  .  . . . . .  .  . . 2216
3.1.  Fibre size  and  type  in cancer associated  myopenia  . .  .  . . . . .  . . . . .  .  . . . . .  . . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . 2217
3.2.  Fibre RNA,  DNA, and protein  content in cancer  associated  myopenia .  . . . . .  .  . . . . .  . . . . .  .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . 2217
3.3.  Dystrophin  glycoprotein  complex (DGC)  . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . . . . . . .  .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . 2218
4.  Mediators  of cancer  associated myopenia:  murine  models  . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . 2218
4.1.  Neural control . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . . . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  . . . . .  .  . . . . .  . . . . . 2218
4.2.  Pro-inflammatory  mediators  . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . .  .  .  . . . . . . . . . .  . . . . . .  . . 2218
4.3.  Catabolic mediators  . . . .  . . . . . .  . . . . .  .  . . . .  .  . . . . . .  . . . . . .  . . . . . .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  . . . . . .  . . . 2219
4.4.  Anabolic mediators  . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . . .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . . . . .  . . . . 2219
5.  Mechanisms  of  cancer associated  myopenia:  murine models . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  . . . . . .  .  . . . . .  . . . . .  . . . . . .  . . . . . . 2219
5.1.  Protein degradation  pathways . . . . .  . . . . . .  . . . . .  . . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . . .  . . . . .  . . . . .  .  . . . . .  . . . . .  .  . . 22195.1.1.  Ubiquitin proteasome  pathway  . . . . . .  . . . . .  .  . . . . .  . . . . . .  .  . . 
5.1.2.  Autophagy/lysosomal pathway  .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . .
5.1.3.  Calpains  . . . .  . . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  
Abbreviations: ACTRIIB, activin receptor type-2B; APC, adenomatosis polyposis col
riphosphate; C-26, colon-26 adenocarcinoma mouse model; CHO, Chinese hamster ovar
ectional area; DGC, dystrophin glycoprotein complex; DM,  diabetes mellitus; DNA, deo
nitiation factor 3  subunit F;  F-bxo40, F-box protein 40;  FCSA, fibre cross sectional are
nterferon; IGF,  insulin-like growth factor; IL,  interleukin; IRS, insulin receptor substrate
A,  megestrol acetate; mAb, monoclonal antibody; MAC16, murine adenocarcinoma 16
itogen  activated kinase; MCR, melanocortin receptor; MRI, magnetic resonance imag
TOR,  mammalian target of rapamycin; MURF-1, muscle-specific RING finger-1; MyHC,
mall cell lung cancer; PBMC, peripheral blood mononuclear cell; PI3K, phosphatidylino
cid;  STAT, signal transducer and activator of transcription; TA, tibialis anterior; TAM, tu
umour necrosis factor; TWEAK, tumour necrosis factor-like weak inducer of apoptosis; U
 This  article is  part of a Directed Issue entitled: Molecular basis of muscle wasting.
∗ Corresponding author. Tel.: +44 0131 242 3615.
E-mail address: k.fearon@ed.ac.uk (K.C.H. Fearon).
357-2725/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.biocel.2013.05.032. . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . . . . . .  . . 2219
 . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . . . . . . .  .  . . . . .  .  . . . . .  . . . . .  . . . . . .  .  . . . . . . 2221
. . . . .  . . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . . . . .  . . . . . . 2221
i; APPR, acute phase protein response; ARC, arcuate nucleus; ATP, adenosine-5′-
y; COPD, chronic obstructive pulmonary disease; CRPc, reactive protein; CSA, cross
xyribonucleic acid; EDL, extensor digitorum longus; EIF3F, eukaryotic translation
a; FOXO, forkhead box class O transcription factor; ICU, intensive care unit; IFN,
; JAK, Janus associated kinase; LBM,  lean body mass; LLC, Lewis lung carcinoma;
 mouse model; MAFbx, muscle-specific F-box (also known as atrogin-1); MAPK,
ing; mRNA, messenger ribonucleic acid; MSH, melanocyte-stimulating hormone;
 myosin heavy chain; NFB, nuclear factor-;  NPY, neuropeptide Y; NSCLC, non-
sitol 3-kinase; POMC, pro-opiomelanocortin; QoL, quality of life;  RNA, ribonucleic
mour-associated macrophage; TGF, transforming growth factor; Th, T helper; TNF,
b, ubiquitin; UPP, ubiquitin-proteasome pathway.
2216 N. Johns et al. / The International Journal of Biochemistry & Cell Biology 45 (2013) 2215– 2229
5.2.  Protein  synthesis  pathways  . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . . . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . .  . . . . . .  . . . . .  . 2222
5.3.  Fat-muscle cross  talk .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . .  .  . . . . . .  . . . . .  . . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  . . . . . .  . . . . . 2222
6.  Skeletal  muscle morphology  and function  in cancer associated  myopenia:  clinical  data  . . . .  . . . . .  .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  . . . . .  .  . . 2222
7.  Mediators of cancer associated  myopenia:  clinical data  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . .  .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  .  . . . . .  . . . . .  .  . . . . .  . . . . .  . . . . . .  . 2223
7.1.  Systemic  mediators of  cachexia  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . 2223
7.1.1.  The acute  phase response  . . .  . . . . . .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . . .  . . . . .  .  . . . .  .  . . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . .  .  . . . . .  . . . . . .  . . . . .  . . . . .  . 2223
7.2.  Pro-inflammatory  cytokines  . . .  . . . . . .  . . . . .  .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . . .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  . . . . .  . 2223
7.3.  Other  circulating mediators  . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  . . . . . .  . . . . .  .  . . . . . . 2223
7.3.1.  Calcium  and  vitamin D . . . . .  . . . . . .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . . .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . .  .  . . . . .  .  . . . .  .  . 2223
7.3.2.  Glucocorticoids .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . . . . . . . . .  . . . . .  . . . . . .  . . . . .  .  . . . . . 2223
7.3.3. Insulin .  . . . .  . . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  . . . . . .  . . . . .  .  . 2223
7.3.4. Ghrelin . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  . . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . .  . . . 2223
7.3.5. Androgens  .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . . .  . . . . .  .  . . . . .  . . . . . . . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . . . . . . . .  . . . . .  .  . . . . . 2224
7.3.6. Myostatin  . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . .  . . . . . .  . . . . .  .  . . . . 2224
8. Mechanisms  of cancer associated  myopenia:  clinical  data . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  . . . . . .  . . . . .  .  . . . . .  . 2224
8.1.  UPP/E3 ubiquitin  ligases. .  .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . .  .  . . . . . 2224
8.2.  Autophagy/lysosomal  pathway  .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . .  . . . . . .  . . . . .  .  . . . . 2224
8.3. Calpains  . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  . . . . .  .  . . . . .  . . . . 2224
8.4. Caspases . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . . .  . . . . . . . . . . .  . . . . . .  .  . . . .  .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . .  . . . . . .  . . . . .  .  . . . . 2224
8.5. Myogenesis  . . . . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . .  .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  .  . . . . .  .  . . . . .  . . . . .  .  . . . . . .  . . . . . .  . . . .  .  .  . . . .  .  . . . . .  .  . . . . . . . . . .  .  . 2225
9. Future prospects  . . . .  .  . . . .  .  . . . . . .  . . . . . .  . . . . .  .  . . . . .  . . . . . .  . . . . .  .  . . . . . .  . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . . .  . . . . .  . . . . . .  .  . . . .  .  .  . . . . .  . . . . .  .  . . . . .  . . . . .  . . 2225





































References  . .  . . . . . . . . . . .  .  . . . .  .  . . . . . .  . . . . . .  . . . . .  .  . . . .  .  .  . . . . .  . . . . . .  . . . . .  .
. Introduction
Weight loss in cancer patients is  associated with excess mor-
idity and mortality (Rennie, 2009; Brandt and Pedersen, 2010).
achexia affects the majority of patients with advanced cancer and
s associated with a reduction in treatment tolerance, response to
herapy, quality of life and duration of survival. Cancer cachexia has
ecently been defined as a multifactorial syndrome characterised by
n ongoing loss of skeletal muscle mass (with or without loss of fat
ass) that cannot be fully reversed by conventional nutritional sup-
ort and leads to progressive functional impairment (Fearon et al.,
011). Although there is  depletion of both adipose tissue and lean
ody mass, it is  skeletal muscle loss that has the greatest impact on
atients’ function and quality of life and is  clearly associated with
 poor outcome (Tan et al., 2009; Fearon et al., 2011; Miller et al.,
012).
. Heterogeneity
Heterogeneity both in clinical and animal models is  one of
he key issues that has impaired research into cancer cachexia.
achexia is not a single phenomenon but evolves through a spec-
rum of pre cachexia, cachexia, and refractory cachexia (Fearon
t al., 2011). The incidence and severity of cachexia can vary
ccording to tumour type, site, and mass (Dewys et al., 1980).
qually, the contribution of reduced food intake versus abnormal
etabolism can vary considerably (Knox et al., 1983). The com-
onents of such abnormal metabolism also vary, and within the
ame model/individual can evolve with time such that hyperme-
abolism (Zylicz et al., 1990) or activation of proteolytic pathways
Khal et al., 2005a,b)  occurs during the early phase of cachexia but
ot during a  more advanced phase. In humans the cause of such
eterogeneity relates not only to the clinical status of the patient
nd specific effects of the tumour (e.g. causing bowel obstruction,
issue destruction or concomitant infection) but also to  co-existing
orbidities (e.g. heart failure, chronic renal failure, or chronic
bstructive pulmonary disease), age related sarcopenia and the
ossibility of a genetic predisposition to develop cachexia (Fig. 1).There are numerous animal models of cancer cachexia. A  recent
eview concluded that for research into cancer cachexia where
here is little evidence of systemic inflammation, the murine adeno-
arcinoma 16 mouse (MAC-16) and XK1 murine tumour models are . . . . .  . . . . . .  .  . . . . .  . . . . .  .  . . . . .  .  . . . . .  .  . . . .  .  . . . . . .  . . . . .  .  . . . . .  . . . . .  . . . . . .  . . . . . 2225
useful (Bennani-Baiti and Walsh, 2011). Weight loss in  mice bear-
ing the MAC-16 tumour appears to  be independent of  reduced food
intake or inflammation (Bennani-Baiti and Walsh, 2011). In con-
trast the XK1 model demonstrates reduced food intake. All  other
models induce a  host inflammatory response. In the Walker 256
and MCG  – 101 models tumour growth is  extremely rapid result-
ing in  a tumour mass exceeding 10% of host body weight in a  matter
of days (Bennani-Baiti and Walsh, 2011). This highlights the prob-
lems with the translational value of relatively acute onset cancer
cachexia seen in  murine models compared with humans where a
cancer may  spread over a period of months or years (with similar
time scale for the evolution of cachexia). One of the most popular
models at present is  a particular clone of the colon-26 adenocar-
cinoma (C26) tumour in mice. This is  thought to be a mainly IL-6
dependant model of cachexia (Strassmann et al., 1992). Whether,
in  fact, this can be considered as representative of the majority of
cancer patients remains highly speculative.
3. Skeletal muscle morphology in  cancer associated
myopenia: murine models
Skeletal muscle is composed of muscle fibres which are  clas-
sified according to their speed of contraction and predominant
type of energy metabolism. Muscle fibres can be classified as type
I, slow-twitch and type II, fast-twitch fibres based on their pre-
dominant myosin heavy chain (MyHC) isoform content. Generally,
type I and type IIa fibres utilise oxidative phosphorylation as their
energy source, whereas type IIx and IIb fibres harness anaero-
bic metabolism to generate ATP (Schiaffino and Reggiani, 1996;
Berchtold et al., 2000). Both the percentage and structural mor-
phology of the fibre type will determine the phenotypic capacity
and functional performance of any given muscle. Environmental
factors in both health and disease have a  direct impact on mus-
cles leading to  changes in  fibre type and morphology which lead
to  changes in muscle functionality; such processes include age-
ing, exercise, diabetes, disuse atrophy, chronic heart failure, and
cachexia (Lipkin et al., 1988; Mancini et al., 1989; Sullivan et al.,
1990; Drexler et al., 1992; Belardinelli et al., 1995; Short and Nair,
2001; Basu et al., 2002; Marx et al., 2002; Short et al., 2004; Schmitt
et al., 2007; Weber et al., 2007; Eley et al., 2008; Harber et al., 2009;
Weber et al., 2009). The change, preservation or loss of fibres may
influence clinical symptoms and there is some evidence that fibre






























ype is  targeted selectively in cancer cachexia (Clarke et al., 2007;
ohen et al., 2009). Ongoing loss of protein in muscle tissue leads
o muscle fibre shrinkage and a reduction in CSA. This loss of CSA
eads to the main muscle groups in the body undergoing changes in
bre composition which leads to a  marked loss of aerobic capacity
VO2max) in healthy subjects as well as cancer patients (Ferretti
t al., 1997; Proctor and Joyner, 1997; Bassett and Howley, 2000;
ette and Staron, 2001; Weber et al., 2007).
.1. Fibre size and type in cancer associated myopenia
The model that has been most frequently studied is the C26
umour grown subcutaneously in  mice (Table 1). The predominant
uscles studied include the gastrocnemius and soleus from the
ower limb. Unlike humans, no model uses old, co-morbid mice
ndergoing concomitant anticancer therapy! A common finding is
 decrease in fibre size. With regard to fibre type, evidence from
nimal models suggests that type II fibres are targeted selectively
Acharyya et al., 2005) with relative preservation of type I  fibres
n fasting (Li and Goldberg, 1976), exposure to Glucocorticoids
Goldberg and Goodman, 1969; Dahlmann et al., 1986), sepsis (Tiao
t al., 1997) and in the gastrocnemius muscle of the C26 model of
ancer cachexia (Acharyya et al., 2004). Not all studies have demon-
trated type 1 and 2 fibre differences. Indeed, in a  recent exposition
f the C26 cachectic mouse model, both glycolytic and oxidative
bres of (extensor digitorum longus) EDL muscle underwent wast-ng (Aulino et al., 2010), whilst in  a  previous study using the same
ouse model there was a significant increase in the amount of type
b MyHC and a significant decrease in  the amount of type 1 MyHC
n soleus muscle (Diffee et al., 2002). cancer cachexia.
The activity patterns of muscle are also key in determining phe-
notype. If muscle cells are recruited infrequently, they develop
into fast/glycolytic units whereas if they are recruited more often,
they form slow/oxidative units. In the C26 mouse model of cancer
cachexia, there have been reports of switching of myosin isoforms
in the soleus muscle of cachectic mice (Diffee et al., 2002).
3.2. Fibre RNA, DNA, and protein content in cancer associated
myopenia
A reduction in total RNA content has been associated with a
depression in  protein synthesis in mice bearing the human hyper-
nephroma XK1 (Emery et al., 1984)  and in mice bearing the MAC-16
tumour (Bhogal et al., 2006). Timing of sampling may  be important
in  the results obtained from such muscle biopsies. A reduction in
the RNA content in the muscle of mice bearing the Ehrlich ascites
tumour has also been reported, but this occurred later than the
onset of depressed protein synthesis (Lopes et al., 1989).
Protein content expressed in relation to  wet  weight of  muscle
has been shown to decrease progressively (in excess of  50%) in the
gastrocnemius muscle of mice bearing the MAC-16 tumour (Bhogal
et al., 2006). Similar changes have been documented in the Yoshida
ascites hepatoma A130 cachexia model (Tessitore et al., 1993a,b).
This suggests that not only is there loss of fibre diameter, but that
the quality of the fibre is altered with loss of either sarcoplasmic
or myofibrillar protein. DNA content of the gastrocnemius muscle
has been shown to remain relatively constant, despite the find-
ing of a decrease in protein and RNA content (Bhogal et al., 2006).
Clearly not  all DNA in  a muscle can be ascribed to  myonuclei. How-
ever, these findings are consistent with the trend towards fibre
2218 N. Johns et al. / The International Journal of Biochemistry & Cell Biology 45 (2013) 2215– 2229
Table  1
Experimental animal data on myosin composition of muscles in cancer cachexia.
Authors Model Muscle group Myosin fibre type Fibre size (FCSA) (m2) Fibre percentage (%)
Aulino et  al. (2010) Mouse C26 colon EDL 1 ↓  ↓
2  ↓  ↓
Acharyya et  al. (2005) Mouse C26 colon TA/gastrocnemius 1 No change No change



















































Diffee et al. (2002) Mouse C26 colon Soleus 
ytoplasmic atrophy without a  decrease in  myonuclear number
bserved in mature mice that undergo long term denervation injury
Wada et al., 2002). The issue of whether nuclear domain size
s reduced in  cancer cachexia remains to be resolved. In partic-
lar, whether apoptosis in skeletal muscle is  increased in  cancer
achexia (van Royen et al., 2000)  and the degree to  which DNA
ontent is maintained or  not via  a compensatory increase in myonu-
lear number (possibly via satellite cell nuclei incorporation) is not
nown. Features of cachexia such as hypogonadism (resulting in
ow testosterone) or systemic inflammation (associated with high
L-6) could influence such regenerative capacity.
.3. Dystrophin glycoprotein complex (DGC)
It is also important to  recognise that in cancer cachexia
here may  be changes in the muscle cytoskeleton as well as
n the myofibrillar contractile apparatus. In recent years, it has
een demonstrated that alterations in the muscular dystrophy-
ssociated DGC also occur in skeletal muscle (Acharyya et al., 2005).
sing both the C26 and Lewis lung carcinoma (LLC) murine can-
er models, it was shown that muscles from tumour-bearing mice
xhibited membrane abnormalities, accompanied by  reduced dys-
rophin (core DGC member) expression and increased glycosylation
f DGC proteins (Acharyya et al., 2005). The DGC is  thought to  play a
ey role in maintaining muscle integrity during contraction cycles
nd clearly loss of this function may  exacerbate overall damage to
he muscle.
. Mediators of cancer associated myopenia: murine
odels
.1. Neural control
Muscle mass is clearly sensitive to food intake. The pathogene-
is of cancer anorexia is  multifactorial and reflects the complexity
f the mechanisms controlling energy homeostasis under physi-
logical conditions. The main molecular mechanisms regulating
he cancer anorexia-cachexia syndrome include alterations in brain
eurochemistry. In particular, the hypothalamic melanocortin sys-
em appears not to respond appropriately to  peripheral inputs, and
ts activity is diverted largely towards the promotion of catabolic
timuli promoting metabolism of carbohydrates, lipids, and pro-
eins in peripheral tissues leading to  insulin resistance, increased
ipolysis, and accelerated muscle proteolysis (Tisdale, 2002)  (Fig. 2).
ro-inflammatory cytokines (TNF and IL-1) and hypothalamic
erotonergic neurons have been implicated in the dysfunction of
he hypothalamic melanocortin system (Inui, 1999). Two  peptide
ystems in  particular appear to be strongly influential in  the con-
rol of feeding behaviour: these are the orexigenic neuropeptide
 (NPY), and the anorexigenic (pro-opiomelanocortin) POMC sys-
ems (Plata-Salaman, 2000). Many of these mediators exert their
ffects through changes in the NPY/POMC systems. Both originate
n the hypothalamic arcuate nucleus (ARC) and extend projections
idely over the brain (Plata-Salaman, 2000). They have been shown ↓
a No change
b  ↑
to  be linked intricately with each other and to operate in  par-
allel. POMC neurons are the source of the potent melanocortin
neuropeptides, such as -melanocyte-stimulating hormone (MSH),
which, via interaction with the central MC3/4 – receptors, induce
an anorectic state. The role of cytokines in cancer anorexia may
be affected through influence on both the NPY and POMC sys-
tems. Hypothalamic IL-1 mRNA has been shown to  be significantly
increased in methylcholanthrene-induced sarcoma bearing rats.
Levels of IL-1 in  cerebrospinal fluid of the same rats are also
increased and inversely correlate inversely with energy intake
(Opara et al., 1995). However, injection of an IL-1 receptor antago-
nist ameliorates anorexia in the same model (Laviano et al., 2000).
In another experimental animal system, injection of IL-1 into
the hypothalamus within hours causes significant change in gene
expression in skeletal muscle including up regulation of  the UPP.
This clearly demonstrates the potential for neural control of muscle
protein synthesis and degradation (Braun et al., 2011). This mech-
anism has not been fully explored in  cancer cachexia.
4.2. Pro-inflammatory mediators
Mediators regulating skeletal muscle atrophy in cachexia are
thought to  derive from immune or tumour cells, or  the targeted tis-
sues undergoing wasting (both adipose tissue and skeletal muscle).
Inflammation is  thought to  be  of paramount importance. Cancer cell
rely on production of pro-inflammatory mediators for growth, pro-
tection from apoptosis, and promotion of angiogenesis/metastasis.
The tumour may  consequently initiate a cytokine cascade that has
multiple, direct, and distant effects including the initiation of  skele-
tal muscle protein degradation.
CHO cells transfected with the human TNF- gene induced
cachexia when implanted into nude mice (Oliff et al., 1987). A sim-
ilar finding was observed with CHO cells constitutively producing
IFN- (Argiles et al., 2003). An anti-IFN- monoclonal antibody
was able to  reverse the wasting syndrome associated with the
murine Lewis lung carcinoma (Matthys et al., 1991). TNF- and
IFN- work co-operatively to down-regulate transcription of  the
MyHC gene in vitro and in  vivo, but not  other core myofibril-
lar proteins (Acharyya et al., 2004). Furthermore, MyHC protein
expression was  decreased in  a specific fashion in the C26 model
(Acharyya et al., 2004), a largely IL-6 dependent model (Strassmann
et al., 1993). TNF has been shown in  vitro to inhibit both adipocyte
and skeletal myocyte differentiation (Guttridge et al., 2000; Ruan
et al., 2002). It also plays a  role in insulin resistance attenuating
the insulin signalling pathway (Hotamisligil, 1999). The presence
of TNF promoted atrophy in  cultured myotubes, resulting from
the induction of E3 ligase genes that mediate the breakdown of
myofibrillar proteins by the UPP (Li et al., 2005; Frost et al., 2007;
Moylan et al., 2008; Sishi and Engelbrecht, 2011). TWEAK, another
important cytokine with structural properties similar to TNF, can
induce a  cachectic phenotype in part by the induction of the E3
ligase MuRF1, and the subsequent degradation of MyHC at the thick
filament of the sarcomere (Dogra et al., 2007; Mittal et al., 2010).
A variety of tumours have been shown to secrete IL-6 and this can







































ig. 2. Integrative physiology of cancer cachexia. The cancer is  able to activate pr
educed  food intake, decreased protein synthesis and increased degradation.
e amplified by host-derived proinflammatory cytokines (e.g. IL-
). Experiments regulating function in tumour bearing mice also
upport the requirement of IL-6 in cachexia (Black et al., 1991;
trassmann et al., 1992, 1993). In mice with a  mutation in  the APC
umour suppressor gene, elevated circulating IL-6 levels are asso-
iated with the presence of muscle wasting (Baltgalvis et al., 2008).
nockout of IL-6 prevents loss of muscle weight and epididymal
at, and reduces intestinal polyp number, implying the existence of
n IL-6 cytokine amplification loop between host and tumour cells.
Other cytokines may  be potential repressors of cachexia. For
xample, IL-4, IL-10 and IL-13 all demonstrate anti-inflammatory,
nd hence potentially anti-cachectic activity (Argiles and Lopez-
oriano, 1999). In  the C26 mouse model, IL-10 gene transfer
educed cachexia and prolonged survival (Fujiki et al., 1997). Other
ytokines (e.g. IL-15) may  have potential ‘antioxidant’ properties
hat can counter the excess levels of reactive oxygen and nitrogen
pecies (caused by the inefficiency of host antioxidant enzymes)
hat have been proposed as mediators of muscle atrophy (Barreiro
t al., 2005). IL-15 was capable of inhibiting skeletal muscle wasting
n the Yoshida AH-130 rat ascites hepatoma model by decreasing
uscle protein degradation rates (Carbo et al., 2000). Overex-
ression of IL-15 in cultured myotubes induced a hypertrophic
orphology and increased myofibrillar protein accumulation in
o-cultured cells (Quinn et al., 2002).
.3. Catabolic mediators
The interplay of anabolic and catabolic hormones has a  dis-
inct role in  the development of skeletal muscle wasting. The
atabolic hormones myostatin and activin are two  members of
he TGF- superfamily that play an important role in growth and
re thought to  be responsible for the development of cachexia in
ice lacking the hormone inhibin (Elliott et al., 2012). In  mice,
oth molecules bind to  activin receptor type-2B (ActRIIB), a  recep-
or in muscle, to initiate a  signalling cascade leading to increased
xpression of MuRF1 and MAFbx/Atrogin-1 and subsequent degra-
ation of myofibrillar proteins (Glass, 2010a,b). In mice bearing the
26 tumour, administration of a  soluble ACTRIIB decoy receptor
esulted not only in  reversal of muscle wasting but an increase in
urvival (Zhou et al., 2010).ammatory, acute phase, and neuro – endocrine responses. The consequences are
4.4. Anabolic mediators
The anabolic hormone IGF1 has been implicated in the devel-
opment of cancer cachexia in murine models. In the rat AH-130
hepatoma ascites model of cancer cachexia, muscle expression
of IGF-1 mRNA decreased progressively whereas IGF-1 receptor
and insulin receptor mRNA levels increased compared with con-
trols (Costelli et al., 2006). Furthermore, circulating levels of  IGF-1
and insulin were reduced. However, the exact mechanism of IGF-1
down-regulation and any role in muscle wasting in this scenario is
unclear, as administration of exogenous IGF-1 to tumour-bearing
rats did not prevent cachexia (Costelli et al., 2006), and other stud-
ies have shown, at least in  experimental animal models of  cancer
cachexia, the IGF-1 signal transduction pathway is  not down-
regulated (Penna et al., 2010; White et al., 2011, 2013).
5. Mechanisms of cancer associated myopenia: murine
models
5.1. Protein degradation pathways
Skeletal muscle atrophy may  occur as a  result of decreased syn-
thesis, increased degradation or  both (Glass, 2010a,b). In cancer
cachexia it is  evident that there is a  complex interplay between
synthesis and degradation. In  mice bearing the MAC-16 adeno-
carcinoma, weight loss was accompanied by loss of whole body
nitrogen in proportion to the overall loss of body mass. Using L-[4-
3H]phenylalanine to label proteins in the gastrocnemius muscle to
determine rates of synthesis and degradation, a significant depres-
sion (60%) in protein synthesis occurred in animals with a  weight
loss between 15% and 30%. This was  accompanied by an increase in
protein degradation, which increased with increasing weight loss
between 15% and 30% (Smith and Tisdale, 1993). Three major path-
ways that may  contribute to such increased protein degradation
include the UPP, autophagy/lysosomal pathway, and the calcium
dependant enzymes (e.g. calpains) (Tisdale, 2009).5.1.1. Ubiquitin proteasome pathway
Various factors including malnutrition, impaired physi-
cal activity and the production of catabolic molecules (e.g.
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Fig. 3. Muscle protein kinetics in cancer cachexia. Regulation of muscle synthesis via IGF – 1 induced hypertrophy (A). Myokine activated JAK/STAT pathway involved in
































reakdown (D). Muscle breakdown mediated by UPP, leading to activation of the E3
F).  NF– signalling (G).
lucocorticoids and/or cytokines) up regulate rates of muscle
roteolysis (Ventadour and Attaix, 2006). A common end point in
athways implicated for increased protein breakdown involves
wo muscle-specific E3 ubiquitin protein ligases, which target
pecifically a  limited number of proteins for breakdown by the
roteasome. These E3 ligases are  called MAFbx/Atrogin-1 and
uRF1 (Fig. 3).
.1.1.1. Pro inflammatory cytokine activation of the UPP. TNF,
WEAK or IL-1 signal to  activate the NF– pathway. NF–
nfluences a  variety of pathways including apoptosis, inflamma-
ion and differentiation. Pro-inflammatory cytokines induce the
ytosolic release of NF– from its inhibitory I proteins to  allow
ranslocation of NF– into the nucleus and subsequent transcrip-
ion of proteolytic pathway components (Ladner et al., 2003). In
oth myocytes and murine models, the cytokine-induced activa-
ion of NF– has been shown to inhibit muscle differentiation
nd function through the suppression of MyoD mRNA and pro-
ein (Guttridge et al., 2000). NF– is required to up-regulate the
xpression of the key E3 ligases (MuRF-1 and MAFbx/atrogin-1)
hich mediate sarcomeric breakdown and inhibition of protein
ynthesis (Glass, 2010a,b). MuRF1 is  up-regulated in  multiple sett-
ngs of muscle atrophy (Bodine et al., 2001a,b). This E3 ubiquitin
igase is responsible for mediating the ubiquitination of the thick
lament of the sarcomere MyHC (Clarke et al., 2007), and other
hick filament components (Cohen et al., 2009). MuRF-1 has also
een shown to  target for breakdown troponin I  (Kedar et al., 2004)
nd actin (Polge et al., 2011), which are components of the thin
lament. Furthermore in  the latter study it was also shown that
uRF-1 protein levels are up-regulated in muscles of non-cachecticitin ligases MuRF1 and MAFbx (E). Activation and transcription of autophagy genes
cancer patients. The cytokine TWEAK, in particular, induces MuRF1
upregulation via NF–,  resulting in MyHC loss (Mittal et al., 2010).
Inhibition of classical NF– is  sufficient to decrease significantly
tumour induced muscle loss, at least in  Yoshida AH-130 ascites hep-
atoma tumour bearing rats in part, by inhibiting the up-regulation
of MuRF1 (Cai  et al., 2004; Moore-Carrasco et al., 2007).
MAFbx/Atrogin-1 is  a highly specific marker of muscle atro-
phy as demonstrated in  other conditions causing cachexia such
as immobilisation, denervation, and glucocorticoid excess (Bodine
et al., 2001a,b; Gomes et al., 2001). MAFbx up regulation occurs
mainly via p38 activation (Li et al., 2005). MAFbx causes the ubiquit-
ination of eIF3f which is  directly involved in skeletal muscle protein
synthesis (Lagirand-Cantaloube et al., 2008). Thus MAFbx may
provide a key link between the simultaneous regulation of both
protein degradation and synthesis in certain models of cachexia
(Smith and Tisdale, 1993). Another E3 ligase, Fbxo40 has been
implicated in  skeletal muscle atrophy (Shi et al., 2011). It has
been suggested Fbox40 induces the ubiquitination of IRS1 there-
fore decreasing protein synthesis. Up regulation of  Fbox40 has been
seen in denervation but, at present little evidence suggests this may
occur in  other models of cachexia (Shi et al., 2011).
Administration of anti murine IL-6 receptor antibody to C26
bearing mice reduced weight loss of the gastrocnemius muscle to
84% of that of control mice. The enzymatic activity of  cathepsin
B + L and mRNA levels of cathepsin L and poly-Ub were signifi-
cantly depressed in control mice compared with C26 bearing mice,
indicating that both the lysosomal cathepsin pathway and the ATP-
dependant proteolytic pathway might be involved (Fujita et al.,
1996). The direct regulation of E3 ligase expression during IL-
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lthough less evidence exists to  demonstrate that IL-6 can lead
irectly to lipid mobilisation or altered skeletal muscle protein
urnover, there is general acceptance from mouse models (Bonetto
t al., 2011) that IL-6 is  produced from activated macrophages
nd may  contribute to net muscle loss in  cancer cachexia by
timulating the liver (Castell et al., 1989)  to induce an acute
hase protein response and subsequent reprioritisation of periph-
ral protein metabolism. The IL-6 receptor signals via the Janus
ssociated kinase/signal transducer and activator of transcription
JAK/STAT) signal transduction pathway (Fig. 3). Downstream acti-
ation results in STAT phosphorylation and translocation to the
ucleus to regulate genetic transcription (Ihle et al., 1995).
.1.1.2. TGF-  ̌ family activating the ubiquitin proteasome pathway.
 more recent factor, which has captured the attention of many
nvestigators, is  the TGF- family member, myostatin. Genetic null
nimals for myostatin, demonstrate dramatic muscle hypertrophy
Mosher et al., 2007). Myostatin is synthesised and secreted mainly
rom skeletal muscle cells. Myostatin acts firstly by  signalling
hrough the activin type II receptor, which then recruits an Alk
amily kinase, resulting in  the activation of a  SMAD2 and SMAD3
ranscription factor complex (Sartori et al., 2009; Trendelenburg
t al., 2009) (Fig. 3). Secondly, Akt and downstream TORC1 path-
ays that promote synthesis are down regulated (Trendelenburg
t al., 2009; Lokireddy et al., 2012). Myostatin excess causes an
ncrease in skeletal muscle atrophy (Zimmers et al., 2002), whilst
nhibition causes a  marked increase in muscle mass and myofibre
ize (Bogdanovich et al., 2002; Whittemore et al., 2003; Lee et al.,
005; Welle et al., 2007). Myostatin antagonism has been shown
o prevent cancer cachexia in the LLC mouse model (Benny Klimek
t al., 2010). Activin A  and B are other members of the TGF- fam-
ly that have been found to be up regulated in  skeletal muscle after
ctivation of the TNF/TAK-1 signalling pathway (Trendelenburg
t al., 2012). Both Activin A and Activin B are potent growth and
ifferentiation factors with a  broad spectrum of biological effects,
ncluding modulation of embryogenesis, neuroprotection, apopto-
is, and fibrosis. These TGF- molecules commonly bind to  the
ctRIIB receptor to initiate a  signalling cascade leading to increased
xpression of MAFbx/Atrogin-1 and MuRF1 and subsequent degra-
ation of myofibrillar proteins (Glass, 2010a,b). Direct evidence
inking muscle wasting to  survival of the host with cancer cachexia
as been lacking until recently (Zhou et al., 2010; Aversa et al., 2012;
usquets et al., 2012; Ju  and Chen, 2012). As mentioned previously,
hou and co-workers found C26 bearing mice that preserving mus-
le mass is vitally important in  the organism’s survival: ActRIIB
ntagonism prolonged survival and prevented muscle wasting and
eversed muscle loss. Further work demonstrated that ActRIIB
athway activation induced the ubiquitin ligases critical in mus-
le wasting and enhanced ubiquitination of muscle proteins, and
hese effects were completely abolished by ActRIIB antagonism. It
as also shown that ActRIIB-SMAD signalling stimulated FOXO3
ctivity in muscle, which induced transcription of MAFbx/Atrogin-1
nd MuRF1. Finally ActRIIB antagonism was shown to  dramatically
timulate satellite cell proliferation, which presumably also con-
ributed to the observed rapid reversal of muscle loss in treated
nimals.
.1.1.3. Deubiquitinating enzymes. Protein ubiquitination is a
eversible process. Much attention has been focused on identi-
cation of the enzymes responsible for conjugation of ubiquitin
o proteins. However, deconjugation of ubiquitin plays an impor-
ant role in regulating ubiquitin-dependent pathways (Kim et al.,
003; Wing, 2003). Previous studies have shown increased levels
f ubiquitination of muscle proteins in several catabolic condi-
ions including cancer (Wing et al., 1995; Tiao et al., 1996; Lecker
t al., 1999; Combaret et al., 2002). In Wistar rats bearing themistry &  Cell Biology 45 (2013) 2215– 2229 2221
Yoshida sarcoma, administration of a  xanthine derivative close to
pentoxifylline that inhibits TNF  production, torbafylline (also
known as HWA  448) prevented muscle wasting by suppressing
elevated proteasome – dependent proteolysis and accumulation of
Ub-protein conjugates (Combaret et al., 2002). However, the deu-
biquinating enzyme USP 19 was shown to be overexpressed in two
models of rats bearing the Yoshida sarcoma or hepatoma (Combaret
et al., 2005). Whether suppression of deubiquitination contributes
to cancer cachexia remains unresolved.
5.1.2. Autophagy/lysosomal pathway
Intracellular lysosomes contain a  number of enzymes required
for the digestion of macromolecules, including proteases, carbo-
hydrases, lipases and nucleases. Cathepsins L, B, D and H  are  the
major lysosomal proteases and determine primarily the proteolytic
capacity of lysosomes (Tisdale, 2009). Cathepsin-L, in particular, is
induced early in catabolic states, and levels correlate with increased
protein breakdown. Increased cathepsin activity has been demon-
strated in various models of muscle wasting, including cancer
cachexia, diabetes mellitus, dexamethasone-induced atrophy, dis-
use, fasting and muscular dystrophy (Helliwell et al., 1998; Wang
et al., 1998). The autophagy pathway is  necessary to drive sub-
strates to  lysosomes, and lysosomal proteolysis is dependent on
the activity of cathepsins (Attaix and Bechet, 2007). In a  recent
study, autophagy was  shown to be increased in  the muscle of
mice implanted with the C26 tumour (Penna et al., 2013). In most
mechanistic studies, induction of autophagy has been associated
with increased activation of FOXO3A-dependent transcription of
autophagy-related genes such as LC3B and BNIP3 (Mammucari et al.,
2007)  (Fig. 3). An elevation of total lysosomal protease activities has
been observed in  muscles and liver of DBA/2 mice inoculated with
L1210 tumour cells (Greenbaum and Sutherland, 1983; Tessitore
et al., 1993a,b) along with increased muscle levels of cathepsin
L mRNA in septic rats (Deval et al., 2001). Autophagy has been
demonstrated to play a  role in cardiac atrophy associated with can-
cer cachexia (Cosper and Leinwand, 2011,2012). In the C26 tumour
mouse model, autophagy (without UPP activation) in cardiac mus-
cle was  demonstrated to be responsible for loss of both myofibrillar
and sarcomeric proteins. The findings in  skeletal muscle in cancer
cachexia models are less clear, some have shown a  selective tar-
geting of MyHC (Acharyya et al., 2004), whereas other studies do
not support a  selective sparing of MyHC (Cosper and Leinwand,
2011,2012). Furthermore, studies into variety of other catabolic
conditions appear not to  show a selective sparing of MyHC (Baehr
et al., 2011; Gomes et al., 2012).
5.1.3. Calpains
Several different calcium-dependent enzyme systems exist,
including the calpains. The calpains are a  family of intracellular,
non-lysosomal, calcium-regulated cysteine proteases that mediate
cleavage of specific substrates in a large number of  regulatory cell
processes (Bertipaglia and Carafoli, 2007). In  excessive amounts,
calpains are capable of degrading cytoskeletal elements, ion chan-
nels, other enzymes, cellular adhesion molecules and cell surface
receptors. The ubiquitous calpains 1 and 2 (also called  and m)
have been implicated in both the initial degradation of myofibrillar
proteins during muscle wasting (Barta et al., 2005) and the necro-
sis associated with muscular dystrophy (Tidball and Spencer, 2002).
Calpains have also been implicated in the degradation of  sarcom-
eric and cytoskeletal proteins in  cultured myotubes (Purintrapiban
et al., 2003) (Fig. 3). In this particular study, the addition of a  calpain
inhibitor resulted in  a  20% reduction in  overall protein degradation.
Similarly, this was  reported in a  mouse hindlimb suspension model
where inhibition of calpain activity preserved sarcomere structure
and furthermore prevented a  fall in the isometric force generating
capability (Salazar et al., 2010). Ubiquitous calpain activity is under
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Table  2
Clinical data on myosin composition of skeletal muscle in cancer cachexia.
Authors Model Definition of cachexia Muscle group Myosin fiber type Fibre size (FCSA) (m2) Fibre percentage (%)
Eley et  al. (2008) Cancer (n =  15) >5% in 6 months Rectus All  ↓
Weber et al. (2007) Cancer (n =  17) >20% in 6 months Quadriceps 1 ↓ ↑
2a ↓ ↓
2x ↓ ↓
Schmitt et al. (2007) Cancer (n =  8)  >10% in 6 months Rectus All  ↓
Weber et al., 2009 Cancer UGI (n = 19) >10% in 6 months Quadriceps All  ↓















































he control of the endogenous inhibitor calpastatin, and downregu-
ation of calpastatin expression has been suggested as one potential
echanism of muscle atrophy. In contrast, overexpression of cal-
astatin may  have potential therapeutic benefits against muscle
trophy. In animal models, transgenic overexpression of calpastatin
an reduce both the atrophy caused by unloading and the necrosis
ssociated with muscular dystrophy (Tidball and Spencer, 2000).
here is little evidence in the literature to allow assessment of the
ole of calpains in models of cancer cachexia.
.2. Protein synthesis pathways
The primary role of suppressed protein synthesis in cancer
achexia has been suggested by  studies with mice bearing the MAC-
6 adenocarcinoma. Using L-[4-3H]phenylalanine to  label proteins
n the gastrocnemius muscle to determine rates of protein synthe-
is, a significant depression (60%) occurred in animals with a  weight
oss between 15% and 30% (Smith and Tisdale, 1993). In muscle
nsulin receptor knockout mice, there is evidence that reductions
n muscle mass and function are due to  depression of synthesis
nd not an increase in degradation (O’Neill et al., 2010). Two major
argets for reduced protein synthesis in cachexia include either
nhibition of amino acid uptake or the suppression of RNA expres-
ion or translation (Acharyya et al., 2004). Indeed, some tumour
odels show as much as a 40% decrease in total muscle RNA com-
ared with control animals (Emery et al., 1984; Baracos et al., 1995).
he concept that skeletal muscle protein synthesis in cachexia
s reduced simply due to  anorexia alone (Tisdale, 2009)  seems
nlikely. In animal models where anorexia is absent, depression of
rotein synthesis has also been demonstrated suggesting that the
rotein synthetic machinery is  defective (Smith and Tisdale, 1993).
n the MAC-16 cancer cachexia model, catabolism and anabolism
ppear to occur in tandem with up to a  60% fall in  protein syn-
hesis (Beck et al., 1991). In another animal model, the Apc(Min/+)
ouse, a reduction in  protein synthesis seemed to precede a rise
n proteolysis, suggesting differential time-dependant activation of
athways (White et al., 2011).
The predominant regulator of skeletal muscle hypertrophy is
hrough stimulation of the PI3K/Akt pathway by  insulin or IGF-1
Bodine et al., 2001a,b; Rommel et al., 2001; Glass, 2010a,b) (Fig. 3).
ice in which Akt is  transgenically expressed and inducibly acti-
ated in skeletal muscle demonstrate dramatic hypertrophy upon
he activation signal (Pallafacchina et al., 2002; Lai et al., 2004;
zumiya et al., 2008), helping to  prove that Akt is  the pathway that
s sufficient to  mediate hypertrophy downstream of IGF1 upregu-
ation. Activation of Akt leads to an increase in  the mTOR/p70S6K
athways and a  rise in protein synthesis. As well as inducing protein
ynthesis, IGF1 can inhibit skeletal muscle atrophy. In the pres-
nce of up regulated IGF1 signalling, the atrophy genes MuRF-1 and
AFbx/atrogin-1 are actively inhibited (Bodine et al., 2001a,b).5.3. Fat-muscle cross talk
Recent work suggests molecular cross-talk between adipose
tissue and muscle that occurs through adipokines and myokines.
Integrative physiology in obesity and diabetes has long empha-
sised the importance of chronic inflammation, increased adipocyte
lipolysis, and increased levels of circulating free fatty acids in
the adipose–muscle cross-talk that contributes to  lipotoxicity and
insulin resistance in muscle. Intracellular accumulation of  diac-
ylglycerol triggers activation of novel protein kinases C with
subsequent impairments in insulin signalling (Samuel et al., 2010).
A recent study in  mice bearing the IL-6 producing, pro-cachectic
C26 tumour showed that genetic ablation of adipose triglyceride
lipase prevented the increase in  lipolysis and the net mobilisation
of adipose tissue associated with tumour growth (Das et al., 2011).
Unexpectedly, skeletal muscle mass was  preserved and activa-
tion of proteasomal degradation and apoptotic pathways in  muscle
was averted. Ablation of hormone-sensitive lipase had similar, but
weaker, effects. Physiologically important and previously unrecog-
nised crosstalk between adipose tissue and skeletal muscle may
therefore exist in  the context of cancer cachexia (Argiles et al., 2005;
Johns et al., 2012; Zechner et al., 2012).
6. Skeletal muscle morphology and function in cancer
associated myopenia: clinical data
Results from morphological studies in  humans to date are
shown in  Table 2.  The limited data available suggest loss of  MyHC
and reduction in  fibre CSA. The rectus muscle of patients with
oesophago-gastric cancer cachexia (Eley et al., 2008)  has been
shown to  lose MyHC content as well as undergo a  reduction in fibre
size. Similarly, the rectus muscle of patients with colorectal cancer
has also been shown to  lose MyHC content (Zampieri et al., 2010). In
pancreatic cancer patients with cachexia MyHC protein levels were
decreased by 45% when compared with controls (Schmitt et al.,
2007). It  has been suggested, based on MRI  CSA muscle measure-
ments and ex vivo muscle biopsies, that cancer-related cachexia
is  associated with a  loss of muscle volume, but not of  muscle
function (Weber et al., 2009). After normalising measured mus-
cle strength for reduced CSA in cachectic patients, although muscle
volume was diminished, the principal ability to  generate force was
maintained. The morphological basis for this finding seemed to  be
smaller mean fibre diameter associated with an increased total fibre
number per area (Weber et al., 2009). In contrast, in  a  larger series
of upper GI cancer patients, muscle mechanical quality measured
by knee extensor strength per unit quadriceps CSA was shown to
be reduced. Furthermore the degree of impairment of lower limb
muscle mass, quality and function and the impact on quality of life
varied with weight-loss and sex (Stephens et al., 2012). Few other
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ata into fibre size, type, myonuclear, and protein content remain
imited.
. Mediators of cancer associated myopenia: clinical data
Unlike murine models where various highly specific treatments
ave been tested (e.g. ActRIIB receptor), there are no licensed treat-
ents for cancer cachexia in  humans and therefore the data on
ediators and mechanisms are entirely of an observation nature.
his naturally restricts the conclusions that can be  reached. There
as, however, been a recent increase in  phase II/III clinical trial
ctivity and results from these trials promise to  provide much
eeded insight.
.1. Systemic mediators of cachexia
As in animal models, cancer cachexia in humans is considered,
t least in part, to  result from interactions between the host and
he tumour.
.1.1. The acute phase response
An organism responds to the presence of acute infection, tissue
njury, trauma or  surgery by mounting an acute phase response
APR), this is  designed to help limit tissue injury by the increased
ynthesis of key defence/repair proteins by  the liver. However, in
ertain circumstances when dietary protein intake is  limited and
he APR is  prolonged or severe, an APR can exacerbate muscle wast-
ng by increasing the demands for certain amino acids to support
ncreased hepatic export protein synthesis.
.2. Pro-inflammatory cytokines
Pro-inflammatory cytokines, in particular IL-6, IL-1, TNF and
FN-, are central to systemic inflammation and the induction of
n APR. Cytokine interaction between host and tumour cells within
he tumour are  thought to activate peripheral blood mononuclear
ells (PBMC) passing through the tumour vasculature. Increased
ro-inflammatory cytokine release by PBMCs has been demon-
trated in cancer patients with evidence of an APR (Wigmore et al.,
002; O’Riordain et al., 1999). Moreover, patients with pancreatic
ancer and cachexia appear to  have higher intra-tumoural IL-6
xpression and this is associated with increased PBMC IL-6 pro-
uction (Martignoni et al., 2005). Tumour associated macrophages
TAM) may  be one important cellular sub-type involved in  the intra-
umoural interaction between host and tumour cells (Yuan et al.,
008). In cancer, host mononuclear cells are recruited to tumours by
arious signals including hypoxia. The resultant Th-2 type micro-
nvironment may  favour tumour progression via the promotion of
ngiogenesis, the remodelling of the extracellular matrix to allow
nvasion, and the suppression of adaptive immunity (Yuan et al.,
008).
Despite the pivotal role of pro-inflammatory cytokines in  the
etiology of cancer cachexia in animal models, human trials to
ate using cytokine antagonists have not  generally been successful
t ameliorating muscle loss. The use of infliximab, an anti-TNF-
onoclonal anitibody (mAb), in conjunction with docetaxel was
hown to be associated with increased fatigue and worsened QoL
cores in NSCLC patients compared with docetaxel with placebo,
nd therefore the trial was stopped (Jatoi et al., 2010). Neither arm
f the study demonstrated palliation of weight loss. A  further trial
f infliximab with gemcitabine in  pancreatic cancer patients was
nable to  demonstrate a significant improvement in  LBM or sur-
ival (Wiedenmann et al., 2008), whereas a  trial of etanercept, a
NF- inhibitor, in cachectic cancer patients was not associated
ith weight gain or improved survival (Jatoi et al., 2007). Trialsmistry &  Cell Biology 45 (2013) 2215– 2229 2223
of pentoxyfilline, a  cytokine inhibitor, have also shown little clin-
ical benefit in the treatment of cachexia and anorexia in cancer
patients (Goldberg et al., 1995). In human trials of an anti-IL6 mAb
early clinical studies in patients with non-small-cell lung cancer
has shown it to be safe and well tolerated. Treatment with BMS-
945429 improved lung symptoms, reversed fatigue, and a trend
towards a  decrease in the loss of lean body mass was  noted (Bayliss
et al., 2011). In another study of patients with cholangiocarcinoma,
selumetinib (MAPK1 and IL-6 secretion inhibitor) was shown to
promote a  gain in  muscle mass (Prado et al., 2012).
7.3. Other circulating mediators
7.3.1. Calcium and vitamin D
A potential role for calcium and vitamin D in muscle wasting
relates to  evidence from the myopathy (predominantly type II fibre
atrophy) seen in  osteomalacia, which can be exacerbated in ageing
(Janssen et al., 2002). In sarcopenia, women with low vitamin D
have been shown to have approximately twice the risk of reduced
muscle mass and strength and a similar relationship was observed
with raised parathyroid hormone levels (Visser et al., 2003). Vita-
min  D  deficiency has been reported in  over 80% of cancer patients
(Stone et al., 2011) and may  be  particularly prominent in  patients
receiving chemotherapy (Fakih et al., 2009). A retrospective study
of advanced cancer patients reported 70% vitamin D  insufficiency
and an association with anorexia and fatigue (Dev  et al., 2011). In
cachectic cancer patients, vitamin D gene receptor polymorphisms
have been linked to a more aggressive form of cachexia (Punzi et al.,
2012).
7.3.2. Glucocorticoids
In cachectic pancreatic cancer patients, elevated serum levels
of cortisol have been shown, along with elevated cortisol:insulin
ratios (Fearon et al., 1998). Glucocorticoids are administered
frequently to cancer patients undergoing chemotherapy or radio-
therapy. This cancer therapy is  often associated with exacerbation
of muscle wasting. Glucocorticoid atrophy seems specific to  type II
fibres. Mechanism may  involve upregulation of protein degradation
pathways, upregulation of myostatin and enhanced glutamine syn-
thetase activity (Carballo-Jane et al., 2004). Glucocorticoids inhibit
physiological secretion of growth hormone and appear to  reduce
IGF-1 activity in  target organs.
7.3.3. Insulin
Insulin can stimulate protein synthesis via  the PI3K/Akt path-
way. Both low insulin production and peripheral insulin resistance
has been demonstrated in  cancer cachexia (Tisdale, 2009). In can-
cer patients, treatment with low dose insulin therapy as part of
a  combination therapy regimen resulted in  a rise in  carbohydrate
intake, and increase in  body fat, and a  fall  in  serum-free fatty acids.
Despite these findings however, there was no change in  lean body
mass, maximum exercise capacity or spontaneous physical activ-
ity (Lundholm et al., 2007). Higher serum insulin did not change
IGF-I levels, which may  explain the dissociated effects by insulin
on whole body fat and lean tissue.
7.3.4. Ghrelin
A randomised controlled trial has investigated the effects of
intravenous ghrelin taken at both low dose and high dose in
patients with a variety of advanced metastatic cancer. No difference
between treatments was  seen for nutritional intake, symptoms,
adverse effects or tolerability (Strasser et al., 2008). In another
study, 31 patients with metastatic gastrointestinal cancer were ran-
domised in  a double-blind manner to  ghrelin at 2  different doses
subcutaneously daily for 8 weeks. In the high-dose group (versus
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here was a trend to less fat-free mass loss and improved energy
alance. There were no differences in food intake, quality of life or
hysical activity (Lundholm et al., 2010). The studies to  date are
mall phase I  and phase II  trials, and therefore, results should be
reated with caution. A phase III, randomised, placebo-controlled
linical trial assessing anamorelin hydrochloride in patients with
on-small-cell lung cancer-associated cachexia is currently recruit-
ng patients (clinicaltrails.gov/NCT01505764).
.3.5. Androgens
Testosterone inhibits release of TNF, IL-1, IL-6 from
acrophages and stimulates production of IL-10 (Li et al., 1993;
’Agostino et al., 1999; Malkin et al., 2004). Low testosterone levels
hypogonadism) may  thus lead to  an increase in pro-inflammatory
ytokine production. A recent study looking at hypogonadism in
ale cancer patients demonstrated low levels of testosterone in
he presence of high plasma IL-6 (Garcia et al., 2006). In  males
ith pancreatic cancer, systemic inflammation was associated
ith hypogonadism which in turn was associated with shortened
urvival (Skipworth et al., 2011). Despite these findings, trials have
ot been able to show an improvement with exogenous androgens.
 trial of nandrolone decanoate in  patients with advanced NSCLC
emonstrated a  trend for decreased weight loss (Chlebowski et al.,
986). In another study comparing fluoxymesterone with mege-
trol acetate or dexamethasone, fluoxymesterone was  inferior in
erms of appetite and weight gain (Loprinzi et al., 1999). Recently,
ARMs have received much attention as potential muscle-targeted
reatments for cancer cachexia. In humans, Phase I  and II  clinical
rials have shown that SARMs increased LBM and enhanced
unctional status (Zilbermint and Dobs, 2009). In a  recent phase
Ib randomised, double blind, placebo controlled study, treatment
ith enobosarm (GTx-024) was shown to  significantly increase
ean body mass and muscle function in 120 healthy elderly men
nd women (Dalton et al., 2011) At present, enobosarm is  being
ssessed in a  randomised, placebo-controlled, phase III clinical
rial in patients with non-small-cell lung cancer receiving first-line
hemotherapy treatment (clinicaltrails.gov/NCT01355497).
.3.6. Myostatin
In a recent study of myostatin expression in muscle biopsies
rom non weight losing lung and gastric cancer patients, there
as evidence of increased expression in the gastric cancer patients
Aversa et al., 2012). This suggests that in human cancer cachexia,
yostatin alterations may  vary by  primary tumour site. There are
t least two ongoing phase II trials of anti myostatin strategies (clin-
caltrials.gov/NCT01505530), (clinicaltrails.gov/NCT01433263).
. Mechanisms of cancer associated myopenia: clinical data
.1. UPP/E3 ubiquitin ligases
In many acute models of cachexia, including cancer, the UPP
s thought to be fundamental in the process of muscle atrophy
Bodine et al., 2001a,b; Gomes et al., 2001). However, human inves-
igations have failed to be conclusive. Studies including patients in
CU with sepsis, following bed rest, amputation for vascular dis-
ase, limb immobilisation, COPD, amyotrophic lateral sclerosis and
geing have demonstrated both increased and decreased expres-
ion of MuRF1 and MAFBx/atrogin-1 (Edstrom et al., 2006; Leger
t al., 2006a,b; Doucet et al., 2007; de Palma et al., 2008; Fredriksson
t al., 2008; Salanova et al., 2008). Likewise, investigations of UPP
ctivity in  quadriceps muscle biopsies have shown similar levels
o healthy controls in patients with lung cancer and weight loss
10% (termed pre-cachexia by  the authors) (Op den Kamp et al.,
012). In a  transcriptomic study of UGI cancer patients, candidate
enes including FOXO and ubiquitin E3 ligases, were not related tomistry & Cell Biology 45 (2013) 2215– 2229
weight loss. Furthermore, promoter analysis identified that weight
loss-associated genes had fewer FOXO binding sites than expected
by chance (Stephens et al., 2010) (Table 3). Another study in lung
cancer patients with low weight loss (mean 2.9%) demonstrated no
change in components of the UPP using Northern blotting, but a
suggestion that the lysosomal pathway was increased (Jagoe et al.,
2002)  (Table 3). In contrast, in  gastric cancer patients with average
weight loss 5.2%, increased UPP activity (determined by  measure-
ment of RNA and cleavage of specific fluorogenic substrates) was
seen compared with controls, with a further effect with increas-
ing tumour stage, weight loss and lower albumin (Bossola et al.,
2003)  (Table 3). The same group also demonstrated higher levels
of ubiquitin mRNA in gastric cancer patients compared with con-
trols, but there was  no relationship with weight loss. This led the
authors to conclude that the UPP was  activated early in disease
before there was overt clinical evidence of cachexia (Bossola et al.,
2001). In another investigation using dot blot for components of  the
UPP in patients with various cancers and minimal weight change,
mRNA levels were increased by 2-4x in cancer patients (Williams
et al., 1999) (Table 3). The authors concluded that the UPP was  upre-
gulated before protein breakdown is  increased given that patients
had minimal weight loss. The concept of changes in activation of
the UPP according to where a  patient is  on the cancer cachexia jour-
ney is supported by the observations by Khal et al. in  both humans
with cancer cachexia (Khal et al., 2005a,b) (Table 3) and the MAC-
16 murine cachexia model (Khal et al., 2005a,b). However, in these
studies, UPP activity seemed to increase after a threshold of ∼10%
weight loss with a  peak between 12% and 19% weight loss.
8.2. Autophagy/lysosomal pathway
Human studies have reported increased cathepsin D enzyme
activity in cancer patients (Schersten and Lundholm, 1972) and
cathepsin B mRNA in lung cancer patients (Jagoe et al., 2002)
Table 3. In the latter study, cathepsins B levels were higher in early
versus late stage tumours. Components of the UPP were unchanged
in  cancer patients, and thus the authors concluded that lysosomal
proteolysis may  be relevant early and the UPP may  be activated
later in the disease process (Jagoe et al., 2002) Table 3.  This perhaps
has some appeal because, although one study detected radio-
labelled myofibrillar proteins in  lysosomes (Gerard and Schneider,
1979), there is  other evidence to suggest that lysosomal proteolysis
in  isolation is not sufficient to  degrade myofibrillar proteins (Lowell
et al., 1986; Furuno et al., 1990; Cohen et al., 2009).
8.3. Calpains
Calpains are  capable of degrading cytoskeletal elements, ion
channels, other enzymes, cellular adhesion molecules and cell sur-
face receptors. Furthermore, calpains cleave the enzyme xanthine
dehydrogenase to xanthine oxidase, thus indirectly creating the
formation of superoxide radicals. Calpains have been implicated in
the degradation of sarcomeric and cytoskeletal proteins in  cultured
myotubes (Purintrapiban et al., 2003). Gastric cancer patients with
minimal weight loss (average 1%), had an increase in rectus mus-
cle calpain activity by 70% compared with controls, suggesting a
role for the calpains early in the cachexia journey before significant
clinical changes are apparent (Smith et al., 2011) Table 3.
8.4. Caspases
Caspases are  a  group of enzymes usually associated with the
induction of cellular apoptosis in response to  death signals. There
is some evidence for a role for apoptosis in muscle wasting
experienced by cachectic patients. Muscle biopsies from weight-
losing patients with upper GI cancer showed a  three-fold increase
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Table  3
Findings of different studies in humans on potential mechanisms of skeletal muscle protein degradation.
Tumour type %  WL UPP mRNA Protea-some activity Calpain activity Cathepsin B mRNA
Williams et  al. (1999) GI 0–10% ↑
Bossola et  al. (2003) GI >5% ↑









































Stephens et al. (2010) GI >5% =
Smith et  al.  (2011) GI 0–5% =  
Jagoe et  al. (2002) Lung <5% =  
n muscle DNA fragmentation compared with control subjects
Busquets et al., 2007). Furthermore, the increase in DNA fragmen-
ation was associated with a four-fold increase in  poly (adenosine
iphosphate-ribose) polymerase (PARP) cleavage, indicating the
resence of apoptosis (Busquets et al., 2007). No human studies
o date have focused on targeting caspases or apoptosis in the pre-
ention of cancer cachexia.
.5. Myogenesis
Decrease in  skeletal muscle regeneration may  also contribute
o the loss of skeletal muscle mass in cancer cachexia. In both
ealth and disease, skeletal muscle is able to undergo an exten-
ive repair process aimed at preventing the loss of muscle mass
ia activation of satellite cells (Zammit et al., 2004; Cossu and
iressi, 2005). The satellite cell starts off as a  myogenic precur-
or during embryonic development, and upon muscle injury starts
roliferating with a  variety of genes being regulated. Myogenin is
ubsequently up-regulated leading to terminal differentiation, fol-
owed by a  permanent exit from the cell cycle. In a  recent study
ooking at patients with gastric cancer these genes were found to be
p regulated compared with a control group (Pessina et al., 2010),
hether this suggests potential for muscle regeneration during
ancer cachexia is  unknown.
. Future prospects
The heterogeneity between morphology, mediators, and mech-
nisms of animal models and human cancer cachexia is vast. There
re some comparisons that can be drawn from the two  but it must
e realised that these may  represent distinct disease processes. The
elatively acute wasting seen in  young, metabolically active animal
odels may  have little bearing on the chronic disease patho – phys-
ology seen in cancer patients with chronic wasting. Progress in
reating the human form of cancer cachexia can only move forwards
hrough carefully designed large randomised controlled clinical tri-
ls of specific therapies with validated biomarkers of relevance to
nderlying mechanisms.
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 CURRENTOPINION Muscle protein kinetics in cancer cachexia
Neil Johnsa, Nathan A. Stephensa, and Tom Prestonb
Purpose of review
Skeletal muscle loss appears to be the most significant event in cancer cachexia and is associated with a
poor outcome. The balance between mechanisms controlling synthesis and degradation is fundamental
when designing new therapies. This review aims to highlight the molecular mechanisms associated with
protein kinetics.
Recent findings
The mechanisms that promote muscle synthesis have been explored in detail recently but moreover have
been the mechanisms behind degradation. Specific advances in cellular signalling molecules related to
autophagy pathways including signal transducer and activators of transcription-3, activin type-2 receptor,
TRAF6, and transcriptomic research have been given special attention in this review to highlight their roles
in degradation as well as potential targets for therapeutics. Ways to quantify muscle loss are badly needed
for outcome measures, and recent research using radiolabelled amino acids has also been discussed in this
review.
Summary
Only by having an appreciation of the complex regulation of muscle protein synthesis and degradation,
will potential new therapeutics be able to be developed. This review identifies known targets in molecular
pathways of current interest, explores methods used to find novel genes which may be involved in muscle
kinetics and also highlights ways in which muscle kinetics may be measured to assess the efficacy of such
interventions.
Keywords
cachexia, cancer, degradation, muscle, synthesis
INTRODUCTION
Cachexia affects the majority of patients with
advanced cancer and is a significant cause of mor-
bidity and mortality [1,2]. A recent international
consensus study defined cancer cachexia as ‘a multi-
factorial syndrome characterized by an ongoing
loss of skeletal muscle mass (with or without
loss of fat mass) that cannot be fully reversed by
conventional nutritional support and leads to pro-
gressive functional impairment. The pathophysio-
logy is characterized by a negative protein and
energy balance driven by a variable combination
of reduced food intake and abnormal metabolism’
[3
&&
]. Patients may present with varying degrees of
weight/tissue loss, and it is important to consider
cachexia as a journey rather than an event.
Although there is depletion of both adipose
tissue and lean body mass, it is skeletal muscle
loss that has the greatest impact on patients and





muscle is the major reservoir of body proteins,
consisting of around 640 separate muscles which
account for 40% of total body weight or 50% of fat-
free mass. In healthy adults, skeletal muscle mass
is maintained by nutritional status and physical
activity, reflecting a dynamic balance between
protein synthesis and degradation. A predominance
of either will result in muscle hypertrophy or
atrophy. Even small changes in protein synthesis
or degradation will lead to large protein deficits
over time due to the continuous process of protein
turnover. The myofibril is the base unit of muscle
comprising thick (predominantly myosin) and
thin (predominantly actin) filaments. Myofibrillar
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proteins account for more than 50% of protein
in skeletal muscle and are integral to muscle
contraction and function. The preservation or loss
of these proteins will dictate the clinical symptoms
and there is some evidence that they are selectively
targeted in cancer cachexia [6,7].
This review aims to detail some of the recent
advances in muscle protein biology and how emerg-
ing techniques and therapies seek to manipulate
these complex biological pathways to attenuate
skeletal muscle loss.
MUSCLE PROTEIN KINETICS IN THE
HEALTHY ADULT
Insulin is the most important endocrine factor
controlling skeletal muscle protein synthesis
(MPS) in the active, well fed, healthy adult. Reduced
peripheral insulin sensitivity is described in terms
of reduced glucose clearance by peripheral tissues,
predominantly skeletal muscle. Glucose uptake and
amino acid uptake are both under insulin control
and impaired MPS can accompany reduced insulin
sensitivity. In patients with reduced peripheral
insulin sensitivity, its normalisation may improve
skeletal MPS.
QUANTIFICATION OF MUSCLE KINETICS
The understanding of the molecular biology of
muscle wasting has increased significantly recently
and this has identified a variety of potential drug
targets in the complex pathways that control muscle
hypertrophy/atrophy. It has been suggested specific
elements of the myofibrillar complex may be tar-
geted early in the wasting process (e.g. myosin heavy
chain). Clinical trial methodology is, however,
limited by the absence of good biomarkers to predict
early response and/or determine the net effect
of combination therapy. Measurement of skeletal
MPS (and perhaps specifically the myofibrillar
protein myosin) may allow not only better under-
standing of the pathophysiology of muscle wasting
in cachexia but also provide an early index of the
response to muscle-directed therapy. Measurement
of protein FSR AQ2involves analysis of the increase in
protein-bound amino acid (product) enrichment
with time with respect to that of the tracer amino
acid in the intracellular pool (precursor). Human
skeletal muscle myosin FSR is low, of the order of
1% day AQ3[8]. Precursors of nonessential amino acids
can label amino acids intrinsically. Deuterium oxide
(heavy water) can be used as an intrinsic tracer.
Water mixes fully within an hour, it does not
stimulate metabolic processes and eliminates slowly
at a predictable rate. Single or multiple oral doses
are given. Nonessential amino acids incorporate
deuterium during de-novo synthesis. In the case
of alanine, four hydrogen atoms come into equi-
librium with body water and are incorporated
into protein. This was first exploited to study
protein synthesis in cell cultures and rodent models
[9]. Low levels of tracer may best be measured after
isolating and hydrolysing the protein and analysing
individual amino acids, most probably alanine.
GCMS can detect enrichments down to approxi-
mately 0.5 mole % excess in individual amino acids
[9]. The newer GC-pyrolysis-IRMS technique can
detect ppm changes in deuterium in individual
molecules. This technique is most suitable for
measuring synthesis in major proteins available at
high concentration [10]. Previs et al. [11] were the
first to use 2H2O and GCMS to measure human
albumin synthesis. GC-pyrolysis-IRMS was first
shown capable of measuring de novo lipogenesis
in a heavy water protocol in human patients [12].
Its use to measure tissue protein synthesis in
humans is under development [13]. In contrast,
modern proteomics platforms, either high resolu-
tion or tandem mass spectrometry can be used
to measure stable isotope enrichment in several
intact peptides simultaneously. As the labelled
amino acids may be minor components of each
peptide, minimum enrichments of approximately
5 mole % in that amino acid may be necessary
for detection. However, modern instrumentation
can detect very low peptide concentrations. Initial
studies have been conducted in rodents [14,15].
In summary, GC-pyrolysis-IRMS may be necessary
to analyse low tracer enrichment human proteins
present at high concentration, whereas proteomics
platforms are compatible and may be used to
measure to measure peptides at low concentration
but with high synthetic rate. GCMS can be applied at
KEY POINTS
 Skeletal muscle loss is one of the most significant events
in cancer cachexia and is associated with a poor
outcome.
 The balance between mechanisms controlling synthesis
and degradation is fundamental when designing
new therapies.
 Specific advances in cellular signalling molecules
related to autophagy pathways including STAT3,
ACTRIIB, TRAF6 and transcriptomic research are
potential targets for development of therapeutics.
 Development of novel tracer techniques will enable in-
vivo quantification of muscle kinetics which will guide
the efficacy and development of molecular therapeutics.
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intermediate enrichments. A further consideration is
that organic mass spectrometry (GCMS or LCMS)
allows isotopomer analysis to verify the labelling
pattern of precursor and product [9]. A single oral
2H2O bolus can raise body water up to 2000 ppm
excess 2H (0.2 atom % 2H excess). Greater enrich-
ments may require multiple oral doses to avoid
transient feelings of vertigo or nausea in a small
proportion of patients. In adults, water half elimin-
ation time of some 7–8 days is typical. Measurement
of MPS by 2H2O incorporation can either be made
using a single bolus with a slow and predictable
decline in precursor enrichment [13] or further boli
can be taken on a daily basis [9] to produce a ‘pseu-
doplateau’ in body water enrichment. An advantage
of the former approach is that total body water can
be measured by deuterium dilution simultaneously
with protein synthesis. In the context of a study to
measure skeletal muscle protein fractional synthetic
rate, this presents a means of estimating skeletal
muscle mass from its proportion to fat-free mass,
which has been validated using MRI data [16], and
thus estimating absolute MPS.
MUSCLE PROTEIN KINETICS IN CANCER
CACHEXIA
In cachexia, there is ongoing debate as to whether a
reduction in protein synthesis, an increase in
protein degradation or a combination of both is
more relevant. Although evidence continues to
emerge, it would appear that many of the relevant
pathways are influenced by the presence of systemic
inflammation [17–19]. Inflammatory-mediated sig-
nalling may limit MPS by several mechanisms.
Tumour necrosis factor (TNF) a can activate the
transcription factor nuclear factor kappa B (NF-
kB), which inhibits the synthesis of the muscle-
specific transcription factor MyoD, thereby inhibit-
ing differentiation [20], the TGF-b family members
induce muscle wasting downstream of SMAD acti-
vation [21
&
], and interleukin-6 activates signalling
by binding to ligand-specific receptors either in
soluble or membrane-bound forms to induce the
signal transducers and activators of transcription-1
and transcription-3 (STAT1/3), ERK and phosphati-
dylinositol 3-kinase (PI3K) AKT pathways [22,23]
(Fig. 1). The ERK pathway has been previously impli-
cated in cancer cachexia and muscle wasting [24],
and the AKT pathway is primarily responsible for
anabolism in skeletal muscle [25].
PROTEOLYTIC PATHWAYS
Many research groups have focussed investigation
on mechanisms responsible for skeletal muscle
protein degradation in cancer cachexia. Although
there are four mammalian proteolytic enzyme
systems (the proteasome, lysosomal/autophagy
pathway, caspases and calpains), it is the protea-
some and lysosomal pathways which have received
most attention.
The majority of signalling pathways contribu-
ting to muscle atrophy in preclinical models
are mediated through activation of the ubiquitin-
proteasome proteolytic pathway (UPP) [26,27]. The
muscle-specific E3 ubiquitin ligases, MuRF-1 and
MAFbx/atrogin-1 are upregulated in animal models
of atrophy [28,29], and MuRF1 selectively targets the
myofibrillar protein myosin heavy chain resulting
in muscle wasting [6,7]. However, the role of the
E3 ligases in human cachexia is less well defined.
Studies including patients following bed rest,
limb amputation for vascular disease, limb immo-
bilisation, COPD, amyotrophic lateral sclerosis
and ageing demonstrate both increased and
decreased expression of MuRF1 and MAFBx [30–
33] and evidence for an increase in human cancer
cachexia is lacking [34]. There is also data that
suggests dissociation between protein dynamics
in vivo and activation of UPP signalling in human
skeletal muscle [35].
Upstream of the E3 ligases, the insulin-regulated
transcription factors FOXO1 and FOXO3a have
been shown to increase expression of MuRF1
and MAFbx in animal models of cachexia [36,37].
Furthermore, in both myotube and mouse models
of muscle atrophy, several autophagy genes are
upregulated appear to be under control of FOXO3
[36–39], linking the autophagy and proteasomal
systems. This makes the FOXO transcription
factors attractive therapeutic targets and indeed,
early evidence of FOXO inhibition in preclinical
models is promising [40
&
].
In cancer patients, there are few studies relating
to the role of the autophagy pathway in muscle
wasting. Increased cathepsin D and acid phospha-
tase activity has been demonstrated in patients with
varying tumour types and degrees of weight loss
[41], and lung cancer patients undergoing resection
were shown to have increased levels of cathepsin B
[42]. Likewise, expression of the autophagy-related
genes GABARAPL1 and BNIP3 has been associated
with the presence of systemic inflammation and/or
weight loss [34], suggesting a potential role in the
development of human cancer cachexia.
SIGNAL TRANSDUCER AND ACTIVATOR
OF TRANSCRIPTION 3
Recent work has focused on STAT3 activation in
skeletal muscle and has linked it with muscle
Muscle protein kinetics in cancer cachexia Johns et al.
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wasting and the acute phase response in cancer
cachexia [43
&&
]. This contemporary study character-
ized serum cytokines and the muscle transcriptome
in the colon-26 adenocarcinoma model of cancer
cachexia. They provided evidence of STAT3 acti-
vation, target gene expression and the acute phase
response in both liver and skeletal muscle in these
mice, providing a molecular link between them.
In addition to this, it was also shown that tran-
scription of SOCS3, a classical feedback inhibitor
of STAT3 activation was shown to be significantly
induced. SOCS3 binds to activated JAKs and
inhibits STAT3 activation [44]. However, in contrast
to the high SOCS3 mRNA levels in muscle little to no
increase in SOCS3 protein either in muscle or in liver
was observed. This lack of SOCS3 protein explains in
part how high pSTAT3 levels could persist regardless
of high SOCS3 RNA levels and how sustained STAT3
activation might continue to drive muscle wasting
while activating its inhibitor.
ACTIVIN TYPE-2 RECEPTOR
Myostatin and activin are two members of the TGF-b
superfamily that play an important role in growth
and are thought to be responsible for the develop-
ment of cachexia in mice lacking the hormone
inhibin [45]. Both molecules bind to activin type-
2 receptor (ActRIIB), a receptor in muscle, to initiate
a signalling cascade leading to increased expression
of atrogin-1 and MuRF1 and subsequent degra-
dation of myofibrillar proteins [25]. Direct evidence
linking muscle wasting to survival of the patient





]. In one particular study found
in murine colon-26 carcinoma-bearing mice that
preserving muscle mass is vitally important in
the organism’s survival AQ4. This experimental evidence
suggests ActRIIB antagonism prolonged survival
and prevented muscle wasting and reversed muscle
loss during cancer cachexia. Further work demon-
























FIGURE 1. Muscle protein kinetics in cancer cachexia. Regulation of muscle synthesis via IGF-1-induced hypertrophy (a).
Myokine-activated JAK/STAT pathway involved in the acute phase response and muscle degradation (b). TGF-b-induced
SMAD pathway, activated by myostatin and activin (c). Ubiquitin proteasome pathway (d). Activation of TRAF6 (e). ActRIIB,
activin type-2 receptor; IL, interleukin; NF-kB, nuclear factor kappa B; STAT, signal transducer and activators of transcription.
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ubiquitin ligases critical in muscle wasting and
enhanced ubiquitination of muscle proteins, and
these effects were completely abolished by ActRIIB
antagonism. They also showed in the tumour-
bearing mice, ActRIIB–SMAD signalling stimulated
FOXO3 activity in muscle, which induced transcrip-
tion of atrogin-1 and MuRF1. Finally, they were
able to show that ActRIIB antagonism drama-
tically stimulated satellite cell proliferation, which
presumably contributes to rapid reversal of
muscle loss in the treated animals. On the basis
of these findings, development of treatments that
block these catabolic actions of tumours should
be explored as a potential therapeutic avenue.
MYOSTATIN
Myostatin and activin have also both been
shown to be expressed 50–100-fold higher in
both subcutaneous and visceral adipose tissue
in obesity [7]. These results demonstrate that expres-
sion of myostatin and activin can be modulated
in adipose tissue and skeletal muscle by chronic
obesity and suggest that alterations in their expres-
sion may contribute to the changes in growth
and metabolism of lean and fat tissues occurr-
ing during both obesity and cachexia [7]. On the
basis of these observations, a therapeutic role
for a myostatin antagonist exists and may
prove of benefit in patients suffering from cancer
cachexia.
TRAF6
TNF receptor-associated factors are proteins
involved in activation of various intracellular signal-
ling. TRAF6 is an important E3 ubiquitin ligase,
which targets proteins for degradation [50,51].
Several studies have shown TRAF6 to be related to
activation of NF-kB, MAPK and PI3K/AKT pathways
[52,53]. TRAF6 expression level and autoubiquitina-
tion have been shown to be enhanced in skeletal
muscle during atrophy in mice [54]. This study also
demonstrated that through the activation of JNK1/
2, p38 mitogen-activated protein kinase, adenosine
monophosphate-activated protein kinase, and NF-
kB, skeletal muscle-restricted depletion of TRAF6
rescues myofibril degradation and preserves muscle
fibre size and strength upon denervation [54].
Inhibition of TRAF6 also preserves the orderly
pattern of intermyofibrillar and subsarcolemmal
mitochondria in denervated muscle. This is direct
evidence that depletion of TRAF6 prevents cancer
cachexia in an experimental mouse model and
provides a novel therapeutic target for prevention
of skeletal muscle wasting in cancer cachexia.
CANDIDATE GENE IDENTIFICATION
Primary investigations to shed light on the
detailed mechanisms that produce cancer cachexia
in patients are increasing. With the development
of high-throughput technologies such as genome
sequencing, microarray gene expression studies and
QTL mapping, new hypotheses may be established
and subsequently investigated in much more detail
than previously possible. This has been based largely
on these high-throughput experiments, generating
vast quantities of data [55]. In a recent transcrip-
tomics study, the expression of 74 genes correlated
positively with weight loss in cancer cachexia
patients, and that of nine correlated negatively
with it [34]. The most significantly positively corre-
lated gene with weight loss, CAMK2B, encodes
calcium/calmodulin-dependent protein kinase II b
(CaMKIIb), a serine/threonine protein kinase that
is activated by Ca2þ/calmodulin, leading to auto-
phosphorylation and maintenance of CaMKII
activity even after the Ca2þ signal has diminished
[56]. CaMKIIb is expressed in skeletal muscle.
Levels of the protein as well as its phosphorylation
status and activity increase after exercise training
[57]. In addition, it has recently been demonstrated
that Ca(2þ)-CaM-eEF2K signalling may be respon-
sible for acute exercise-induced inhibition of MPS,
and it is, thus, conceivable that chronic inappro-
priate activation of this ‘endurance training’-related
signalling molecule subdues normal maintenance
of skeletal muscle mass. Additional factors that
could modulate CaMKII activity include alterations
in lipid metabolism [58]. Finally, CaMKII has
also been implicated in muscle adaptation through
phosphorylation of HDAC5 leading to MyoD/MEF2-
driven differentiation of muscle cells [59]. CAMK2B
may, thus, have an important role in regulating
skeletal muscle function and metabolism. In a
recent follow-up study, metabolic and protein turn-
over-related pathways were found to be suppressed
in weight-losing patients with UGIC, whereas
removal of the cancer appeared to facilitate a return
to a healthy state, independent of changes in the




Circulating mediators in differing concentrations,
interplay of synthesis and degradation pathways,
and novel gene identification are just some ways
in which body composition, particularly involving
muscle kinetics are regulated. Although cachectic
cancer patients demonstrate systemic inflamma-
tion, increased lipolysis and insulin resistance
[61], there has been little effort until recently to
exploit regulation of muscle mass for therapeutic
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gain. Treating clinicians have traditionally focused
on curing cancer leaving the cachexia to take care of
itself. However, symptom management on its own
can improve survival in advanced cancer [62], and
multimodal management of cachexia has prompted
an increasing number of phase I/II studies using
highly specific/potent therapeutics targeted at
either upstream mediators or downstream endorgan
hypoanabolism/hypercatabolism. Currently, to treat
muscle wasting, much of the outcome evidence is
based upon observations on loss of muscle mass.
However, with the development of novel tracer
techniques, quantification of muscle kinetics can
be established which will guide the efficacy and
development of molecular therapeutics.
The recent work into the regulation of muscle
in this review, suggests that understanding of the
integrative physiology of this complex system
may yet lead to further developments of novel
therapeutics, particularly for those patients suffer-
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ABSTRACT: Recent work suggests molecular cross-talk between adipose tissue and muscle that occurs through adipokines and 
myokines. These molecules act in an endocrine fashion to play an intricate role in regulating body composition in both health and 
disease. Studies in exercise physiology have focused on the molecular cross-talk between adipose tissue and muscle that occurs 
through adipokines and myokines and on the role these molecules may play in chronic diseases. Similarly, integrative physiology 
in obesity and diabetes has long emphasised the importance of chronic inflammation, increased adipocyte lipolysis, and increased 
levels of circulating free fatty acids in the adipose-muscle cross-talk that contributes to lipotoxicity and insulin resistance in 
muscle. Cachexia affects the majority of patients with advanced cancer and is associated with a reduction in treatment tolerance, 
response to therapy, quality of life, and duration of survival. Although cachexia in patients with cancer is characterized by systemic 
inflammation, increased lipolysis, insulin resistance, and reduced physical activity, there has been little effort to manipulate the 
integrative physiology of adipose tissue and muscle tissue for therapeutic gain. 
KEY WORDS: cancer, cachexia, skeletal muscle, adipokines, myokines
ABBREVIATIONS
AA: amino acid; AMPK: adenosine monophosphate–activated protein kinase; ATGL: adipose triglyceride lipase; BMI: Body 
Mass Index; CRP: C reactive protein; CT: computerized tomography; FA: fatty acid; HSL: hormone sensitive lipase; IL-1: 
interleukin 1; IL-10: interleukin 10; IL-15: interleukin 15; IL-6: interleukin 6; JAK/STATS: Janus kinases/signal transducers and 
activators of transcription; LMF: lipid mobilising factor; LPL: lipoprotein lipase; mRNA: messenger RNA; PPAR: peroxisome 
proliferator–activated receptors; RCT: randomized controlled trial; TNF-b: tumour necrosis factor alpha; VLDL: very low density 
lipoprotein; ZAG: zinc-a-2-glycoprotein
I. INTRODUCTION
Cachexia affects the majority of patients with 
advanced cancer and is associated with a reduction 
in treatment tolerance, response to therapy, quality 
of life, and duration of survival. Cancer cachexia has 
recently been defined as a multifactorial syndrome 
characterised by an ongoing loss of skeletal muscle 
mass (with or without loss of fat mass) that cannot 
be fully reversed by conventional nutritional support 
and leads to progressive functional impairment.1 
However, recent research using animal models of 
cancer cachexia suggests that mobilization of lipid 
may not simply be a reflection of a negative energy 
balance or the effect of tumor-induced lipid mobiliz-
ing factors, but may play an active role in regulat-
ing loss of skeletal muscle mass.1 In the modern 
epidemic of obesity there is now a cohort of cancer 
patients who although obese (not lacking energy 
reserves) have severe muscle wasting (sarcopenia).2 
These individuals appear to be at increased risk of 
accelerated demise. 
II. NORMAL PHYSIOLOGY
A. Energy Storage and Utilization
After a meal, blood glucose rises and insulin is 
released. Insulin promotes the storage of glu-
cose as glycogen from the circulation in the  liver 
and  muscle. When glycogen stores are saturated, 
additional glucose is transformed into fatty acids 
and glycerol, which are synthesized into triglycerides 
and subsequently stored in adipose tissue. Excess 
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amino acids undergo deamination and the carbon 
chains are metabolized via the citric acid cycle to 
allow the synthesis of free fatty acids that can be 
stored in adipose tissue as triglycerides, making 
adipose tissue the major site of energy storage 
for all three classes of macronutrients. The third 
potential store of energy comes from the auto-
cannabolism of structural proteins, primarily in 
muscle. Increased circulating insulin inhibits the 
release of glucagon and prevents the use of fat as an 
energy source in preference for glucose. The trigger 
for glucagon release is a decline in plasma glucose; 
glucagon stimulates glycogenolysis by binding to G 
protein coupled glucagon receptors. Glucagon also 
stimulates the liver to synthesize new glucose (glu-
coneogenesis). In addition, glucagon regulates the 
rate of glucose production through lipolysis. When 
the level of blood glucose exceeds normal limits, 
insulin is released and allows glucose to be taken 
up by insulin-sensitive tissues. As the homeostatic 
mechanisms governing insulin and glucagon play a 
fundamental role in the central metabolic control 
mechanism, they are tightly regulated.3
B. THE FAST/FEED CYCLE 
Storage and metabolism of organic molecules 
depend upon the body’s metabolic state. The major 
functional metabolic states experienced throughout 
the day are the feeding (absorptive state) and the 
fasting (post-absorptive state). During times of 
feeding and up to 4 hours after, the glucose sup-
ply in the blood is plentiful and is the preferred 
substrate for energy production. Ingested fat and 
protein (amino acids) are rarely utilized and are 
more readily stored as glycogen or triglycerides. 
After four hours, insulin levels decrease and cells 
switch to fat for energy production, with glucose 
being reserved primarily for the brain. Blood glucose 
is maintained via hepatic glycogenolysis. After 24 
hours when glycogen stores are depleted, blood 
glucose is maintained by hepatic gluconeogenesis 
utilizing substrates including lactic acid, glycerol, and 
certain amino acids (e.g., alanine). The liver oxidizes 
fatty acids only to acetyl coenzyme A (acetyl CoA), 
which is unable to progress through the citric acid 
cycle for further energy extraction. The liver only 
partially extracts available energy and converts the 
remaining molecules into ketone bodies, which may 
be utilized by peripheral tissues in times of low 
glucose availability. If fasting continues, the body 
continues into a state of skeletal muscle and adipose 
tissue breakdown for fuel utilization. To partially 
compensate for this, ketone-body production by the 
liver increases. Ketone bodies are metabolites of fatty 
acids and may be utilized by the brain. Hence the 
requirement for glucose decreases with subsequent 
decline in gluconeogenesis as well as fat and muscle 
catabolism. When fat reserves are depleted the 
remaining source of glucose is protein. If this were 
to continue, the body would progress into a state of 
auto-cannibalism with eventual breakdown of vital 
organs. However, in Western society this is rare, 
given that in a typical day, 3 meals are consumed 
and little or no absorption is taking place 4 hours 
after a meal or during the night.3 
C. INFLUENCE OF ExERCISE ON MUSCLE 
PROTEIN SYNTHESIS: RELEVANCE TO 
CANCER CACHExIA
Physical inactivity results in the accumulation of 
visceral fat and activation of a network of inflam-
matory pathways that promote the development of 
insulin resistance and tumor growth.4  Exercise has 
been shown to be beneficial in a number of chronic 
diseases such as cancer and associated morbidity. 
Both resistance and endurance exercise exert a 
number of important effects on skeletal muscle 
metabolism. Skeletal muscle protein synthesis is 
highly responsive to its environment. The onset of 
exercise signals the initiation of transcription of 
new messenger RNA (mRNA) and encourages the 
translation of existing mRNA.5  This short-term 
change is accompanied by the translation of growth 
factors and other signaling mediators, which may 
persist for up to 72 hours, enabling an enhanced 
anabolic response to exercise.5 Muscle protein 
synthesis is increased between two- and five-fold 
in the post-exercise recovery period of individuals 
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undergoing resistance exercise for up to 48 hours 
(in well fed individuals).6,7 Muscle protein synthesis 
has been shown to occur in both the myofibrillar 
and mitochondrial pools in resistance training.8 
Muscle protein breakdown does occur and is at its 
highest in the post-absorptive state after resistance 
exercise.9,10 For endurance exercise, after treadmill 
walking in the post-absorptive state, an increase 
in mixed muscle protein synthesis of up to 45% 
has been documented.11 Even larger elevations of 
myofibrillar fractional synthetic rate can be pro-
duced by more intense exercise in the fed state. The 
responsiveness of protein synthesis rates to exercise 
has been shown to be influenced by physical fit-
ness. Endurance training increases baseline muscle 
protein synthesis rate and diminishes responsiveness 
to acute bouts of exercise.12 Changes observed in 
both resistance and endurance exercise may not 
differ greatly.12 It has been demonstrated there is 
little difference in muscle protein synthesis rates 
and responses after acute exercise in muscles of 
legs working in different modes, i.e., resistance and 
endurance in the same individual in the untrained 
state.8 Muscle protein synthesis is a complex and 
tightly regulated phenomenon. There would appear 
to be a transient storage potential immediately after 
feeding, whereas the post-exercise period stimulates 
a longer-term adaptive response.12 Under normal 
conditions, the body enters a state of anabolism after 
exercise (via increased protein synthesis) and this is 
sustained by the ingestion of protein immediately 
thereafter (via further increased protein synthesis).8 
Obvious phenotypic changes can be observed fol-
lowing specific resistance or endurance training 
programs. Perhaps the acute anabolic response after 
a specific type of training influences the type of 
muscle protein synthesis an individual will undergo. 
Recent research has shown that cancer cachexia is 
associated with a loss of muscle volume but not of 
functionality; furthermore, muscle capillarization 
is maintained.13 This suggests that exercise should 
be encouraged in cachectic patients, as fitness is 
reduced in cancer cachexia. However, it is unclear 
how responsive to exercise (in terms of muscle 
function) cachectic patients are and therefore how 
successful exercise regimes would be. 
III. PATHOPHYSIOLOGY
A. Anabolic Resistance
Previous research has shown that depression of muscle 
protein synthesis is a major common feature of con-
ditions associated with either slow chronic wasting 
(cancer, renal failure, chronic obstructive pulmonary 
disease, and congestive cardiac failure) or acute dete-
rioration (critical illness).14,15 The phenomenon of 
anabolic resistance has been proposed, in which there 
is a reduction in the ability to maintain muscle protein 
balance by appropriate stimulation of muscle protein 
synthesis and inhibition of protein breakdown.5 In 
the face of a catabolic stimulus and massive protein 
breakdown, the concurrent rise in free amino acids 
should stimulate anabolism via synthesis of muscle 
protein. However, this is not observed in older adults 
or in immobilized or chronically ill patients.15 The 
suggested mechanisms in the elderly include older 
muscle being less sensitive to the anabolic properties 
of insulin alongside a decreased capacity for protein 
synthesis and decreased sensitivity to free amino acids 
and other anabolic hormones.15 Anabolic resistance 
that cannot be overcome by increasing amino acid 
availability has been shown in immobile or less 
physically active people.15 Exercise may help prevent 
anabolic resistance observed in older adults or in 
immobilized or chronically ill patients by encouraging 
muscle protein synthesis and anabolism. Mechanisms 
proposed include improved amino acid sensitivity and 
(or) insulin sensitivity of muscle.16 Recent research 
has also demonstrated that immobilization induces 
anabolic resistance in human myofibrillar protein 
synthesis with low- and high-dose amino acid infu-
sion.15 Post-absorptive muscle protein synthesis is 
reduced in the muscle of an immobilized limb. It has 
been shown that suppressed muscle protein synthesis 
also extends to the postprandial state, even when the 
free amino acid concentration is high. 
Impaired delivery of nutrients may also play a 
role in the development of anabolic resistance: two 
vascular routes within, or closely associated with 
skeletal muscle exist to provide nutrients. The first 
route is nutritive; this is closely associated with the 
muscle architecture and supplies it with amino acids, 
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hormones, and other substrates. The second func-
tions as a vascular shunt and bypasses the majority 
of the skeletal muscle tissue. The effect of exercise 
on the microcirculation has been studied exten-
sively.17 While there appears to be a strong body of 
evidence suggesting endurance or chronic training 
can positively affect structural changes to capillaries, 
there is conflicting evidence regarding the effects 
of resistance or exercise training.17 Recent evidence 
suggests that the hypertrophic effect of resistance 
training occurs without an increase in the in vivo 
microcirculation of the skeletal muscles at rest.18 
Blood flow in both resting and exercise conditions 
is tightly regulated, influencing muscle metabolism 
and contraction by regulating hormone and substrate 
delivery as well as product removal. Recent research 
has demonstrated that nutritive blood flow is an 
important element of the skeletal muscle response 
to food and also insulin.19 Nutritive blood flow is 
particularly sensitive to low levels of circulating 
insulin and is recruited at levels lower than that 
activating glucose uptake.19 This may be the mecha-
nism by which insulin stimulates muscle protein 
synthesis and inhibits protein breakdown. Anabolic 
resistance may be the result of up-regulation of 
non-nutritive blood flow, effectively becoming the 
primary source of blood circulation in the critically 
ill, and resulting in a bypass of skeletal muscle with 
the nutrients that would normally stimulate protein 
synthesis.20 Whether nutritive blood flow is altered 
in conditions such as cancer cachexia is not known. 
All these observations need to be taken into context 
when developing a treatment strategy, as nutrition 
may not be sufficient to promote net anabolism, 
especially in cancer cachexia.21 It is not known 
whether impaired sensitivity is at all reversible in 
cancer cachexia.
B. Obesity and Diabetes
The incidence of obesity and diabetes continues to 
increase worldwide. The obese patient is generating 
a new challenge in medicine and treatment. The 
physiology of obese patients differs remarkably from 
a normal-weighted individual. Recently, patients 
suffering from advanced cancer have been found to 
be overweight rather than underweight.22 This has 
been shown to confound conventional measurements 
for risk stratification such as BMI. A recent study 
of pancreatic-cancer patients has shown sarcopenia 
when combined with obesity to be an independent 
adverse prognostic indicator in this patient group 
and an alternative and more powerful means of risk 
stratification should be considered.2 It is, however, 
unclear how being sarcopenic and overweight/obese 
causes accelerated demise. The adipokines secreted 
by excess adipose tissue may act as systemic inflam-
matory mediators, inducing insulin resistance in 
skeletal muscle and leading to a further increase in 
muscle protein loss. Supportive evidence for this 
hypothesis comes from the observation that in obesity 
adipocytes swell, increase in size, and eventually die, 
causing endoplasmic reticulum stress.23 A chronic 
inflammatory state ensues secondary to macrophage 
infiltration, and a cycle of adipose inflammation and 
insulin resistance results within adipose tissue. The 
inflammation is set up by a variety of mediators, which 
act as circulatory factors to regulate insulin sensitivity 
in distant organs. In obese people, elevated circulating 
levels of inflammatory cytokines including interleu-
kin 6 (IL-6), tumor necrosis factor alpha (TNF-a), 
leptin, CRP, and resistin have been detected. These 
pro-inflammatory cytokines are thought to arise from 
adipose tissue infiltrated with macrophages in response 
to low-grade inflammation. Conversely, weight loss 
is associated with a reduction in macrophage infil-
tration of adipose tissue,24 a finding confirmed in a 
recent study of patients undergoing gastric bypass 
surgery for weight loss.25 Thus adipose tissue acts as 
an endocrine organ, and secreted cytokines can act 
both locally and at a distance. 
Lipotoxicity may also have a role in the metabolic 
response to obesity. Lipids accumulate in non-adipose 
tissue (e.g., skeletal muscle) in the presence of high 
plasma free fatty acids or triglycerides.26 The excess 
fat activates a serine/threonine kinase cascade, which 
has a direct reducing effect on insulin signaling and 
leads to failure of activation of the GLUT4 trans-
porter to locate to the plasma membrane, thereby 
initiating insulin resistance.27 
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IV. ADIPOSE SECRETING ADIPOKINES 
Adipose tissue, like skeletal muscle, is an active 
metabolic and endocrine organ. A number of inflam-
matory cytokines secreted by adipose tissue have 
been shown with varying effect to influence the 
development of diseases such as insulin resistance, 
diabetes, and cancer cachexia by acting on muscle 
and fat metabolism. Adipokines include IL-6, TNF-
a, IL-1, leptin, zinc-a-2-glycoprotein (ZAG) (other 
name: lipid mobilising factor [LMF]), and resistin.28 
IL-6 secreted by adipose tissue appears to play 
a different role from that secreted by skeletal muscle 
(Fig. 1). In adipose tissue, IL-6 has been shown to be 
up-regulated in insulin-resistant and obese patients.4 
Visceral adipose tissue secretes more IL-6 than 
subcutaneous adipose tissue and is the main source 
of adipose tissue–secreted IL-6. Higher concentra-
tions of IL-6 in the obese population are thought 
to cause hepatic CRP production, a major risk index 
for cardiovascular disease.29 The IL-6 receptor signals 
via the JAK/STATs ( Janus kinases/signal transducers 
FIGURE 1. Adipose-muscle cross-talk. The main myokines and adipokines involved in the process are shown. Obesity 
and exercise represent opposite situations concerning expression of these molecules and thus different metabolic 
balance concerning fatty acid metabolism and insulin sensitivity. In cancer the secretion of the main cytokines leads 
to degradation of both adipose and muscle mass. FA, fatty acid; FFA, free fatty acid; TG, triglycerides. (Figure 
adapted from Ref. 73.)
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and activators of transcription) signal transduction 
pathway. Downstream activation results in STAT 
phosphorylation and translocation to the nucleus 
to regulate genetic transcription.30 How IL-6 affects 
insulin action is not well established; however, it is 
widely accepted that this adipokine is associated with 
insulin resistance in the obese patient.4,23
TNF-a has been shown to play a role in both 
animal models and humans in insulin resistance.31 
TNF-a has been shown to initially have a protective 
role of trying to limit adipose tissue mass by stimu-
lating lipolysis and decreasing LPL expression and 
activity.32 TNF-a also has a role in the inhibition of 
adipose hypertrophy,33 possibly via paracrine signaling. 
The latter, however, results in an increase of insulin 
resistance and prevention of glucose entry into the 
cell, all mechanisms designed to prevent the adipo-
cyte form swelling. In obesity and insulin resistance, 
TNF-a may enter a pathologically positive feedback 
loop, where the production of TNF-a  rises in response 
to increasing lipid deposition in adipocytes and tries 
to prevent the adipocyte from swelling but thereby 
increases insulin resistance, which in turn is associ-
ated with chronic inflammation and further TNF-a 
production. The role of TNF-a in obesity and insulin 
resistance remains poorly explained. TNF-a may well 
play a role in the inflammatory response to insulin 
resistance, but secretion from other sources other than 
adipose tissue may account for this.
Leptin is produced by adipose tissue and acts on 
the hypothalamus to regulate the amount of energy 
stored in fat via its influence on appetite. There is little 
doubt this adipokine has a positive association with 
BMI.25,34 A marked reduction of circulating leptin has 
also been shown as a result of bariatric surgery.35 Stud-
ies of leptin-deficient mice (ob/ob) have demonstrated 
that this adipokine is fundamental in the control of 
body weight and lipid metabolism.36 Experimental 
administration of leptin has been shown to reduce 
food intake and promote weight loss.37 Physiologically, 
leptin is thought to protect adipocyes from lipotoxic-
ity by inhibiting lipogenesis and increasing fatty acid 
oxidation.37 These studies highlight the role of leptin 
in regulation of body weight. Furthermore, leptin-
deficient ob/ob mice have been shown to develop 
obesity due to lack of appetite suppression. Pathologi-
cally, leptin may also act as an adipokine potentiating 
the chronic inflammation seen in obesity and insulin 
resistance. Studies have shown that hyperleptinemia 
is associated with a chronic inflammatory state in the 
non-obese.38 Although leptin reduces appetite, levels 
tend to be exceptionally high in the obese, implying 
leptin resistance.39,40
Adiponectin is produced by the adipocyte and 
has been shown to decrease insulin resistance. Unlike 
other adipokines associated with chronic inflam-
mation, adiponectin is inversely related to insulin 
resistance and BMI. It appears to have protective 
metabolic and anti-inflammatory properties.41
ZAG is involved in the specific mobilization of 
adipose tissue and increased oxidation of released 
fatty acids (possibly via induction of uncoupling 
protein [UCP] expression). ZAG mobilizes fat via 
the  b2-adrenergic receptor. It is produced by both 
host and certain tumors. Adipose tissue secretes large 
amounts of ZAG; this is accelerated in cancer cachexia 
patients and correlates with the reported weight loss.42 
V. MUSCLE SECRETING MYOKINES 
Skeletal muscle, like adipose tissue, is now widely 
viewed as an endocrine organ, with many studies 
demonstrating that cytokines produced by muscle 
fibers exert paracrine and endocrine effects; such 
cytokines (IL-6, IL-15, and TNF-a ) have been 
labeled myokines4 and exert metabolic effects on 
a number of other tissues, including the liver and 
adipose tissue.
IL-6 secretion via skeletal muscle has been shown 
to increase during exercise when insulin action is 
enhanced (Fig. 1). It is proposed that IL-6 acts not 
only locally, via activation of AMPK in response to 
muscle contraction, but also has endocrine functions. 
Intramuscular IL-6 expression is regulated by a net-
work of signaling cascades that are likely to involve 
cross-talk between the Ca2+/NFAT and glycogen/
p38 MAPK pathways. Further studies suggest that 
IL-6 derived from muscle mediates anti-inflamma-
tory effects, and IL-6 can inhibit TNF production 
and stimulate synthesis of cytokine antagonists such 
as IL-1 receptor antagonist (IL-1ra) and IL-10.4 This 
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may account for IL-6 being primarily involved not 
only in local glucose uptake but also in adipose tissue 
lipolysis. IL-6 is widely known to act as both a pro- 
and anti-inflammatory cytokine. This is determined 
mainly by concentration and which tissue it is acting 
on, whether muscle, adipose tissue, or immune cell.43
IL-15 is an important myokine in the regulation of 
skeletal muscle.44 IL-15 has a role in the differentiation 
of myocytes and the ability of muscle fibers to increase 
the density of contractile proteins.45 This is confirmed 
with mouse models, where skeletal myoblast differen-
tiation occurs under certain conditions in response to 
IL-15.46 Mechanisms include the transcription factor 
PPAR-g activating protein synthesis.47 IL-15 has also 
been shown to regulate muscle mass in response to 
resistance exercise training in humans. A recent study 
proposed that IL-15 is predominantly expressed by 
type 2 skeletal muscle fibers, and that resistance exercise 
regulates IL-15 expression in muscle.48 IL-15 mRNA 
level was enhanced in skeletal muscles dominated by 
type 2 fibers and resistance exercise induced increased 
muscular IL-15 mRNA levels. IL-15 mRNA levels in 
skeletal muscle were not paralleled by similar changes 
in muscular IL-15 protein expression, suggesting that 
muscle IL-15 may exist in a translationally inactive 
pool.48 IL-15 has also been proposed to play a role 
in the prevention of diabetes by modulating glucose 
uptake in skeletal muscle.49 A recent study analyzed 
the effects of IL-15 on glucose metabolism in skeletal 
muscle. A single dose of IL-15 resulted in a significant 
increase in glucose uptake in human skeletal muscle, 
animal models, and in C2C12 cells.49
TNF-a has been shown to be released by both 
adipose tissue and muscle. When acting on muscle, 
TNF-a has been shown to play a role in muscle 
protein degradation; it has also been shown to 
induce muscle cell apoptosis.50 Release of TNF-a 
may augment skeletal muscle insulin resistance as 
well as signaling and potentiating a similar response 
in adipose tissue.
VI. ADIPOSE-MUSCLE CROSS TALK 
IL-6 has a different role to play in exercise compared 
with insulin resistance/diabetes. Chronically elevated 
IL-6 levels lead to inappropriate hyperinsulinemia, 
reduced body mass, and impaired insulin-stimulated 
glucose uptake in skeletal muscle.51 Conversely, IL-6 
knockout mice develop obesity and insulin resistance, 
providing evidence against a causative effect of IL-6 
in insulin resistance.52 Clearly IL-6 has numerous 
roles to play depending on the clinical context; one 
proposal is that after the peak of IL-6 after exercise, 
baseline levels return to lower than original and 
muscle-based receptors are down-regulated.53 Thus 
changes in IL-6 levels appear to signify a change 
between a physiological response and a pathophysi-
ological one. 
The myokine IL-15 is an anabolic factor involved 
in the development of skeletal muscle; it has also been 
shown to play a part in lipid metabolism.54 In a study 
by Nielsen and co-workers,48 a negative association 
between IL-15 concentration and trunk fat mass, but 
not limb fat mass, was observed following exercise. 
IL-15 secretion from muscle can reduce visceral fat 
without any change to muscle mass, demonstrating a 
potent endocrine function.44 Argiles and co-workers 
have shown IL-15 acting not just on adipose tissue 
but on endothelial cells, the gastrointestinal tract, and 
the liver.55 IL-15 could have therapeutic roles in the 
treatment of a number of diseases. In obesity it has 
been shown to have an anti-adipogenic effect and 
could be used to prevent lipogenesis. Animal models 
receiving IL-15 demonstrated a 33% decrease of white 
adipose tissue mass. This is achieved through a reduc-
tion of lipogenesis coupled with a decreased uptake 
of VLDL triacylglycerol through lipoprotein lipase 
(LPL).56 IL-15 facilitates glucose uptake by insulin-
sensitive tissues such as skeletal muscle.55 Argiles 
and co-workers propose a reciprocal control between 
adipose and skeletal muscle size. They propose that 
IL-15 is released from skeletal muscle with the aim 
of controlling fat deposition and, thus, adipose tissue 
growth and mass. The anabolic effects of IL-15 have 
also been shown in animal models.56 In rats bearing the 
Yoshida AH-130 ascites hepatoma, IL-15 treatment 
partly inhibited skeletal muscle wasting by decreasing 
protein degradation rates to values even lower than 
those observed in non-tumor-bearing animals. These 
alterations in protein breakdown rates were associated 
with an inhibition of the ATP-ubiquitin-dependent 
Johns, Greig, & Fearon270
Critical Reviews™ in Oncogenesis
proteolytic pathway. This opens the potential for IL-15 
to be used as a therapeutic in wasting diseases such 
as cancer cachexia. 
TNF-a has been shown to play a role in both 
animal models and humans with insulin resistance.31 
TNF-a may initially have a protective role and limit 
adipose tissue mass by stimulating lipolysis and 
decreasing LPL expression and activity.32 TNF-a 
also acts to inhibit adipose hypertrophy,33 possibly 
via paracrine signaling. This, however, results in an 
increase in insulin resistance and prevents glucose 
entry into the cell, all mechanisms designed to pre-
vent the adipocyte from accumulating substrates for 
energy storage. The role of TNF-a in obesity and 
insulin resistance remains poorly explained. TNF-a 
may well play a role in the inflammatory response to 
insulin resistance, but secretion from other sources 
other than adipose tissue may be important.
Leptin from adipose tissue is responsible for an 
increase in fatty acid (FA) oxidation and reduced 
esterification in resting rodent skeletal muscle.40 In 
the absence of leptin, obese human skeletal muscle 
demonstrates significantly elevated levels of total 
FA uptake and enhanced rates of FA esterification 
into triacylglycerol compared with lean subjects.40 
In the presence of leptin, lean muscle demonstrates 
elevated rates of endogenous and exogenous pal-
mitate oxidation. Leptin also reduces the ratio of 
esterification to exogenous oxidation, demonstrating 
the increased partitioning of FA toward oxidation 
and away from storage. Contrary to these findings in 
lean muscle, leptin has no effect on FA metabolism 
in skeletal muscle of the obese. Thus, leptin increases 
FA oxidation in skeletal muscle of lean, but not 
obese, humans, demonstrating the development of 
leptin resistance in obese human skeletal muscle.40 
Leptin has a fundamental role to play in adipose 
tissue regulation both in health and disease, some 
of which influences skeletal muscle. 
Adiponectin induces fatty acid oxidation in 
skeletal muscle, and reduced levels are associated 
with insulin resistance both in mice and humans.57,58 
The proposed mechanism centers around activation 
of AMP activated protein kinase (AMPK), which 
is known to regulate cellular malonyl CoA con-
centrations by inhibiting acetyl CoA carboxylase.59 
Consequently there is a decrease in lipogenesis 
associated with increased mitochondrial fatty acid 
beta-oxidation. Adiponectin may also have a role in 
damping down the inflammatory effects of TNF-a, 
while TNF-a and IL-6 have a role in decreasing 
adiponectin levels60 (Fig. 1).
Adipokines and myokines interact and play a 
complex role in insulin resistance, obesity, and the 
regulation of skeletal muscle. It would appear that 
regulation of any of these adipose-muscle-derived 
cytokines has a direct effect on the others and on 
the mass/composition of a variety of tissues in the 
body. Adipokines have a number of primary and 
secondary effects throughout the body; however, all 
seem to be associated directly or indirectly in regulat-
ing a chronic inflammatory state, which influences 
insulin resistance and body composition. Adipokines 
may also have a role in pre-cachexia, cachexia, and 
refractory cachexia states. Disruption in the normal 
physiology of fat metabolism in cancer plays a cru-
cial role in distant organ signaling. On development 
of insulin resistance, other organs such as the liver, 
skeletal muscle, and the hypothalamus alter their 
responsiveness and change how they react to insulin.31 
Therefore, adipose tissue and skeletal muscle can be 
seen as a producer of cytokines, hormones, and lipids 
that signal these distant organs to regulate systemic 
metabolic homeostasis and metabolism. Therapeutic 
targets may be available to modulate this process. 
There is little doubt that adipokines and myokines 
are intricately involved in adipose-muscle tissue cross-
talk both in normal physiology and pathophysiology.
VII. PLASMA LEVELS OF CYTOKINES  
IN CANCER
With the varying roles described in adipose-muscle 
cross-talk, actual plasma levels of adipokines and 
myokines will have an important bearing on how 
they influence body composition in cancer and 
whether these levels differ in cancer sufferers with 
or without weight loss. A number of studies have 
investigated the plasma levels of adipokines and 
myokines; however, there appears to be great vari-
ance in the results obtained61–65 (Table 1). A recent 
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study demonstrated adiponectin levels were similarly 
elevated in cachectic and noncachectic cancer patients 
compared with noncancer controls. Leptin levels 
were significantly decreased in cancer cachexia and 
were found to be associated with lack of appetite 
and insulin resistance.61 Contrary to this, adiponectin 
levels were found to be significantly decreased among 
a cohort of patients with gastric cancer.63 Another 
study demonstrated increased leptin levels in patients 
with lung cancer.64 These differences may be a result 
of inadequate phenotyping in the subjects studied; 
for example, gender and age differences should be 
taken into account, as should the type and staging 
of the tumor. Characterization for body composition 
(e.g., subtyping for sarcopenic obesity) is another 
phenotypic variable that is becoming increasingly 
important, as body composition of adipose and 
muscle mass will have a significant difference in the 
circulating levels of adipokines and myokines. 
VIII. CANCER CACHExIA: TARGETS  
FOR TREATMENT
At diagnosis, one-third of all cancer patients will 
have lost >5% of their original body weight, and 
20% of cancer-related deaths are directly caused by 
malnutrition and cachexia due to immobility and 
cardiorespiratory failure.28 While appetite stimulants 
or nutritional support can help reverse fat loss, the 
reversal of muscle wasting is much more challeng-
ing and is the core reason why cachexia remains an 
important unmet medical need. Cancer cachexia 
results from interactions between the host and the 
tumor, but the mechanisms behind this interaction 
are not fully understood. The tumor induces activation 
of both the acute phase and neuroendocrine stress 
response. There is a two-way interaction between 
production of inflammatory cytokines by both host 
and tumor cells. It is this interplay between a net 
inadequate nutritional intake and an increasing 
metabolic demand that is vitally important in cancer 
cachexia. By understanding the mechanisms involved 
in normal physiology, the physiology of obesity, and 
the mechanisms of skeletal muscle loss and fat in 
disease, a deeper understanding of the mechanisms 
behind cancer cachexia may be achieved.
A. Nutrition
Skeletal muscle provides a dynamic store of amino 
acids (AA) that is highly adaptive and responsive to the 
body and its needs. In the fed state, AA act to stimulate 
muscle protein synthesis. The converse is true in starva-
tion, when skeletal muscle protein is broken down to 
maintain the free AA pool.14 The body’s ability to react 
in this way has been studied extensively.16,15 Dietary 
intake of essential AA increases skeletal muscle protein 
synthesis, whereas non-essential AA does not elicit 
the same response. Therefore, the ingestion of essential 
amino acids signals that a meal has been consumed, 
particularly leucine, which has been demonstrated to 
act not only as a substrate but also a signal.66 In the 
presence of sufficient nutrition, skeletal muscle mass 
remains constant, with protein balance depending 
on the time of day and when meals are consumed in 
line with the fast/feeding cycle. Feeding aids a short 
increase in the AA pool to compensate for times of 
fasting rather than modulate longer term phenotypic 
TABLE 1. Plasma Levels of Circulating Leptin and Adiponectin in Cancer Patients
Study Leptin Adiponectin
Smiechowska et al.61 Decreased* Increased
Kemik et al62 Increased Decreased
Nakajima et al.63 — Decreased
Terzidis et al.64 Increased —
Wolf et al.65 Decreased —
*Leptin levels were significantly decreased in patients with established cachexia.
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changes.14,15 Nutrition has a vital adjuvant role to play 
in the management of cancer cachexia. Many cancer 
patients undergoing treatment are malnourished, and 
a number of interventions such as chemotherapy and 
radiotherapy further exacerbate this. A multiprofes-
sional and multimodal approach including nutrition 
and physical activity interventions aimed at prevent-
ing or delaying cancer-related malnutrition has been 
suggested to be of key importance for the efficacy of 
the oncological therapies.67 A number of RCTs have 
also demonstrated that adequate feeding via entral or 
parenteral methods improves outcome and reduces 
the side-effect profile of chemoradiotherapy and sur-
gery.68,69 Cachexia prevention via adequate nutrition 
remains a primary goal in the treatment of cancer.
B. Importance of Adipose Tissue
The mechanism of fat loss in cancer cachexia centers 
on the adipocyte. A reduction of the adipocyte size 
is the primary way fat is lost in cancer cachexia. 
The lipids, which consist mainly of triglycerides, 
are broken down by two specific enzymes: adipose 
triglyceride lipase (ATGL), which is responsible 
for the formation of diglycerides, and hormone-
sensitive lipase (HSL), which activates further 
hydrolysis to generate the end products fatty acids 
and glycerol. The activator for lipolysis comes from 
enhanced production of catecholamines, which are 
responsible for stimulating and up-regulating these 
two lipolytic hormones.70 A recent study examined 
the therapeutic potential of inhibiting lipolysis 
through genetic ablation of ATGL or HSL in two 
murine models of cancer cachexia.23 These models 
represent the metabolic end of the cachexia-anorexia 
spectrum: pro-inflammatory cytokines and ZAG are 
increased while (during the early and middle phase 
of tumor growth/cachexia) food intake is normal. 
They took wild-type C57BL/6 mice and injected 
Lewis lung carcinoma or B16 melanoma cells to 
cause tumor growth. In both models, ablation of 
ATGL prevents the increased lipolysis and net 
mobilization of adipose tissue associated with tumor 
growth. Unexpectedly, the authors also demonstrate 
that skeletal muscle mass is preserved and that 
activation of proteasomal and apoptotic pathways 
in muscle is averted. Ablation of HSL had similar 
but less significant effects.23 
This study suggests the possibility of until now 
unrecognized, physiologically important cross-talk 
between adipose tissue and skeletal muscle in the 
context of cancer cachexia. The study also raises the 
possibility of pharmacological inhibition of lipases 
as a new therapeutic approach to cancer cachexia. 
This study adds further weight to the argument that 
lipolysis plays an instrumental role in the pathogenesis 
of cancer cachexia. The mouse model has limitations; 
ATGL deficiency in mice and humans is associated 
with major impairment of cardiac function, which 
could possibly negate any advantages of a potential 
therapy based upon ATGL deficiency.71 Cachexia is 
a spectrum that has different phases (pre-cachexia, 
cachexia, and refractory cachexia) and degrees of 
severity. In this recent study the ablation of lipoly-
sis was present from the onset of tumor growth.23 
Thus the intervention remains untested when, as in 
clinical practice, the cancer cachexia is often well 
established. It also remains to be shown whether 
or not the protection of adipose and muscle loss in 
lipase-deficient mice is a consequence of defective 
tissue autonomous lipolysis or due to endocrine sig-
naling from the tumor or adipose tissue. In addition, 
patients generally receive systemic anti-neoplastic 
therapy until a late stage in their disease trajectory, 
and the interaction with such therapy (some of which 
may induce muscle wasting) is unknown. These issues 
highlight the importance of understanding the precise 
mechanism of the findings by Das23 and colleagues.
C. Importance of Muscle Mass
In the modern epidemic of obesity there is now a 
cohort of cancer patients who, although obese (not 
lacking energy reserves), have severe muscle wast-
ing (sarcopenia).2 These individuals appear to be at 
increased risk of accelerated demise. In an evaluation 
of body composition using CT scans in patients with 
weight-losing pancreatic cancer undergoing palliative 
therapy, 56% of the patients assessed were sarcopenic, 
40% were overweight/obese, and 16% were both. 
Sarcopenic obesity was shown to be an independent 
adverse prognostic indicator that should be considered 
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for stratification of patients entering clinical trials, 
systemic therapy, or support care programs. This 
particular toxic combination of excess adipose tissue 
and minimal skeletal muscle mass is a real therapeutic 
challenge. The obvious treatment would be to advise 
exercise, but many advanced, elderly cancer patients 
are incapable of significant exercise. Thus, the issue 
of pharmacological intervention is raised. Increased 
understanding of adipose-muscle cross-talk may be 
key to identifying suitable targets. 
Ix. CONCLUSIONS
Although cachectic cancer patients demonstrate sys-
temic inflammation, increased lipolysis and insulin 
resistance, and reduced physical activity,28 there has 
been little effort to exploit adipose/muscle cross-talk 
for therapeutic gain. Oncologists have traditionally 
focused on curing cancer, leaving the cachexia to take 
care of itself. However, symptom management on its 
own can improve survival in advanced cancer,72 and 
multimodal management of cachexia has prompted an 
increasing number of Phase I/II studies using highly 
specific/potent therapeutics targeted at either upstream 
mediators or downstream end-organ hypo-anabolism/
hyper-catabolism. The recent work into the cross-talk of 
organs mentioned in this review, mainly skeletal muscle 
and adipose tissue, suggests that understanding of the 
integrative physiology of this complex syndrome may 
yet further novel therapeutics approaches, particularly 
for those patients suffering from sarcopenic obesity.
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